[{"id":5349,"regimens":[{"id":9907,"duration":{"id":3993,"approximate_duration":"4 Day(s)","dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[],"created":"2020-04-14T16:51:22.266947Z","updated":"2020-05-27T19:35:46.494205Z","dose":"400 bid the 200mg bid for 4 more days","frequency":"BID","route":"po","severity":"ICU/Critical Care","severity_detail":null,"comments":null,"report":5349},{"id":9908,"duration":{"id":3994,"approximate_duration":"4 Day(s)","dates_unknown":false},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":5599,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":9908}],"created":"2020-04-14T16:51:22.273651Z","updated":"2020-05-27T19:35:46.501943Z","dose":"500mg qd first day then 250 daily for 5 days","frequency":"qd","route":"po","severity":"ICU/Critical Care","severity_detail":null,"comments":null,"report":5349},{"id":9909,"duration":{"id":3995,"approximate_duration":"","dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":5600,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":9909}],"created":"2020-04-14T16:51:22.279094Z","updated":"2020-05-27T19:35:46.508183Z","dose":"400mg","frequency":"single dose","route":"iv","severity":"ICU/Critical Care","severity_detail":null,"comments":null,"report":5349}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":7051,"answer":"Clinical assessment","answer_other":"","report":5349}],"how_diagnosis":[{"id":11709,"answer":"PCR","answer_other":"","report":5349},{"id":11710,"answer":"Clinical assessment","answer_other":"","report":5349}],"author_username":"Leonard Sacks","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1886,"name":"Sars-cov-2"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"Fda","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"","why_new_way":[{"id":3165,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":5349}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[],"races":[],"created":"2020-04-14T16:48:52.687301Z","updated":"2020-05-27T19:35:46.481138Z","title":null,"status":"Approved","anonymous":false,"published":false,"pubmed_id":null,"doi":"","article_url":null,"pub_year":null,"published_authors":"","article_author_email":"","journal":"","abstract":"","article_type":"","study_type":"Case Report","number_of_patients":null,"article_patient_number":"","full_text_available":false,"outcome":"Patient improved","surgery":"No","age":"51-60 years","sex":"Male","ethnicity":null,"country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"Hypertension,  obstructive, sleep apnea obesity, diabetes","pregnant":false,"unknown":false,"site_of_disease":"","clinical_syndrome":"cough and dyspnea, began azithro prior to ICU admission -on nasal canula","severity":"ICU/Critical Care","prev_treatment":"The patient was not previously treated for this infection","unusual":"","drug_treatment_features":"","have_adverse_events":true,"adverse_events":"none","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"2 weeks","additional_info":"","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6122,8342,10776]},{"id":5355,"regimens":[{"id":9918,"duration":{"id":4004,"approximate_duration":"2 Day(s)","dates_unknown":false},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":5616,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":9918}],"created":"2020-04-15T20:07:57.099965Z","updated":"2020-05-06T00:20:18.755484Z","dose":"500mg X 1 250mg daily for 2 days","frequency":"qd","route":"","severity":"","severity_detail":null,"comments":null,"report":5355},{"id":9919,"duration":{"id":4005,"approximate_duration":"","dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":5617,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":9919}],"created":"2020-04-15T20:07:57.106442Z","updated":"2020-05-06T00:20:10.427345Z","dose":"400mg single dose","frequency":"qd","route":"iv","severity":"","severity_detail":null,"comments":null,"report":5355}],"site_of_infection":[],"specific_site":[],"how_outcome":[],"how_diagnosis":[{"id":11722,"answer":"PCR","answer_other":"","report":5355},{"id":11723,"answer":"Clinical assessment","answer_other":"","report":5355}],"author_username":"Leonard Sacks","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1886,"name":"Sars-cov-2"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"Fda","author_country":"","outcome_computed":"Deteriorated","previous_drugs":[],"comments":[{"id":366,"author_username":"Parvesh Paul","author_qualification":"Medical Doctor","author_affiliation":"Christian Medical College, Ludhiana, Punjab, India.","author_country":"India","created":"2020-04-15T20:42:46.542792Z","updated":"2020-04-15T20:42:46.542824Z","body":"Thanks for sharing your experience Dr. Leonard. Lately, much like others, I have been thinking - would starting Tocilizumab early in high risk patients be more beneficial? The rationale being, once the cytokine storm has started and ARDS ensued, the damage is already done.","datetime":"2020-04-15T20:42:46.542885Z","anonymous":false,"deleted":false,"flagged":false,"report":5355},{"id":368,"author_username":"Leonard Sacks","author_qualification":"Medical Doctor","author_affiliation":"Fda","author_country":"","created":"2020-04-15T21:29:42.131866Z","updated":"2020-04-15T21:29:42.131899Z","body":"Sometimes the disease progresses so fast that  by the time you realize the patient is at high risk, you've already missed the boat. Also supplies of tocilizumab are very precious. I completely agree that  a clinical trial is needed in COVID 19 patients early in their disease.","datetime":"2020-04-15T21:29:42.131947Z","anonymous":false,"deleted":false,"flagged":false,"report":5355},{"id":369,"author_username":"Parvesh Paul","author_qualification":"Medical Doctor","author_affiliation":"Christian Medical College, Ludhiana, Punjab, India.","author_country":"India","created":"2020-04-15T21:40:54.703939Z","updated":"2020-04-15T21:40:54.703971Z","body":"Thanks for your response. We do need more evidence via clinical trials.","datetime":"2020-04-15T21:40:54.704020Z","anonymous":false,"deleted":false,"flagged":false,"report":5355}],"article_language":"","why_new_way":[{"id":3171,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":5355}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[],"races":[],"created":"2020-04-15T20:06:43.659012Z","updated":"2020-05-06T00:19:56.747956Z","title":null,"status":"Approved","anonymous":false,"published":false,"pubmed_id":null,"doi":"","article_url":null,"pub_year":null,"published_authors":"","article_author_email":"","journal":"","abstract":"","article_type":"","study_type":"Case Report","number_of_patients":null,"article_patient_number":"","full_text_available":false,"outcome":"Patient died","surgery":"No","age":"51-60 years","sex":"Male","ethnicity":null,"country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"hypertension, hyperlipidemia, alcohol abuse","pregnant":false,"unknown":false,"site_of_disease":"","clinical_syndrome":"","severity":"","prev_treatment":"The patient was not previously treated for this infection","unusual":"","drug_treatment_features":"","have_adverse_events":true,"adverse_events":"none","when_outcome":"While the patient was still on treatment","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"2 weeks","additional_info":"hospitalized on nasal Oxygen, deteriorated on azithro, intubated then given tocilizumab, died the following day","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6122,10776]},{"id":5361,"regimens":[{"id":9930,"duration":{"id":4016,"approximate_duration":"2 Day(s)","dates_unknown":false},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":5623,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":9930}],"created":"2020-04-16T19:39:13.012032Z","updated":"2020-05-06T00:20:18.766204Z","dose":"500mg the first day the 250mg qdaily the next 4 days","frequency":"qdaily","route":"IV","severity":"ICU/Critical Care","severity_detail":null,"comments":null,"report":5361},{"id":9931,"duration":{"id":4017,"approximate_duration":"","dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":5624,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":9931}],"created":"2020-04-16T19:39:13.018985Z","updated":"2020-05-06T00:20:18.763519Z","dose":"400mg","frequency":"once","route":"IV","severity":"ICU/Critical Care","severity_detail":null,"comments":null,"report":5361}],"site_of_infection":[],"specific_site":[],"how_outcome":[],"how_diagnosis":[],"author_username":"Adam Klein","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1886,"name":"Sars-cov-2"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"","outcome_computed":"Deteriorated","previous_drugs":[],"comments":[],"article_language":"","why_new_way":[{"id":3178,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":5361}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[],"races":[],"created":"2020-04-16T19:38:07.886358Z","updated":"2020-04-16T19:42:12.361234Z","title":null,"status":"Approved","anonymous":false,"published":false,"pubmed_id":null,"doi":"","article_url":null,"pub_year":null,"published_authors":"","article_author_email":"","journal":"","abstract":"","article_type":"","study_type":"Case Report","number_of_patients":null,"article_patient_number":"","full_text_available":false,"outcome":"Patient died","surgery":"No","age":"61-70 years","sex":"Male","ethnicity":null,"country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"hypertension, obstructive sleep apnea","pregnant":false,"unknown":false,"site_of_disease":"","clinical_syndrome":"","severity":"ICU/Critical Care","prev_treatment":null,"unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"2 weeks","additional_info":"Tocilizumab administered 24 hours after recommendation","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6122,10776]},{"id":5362,"regimens":[{"id":9932,"duration":{"id":4018,"approximate_duration":"","dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":5625,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":9932}],"created":"2020-04-16T19:44:27.011277Z","updated":"2020-05-06T00:20:18.670668Z","dose":"400mg","frequency":"once","route":"IV","severity":"ICU/Critical Care","severity_detail":null,"comments":null,"report":5362},{"id":9933,"duration":{"id":4019,"approximate_duration":"4 Day(s)","dates_unknown":false},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":5626,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":9933}],"created":"2020-04-16T19:44:27.017496Z","updated":"2020-05-06T00:20:18.774325Z","dose":"500mg once then 250mg daily for 4 more days","frequency":"qdaily","route":"PO","severity":"ICU/Critical Care","severity_detail":null,"comments":null,"report":5362},{"id":9934,"duration":{"id":4020,"approximate_duration":"4 Day(s)","dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":5627,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":9934}],"created":"2020-04-16T19:44:27.022699Z","updated":"2020-05-06T00:20:18.771620Z","dose":"400mg BID the first day then 200mg BID for 4 more days","frequency":"BID","route":"PO","severity":"ICU/Critical Care","severity_detail":null,"comments":null,"report":5362}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":7058,"answer":"Clinical assessment","answer_other":"","report":5362}],"how_diagnosis":[{"id":11728,"answer":"Clinical assessment","answer_other":"","report":5362},{"id":11729,"answer":"PCR","answer_other":"","report":5362}],"author_username":"Adam Klein","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1886,"name":"Sars-cov-2"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[{"id":372,"author_username":"Rita Abbud","author_qualification":"Medical Doctor","author_affiliation":null,"author_country":"","created":"2020-04-27T01:38:54.170589Z","updated":"2020-04-27T01:38:54.170632Z","body":"Had similar experience in my practice","datetime":"2020-04-27T01:38:54.170680Z","anonymous":false,"deleted":false,"flagged":false,"report":5362},{"id":373,"author_username":"CURE ID Admin","author_qualification":"Medical Doctor","author_affiliation":"FDA/NCATS","author_country":"United States","created":"2020-04-27T13:31:18.076319Z","updated":"2020-04-27T13:31:18.076353Z","body":"Dr. Abbud, please consider sharing your experiences as case reports as well. Thanks for adding your comment!","datetime":"2020-04-27T13:31:18.076402Z","anonymous":false,"deleted":false,"flagged":false,"report":5362}],"article_language":"","why_new_way":[{"id":3179,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":5362}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[],"races":[],"created":"2020-04-16T19:44:07.167223Z","updated":"2020-04-16T19:47:14.471339Z","title":null,"status":"Approved","anonymous":false,"published":false,"pubmed_id":null,"doi":"","article_url":null,"pub_year":null,"published_authors":"","article_author_email":"","journal":"","abstract":"","article_type":"","study_type":"Case Report","number_of_patients":null,"article_patient_number":"","full_text_available":false,"outcome":"Patient improved","surgery":"No","age":"51-60 years","sex":"Male","ethnicity":null,"country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"diabetes","pregnant":false,"unknown":false,"site_of_disease":"","clinical_syndrome":"","severity":"ICU/Critical Care","prev_treatment":null,"unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"No","reminder":true,"when_reminder":"1 week","additional_info":"","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6122,8342,10776]},{"id":5451,"regimens":[{"id":10199,"duration":{"id":4045,"approximate_duration":"","dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":5709,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":10199}],"created":"2020-04-30T18:17:18.162458Z","updated":"2020-05-27T19:40:12.097527Z","dose":"400mg","frequency":"single dose","route":"IV","severity":"ICU/Critical Care","severity_detail":null,"comments":null,"report":5451},{"id":10200,"duration":{"id":4046,"approximate_duration":null,"dates_unknown":false},"drug":{"id":9077,"name":"Methylprednisolone","url":"cure-api2.ncats.io/v1/drugs/9077","rxNorm_id":null,"notes":null},"use_drug":[{"id":5710,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":10200}],"created":"2020-04-30T18:17:18.169206Z","updated":"2020-05-27T19:40:12.105287Z","dose":"40mg","frequency":"bid","route":"iv","severity":"ICU/Critical Care","severity_detail":null,"comments":null,"report":5451}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":7065,"answer":"Clinical assessment","answer_other":"","report":5451},{"id":7066,"answer":"Imaging","answer_other":"","report":5451}],"how_diagnosis":[{"id":11817,"answer":"Clinical assessment","answer_other":"","report":5451},{"id":11818,"answer":"PCR","answer_other":"","report":5451}],"author_username":"Leonard Sacks","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1886,"name":"Sars-cov-2"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"Fda","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"","why_new_way":[{"id":3268,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":5451}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[],"races":[],"created":"2020-04-30T18:15:45.723349Z","updated":"2020-05-27T19:40:12.084603Z","title":null,"status":"Approved","anonymous":false,"published":false,"pubmed_id":null,"doi":"","article_url":null,"pub_year":null,"published_authors":"","article_author_email":"","journal":"","abstract":"","article_type":"","study_type":"Case Report","number_of_patients":null,"article_patient_number":"","full_text_available":false,"outcome":"Patient improved","surgery":"No","age":"51-60 years","sex":"Male","ethnicity":null,"country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"obesity diabetes hypertension","pregnant":false,"unknown":false,"site_of_disease":"","clinical_syndrome":"","severity":"ICU/Critical Care","prev_treatment":"The patient was not previously treated for this infection","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"2 weeks","additional_info":"","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[9077,10776]},{"id":5452,"regimens":[{"id":10201,"duration":{"id":4047,"approximate_duration":"1 day","dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":5711,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":10201}],"created":"2020-04-30T18:28:09.741960Z","updated":"2020-06-03T13:35:34.614681Z","dose":"400mg","frequency":"once","route":"IV","severity":"ICU/Critical Care","severity_detail":null,"comments":null,"report":5452}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":7067,"answer":"Clinical assessment","answer_other":"","report":5452},{"id":7068,"answer":"Imaging","answer_other":"","report":5452}],"how_diagnosis":[{"id":11819,"answer":"Clinical assessment","answer_other":"","report":5452},{"id":11820,"answer":"PCR","answer_other":"","report":5452},{"id":11821,"answer":"Imaging","answer_other":"","report":5452}],"author_username":"Adam Klein","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1886,"name":"Sars-cov-2"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"","outcome_computed":"Deteriorated","previous_drugs":[],"comments":[],"article_language":"","why_new_way":[{"id":3269,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":5452}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[],"races":[],"created":"2020-04-30T18:26:48.062150Z","updated":"2020-06-03T13:35:34.601356Z","title":null,"status":"Approved","anonymous":false,"published":false,"pubmed_id":null,"doi":"","article_url":null,"pub_year":null,"published_authors":"","article_author_email":"","journal":"","abstract":"","article_type":"","study_type":"Case Report","number_of_patients":null,"article_patient_number":"","full_text_available":false,"outcome":"Patient deteriorated","surgery":"No","age":"90+ years","sex":"Male","ethnicity":null,"country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"atrial fibrillation, hypertension","pregnant":false,"unknown":false,"site_of_disease":"","clinical_syndrome":"","severity":"ICU/Critical Care","prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":true,"adverse_events":"stroke","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"2 weeks","additional_info":"","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[10776]},{"id":5464,"regimens":[{"id":10226,"duration":{"id":4093,"approximate_duration":"","dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":5921,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":10226}],"created":"2020-05-04T20:15:02.959327Z","updated":"2020-05-06T00:20:10.679927Z","dose":"400mg","frequency":"single dose","route":"IV","severity":"Inpatient","severity_detail":null,"comments":null,"report":5464}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":7128,"answer":"Clinical assessment","answer_other":"","report":5464}],"how_diagnosis":[{"id":11883,"answer":"Clinical assessment","answer_other":"","report":5464},{"id":11884,"answer":"PCR","answer_other":"","report":5464}],"author_username":"Leonard Sacks","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1886,"name":"Sars-cov-2"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"Fda","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"","why_new_way":[{"id":3279,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":5464}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[],"races":[],"created":"2020-05-04T20:14:53.004840Z","updated":"2020-05-06T00:19:56.525631Z","title":null,"status":"Approved","anonymous":false,"published":false,"pubmed_id":null,"doi":"","article_url":null,"pub_year":null,"published_authors":"","article_author_email":"","journal":"","abstract":"","article_type":"","study_type":"Case Report","number_of_patients":null,"article_patient_number":"","full_text_available":false,"outcome":"Patient improved","surgery":"No","age":"51-60 years","sex":"Male","ethnicity":null,"country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"Hypertension diabetes","pregnant":false,"unknown":false,"site_of_disease":"","clinical_syndrome":"","severity":"Inpatient","prev_treatment":"The patient was not previously treated for this infection","unusual":"","drug_treatment_features":"","have_adverse_events":true,"adverse_events":"none","when_outcome":"After a period of follow-up","follow_up_period":"5 days","relapse":"No","reminder":false,"when_reminder":"2 weeks","additional_info":"","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[10776]},{"id":5552,"regimens":[{"id":10354,"duration":{"id":4333,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":6272,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":10354},{"id":6273,"answer":"In a novel combination with another drug","answer_other":"","regimen":10354}],"created":"2020-05-20T02:01:36.134569Z","updated":"2020-05-20T02:19:03.239165Z","dose":"500 mg","frequency":"","route":"PO","severity":"ICU/Critical Care","severity_detail":null,"comments":null,"report":5552},{"id":10355,"duration":{"id":4334,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6675,"name":"Ceftriaxone","url":"cure-api2.ncats.io/v1/drugs/6675","rxNorm_id":null,"notes":null},"use_drug":[{"id":6274,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":10355},{"id":6275,"answer":"In a novel combination with another drug","answer_other":"","regimen":10355}],"created":"2020-05-20T02:01:36.142896Z","updated":"2020-05-20T02:19:03.240179Z","dose":"1 g","frequency":"","route":"IV","severity":"ICU/Critical Care","severity_detail":null,"comments":null,"report":5552},{"id":10356,"duration":{"id":4337,"approximate_duration":"7 days","dates_unknown":true},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":6276,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":10356},{"id":6277,"answer":"In a novel combination with another drug","answer_other":"","regimen":10356}],"created":"2020-05-20T02:01:36.149701Z","updated":"2020-05-20T02:19:03.241090Z","dose":"200 mg","frequency":"BD","route":"PO","severity":"ICU/Critical Care","severity_detail":"400 mg loading dose followed by 200 mg twice daily for a 7-day course","comments":null,"report":5552},{"id":10357,"duration":{"id":4336,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":6278,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":10357},{"id":6279,"answer":"In a novel combination with another drug","answer_other":"","regimen":10357}],"created":"2020-05-20T02:01:36.156407Z","updated":"2020-05-20T02:19:03.242058Z","dose":"8 mg/Kg x 2","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":null,"comments":null,"report":5552}],"site_of_infection":[],"specific_site":[],"how_outcome":[],"how_diagnosis":[{"id":12136,"answer":"Clinical assessment","answer_other":"","report":5552},{"id":12137,"answer":"Imaging","answer_other":"","report":5552},{"id":12138,"answer":"PCR","answer_other":"","report":5552}],"author_username":"Parvesh Paul","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"Christian Medical College, Ludhiana, Punjab, India.","author_country":"India","outcome_computed":"Deteriorated","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":3375,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":5552}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-05-20T01:59:01.873192Z","updated":"2020-05-20T02:19:03.176207Z","title":"Novel coronavirus 2019 (COVID-19): A case report and review of treatments.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32384516,"doi":"10.1097/MD.0000000000020207","article_url":"https://www.ncbi.nlm.nih.gov/pubmed/?term=32384516","pub_year":2020,"published_authors":"Douedi S\r\nMiskoff J","article_author_email":"Author email could not be found.","journal":"Medicine","abstract":"A 77-year-old female with a history of hypertension and hyperlipidemia who presented as a transfer to our hospital facility with worsening fevers, cough, and respiratory distress.  Chest X-rays revealed bilateral infiltrates worse at the lung bases and CT scan of the chest showed bilateral ground-glass opacities consistent with COVID-19. While our testing revealed a negative COVID-19 result at our institution, the result at a previous hospital returned a positive result. She was being treated aggressively in the intensive care unit with high dose intravenous ascorbic acid, hydroxychloroquine, and anti-interleukin-6 monoclonal antibody. She also received a loading dose of remdesivir however was unable to complete the course due to organ failure and requirement of vasopressors for hemodynamic stability.","article_type":"Original","study_type":"Case Report","number_of_patients":1,"article_patient_number":"","full_text_available":true,"outcome":"Patient died","surgery":"","age":"71-80 years","sex":"Female","ethnicity":null,"country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"hypertension and hyperlipidemia","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"fevers, cough, and respiratory distress","severity":"ICU/Critical Care","prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"","follow_up_period":null,"relapse":"","reminder":false,"when_reminder":"1 week","additional_info":"she was admitted for possible pneumonia with isolation precautions for suspected COVID-19 and was started on oxygen via nasal cannula and on 1-gram ceftazidime intravenously every 8 hours and 500 mg azithromycin orally daily.\r\n\r\nShe was intubated and transferred to the intensive care unit (ICU) for further management and was switched to ceftriaxone 1 g intravenously daily.\r\n\r\n12 hours later, the COVID-19 test from the initial facility returned positive results. \r\n\r\nOn day 3 of hospitalization she was started on 6 g of IV ascorbic acid twice daily. \r\n\r\nShe also received a loading dose of remdesivir however was unable to complete the course due to organ failure and requirement of vasopressors for hemodynamic stability.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6122,6675,8342,10776]},{"id":5559,"regimens":[{"id":10381,"duration":{"id":4375,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":6326,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":10381},{"id":6327,"answer":"In a novel combination with another drug","answer_other":"","regimen":10381}],"created":"2020-05-21T13:47:51.732331Z","updated":"2020-05-21T14:03:36.516808Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":5559},{"id":10382,"duration":{"id":4376,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":6328,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":10382},{"id":6329,"answer":"In a novel combination with another drug","answer_other":"","regimen":10382}],"created":"2020-05-21T13:47:51.740845Z","updated":"2020-05-21T14:03:36.523770Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":5559},{"id":10383,"duration":{"id":4377,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":6330,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":10383},{"id":6331,"answer":"In a novel combination with another drug","answer_other":"","regimen":10383}],"created":"2020-05-21T13:47:51.747946Z","updated":"2020-05-21T14:03:36.530100Z","dose":"one dose","frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":5559},{"id":10384,"duration":{"id":4378,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8598,"name":"Ivermectin","url":"cure-api2.ncats.io/v1/drugs/8598","rxNorm_id":null,"notes":null},"use_drug":[{"id":6332,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":10384},{"id":6333,"answer":"In a novel combination with another drug","answer_other":"","regimen":10384}],"created":"2020-05-21T13:47:51.754625Z","updated":"2020-05-21T14:03:36.536359Z","dose":"0.2 mg/kg","frequency":"one dose","route":"","severity":null,"severity_detail":null,"comments":null,"report":5559}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":7324,"answer":"Clinical assessment","answer_other":"","report":5559}],"how_diagnosis":[{"id":12159,"answer":"Clinical assessment","answer_other":"","report":5559},{"id":12160,"answer":"Imaging","answer_other":"","report":5559},{"id":12161,"answer":"PCR","answer_other":"","report":5559}],"author_username":"Alexis Lieberman","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"","why_new_way":[{"id":3382,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":5559}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-05-21T13:35:36.972496Z","updated":"2020-05-21T14:03:36.503944Z","title":null,"status":"Approved","anonymous":false,"published":false,"pubmed_id":null,"doi":"","article_url":null,"pub_year":null,"published_authors":"","article_author_email":"","journal":"","abstract":"","article_type":"","study_type":"Case Report","number_of_patients":null,"article_patient_number":"","full_text_available":false,"outcome":"Patient improved","surgery":"","age":"51-60 years","sex":"Male","ethnicity":null,"country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Respiratory tract infection","severity":"Inpatient","prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"","reminder":false,"when_reminder":"1 week","additional_info":"During his hospital course, the patient had been treated with Hydroxychloroquine and Azithromycin and was on high dose steroids after a dose of tocilizumab.  \r\nHis chest x-ray was worsening as was his oxygenation.  He was on 50 liters high flow oxygen trying to avoid intubation. \r\nHis D-Dimer was greater than 20, and the patient was started on full dose lovenox.  \r\nThe patient and his wife requested that the treating physician try Ivermectin (0.2 mg/kg x 1 dose).  \r\nThe treating physician agreed after full informed consent and chart review to look for contraindications and drug to drug interactions. \r\n Within 3-4 days, the patient was afebrile, his respiratory rate dropped to 16-18","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6122,8342,8598,10776]},{"id":5592,"regimens":[{"id":10442,"duration":{"id":4445,"approximate_duration":"5 days","dates_unknown":true},"drug":{"id":11301,"name":"Remdesivir","url":"cure-api2.ncats.io/v1/drugs/11301","rxNorm_id":null,"notes":null},"use_drug":[],"created":"2020-06-07T11:05:32.347369Z","updated":"2020-06-07T11:18:56.407484Z","dose":"100mg","frequency":"Every 24 hours","route":"IV","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":5592},{"id":10443,"duration":{"id":4446,"approximate_duration":"3 days","dates_unknown":true},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[],"created":"2020-06-07T11:05:32.356063Z","updated":"2020-06-07T11:18:56.417538Z","dose":"400 mg","frequency":"Daily","route":"IV","severity":"Inpatient","severity_detail":"","comments":null,"report":5592},{"id":10444,"duration":{"id":4447,"approximate_duration":null,"dates_unknown":false},"drug":{"id":11339,"name":"Convalescent plasma","url":"cure-api2.ncats.io/v1/drugs/11339","rxNorm_id":null,"notes":null},"use_drug":[],"created":"2020-06-07T11:05:32.363667Z","updated":"2020-06-07T11:18:56.426094Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":5592}],"site_of_infection":[],"specific_site":[],"how_outcome":[],"how_diagnosis":[{"id":12241,"answer":"Clinical assessment","answer_other":"","report":5592},{"id":12242,"answer":"PCR","answer_other":"","report":5592}],"author_username":"Mitchell Grohowski","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1892,"name":"Coronavirus - covid-19"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"","outcome_computed":"Undetermined","previous_drugs":[],"comments":[],"article_language":"","why_new_way":[{"id":3424,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":5592},{"id":3425,"answer":"There is no standard/approved therapy in this patient population","answer_other":"","report":5592}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[],"races":[],"created":"2020-06-07T11:03:58.800599Z","updated":"2020-06-07T11:18:56.389746Z","title":null,"status":"Approved","anonymous":false,"published":false,"pubmed_id":null,"doi":"","article_url":null,"pub_year":null,"published_authors":"","article_author_email":"","journal":"","abstract":"","article_type":"","study_type":"Case Report","number_of_patients":null,"article_patient_number":"","full_text_available":false,"outcome":"Outcome is unknown/not yet determined","surgery":"No","age":"41-50 years","sex":"Male","ethnicity":"Hispanic/Latino","country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":true,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"","clinical_syndrome":"Chills, myalgia, fatigue, dyspnea on exertion, cough, shortness of breath, hypoxia","severity":null,"prev_treatment":null,"unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"While the patient was still on treatment","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"2 weeks","additional_info":"","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[11339,11301,10776]},{"id":5776,"regimens":[{"id":10722,"duration":{"id":4778,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8783,"name":"Lopinavir-Ritonavir","url":"cure-api2.ncats.io/v1/drugs/8783","rxNorm_id":null,"notes":null},"use_drug":[{"id":6826,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":10722},{"id":6827,"answer":"In a novel combination with another drug","answer_other":"","regimen":10722}],"created":"2020-09-03T20:05:22.532882Z","updated":"2020-09-03T20:18:39.049516Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":5776},{"id":10723,"duration":{"id":4779,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":6828,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":10723},{"id":6829,"answer":"In a novel combination with another drug","answer_other":"","regimen":10723}],"created":"2020-09-03T20:05:22.540775Z","updated":"2020-09-03T20:18:39.057055Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":5776},{"id":10724,"duration":{"id":4780,"approximate_duration":null,"dates_unknown":false},"drug":{"id":7230,"name":"Dexamethasone","url":"cure-api2.ncats.io/v1/drugs/7230","rxNorm_id":null,"notes":null},"use_drug":[{"id":6830,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":10724},{"id":6831,"answer":"In a novel combination with another drug","answer_other":"","regimen":10724}],"created":"2020-09-03T20:05:22.547636Z","updated":"2020-09-03T20:18:39.063639Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":5776},{"id":10725,"duration":{"id":4781,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":6832,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":10725},{"id":6833,"answer":"In a novel combination with another drug","answer_other":"","regimen":10725}],"created":"2020-09-03T20:05:22.554284Z","updated":"2020-09-03T20:18:39.070025Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":5776}],"site_of_infection":[],"specific_site":[],"how_outcome":[],"how_diagnosis":[{"id":12783,"answer":"Clinical assessment","answer_other":"","report":5776},{"id":12784,"answer":"Imaging","answer_other":"","report":5776},{"id":12785,"answer":"PCR","answer_other":"","report":5776}],"author_username":"Parvesh Paul","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"Christian Medical College, Ludhiana, Punjab, India.","author_country":"India","outcome_computed":"Deteriorated","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":3681,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":5776},{"id":3682,"answer":"Co-Infection or Complex Co-morbidities","answer_other":"","report":5776}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[{"id":108,"answer":"White","answer_other":""}],"created":"2020-09-03T20:04:22.010572Z","updated":"2020-09-03T20:18:39.039483Z","title":"A single center observational study ofÂ the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia. Case 4","status":"Approved","anonymous":false,"published":true,"pubmed_id":32354634,"doi":"10.1016/j.kint.2020.04.002","article_url":"https://www.ncbi.nlm.nih.gov/pubmed/?term=32354634","pub_year":2020,"published_authors":"Alberici F\r\nDelbarba E\r\nManenti C\r\nEconimo L\r\nValerio F\r\nPola A\r\nMaffei C\r\nPossenti S\r\nZambetti N\r\nMoscato M\r\nVenturini M\r\nAffatato S\r\nGaggiotti M\r\nBossini N\r\nScolari F","article_author_email":"federico.alberici@unibs.it","journal":"Kidney international","abstract":"The outcome of SARS-CoV2 infection in patients who have received a kidney allograft and are being treated with immunosuppression is unclear. We describe 20 kidney transplant recipients (median age 59 years [inter quartile range 51-64 years], median age of transplant 13 years [9-20 years], baseline eGFR 36.5 [23-47.5]) with SARS-CoV2 induced pneumonia. At admission, all had immunosuppression withdrawn and were started on methylprednisolone 16 mg/day, all but one was commenced on antiviral therapy and hydroxychloroquine with doses adjusted for kidney function. At baseline, all patients presented fever but only one complained of difficulty in breathing. Half of patients showed chest radiographic evidence of bilateral infiltrates while the other half showed unilateral changes or no infiltrates. During a median follow-up of seven days, 87% experienced a radiological progression and among those 73% required escalation of oxygen therapy. Six patients developed acute kidney injury with one requiring hemodialysis. Six of 12 patients were treated with tocilizumab, a humanized monoclonal antibody to the IL-6 receptor. Overall, five kidney transplant recipients died after a median period of 15 days [15-19] from symptom onset. These preliminary findings describe a rapid clinical deterioration associated with chest radiographic deterioration and escalating oxygen requirement in renal transplant recipients with SARS-Cov2 pneumonia. Thus, in this limited cohort of long-term kidney transplant patients, SARS-CoV-2 induced pneumonia is characterized by high risk of progression and significant mortality.","article_type":"Original","study_type":"Case Report","number_of_patients":20,"article_patient_number":"","full_text_available":true,"outcome":"Patient died","surgery":"No","age":"51-60 years","sex":"Male","ethnicity":"Not Hispanic/Latino","country_contracted":"Italy","country_treated":"Italy","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":true,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"HCV infection, Post renal transplant in 2018","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Respiratory tract infection","severity":null,"prev_treatment":"","unusual":"Patient developed ARDS and required ICU admission","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"","follow_up_period":null,"relapse":"","reminder":false,"when_reminder":"1 week","additional_info":"","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[7230,8342,8783,10776]},{"id":5781,"regimens":[{"id":10735,"duration":{"id":4791,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8783,"name":"Lopinavir-Ritonavir","url":"cure-api2.ncats.io/v1/drugs/8783","rxNorm_id":null,"notes":null},"use_drug":[{"id":6854,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":10735},{"id":6855,"answer":"In a novel combination with another drug","answer_other":"","regimen":10735}],"created":"2020-09-04T13:52:00.660872Z","updated":"2020-09-04T14:00:53.186683Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":5781},{"id":10736,"duration":{"id":4792,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":6856,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":10736},{"id":6857,"answer":"In a novel combination with another drug","answer_other":"","regimen":10736}],"created":"2020-09-04T13:52:00.668929Z","updated":"2020-09-04T14:00:53.193653Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":5781},{"id":10737,"duration":{"id":4793,"approximate_duration":null,"dates_unknown":false},"drug":{"id":7230,"name":"Dexamethasone","url":"cure-api2.ncats.io/v1/drugs/7230","rxNorm_id":null,"notes":null},"use_drug":[{"id":6858,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":10737},{"id":6859,"answer":"In a novel combination with another drug","answer_other":"","regimen":10737}],"created":"2020-09-04T13:52:00.675620Z","updated":"2020-09-04T14:00:53.200633Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":5781},{"id":10738,"duration":{"id":4794,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":6860,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":10738},{"id":6861,"answer":"In a novel combination with another drug","answer_other":"","regimen":10738}],"created":"2020-09-04T13:52:00.682401Z","updated":"2020-09-04T14:00:53.206847Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":5781}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":7535,"answer":"Clinical assessment","answer_other":"","report":5781},{"id":7536,"answer":"Imaging","answer_other":"","report":5781}],"how_diagnosis":[{"id":12798,"answer":"Clinical assessment","answer_other":"","report":5781},{"id":12799,"answer":"Imaging","answer_other":"","report":5781},{"id":12800,"answer":"PCR","answer_other":"","report":5781}],"author_username":"Parvesh Paul","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"Christian Medical College, Ludhiana, Punjab, India.","author_country":"India","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":3688,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":5781},{"id":3689,"answer":"Co-Infection or Complex Co-morbidities","answer_other":"","report":5781}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[{"id":114,"answer":"White","answer_other":""}],"created":"2020-09-04T13:50:54.371373Z","updated":"2020-09-04T14:00:53.177501Z","title":"A single center observational study ofÂ the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia. Case 5","status":"Approved","anonymous":false,"published":true,"pubmed_id":32354634,"doi":"10.1016/j.kint.2020.04.002","article_url":"https://www.ncbi.nlm.nih.gov/pubmed/?term=32354634","pub_year":2020,"published_authors":"Alberici F\r\nDelbarba E\r\nManenti C\r\nEconimo L\r\nValerio F\r\nPola A\r\nMaffei C\r\nPossenti S\r\nZambetti N\r\nMoscato M\r\nVenturini M\r\nAffatato S\r\nGaggiotti M\r\nBossini N\r\nScolari F","article_author_email":"Author email could not be found.","journal":"Kidney international","abstract":"The outcome of SARS-CoV2 infection in patients who have received a kidney allograft and are being treated with immunosuppression is unclear. We describe 20 kidney transplant recipients (median age 59 years [inter quartile range 51-64 years], median age of transplant 13 years [9-20 years], baseline eGFR 36.5 [23-47.5]) with SARS-CoV2 induced pneumonia. At admission, all had immunosuppression withdrawn and were started on methylprednisolone 16 mg/day, all but one was commenced on antiviral therapy and hydroxychloroquine with doses adjusted for kidney function. At baseline, all patients presented fever but only one complained of difficulty in breathing. Half of patients showed chest radiographic evidence of bilateral infiltrates while the other half showed unilateral changes or no infiltrates. During a median follow-up of seven days, 87% experienced a radiological progression and among those 73% required escalation of oxygen therapy. Six patients developed acute kidney injury with one requiring hemodialysis. Six of 12 patients were treated with tocilizumab, a humanized monoclonal antibody to the IL-6 receptor. Overall, five kidney transplant recipients died after a median period of 15 days [15-19] from symptom onset. These preliminary findings describe a rapid clinical deterioration associated with chest radiographic deterioration and escalating oxygen requirement in renal transplant recipients with SARS-Cov2 pneumonia. Thus, in this limited cohort of long-term kidney transplant patients, SARS-CoV-2 induced pneumonia is characterized by high risk of progression and significant mortality.","article_type":"Original","study_type":"Case Report","number_of_patients":20,"article_patient_number":"","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"No","age":"51-60 years","sex":"Male","ethnicity":"Not Hispanic/Latino","country_contracted":"Italy","country_treated":"Italy","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":true,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":true,"immunosuppressant_drugs":true,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"HCV Infection, Post renal transplant in 1997","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Respiratory tract infection","severity":"ICU/Critical Care","prev_treatment":"","unusual":"Patient was on immune-suppressants","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"The patient required NIV support","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[7230,8342,8783,10776]},{"id":5785,"regimens":[{"id":10748,"duration":{"id":4804,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8783,"name":"Lopinavir-Ritonavir","url":"cure-api2.ncats.io/v1/drugs/8783","rxNorm_id":null,"notes":null},"use_drug":[{"id":6880,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":10748},{"id":6881,"answer":"In a novel combination with another drug","answer_other":"","regimen":10748}],"created":"2020-09-04T16:05:02.206416Z","updated":"2020-09-08T19:40:05.470860Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":5785},{"id":10749,"duration":{"id":4805,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":6882,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":10749},{"id":6883,"answer":"In a novel combination with another drug","answer_other":"","regimen":10749}],"created":"2020-09-04T16:05:02.215891Z","updated":"2020-09-08T19:40:05.477747Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":5785},{"id":10751,"duration":{"id":4807,"approximate_duration":null,"dates_unknown":false},"drug":{"id":7230,"name":"Dexamethasone","url":"cure-api2.ncats.io/v1/drugs/7230","rxNorm_id":null,"notes":null},"use_drug":[{"id":6884,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":10751},{"id":6885,"answer":"In a novel combination with another drug","answer_other":"","regimen":10751}],"created":"2020-09-04T16:08:42.189615Z","updated":"2020-09-08T19:40:05.483956Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":5785},{"id":10752,"duration":{"id":4808,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":6886,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":10752},{"id":6887,"answer":"In a novel combination with another drug","answer_other":"","regimen":10752}],"created":"2020-09-04T16:08:42.198200Z","updated":"2020-09-08T19:40:05.490071Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":5785}],"site_of_infection":[],"specific_site":[],"how_outcome":[],"how_diagnosis":[{"id":12810,"answer":"Clinical assessment","answer_other":"","report":5785},{"id":12811,"answer":"Imaging","answer_other":"","report":5785},{"id":12812,"answer":"PCR","answer_other":"","report":5785}],"author_username":"Parvesh Paul","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"Christian Medical College, Ludhiana, Punjab, India.","author_country":"India","outcome_computed":"Deteriorated","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":3696,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":5785},{"id":3697,"answer":"Co-Infection or Complex Co-morbidities","answer_other":"","report":5785}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[{"id":118,"answer":"White","answer_other":""}],"created":"2020-09-04T16:00:02.500161Z","updated":"2020-09-08T19:40:05.404192Z","title":"A single center observational study ofÂ the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia. Case 12","status":"Approved","anonymous":false,"published":true,"pubmed_id":32354634,"doi":"10.1016/j.kint.2020.04.002","article_url":"https://www.ncbi.nlm.nih.gov/pubmed/?term=32354634","pub_year":2020,"published_authors":"Alberici F\r\nDelbarba E\r\nManenti C\r\nEconimo L\r\nValerio F\r\nPola A\r\nMaffei C\r\nPossenti S\r\nZambetti N\r\nMoscato M\r\nVenturini M\r\nAffatato S\r\nGaggiotti M\r\nBossini N\r\nScolari F","article_author_email":"Author email could not be found.","journal":"Kidney international","abstract":"The outcome of SARS-CoV2 infection in patients who have received a kidney allograft and are being treated with immunosuppression is unclear. We describe 20 kidney transplant recipients (median age 59 years [inter quartile range 51-64 years], median age of transplant 13 years [9-20 years], baseline eGFR 36.5 [23-47.5]) with SARS-CoV2 induced pneumonia. At admission, all had immunosuppression withdrawn and were started on methylprednisolone 16 mg/day, all but one was commenced on antiviral therapy and hydroxychloroquine with doses adjusted for kidney function. At baseline, all patients presented fever but only one complained of difficulty in breathing. Half of patients showed chest radiographic evidence of bilateral infiltrates while the other half showed unilateral changes or no infiltrates. During a median follow-up of seven days, 87% experienced a radiological progression and among those 73% required escalation of oxygen therapy. Six patients developed acute kidney injury with one requiring hemodialysis. Six of 12 patients were treated with tocilizumab, a humanized monoclonal antibody to the IL-6 receptor. Overall, five kidney transplant recipients died after a median period of 15 days [15-19] from symptom onset. These preliminary findings describe a rapid clinical deterioration associated with chest radiographic deterioration and escalating oxygen requirement in renal transplant recipients with SARS-Cov2 pneumonia. Thus, in this limited cohort of long-term kidney transplant patients, SARS-CoV-2 induced pneumonia is characterized by high risk of progression and significant mortality.","article_type":"Original","study_type":"Case Report","number_of_patients":20,"article_patient_number":"","full_text_available":true,"outcome":"Patient died","surgery":"No","age":"61-70 years","sex":"Male","ethnicity":"Not Hispanic/Latino","country_contracted":"Italy","country_treated":"Italy","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":true,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":true,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"Post renal transplant in 2004","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Respiratory tract infection","severity":null,"prev_treatment":"","unusual":"Patient required NIV and had also developed ARDS","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"","follow_up_period":null,"relapse":"","reminder":false,"when_reminder":"1 week","additional_info":"","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[7230,8342,8783,10776]},{"id":5792,"regimens":[{"id":10764,"duration":{"id":4820,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":6907,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":10764}],"created":"2020-09-04T18:47:22.767454Z","updated":"2020-09-27T00:28:53.128119Z","dose":"8 mg/kg","frequency":"One pulse","route":"IV","severity":"ICU/Critical Care","severity_detail":"Non-invasive intubation required along with red cell transfusion","comments":null,"report":5792}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":7546,"answer":"Clinical assessment","answer_other":"","report":5792},{"id":7547,"answer":"Imaging","answer_other":"","report":5792}],"how_diagnosis":[{"id":12823,"answer":"Clinical assessment","answer_other":"","report":5792},{"id":12824,"answer":"Imaging","answer_other":"","report":5792},{"id":12825,"answer":"Pathology","answer_other":"","report":5792}],"author_username":"Shira Strongin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":3702,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":5792},{"id":3703,"answer":"Co-Infection or Complex Co-morbidities","answer_other":"","report":5792}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-09-04T18:46:34.586363Z","updated":"2020-09-27T00:28:53.120186Z","title":"Dramatic improvement after tocilizumab of severe COVID-19 in a child with sickle cell disease and acute chest syndrome.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32358817,"doi":"10.1002/ajh.25855","article_url":"https://www.ncbi.nlm.nih.gov/pubmed/?term=32358817","pub_year":2020,"published_authors":"OdiÃ¨vre MH\r\nde Marcellus C\r\nDucou Le Pointe H\r\nAllali S\r\nRomain AS\r\nYoun J\r\nTaytard J\r\nNathan N\r\nCorvol H","article_author_email":"Author email could not be found.","journal":"American journal of hematology","abstract":"This 16âyearâold girl has a severe form of homozygous SCD with bilateral ischemic retinopathy. Given the recurrence of vasoâocclusive crises and abnormal transcranial doppler evaluations, she was treated with exchange transfusions from 5 to 11âyears old, switched thereafter for hydroxyurea (22âmg/kg/day), with a favorable clinical outcome on vasoâocclusive events.","article_type":"Original","study_type":"Case Report","number_of_patients":1,"article_patient_number":"","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"No","age":"11-15 years","sex":"Female","ethnicity":"Not Hispanic/Latino","country_contracted":"France","country_treated":"France","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":true,"other_comorbid":"Sickle Cell Disease","pregnant":false,"unknown":false,"site_of_disease":"Chest, blood, lungs","clinical_syndrome":"Acute Chest Syndrome, thrombosis","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"\"The patient improved rapidly after TCZ treatment. Nonâinvasive ventilation was stopped 4âdays after TCZ, with no oxygen requirement thereafter, allowing the discharge from ICU.\"","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[10776]},{"id":5807,"regimens":[{"id":10807,"duration":{"id":4864,"approximate_duration":"5 days (Days 2 - 6)","dates_unknown":true},"drug":{"id":9077,"name":"Methylprednisolone","url":"cure-api2.ncats.io/v1/drugs/9077","rxNorm_id":null,"notes":null},"use_drug":[{"id":6981,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":10807},{"id":6982,"answer":"In a novel combination with another drug","answer_other":"","regimen":10807}],"created":"2020-09-07T18:47:18.278221Z","updated":"2020-09-07T19:17:50.417289Z","dose":"40 mg","frequency":"OD","route":"IV","severity":"Inpatient","severity_detail":"","comments":null,"report":5807},{"id":10808,"duration":{"id":4865,"approximate_duration":"3 days","dates_unknown":true},"drug":{"id":9197,"name":"Moxifloxacin","url":"cure-api2.ncats.io/v1/drugs/9197","rxNorm_id":null,"notes":null},"use_drug":[{"id":6983,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":10808},{"id":6984,"answer":"In a novel combination with another drug","answer_other":"","regimen":10808}],"created":"2020-09-07T18:47:18.286616Z","updated":"2020-09-07T19:17:50.424456Z","dose":"400 mg","frequency":"OD","route":"IV","severity":"Inpatient","severity_detail":"","comments":null,"report":5807},{"id":10809,"duration":{"id":4866,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10942,"name":"Umifenovir","url":"cure-api2.ncats.io/v1/drugs/10942","rxNorm_id":null,"notes":null},"use_drug":[{"id":6985,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":10809},{"id":6986,"answer":"In a novel combination with another drug","answer_other":"","regimen":10809}],"created":"2020-09-07T18:47:18.293323Z","updated":"2020-09-07T19:17:50.430752Z","dose":"200 mg","frequency":"TDS","route":"PO","severity":"Inpatient","severity_detail":"","comments":null,"report":5807},{"id":10810,"duration":{"id":4867,"approximate_duration":"Once","dates_unknown":true},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":6987,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":10810},{"id":6988,"answer":"In a novel combination with another drug","answer_other":"","regimen":10810}],"created":"2020-09-07T18:47:18.300334Z","updated":"2020-09-07T19:17:50.437916Z","dose":"8mg/Kg","frequency":"Once","route":"IV","severity":"Inpatient","severity_detail":"","comments":null,"report":5807}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":7572,"answer":"Clinical assessment","answer_other":"","report":5807},{"id":7573,"answer":"Imaging","answer_other":"","report":5807}],"how_diagnosis":[{"id":12866,"answer":"Clinical assessment","answer_other":"","report":5807},{"id":12867,"answer":"Imaging","answer_other":"","report":5807},{"id":12868,"answer":"PCR","answer_other":"","report":5807}],"author_username":"Reema Charles","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":3720,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":5807}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[{"id":132,"answer":"Asian","answer_other":""}],"created":"2020-09-07T18:44:14.704759Z","updated":"2020-09-07T19:17:50.408598Z","title":"First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32243501,"doi":"10.1182/bloodadvances.2020001907","article_url":"https://www.ncbi.nlm.nih.gov/pubmed/?term=32243501","pub_year":2020,"published_authors":"Zhang X\r\nSong K\r\nTong F\r\nFei M\r\nGuo H\r\nLu Z\r\nWang J\r\nZheng C","article_author_email":"Author email could not be found.","journal":"Blood advances","abstract":"The patient had a history of symptomatic MM (immunoglobulin AÎ» [IgAÎ»], IgIIIA), which was diagnosed on 12 May 2015. At that time, a bone marrow aspirate showed 17.1% clonal plasma cells, and multiple osteolytic bone lesions obvious in frontal and temporal bone on radiography. His kidney biopsy confirmed amyloidosis; laboratory testing also showed proteinuria. The patient received 2 cycles of induction chemotherapy consisting of bortezomib, thalidomide, and dexamethasone, and his symptoms completely disappeared. After that, he refused bortezomib-based treatment and only received thalidomide for maintenance.","article_type":"Original","study_type":"Case Report","number_of_patients":1,"article_patient_number":"","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"No","age":"51-60 years","sex":"Male","ethnicity":"Not Hispanic/Latino","country_contracted":"China","country_treated":"China","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":true,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"Symptomatic MM (immunoglobulin AÎ» [IgAÎ»], IgIIIA). Kidney biopsy - Amyloidosis.","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Respiratory tract infection","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"For MM, the patient received 2 cycles of induction chemotherapy consisting of bortezomib, thalidomide, and dexamethasone, and his symptoms completely disappeared. After that, he refused bortezomib-based treatment and only received thalidomide for maintenance.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[9077,9197,10776,10942]},{"id":5833,"regimens":[{"id":10877,"duration":{"id":4935,"approximate_duration":"For 2 doses","dates_unknown":true},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":7100,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":10877}],"created":"2020-09-09T14:35:53.087674Z","updated":"2020-09-27T01:51:07.377801Z","dose":"8mg/kg","frequency":"Q12H","route":"IV","severity":"ICU/Critical Care","severity_detail":"Patient was on assisted ventilation when treatment was started.","comments":null,"report":5833}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":7606,"answer":"Clinical assessment","answer_other":"","report":5833},{"id":7607,"answer":"Imaging","answer_other":"","report":5833}],"how_diagnosis":[{"id":12943,"answer":"Clinical assessment","answer_other":"","report":5833},{"id":12944,"answer":"Imaging","answer_other":"","report":5833},{"id":12945,"answer":"PCR","answer_other":"","report":5833},{"id":12946,"answer":"Serology","answer_other":"","report":5833}],"author_username":"Kate Borkowski","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Nurse","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":3753,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":5833}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[{"id":154,"answer":"White","answer_other":""}],"created":"2020-09-09T14:34:22.406205Z","updated":"2020-09-27T01:51:07.369747Z","title":"Favorable changes of CT findings in a patient with COVID-19 pneumonia after treatment with tocilizumab.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32278585,"doi":"10.1016/j.diii.2020.03.010","article_url":"https://www.ncbi.nlm.nih.gov/pubmed/?term=32278585","pub_year":2020,"published_authors":"Cellina M\r\nOrsi M\r\nBombaci F\r\nSala M\r\nMarino P\r\nOliva G","article_author_email":"Author email could not be found.","journal":"Diagnostic and interventional imaging","abstract":"Abstract could not be found.","article_type":"Original","study_type":"Case Report","number_of_patients":1,"article_patient_number":"","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"61-70 years","sex":"Male","ethnicity":"Not Hispanic/Latino","country_contracted":"Italy","country_treated":"Italy","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Pleural effusions, mediastinal lymphadenopathy","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"After a period of follow-up","follow_up_period":"5 days after treatment was completed","relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[10776]},{"id":5836,"regimens":[{"id":10885,"duration":{"id":4943,"approximate_duration":"One Dose","dates_unknown":true},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":7111,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":10885},{"id":8683,"answer":"In a novel combination with another drug","answer_other":"","regimen":10885}],"created":"2020-09-09T16:09:14.707404Z","updated":"2020-10-01T05:42:22.870725Z","dose":"8mg/kg","frequency":"Once","route":"IV","severity":"Inpatient","severity_detail":"Needed supplemental oxygen through a Venturi mask","comments":null,"report":5836},{"id":11732,"duration":null,"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":8684,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11732},{"id":8685,"answer":"In a novel combination with another drug","answer_other":"","regimen":11732}],"created":"2020-10-01T05:42:22.866136Z","updated":"2020-10-01T05:42:22.871599Z","dose":"200 mg","frequency":"TDS","route":"PO","severity":null,"severity_detail":null,"comments":null,"report":5836}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":7613,"answer":"Clinical assessment","answer_other":"","report":5836}],"how_diagnosis":[{"id":12954,"answer":"Clinical assessment","answer_other":"","report":5836},{"id":12955,"answer":"PCR","answer_other":"","report":5836},{"id":12956,"answer":"Serology","answer_other":"","report":5836}],"author_username":"Kate Borkowski","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Nurse","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":3758,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":5836},{"id":3759,"answer":"Co-Infection or Complex Co-morbidities","answer_other":"","report":5836}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-09-09T16:08:37.559973Z","updated":"2020-10-01T05:42:22.833112Z","title":"Rapid and severe Covid-19 pneumonia with severe acute chest syndrome in a sickle cell patient successfully treated with tocilizumab.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32282956,"doi":"10.1002/ajh.25833","article_url":"https://www.ncbi.nlm.nih.gov/pubmed/?term=32282956","pub_year":2020,"published_authors":"De Luna G\r\nHabibi A\r\nDeux JF\r\nColard M\r\nPham Hung d'Alexandry d'Orengiani AL\r\nSchlemmer F\r\nJoher N\r\nKassasseya C\r\nPawlotsky JM\r\nOurghanlian C\r\nMichel M\r\nMekontso-Dessap A\r\nBartolucci P","article_author_email":"Author email could not be found.","journal":"American journal of hematology","abstract":"Abstract could not be found.","article_type":"Original","study_type":"Case Report","number_of_patients":1,"article_patient_number":"","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"No","age":"41-50 years","sex":"Male","ethnicity":"Not Hispanic/Latino","country_contracted":"France","country_treated":"France","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"Homozygous sickle cell disease","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Pneumonia, Acute Chest Syndrome","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"Antibiotic therapy was immediately started with amoxicillinâclavulanic acid and the patient received supplemental oxygen through a nasal cannula at a rate of 3 L/min.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[8342,10776]},{"id":5854,"regimens":[{"id":10922,"duration":{"id":4980,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":7170,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":10922},{"id":7171,"answer":"In a novel combination with another drug","answer_other":"","regimen":10922}],"created":"2020-09-10T01:45:54.943235Z","updated":"2020-09-10T01:54:54.251478Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":5854},{"id":10923,"duration":{"id":4981,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6772,"name":"Chloroquine","url":"cure-api2.ncats.io/v1/drugs/6772","rxNorm_id":null,"notes":null},"use_drug":[{"id":7172,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":10923},{"id":7173,"answer":"In a novel combination with another drug","answer_other":"","regimen":10923}],"created":"2020-09-10T01:45:54.952138Z","updated":"2020-09-10T01:54:54.258564Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":5854}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":7649,"answer":"Clinical assessment","answer_other":"","report":5854}],"how_diagnosis":[{"id":13004,"answer":"Clinical assessment","answer_other":"","report":5854},{"id":13005,"answer":"Imaging","answer_other":"","report":5854},{"id":13006,"answer":"PCR","answer_other":"","report":5854},{"id":13007,"answer":"Pathology","answer_other":"","report":5854}],"author_username":"Parvesh Paul","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"Christian Medical College, Ludhiana, Punjab, India.","author_country":"India","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":3780,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":5854},{"id":3781,"answer":"Co-Infection or Complex Co-morbidities","answer_other":"","report":5854}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[{"id":166,"answer":"White","answer_other":""}],"created":"2020-09-10T01:44:36.302115Z","updated":"2020-09-10T01:54:54.241793Z","title":"Early histologic findings of pulmonary SARS-CoV-2 infection detected in a surgical specimen.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32356025,"doi":"10.1007/s00428-020-02829-1","article_url":"https://www.ncbi.nlm.nih.gov/pubmed/?term=32356025","pub_year":2020,"published_authors":"Pernazza A\r\nMancini M\r\nRullo E\r\nBassi M\r\nDe Giacomo T\r\nRocca CD\r\nd'Amati G","article_author_email":"Author email could not be found.","journal":"Virchows Archiv : an international journal of pathology","abstract":"Despite the current pandemic season, reports on pathologic features of coronavirus disease 19 (Covid-19) are exceedingly rare at the present time. Here we describe the pathologic features of early lung involvement by Covid-19 in a surgical sample resected for carcinoma from a patient who developed SARS-CoV-2 infection soon after surgery. The main histologic findings observed were pneumocyte damage, alveolar hemorrhages with clustering of macrophages, prominent and diffuse neutrophilic margination within septal vessels, and interstitial inflammatory infiltrates, mainly represented by CD8+ T lymphocytes. These features are similar to those previously described in SARS-CoV-2 infection. Subtle histologic changes suggestive pulmonary involvement by Covid-19 may be accidentally encountered in routine pathology practice, especially when extensive sampling is performed for histology. These findings should be carefully interpreted in light of the clinical context of the patient and could prompt a pharyngeal swab PCR test to rule out the possibility of SARS-CoV-2 infection in asymptomatic patients.","article_type":"Original","study_type":"Case Report","number_of_patients":1,"article_patient_number":"","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"No","age":"61-70 years","sex":"Male","ethnicity":"Not Hispanic/Latino","country_contracted":"Italy","country_treated":"Italy","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"Lung adenocarcinoma, MALT lymphoma diagnosed 6 months before, with complete remission after therapy.","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Respiratory tract infection","severity":null,"prev_treatment":"","unusual":"According to pre-operatory imaging, obtained 3 weeks before surgery, the lesion was localized in the right inferior lobe, measured 2 cm and showed a solid appearance. There were no ground glass opacities. At admission, the patient was in good general condition, afebrile. A thoracoscopic lobectomy with lymph node dissection (stations 2, 4, 7, 8, 9, and 10) was performed, without intraoperative complications. After surgery, the patient developed progressive lymphopenia (with values ranging between 920 and 340 lymphocytes/Î¼L from the first to the fifth post-operative day) and, on the scheduled date for discharge, had an episode of fever (38 Â°C) in the absence of respiratory symptoms. Thus, his antibiotic therapy was changed, with no improvement. A pharyngeal swab PCR test was performed, which confirmed the suspicion of SARS-CoV-2 infection. The patient was immediately transferred to the isolation ward where he developed cough, dyspnea, fatigue, and high fever (38â39 Â°C). SpO2 was stable between 96 and 98%. Both white blood cells (2570/Î¼L) and lymphocytes counts were low (280/Î¼L). A chest CT scan showed post-resection changes and bilateral, peripheral, and ill-defined ground-glass opacities, mainly involving the lower lobe, consistent with Covid-19 pneumonia.","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"While the patient was still on treatment","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"Since oxygen saturation had dropped to 35%, he received supplemental oxygen through a CPAP mask. On a second CT scan, performed 1 week later, the ground-glass opacities were enlarged, with areas of consolidation. He received a therapy based on antibiotics (meropenem and bactrim), antiviral drugs (acyclovir and darunavir), and on two recently approved experimental drugs for SARS-CoV-2 infection: tocilizumab (commonly used for the therapy of rheumatoid arthritis) and chloroquine hydrate (a common antimalarial drug), with an improvement of his conditions and clinical remission in the following weeks.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6772,10776]},{"id":5860,"regimens":[{"id":10936,"duration":{"id":4994,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":7197,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":10936},{"id":7198,"answer":"In a novel combination with another drug","answer_other":"","regimen":10936}],"created":"2020-09-10T02:29:32.298300Z","updated":"2020-09-10T02:39:53.711477Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":5860},{"id":10937,"duration":{"id":4995,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":7199,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":10937},{"id":7200,"answer":"In a novel combination with another drug","answer_other":"","regimen":10937}],"created":"2020-09-10T02:29:32.306177Z","updated":"2020-09-10T02:39:53.719401Z","dose":"8mg/kg","frequency":"2 doses","route":"IV","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":5860}],"site_of_infection":[],"specific_site":[],"how_outcome":[],"how_diagnosis":[{"id":13023,"answer":"Imaging","answer_other":"","report":5860},{"id":13024,"answer":"Clinical assessment","answer_other":"","report":5860},{"id":13025,"answer":"PCR","answer_other":"","report":5860}],"author_username":"Parvesh Paul","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"Christian Medical College, Ludhiana, Punjab, India.","author_country":"India","outcome_computed":"Deteriorated","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":3787,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":5860},{"id":3788,"answer":"Co-Infection or Complex Co-morbidities","answer_other":"","report":5860}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-09-10T02:27:35.853731Z","updated":"2020-09-10T02:39:53.702402Z","title":"The Imperfect Cytokine Storm: Severe COVID-19 With ARDS in a Patient on DurableÂ LVADÂ Support.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32292915,"doi":"10.1016/j.jaccas.2020.04.001","article_url":"https://www.ncbi.nlm.nih.gov/pubmed/?term=32292915","pub_year":2020,"published_authors":"Chau VQ\r\nOliveros E\r\nMahmood K\r\nSinghvi A\r\nLala A\r\nMoss N\r\nGidwani U\r\nMancini DM\r\nPinney SP\r\nParikh A","article_author_email":"Author email could not be found.","journal":"JACC. Case reports","abstract":"As health systems worldwide grapple with the coronavirus disease-2019 (COVID-19) pandemic, patients with durable LVAD support represent a unique population at risk for the disease. This paper outlines the case of such a patient who developed COVID-19 complicated by a \"cytokine storm\" with severe acute respiratory distress syndrome and myocardial injury and describes the challenges that arose during management.","article_type":"Original","study_type":"Case Report","number_of_patients":1,"article_patient_number":"","full_text_available":true,"outcome":"Patient died","surgery":"No","age":"61-70 years","sex":"Male","ethnicity":"Not Hispanic/Latino","country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"Ischemic cardiomyopathy, stage 3 chronic kidney disease, and obesity, status post LVAD in 2016","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Respiratory tract infection","severity":null,"prev_treatment":"","unusual":"The patient was a 70-year-old male with a destination therapy HeartMate 3 (Abbott Laboratory, Lake Bluff, Illinois) left ventricular assist device (LVAD) implanted in 2016 who developed fever, flank pain, and hematuria 3 days after attending a party. He was evaluated for nephrolithiasis at a local emergency department by abdomen and pelvis computed tomography imaging, which incidentally found possible atypical or viral pneumonia. He was tested for coronavirus disease-2019 (COVID-19), but he left against medical advice. In the ensuing days, he continued to have fever, new onset myalgia, diarrhea, and dyspnea. He returned to the emergency department and was in acute hypoxic respiratory failure requiring supplemental oxygen to maintain peripheral oxygen saturation â¥94%.","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"","follow_up_period":null,"relapse":"","reminder":false,"when_reminder":"1 week","additional_info":"The patient was started on hydroxychloroquine therapy for COVID-19 pneumonia while his QTc complex was monitored. He experienced severe acute respiratory distress syndrome (ARDS) necessitating endotracheal intubation and ventilator support with low tidal volume, according to the ARDSNet protocol. Despite aggressive supportive care, a âcytokine stormâ ensued consisting of multiple organ dysfunction syndrome (MODS) with evidence of: 1) elevated inflammatory markers; 2) severe ARDS; 3) myocardial injury; and 4) vasodilatory shock requiring vasopressors. Two successive doses of intravenous tocilizumab (interleukin-6 receptor antagonist) at 8 mg/kg (maximum dose of 800 mg) were administered. Although clinical improvement was observed after the initial tocilizumab therapy, the patient developed worsening shock, refractory hypoxemia, and pulseless electrical activity (PEA) arrest with successful return of spontaneous circulation. Although this patientâs inflammatory profile improved after tocilizumab therapy, he remained in critical condition on maximal ventilatory support and on vasopressors for shock. Given his multiple complications, early discussion of palliative care was initiated. His MODS continued to worsen, and methylene blue was administered without improvement in hemodynamics. The patient ultimately expired on hospital day 8.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[8342,10776]},{"id":5866,"regimens":[{"id":10952,"duration":{"id":5010,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8783,"name":"Lopinavir-Ritonavir","url":"cure-api2.ncats.io/v1/drugs/8783","rxNorm_id":null,"notes":null},"use_drug":[{"id":7229,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":10952},{"id":7230,"answer":"In a novel combination with another drug","answer_other":"","regimen":10952}],"created":"2020-09-10T15:23:15.225417Z","updated":"2020-09-10T15:29:58.632222Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":5866},{"id":10953,"duration":{"id":5011,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":7231,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":10953},{"id":7232,"answer":"In a novel combination with another drug","answer_other":"","regimen":10953}],"created":"2020-09-10T15:23:15.233478Z","updated":"2020-09-10T15:29:58.639635Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":5866},{"id":10954,"duration":{"id":5012,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":7233,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":10954},{"id":7234,"answer":"In a novel combination with another drug","answer_other":"","regimen":10954}],"created":"2020-09-10T15:23:15.240313Z","updated":"2020-09-10T15:29:58.646977Z","dose":"","frequency":"2 doses 12hrs apart","route":"IV","severity":"Inpatient","severity_detail":"","comments":null,"report":5866}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":7678,"answer":"Clinical assessment","answer_other":"","report":5866},{"id":7679,"answer":"PCR","answer_other":"","report":5866}],"how_diagnosis":[{"id":13040,"answer":"Clinical assessment","answer_other":"","report":5866},{"id":13041,"answer":"Imaging","answer_other":"","report":5866},{"id":13042,"answer":"PCR","answer_other":"","report":5866}],"author_username":"Parvesh Paul","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"Christian Medical College, Ludhiana, Punjab, India.","author_country":"India","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":3795,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":5866}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[{"id":176,"answer":"White","answer_other":""}],"created":"2020-09-10T15:21:50.198806Z","updated":"2020-09-10T15:29:58.623368Z","title":"Off-label use of tocilizumab in patients with SARS-CoV-2 infection. Case 1","status":"Approved","anonymous":false,"published":true,"pubmed_id":32297987,"doi":"10.1002/jmv.25897","article_url":"https://www.ncbi.nlm.nih.gov/pubmed/?term=32297987","pub_year":2020,"published_authors":"Di Giambenedetto S\r\nCiccullo A\r\nBorghetti A\r\nGambassi G\r\nLandi F\r\nVisconti E\r\nZileri Dal Verme L\r\nBernabei R\r\nTamburrini E\r\nCauda R\r\nGasbarrini A","article_author_email":"Author email could not be found.","journal":"Journal of medical virology","abstract":"The spread of the novelâCoronavirus infection worldwide represents a challenge for physicians. Particularly, no approved therapy has demonstrated to have an impact in treating patients who develop severe respiratory insufficiency so far. The use of humanized antiâhuman inteleukineâ6 receptor antibody tocilizumab seems a promising strategy for these patients.","article_type":"Original","study_type":"Case Report","number_of_patients":3,"article_patient_number":"","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"No","age":"71-80 years","sex":"Male","ethnicity":"Not Hispanic/Latino","country_contracted":"Italy","country_treated":"Italy","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":true,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Respiratory tract infection","severity":null,"prev_treatment":"","unusual":"After diagnosis he was started antiviral therapy (lopinavir/ritonavir plus  hydroxycholoroquine) the 6th of March. Fever continued and respiratory exchanges worsened (PaO2-to-Fio2 ratio: 129 the 14thof March). Repeat chest X-ray showed multiple enlarging  areas  of  consolidation. C-reactive  protein  (CRP)  at  that  time was  117  mg/L (normal value: <5 mL/min).","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"Two doses of tocilizumab 12 hours apart were administered, starting March 14th. Fever resolved after 3 days, together with improvement in PaO2-to-Fio2 ratio (210 the 21stof March). CRP was within normal range the 20thof March. Also, the 19th and 21st of March repeat nasopharyngeal swabs tested negative for SARS-CoV-2.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[8342,8783,10776]},{"id":5867,"regimens":[{"id":10955,"duration":{"id":5013,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":7235,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":10955}],"created":"2020-09-10T15:31:14.345007Z","updated":"2020-09-10T15:37:02.817114Z","dose":"","frequency":"2 doses 12 hrs apart","route":"IV","severity":"Inpatient","severity_detail":"","comments":null,"report":5867}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":7680,"answer":"Clinical assessment","answer_other":"","report":5867},{"id":7681,"answer":"PCR","answer_other":"","report":5867}],"how_diagnosis":[{"id":13043,"answer":"Clinical assessment","answer_other":"","report":5867},{"id":13044,"answer":"Imaging","answer_other":"","report":5867},{"id":13045,"answer":"PCR","answer_other":"","report":5867}],"author_username":"Parvesh Paul","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"Christian Medical College, Ludhiana, Punjab, India.","author_country":"India","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":3796,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":5867}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[{"id":177,"answer":"White","answer_other":""}],"created":"2020-09-10T15:30:28.180317Z","updated":"2020-09-10T15:37:02.808329Z","title":"Off-label use of tocilizumab in patients with SARS-CoV-2 infection. Case 2","status":"Approved","anonymous":false,"published":true,"pubmed_id":32297987,"doi":"10.1002/jmv.25897","article_url":"https://www.ncbi.nlm.nih.gov/pubmed/?term=32297987","pub_year":2020,"published_authors":"Di Giambenedetto S\r\nCiccullo A\r\nBorghetti A\r\nGambassi G\r\nLandi F\r\nVisconti E\r\nZileri Dal Verme L\r\nBernabei R\r\nTamburrini E\r\nCauda R\r\nGasbarrini A","article_author_email":"Author email could not be found.","journal":"Journal of medical virology","abstract":"The spread of the novelâCoronavirus infection worldwide represents a challenge for physicians. Particularly, no approved therapy has demonstrated to have an impact in treating patients who develop severe respiratory insufficiency so far. The use of humanized antiâhuman inteleukineâ6 receptor antibody tocilizumab seems a promising strategy for these patients.","article_type":"Original","study_type":"Case Report","number_of_patients":3,"article_patient_number":"","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"No","age":"41-50 years","sex":"Male","ethnicity":"Not Hispanic/Latino","country_contracted":"Italy","country_treated":"Italy","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Respiratory tract infection","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"45  years-old,  previously  healthy  male,  hospitalized  the  10thof  March because  of  fever,  worsening  dyspnoea  and  chest  pain.  Chest  X-ray  showed  reduced diaphany in the lower right lobe. After COVID-19-diagnosis antiviral therapy was started. Despite  initial  improvement  he  developed  dyspnoea  for  mild  efforts,  accompanied  by increase   in   C-reactive   protein (151   mg/L) and   appearance   of   bilateral   interstitial pneumonia at chest X-ray. Two doses of tocilizumab were prescribed, starting the 14thof March.  Clinical  condition  improved,  with  resolution  of  fever  after  48  hoursand  rapid reduction in CRP (13 mg/L the 18thof March).","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[10776]},{"id":5869,"regimens":[{"id":10959,"duration":{"id":5017,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":7236,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":10959}],"created":"2020-09-10T15:38:18.149800Z","updated":"2020-09-10T15:42:25.572905Z","dose":"","frequency":"3 doses","route":"IV","severity":"Inpatient","severity_detail":"","comments":null,"report":5869}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":7682,"answer":"Clinical assessment","answer_other":"","report":5869},{"id":7683,"answer":"PCR","answer_other":"","report":5869}],"how_diagnosis":[{"id":13048,"answer":"Clinical assessment","answer_other":"","report":5869},{"id":13049,"answer":"Imaging","answer_other":"","report":5869},{"id":13050,"answer":"PCR","answer_other":"","report":5869}],"author_username":"Parvesh Paul","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"Christian Medical College, Ludhiana, Punjab, India.","author_country":"India","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":3798,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":5869}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[{"id":179,"answer":"White","answer_other":""}],"created":"2020-09-10T15:38:00.881239Z","updated":"2020-09-10T15:42:25.564215Z","title":"Off-label use of tocilizumab in patients with SARS-CoV-2 infection. Case 3","status":"Approved","anonymous":false,"published":true,"pubmed_id":32297987,"doi":"10.1002/jmv.25897","article_url":"https://www.ncbi.nlm.nih.gov/pubmed/?term=32297987","pub_year":2020,"published_authors":"Di Giambenedetto S\r\nCiccullo A\r\nBorghetti A\r\nGambassi G\r\nLandi F\r\nVisconti E\r\nZileri Dal Verme L\r\nBernabei R\r\nTamburrini E\r\nCauda R\r\nGasbarrini A","article_author_email":"Author email could not be found.","journal":"Journal of medical virology","abstract":"The spread of the novelâCoronavirus infection worldwide represents a challenge for physicians. Particularly, no approved therapy has demonstrated to have an impact in treating patients who develop severe respiratory insufficiency so far. The use of humanized antiâhuman inteleukineâ6 receptor antibody tocilizumab seems a promising strategy for these patients.","article_type":"Original","study_type":"Case Report","number_of_patients":3,"article_patient_number":"","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"No","age":"51-60 years","sex":"Male","ethnicity":"Not Hispanic/Latino","country_contracted":"Italy","country_treated":"Italy","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":true,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Respiratory tract infection","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"53 years-old, hypertensive male, who came to first aid the 13thof March for   non-resolving   flu-like   symptoms.   His   chest-X   ray   showed   interstitial   bilateral pneumonia. CRP  at  first  aid  was  250  mg/L. After  diagnosis  antiviral  therapy  was immediately started. After 48 hours respiratory symptoms worsened and  before the  new chest-X-ray  (which  confirmed  the  bilateral  interstitial  involvement)  tocilizumab  was administered in three doses, starting March 15th, with progressive resolution of dyspnoea (oxygen saturation was 98% with FiO2 0.31 the 21stof March). After 48 hours CRP was 92 mg/L and subsequent control (the 25th March) was within normal range.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[10776]},{"id":5886,"regimens":[{"id":10993,"duration":{"id":5051,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8373,"name":"Ibrutinib","url":"cure-api2.ncats.io/v1/drugs/8373","rxNorm_id":null,"notes":null},"use_drug":[{"id":7288,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":10993},{"id":7289,"answer":"In a novel combination with another drug","answer_other":"","regimen":10993}],"created":"2020-09-12T05:30:08.399293Z","updated":"2020-09-12T05:44:56.047699Z","dose":"420 mg","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":5886},{"id":10994,"duration":{"id":5052,"approximate_duration":"5 days","dates_unknown":true},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":7290,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":10994},{"id":7291,"answer":"In a novel combination with another drug","answer_other":"","regimen":10994}],"created":"2020-09-12T05:30:08.407027Z","updated":"2020-09-12T05:44:56.054723Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":5886},{"id":10995,"duration":{"id":5053,"approximate_duration":"3 days","dates_unknown":true},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":7292,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":10995},{"id":7293,"answer":"In a novel combination with another drug","answer_other":"","regimen":10995}],"created":"2020-09-12T05:30:08.413333Z","updated":"2020-09-12T05:44:56.060483Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":5886},{"id":10996,"duration":{"id":5054,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":7294,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":10996},{"id":7295,"answer":"In a novel combination with another drug","answer_other":"","regimen":10996}],"created":"2020-09-12T05:30:08.419673Z","updated":"2020-09-12T05:44:56.066261Z","dose":"400 mg","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":5886},{"id":10997,"duration":{"id":5055,"approximate_duration":"5 days","dates_unknown":true},"drug":{"id":8412,"name":"Immunoglobulins, Intravenous","url":"cure-api2.ncats.io/v1/drugs/8412","rxNorm_id":null,"notes":null},"use_drug":[{"id":7296,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":10997},{"id":7297,"answer":"In a novel combination with another drug","answer_other":"","regimen":10997}],"created":"2020-09-12T05:37:51.904451Z","updated":"2020-09-12T05:44:56.071924Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":5886}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":7702,"answer":"Clinical assessment","answer_other":"","report":5886}],"how_diagnosis":[{"id":13095,"answer":"Clinical assessment","answer_other":"","report":5886},{"id":13096,"answer":"Imaging","answer_other":"","report":5886},{"id":13097,"answer":"PCR","answer_other":"","report":5886}],"author_username":"Reema Charles","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":3818,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":5886}],"adverse_event_outcome":[{"id":29,"answer":"Life-threatening","report":5886}],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"},{"id":550,"name":"Respiratory Tract Infections"}],"races":[{"id":190,"answer":"White","answer_other":""}],"created":"2020-09-12T05:28:37.435192Z","updated":"2020-09-12T05:44:56.039857Z","title":"The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. Case 6.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32302379,"doi":"10.1182/blood.2020006288","article_url":"https://pubmed.ncbi.nlm.nih.gov/32302379/","pub_year":2020,"published_authors":"Treon SP\r\nCastillo JJ\r\nSkarbnik AP\r\nSoumerai JD\r\nGhobrial IM\r\nGuerrera ML\r\nMeid K\r\nYang G","article_author_email":"Author email could not be found.","journal":"Blood","abstract":"The Bruton tyrosine kinase (BTK) inhibitor ibrutinib is used to treat indolent B-cell malignancies and chronic graft-versus-host disease (cGVHD). The potential for ibrutinib to abrogate pulmonary inflammatory cytokines, lung injury, and death was demonstrated in a highly relevant lethal flu animal model. Therefore, we sought to clarify the impact of ibrutinib in COVID-19 patients.","article_type":"Original","study_type":"Case Report","number_of_patients":6,"article_patient_number":"","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"51-60 years","sex":"Male","ethnicity":"Not Hispanic/Latino","country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":true,"other_comorbid":"Waldenstrom macroglobulinemia","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Respiratory tract infection","severity":"ICU/Critical Care","prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":true,"adverse_events":"Azithromycin - wide QRS complex tachyarrhythmia, which was then stopped after 3 days","when_outcome":"","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"Patient was on 140 mg/d of ibrutinib prior to hospitalization that was held upon admission; he experienced worsening hypoxia after ibrutinib was held and required mechanical ventilation, following which he was restarted on 420 mg/d of ibrutinib and showed rapid improvement in oxygenation.\r\n\r\nPatient also received mechanical ventilation.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6122,8342,8373,8412,10776]},{"id":5903,"regimens":[{"id":11035,"duration":{"id":5094,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":7355,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11035},{"id":7356,"answer":"In a novel combination with another drug","answer_other":"","regimen":11035}],"created":"2020-09-15T01:00:12.890671Z","updated":"2020-12-17T19:40:53.558531Z","dose":null,"frequency":"","route":"","severity":"Inpatient","severity_detail":null,"comments":null,"report":5903},{"id":11036,"duration":{"id":5095,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":7357,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11036},{"id":7358,"answer":"In a novel combination with another drug","answer_other":"","regimen":11036}],"created":"2020-09-15T01:00:12.898006Z","updated":"2020-12-17T19:40:53.536634Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":5903}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":7718,"answer":"Clinical assessment","answer_other":"","report":5903}],"how_diagnosis":[{"id":13135,"answer":"Clinical assessment","answer_other":"","report":5903},{"id":13136,"answer":"Imaging","answer_other":"","report":5903},{"id":13137,"answer":"PCR","answer_other":"","report":5903}],"author_username":"Parvesh Paul","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"Christian Medical College, Ludhiana, Punjab, India.","author_country":"India","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":3839,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":5903},{"id":3840,"answer":"Co-Infection or Complex Co-morbidities","answer_other":"","report":5903}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"},{"id":550,"name":"Respiratory Tract Infections"}],"races":[{"id":200,"answer":"White","answer_other":""}],"created":"2020-09-15T00:58:39.730713Z","updated":"2020-12-17T19:40:53.521431Z","title":"Case Report: The Importance of Novel Coronavirus Disease (COVID-19) and Coinfection with Other Respiratory Pathogens in the Current Pandemic.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32314699,"doi":"10.4269/ajtmh.20-0266","article_url":"https://pubmed.ncbi.nlm.nih.gov/32314699/","pub_year":2020,"published_authors":"Khaddour K\r\nSikora A\r\nTahir N\r\nNepomuceno D\r\nHuang T","article_author_email":"Author email could not be found.","journal":"The American journal of tropical medicine and hygiene","abstract":"The early shortage of novel coronavirus disease (COVID-19) tests in the United States led many hospitals to first screen for common respiratory pathogens, and only if this screen was negative to proceed with COVID-19 testing. We report a case of a 56-year-old woman with severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) coinfection with group A \r\nStreptococcus. A 56-year-old female presented to the hospital with complaints of fever, sore throat, dry cough, and myalgia for 2 weeks. Past medical history was significant for hypertension, treated with amlodipine and benazepril, and chronic back pain. She had no recent travel history or known ill contacts. Chest X-ray showed scattered patchy airspace opacities bilaterally.  The initial testing strategy resulted in delays in both diagnosis and implementation of appropriate precautions. Underlined is the importance of testing for both SARS-CoV-2 and other common respiratory pathogens during the current pandemic.","article_type":"Original","study_type":"Case Report","number_of_patients":1,"article_patient_number":"","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"51-60 years","sex":"Female","ethnicity":"Not Hispanic/Latino","country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":true,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"Amlodipine and benazepril","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Respiratory tract infection","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"Rapid Streptococcus A antigen testing was positive. She was treated with ceftriaxone and azithromycin.\r\nThe patient was started on hydroxychloroquine sulfate and tocilizumab on the second day of admission. On the fourth day of admission, the patient remained hypoxic without signs of multiorgan damage. She was started on extracorporeal membranous oxygenation (ECMO) for 1 week, and then later taken off ECMO in stable condition. Three weeks after admission, the patient was extubated and discharged to inpatient rehabilitation.","previously_treated":"","flagged":false,"other_coinfections":"Group A Streptococcus","disease":630,"drugs":[8342,10776]},{"id":5916,"regimens":[{"id":11064,"duration":{"id":5123,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8783,"name":"Lopinavir-Ritonavir","url":"cure-api2.ncats.io/v1/drugs/8783","rxNorm_id":null,"notes":null},"use_drug":[{"id":7401,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11064}],"created":"2020-09-15T17:57:33.720397Z","updated":"2020-09-15T18:16:43.166387Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":5916},{"id":11065,"duration":{"id":5124,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":7402,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11065},{"id":7403,"answer":"In a novel combination with another drug","answer_other":"","regimen":11065}],"created":"2020-09-15T17:57:33.727996Z","updated":"2020-09-15T18:16:43.172967Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":5916},{"id":11066,"duration":{"id":5125,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":7404,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11066},{"id":7405,"answer":"In a novel combination with another drug","answer_other":"","regimen":11066}],"created":"2020-09-15T17:57:33.734590Z","updated":"2020-09-15T18:16:43.179060Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":5916},{"id":11067,"duration":{"id":5126,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8314,"name":"Hydrocortisone","url":"cure-api2.ncats.io/v1/drugs/8314","rxNorm_id":null,"notes":null},"use_drug":[{"id":7406,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11067},{"id":7407,"answer":"In a novel combination with another drug","answer_other":"","regimen":11067}],"created":"2020-09-15T17:57:33.740761Z","updated":"2020-09-15T18:16:43.184835Z","dose":"50 mg","frequency":"Q6h","route":"IV","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":5916},{"id":11068,"duration":{"id":5127,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":7408,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11068},{"id":7409,"answer":"In a novel combination with another drug","answer_other":"","regimen":11068}],"created":"2020-09-15T17:57:33.747112Z","updated":"2020-09-15T18:16:43.220626Z","dose":"Total dose of 560 mg administered over two days","frequency":"","route":"IV","severity":"ICU/Critical Care","severity_detail":null,"comments":null,"report":5916}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":7739,"answer":"Clinical assessment","answer_other":"","report":5916},{"id":7740,"answer":"Imaging","answer_other":"","report":5916},{"id":7741,"answer":"PCR","answer_other":"","report":5916}],"how_diagnosis":[{"id":13173,"answer":"Clinical assessment","answer_other":"","report":5916},{"id":13174,"answer":"Imaging","answer_other":"","report":5916},{"id":13175,"answer":"PCR","answer_other":"","report":5916}],"author_username":"Parvesh Paul","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"Christian Medical College, Ludhiana, Punjab, India.","author_country":"India","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":3855,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":5916},{"id":3856,"answer":"Co-Infection or Complex Co-morbidities","answer_other":"","report":5916}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"},{"id":550,"name":"Respiratory Tract Infections"}],"races":[{"id":213,"answer":"Asian","answer_other":""}],"created":"2020-09-15T17:50:45.841118Z","updated":"2020-09-15T18:16:43.158018Z","title":"An elderly couple with COVID-19 pneumonia treated in Singapore: contrasting clinical course and management. Case 2","status":"Approved","anonymous":false,"published":true,"pubmed_id":32312026,"doi":"10.11622/smedj.2020064","article_url":"https://pubmed.ncbi.nlm.nih.gov/32312026/","pub_year":2020,"published_authors":"Wong SY\r\nLeong KH\r\nNg KS\r\nTan SH\r\nLo PLC\r\nChan K","article_author_email":"Author email could not be found.","journal":"Singapore medical journal","abstract":"Patient B was an 82-year-old man who developed a fever on the evening of 8 March 2020. There were no symptoms that were referable to the respiratory, gastrointestinal or genitourinary tracts. He saw a doctor in Indonesia on 9 March, but investigations, including full blood count, urine microscopy and dengue tests, were unremarkable. He arrived with his family for a holiday in Singapore on 9 March. The fever recurred, and he attended the 24-hour clinic at Gleneagles Hospital for evaluation. At midday on 10 March, he had no other symptoms other than fever. He had no contact with persons known to have COVID-19.","article_type":"Original","study_type":"Case Report","number_of_patients":2,"article_patient_number":"2","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"81-89 years","sex":"Male","ethnicity":"Not Hispanic/Latino","country_contracted":"Indonesia","country_treated":"Singapore","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":true,"hypertension":true,"cardiovascular_disease":true,"chronic_renal_disease":true,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"Diabetes mellitus, dyslipidaemia and gout, moderate coronary artery disease and Stage 3 chronic kidney disease. He had a minor allergy to contrast, he had undergone ablation for atrial flutter. He had stopped smoking for more than 30 years.","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Respiratory tract infection","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"","follow_up_period":null,"relapse":"","reminder":false,"when_reminder":"1 week","additional_info":"Mechanical ventilation and ionotropes +\r\n Baseline electrocardiography showed mild first-degree atrioventricular block and normal QT interval. During his illness, he developed intermittent atrial fibrillation. Echocardiography showed normal resting left ventricular systolic function.\r\nTracheostomy - to facilitate weaning from the ventilator.\r\nAcute on chronic renal failure with oliguria and was placed on continuous renal replacement therapy , then subsequently switched to sustained low-efficiency dialysis when he improved haemodynamically.\r\nProgressive thrombocytopenia, which was assessed to be drug-related. Heparin and hydroxychloroquine were discontinued.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6122,8314,8342,8783,10776]},{"id":5922,"regimens":[{"id":11072,"duration":{"id":5131,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":7413,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11072}],"created":"2020-09-15T22:43:59.882123Z","updated":"2020-09-15T22:56:44.480942Z","dose":"8 mg/kg body-weight","frequency":"Single IV dose","route":"IV","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":5922}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":7745,"answer":"Clinical assessment","answer_other":"","report":5922},{"id":7746,"answer":"Imaging","answer_other":"","report":5922}],"how_diagnosis":[{"id":13190,"answer":"Clinical assessment","answer_other":"","report":5922},{"id":13191,"answer":"Imaging","answer_other":"","report":5922},{"id":13192,"answer":"PCR","answer_other":"","report":5922}],"author_username":"Reema Charles","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":3863,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":5922}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"},{"id":550,"name":"Respiratory Tract Infections"}],"races":[{"id":217,"answer":"White","answer_other":""}],"created":"2020-09-15T22:43:19.077863Z","updated":"2020-09-15T22:56:44.473399Z","title":"Tocilizumab in Severe COVID-19 Pneumonia and Concomitant Cytokine Release Syndrome.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32399455,"doi":"10.12890/2020_001675","article_url":"https://pubmed.ncbi.nlm.nih.gov/32399455/","pub_year":2020,"published_authors":"van Kraaij TD\r\nMostard RL\r\nRamiro S\r\nMagro Checa C\r\nvan Dongen CM\r\nvan Haren EH\r\nBuijs J\r\nLandewÃ© RB","article_author_email":"Author email could not be found.","journal":"European journal of case reports in internal medicine","abstract":"Younger patients with COVID-19 may experience an exaggerated immune response to SARS-CoV-2 infection and develop cytokine release syndrome (CRS), which may be life threatening. There is no proven antiviral therapy for COVID-19 so far, but profound immunosuppression has recently been suggested as a treatment for COVID-19-associated CRS. We present a case of life-threatening CRS caused by COVID-19 infection with a favourable response to immunosuppressive therapy with tocilizumab (TCZ). The rapid clinical and biochemical improvement following TCZ administration suggests that treatment with immunotherapy can be life-saving in selected patients with COVID-19-induced CRS.          \r\n        Learning points:      \r\n              Cytokine release syndrome may cause sudden and potentially life-threatening clinical deterioration in COVID-19 pneumonia, particularly in younger patients.Immunosuppressive therapy may provide important additional therapeutic benefit in these patients.Tocilizumab, a specific IL-6 inhibitor, led to dramatic clinical improvement in a young patient with severe COVID-19-associated cytokine release syndrome.","article_type":"Original","study_type":"Case Report","number_of_patients":1,"article_patient_number":"","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"21-30 years","sex":"Male","ethnicity":"Not Hispanic/Latino","country_contracted":"Netherlands","country_treated":"Netherlands","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Respiratory tract infection","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"Intubated for invasive ventilation in the prone position.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[10776]},{"id":5928,"regimens":[{"id":11087,"duration":{"id":5146,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8783,"name":"Lopinavir-Ritonavir","url":"cure-api2.ncats.io/v1/drugs/8783","rxNorm_id":null,"notes":null},"use_drug":[{"id":7434,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11087},{"id":7435,"answer":"In a novel combination with another drug","answer_other":"","regimen":11087}],"created":"2020-09-16T03:10:49.507076Z","updated":"2020-09-16T03:28:15.816546Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":5928},{"id":11088,"duration":{"id":5147,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":7436,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11088},{"id":7437,"answer":"In a novel combination with another drug","answer_other":"","regimen":11088}],"created":"2020-09-16T03:10:49.515136Z","updated":"2020-09-16T03:28:15.823028Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":5928},{"id":11089,"duration":{"id":5148,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":7438,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11089},{"id":7439,"answer":"In a novel combination with another drug","answer_other":"","regimen":11089}],"created":"2020-09-16T03:10:49.521591Z","updated":"2020-09-16T03:28:15.828736Z","dose":"2 doses","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":5928},{"id":11090,"duration":{"id":5149,"approximate_duration":null,"dates_unknown":false},"drug":{"id":11301,"name":"Remdesivir","url":"cure-api2.ncats.io/v1/drugs/11301","rxNorm_id":null,"notes":null},"use_drug":[{"id":7440,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11090},{"id":7441,"answer":"In a novel combination with another drug","answer_other":"","regimen":11090}],"created":"2020-09-16T03:10:49.527838Z","updated":"2020-09-16T03:28:15.834478Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"withdrawn for acute liver injury after 5 days","comments":null,"report":5928}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":7756,"answer":"Clinical assessment","answer_other":"","report":5928}],"how_diagnosis":[{"id":13208,"answer":"Clinical assessment","answer_other":"","report":5928},{"id":13209,"answer":"Imaging","answer_other":"","report":5928},{"id":13210,"answer":"PCR","answer_other":"","report":5928}],"author_username":"Reema Charles","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":3869,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":5928}],"adverse_event_outcome":[{"id":36,"answer":"Other Serious or Important Medical Events","report":5928}],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"},{"id":550,"name":"Respiratory Tract Infections"}],"races":[{"id":223,"answer":"White","answer_other":""}],"created":"2020-09-16T02:50:43.704298Z","updated":"2020-09-16T03:28:15.808600Z","title":"Darunavir does not prevent SARS-CoV-2 infection in HIV patients. Case 1","status":"Approved","anonymous":false,"published":true,"pubmed_id":32325127,"doi":"10.1016/j.phrs.2020.104826","article_url":"https://pubmed.ncbi.nlm.nih.gov/32325127/","pub_year":2020,"published_authors":"Riva A\r\nConti F\r\nBernacchia D\r\nPezzati L\r\nSollima S\r\nMerli S\r\nSiano M\r\nLupo A\r\nRusconi S\r\nCattaneo D\r\nGervasoni C","article_author_email":"Author email could not be found.","journal":"Pharmacological research","abstract":"2-years-old HIV-positive man was admitted at our emergency department referring dry cough and fever up to 38.8 Â°C for at least 7 days. His ARV regimen consisted of darunavir/cobicistat 800/150 mg and lamivudine 300 mg once daily. Blood tests performed less than 2 months earlier showed an undetectable viral load (<20 copies/mL) and a CD4+ count of 0.441 Ã 10^3/Î¼L.","article_type":"Original","study_type":"Case Report","number_of_patients":3,"article_patient_number":"1","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"61-70 years","sex":"Male","ethnicity":"Not Hispanic/Latino","country_contracted":"Italy","country_treated":"Italy","began_treatment_year":"2020","hiv":true,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":true,"cardiovascular_disease":true,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"Ischaemic heart disease","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Respiratory tract infection","severity":"ICU/Critical Care","prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":true,"adverse_events":"Remdesivir - withdrawn for acute liver injury after 5 days","when_outcome":"","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"His ARV regimen consisted of darunavir/cobicistat 800/150 mg and lamivudine 300 mg once daily.\r\n\r\nHe was also on maintenance therapy with doxazosin, metoprolole and amlodipine for arterial hypertension and ischemic heart disease.\r\n\r\nDarunavir/cobicistat was replaced by lopinavir/ritonavir plus hydroxychloroquine. In the following days, the patientâs respiratory function quickly worsened despite Venturi mask and continuous positive airway pressure therapy and, one week after admission, the patient required mechanic ventilation. \r\n\r\nIn the intensive care unit lopinavir/ritonavir plus hydroxychloroquine were replaced by tocilizumab (two doses) and remdesivir (withdrawn for acute liver injury after 5 days) with improved respiratory conditions. \r\n\r\nAt the last available follow-up (April 1), the patient is still inpatient with no fever and requiring only low-flow oxygen delivery.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[8342,8783,11301,10776]},{"id":5940,"regimens":[{"id":11121,"duration":{"id":5180,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":7479,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11121}],"created":"2020-09-16T18:11:20.277096Z","updated":"2020-09-27T18:29:47.173741Z","dose":"8mg/kg","frequency":"QD","route":"","severity":"ICU/Critical Care","severity_detail":"Patient was intubated at the time of treatment","comments":null,"report":5940}],"site_of_infection":[],"specific_site":[],"how_outcome":[],"how_diagnosis":[{"id":13240,"answer":"Clinical assessment","answer_other":"","report":5940},{"id":13241,"answer":"PCR","answer_other":"","report":5940}],"author_username":"Kate Borkowski","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Nurse","author_affiliation":"None","author_country":"","outcome_computed":"Deteriorated","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":3882,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":5940}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-09-16T18:09:58.236544Z","updated":"2020-09-27T18:29:47.166106Z","title":"A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia. Case 3.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32333914,"doi":"10.1016/j.jaci.2020.04.013","article_url":"https://pubmed.ncbi.nlm.nih.gov/32333914/","pub_year":2020,"published_authors":"Quinti I\r\nLougaris V\r\nMilito C\r\nCinetto F\r\nPecoraro A\r\nMezzaroma I\r\nMastroianni CM\r\nTurriziani O\r\nBondioni MP\r\nFilippini M\r\nSoresina A\r\nSpadaro G\r\nAgostini C\r\nCarsetti R\r\nPlebani A","article_author_email":"isabella.quinti@uniroma1.it","journal":"The Journal of allergy and clinical immunology","abstract":"No abstract available","article_type":"Original","study_type":"Case Report","number_of_patients":7,"article_patient_number":"3","full_text_available":true,"outcome":"Patient died","surgery":"No","age":"51-60 years","sex":"Female","ethnicity":"Not Hispanic/Latino","country_contracted":"Italy","country_treated":"Italy","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":true,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":true,"other_comorbid":"common variable immune deficiency (CVID), chronic sinusitis, chronic bronchitis, and chronic gastritis","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Fever, dyspnea","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"","follow_up_period":null,"relapse":"","reminder":false,"when_reminder":"1 week","additional_info":"","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[10776]},{"id":5941,"regimens":[{"id":11122,"duration":{"id":5181,"approximate_duration":"6 days","dates_unknown":true},"drug":{"id":11364,"name":"Ritonavir/ Darunavir","url":"cure-api2.ncats.io/v1/drugs/11364","rxNorm_id":null,"notes":null},"use_drug":[{"id":7480,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11122},{"id":8362,"answer":"In a novel combination with another drug","answer_other":"","regimen":11122}],"created":"2020-09-16T18:45:21.976174Z","updated":"2020-09-27T18:26:07.483010Z","dose":"100mg/800mg","frequency":"QD","route":"","severity":"Inpatient","severity_detail":null,"comments":null,"report":5941},{"id":11123,"duration":{"id":5182,"approximate_duration":"6 days","dates_unknown":true},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":7481,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11123},{"id":8363,"answer":"In a novel combination with another drug","answer_other":"","regimen":11123}],"created":"2020-09-16T18:45:21.984729Z","updated":"2020-09-27T18:26:07.483808Z","dose":"200 mg","frequency":"BID","route":"","severity":"Inpatient","severity_detail":null,"comments":null,"report":5941},{"id":11124,"duration":{"id":5183,"approximate_duration":"2 doses","dates_unknown":true},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":7482,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11124},{"id":8364,"answer":"In a novel combination with another drug","answer_other":"","regimen":11124}],"created":"2020-09-16T18:45:21.991199Z","updated":"2020-09-27T18:26:07.484553Z","dose":"8mg/kg","frequency":"QD","route":"IV","severity":"Inpatient","severity_detail":null,"comments":null,"report":5941}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":7779,"answer":"Clinical assessment","answer_other":"","report":5941}],"how_diagnosis":[{"id":13242,"answer":"Clinical assessment","answer_other":"","report":5941},{"id":13243,"answer":"PCR","answer_other":"","report":5941}],"author_username":"Kate Borkowski","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Nurse","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":3883,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":5941}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-09-16T18:26:14.437249Z","updated":"2020-09-27T18:26:07.439327Z","title":"A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia. Case 4.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32333914,"doi":"10.1016/j.jaci.2020.04.013","article_url":"https://pubmed.ncbi.nlm.nih.gov/32333914/","pub_year":2020,"published_authors":"Quinti I\r\nLougaris V\r\nMilito C\r\nCinetto F\r\nPecoraro A\r\nMezzaroma I\r\nMastroianni CM\r\nTurriziani O\r\nBondioni MP\r\nFilippini M\r\nSoresina A\r\nSpadaro G\r\nAgostini C\r\nCarsetti R\r\nPlebani A","article_author_email":"isabella.quinti@uniroma1.it","journal":"The Journal of allergy and clinical immunology","abstract":"No abstract available","article_type":"Original","study_type":"Case Report","number_of_patients":7,"article_patient_number":"4","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"31-40 years","sex":"Female","ethnicity":"Not Hispanic/Latino","country_contracted":"Italy","country_treated":"Italy","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":true,"other_comorbid":"common variable immune deficiency (CVID), endometriosis, skin cancer","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Pneumonia","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"While the patient was still on treatment","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[8342,11364,10776]},{"id":5990,"regimens":[{"id":11243,"duration":{"id":5299,"approximate_duration":"5 days","dates_unknown":true},"drug":{"id":9077,"name":"Methylprednisolone","url":"cure-api2.ncats.io/v1/drugs/9077","rxNorm_id":null,"notes":null},"use_drug":[{"id":7722,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11243},{"id":7723,"answer":"In a novel combination with another drug","answer_other":"","regimen":11243}],"created":"2020-09-18T16:09:46.780372Z","updated":"2020-09-18T20:18:18.606304Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":5990},{"id":11266,"duration":{"id":5322,"approximate_duration":"7 days","dates_unknown":true},"drug":{"id":6772,"name":"Chloroquine","url":"cure-api2.ncats.io/v1/drugs/6772","rxNorm_id":null,"notes":null},"use_drug":[{"id":7724,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11266},{"id":7725,"answer":"In a novel combination with another drug","answer_other":"","regimen":11266}],"created":"2020-09-18T20:08:37.514668Z","updated":"2020-09-18T20:18:18.612491Z","dose":"500 mg","frequency":"BD","route":"PO","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":5990},{"id":11267,"duration":{"id":5323,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":7726,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11267},{"id":7727,"answer":"In a novel combination with another drug","answer_other":"","regimen":11267}],"created":"2020-09-18T20:08:37.521127Z","updated":"2020-09-18T20:18:18.617943Z","dose":"8 mg/kg","frequency":"single dose","route":"IV","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":5990}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":7859,"answer":"Clinical assessment","answer_other":"","report":5990}],"how_diagnosis":[{"id":13359,"answer":"Clinical assessment","answer_other":"","report":5990},{"id":13360,"answer":"Imaging","answer_other":"","report":5990},{"id":13361,"answer":"PCR","answer_other":"","report":5990}],"author_username":"Reema Charles","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":3941,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":5990}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"},{"id":550,"name":"Respiratory Tract Infections"}],"races":[{"id":267,"answer":"Asian","answer_other":""}],"created":"2020-09-18T16:07:13.908753Z","updated":"2020-09-18T20:18:18.598395Z","title":"Combined treatment of tocilizumab and chloroquine on severe COVID-19: a case report.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32365207,"doi":"10.1093/qjmed/hcaa153","article_url":"https://pubmed.ncbi.nlm.nih.gov/32365207/","pub_year":2020,"published_authors":"Xu CY\r\nLu SD\r\nYe X\r\nCao MY\r\nXu GD\r\nYu Q\r\nQian JX\r\nZeng G","article_author_email":"Author email could not be found.","journal":"QJM : monthly journal of the Association of Physicians","abstract":"A 63-year-old male patient who was diagnosed with infection by SARS-CoV-2\r\nreal time polymerase chain reaction test screening (Feb 17, 2020) before\r\nhospitalization and had a history of hypertension. Three days later, he presented with\r\nfever of 39.0Â°C, mild cough, then he developed chest tightness, and chest\r\ncomputerized tomography (CT) scan revealed bilateral patchy of ground-glass\r\nopacities on Feb 24, 2020 (","article_type":"Original","study_type":"Case Report","number_of_patients":1,"article_patient_number":"","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"No","age":"61-70 years","sex":"Male","ethnicity":"Not Hispanic/Latino","country_contracted":"China","country_treated":"China","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":true,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Respiratory tract infection","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"","follow_up_period":null,"relapse":"","reminder":false,"when_reminder":"1 week","additional_info":"There was a mild impairment of liver function on day10 and a transient decrease in white blood cells on day16. Leukopenia was relieved by itself and liver injury was reduced by polyunsaturated phosphatidylcholine (PPC). Ultimately, the patient was clinically recovered and was sent to the isolation point to observe for 14 days.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6772,9077,10776]},{"id":5995,"regimens":[{"id":11256,"duration":{"id":5312,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8971,"name":"Meropenem","url":"cure-api2.ncats.io/v1/drugs/8971","rxNorm_id":null,"notes":null},"use_drug":[{"id":7695,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11256},{"id":7696,"answer":"In a novel combination with another drug","answer_other":"","regimen":11256},{"id":7697,"answer":"In a novel population (e.g. pediatrics/neonates, pregnant women, immunosuppressed, etc.)","answer_other":"","regimen":11256}],"created":"2020-09-18T19:24:46.818795Z","updated":"2020-09-27T21:51:14.126582Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"Pediatric intensive care unit","comments":null,"report":5995},{"id":11257,"duration":{"id":5313,"approximate_duration":null,"dates_unknown":false},"drug":{"id":11121,"name":"Vancomycin","url":"cure-api2.ncats.io/v1/drugs/11121","rxNorm_id":11124,"notes":""},"use_drug":[{"id":7698,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11257},{"id":7699,"answer":"In a novel combination with another drug","answer_other":"","regimen":11257},{"id":7700,"answer":"In a novel population (e.g. pediatrics/neonates, pregnant women, immunosuppressed, etc.)","answer_other":"","regimen":11257}],"created":"2020-09-18T19:24:46.826307Z","updated":"2020-09-27T21:51:14.133053Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"Pediatric ICU","comments":null,"report":5995},{"id":11258,"duration":{"id":5314,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6928,"name":"Clindamycin","url":"cure-api2.ncats.io/v1/drugs/6928","rxNorm_id":null,"notes":null},"use_drug":[{"id":7701,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11258},{"id":7702,"answer":"In a novel combination with another drug","answer_other":"","regimen":11258},{"id":7703,"answer":"In a novel population (e.g. pediatrics/neonates, pregnant women, immunosuppressed, etc.)","answer_other":"","regimen":11258}],"created":"2020-09-18T19:24:46.832363Z","updated":"2020-09-27T21:51:14.139053Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"Pediatric ICU","comments":null,"report":5995},{"id":11259,"duration":{"id":5315,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8412,"name":"Immunoglobulins, Intravenous","url":"cure-api2.ncats.io/v1/drugs/8412","rxNorm_id":null,"notes":null},"use_drug":[{"id":7704,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11259},{"id":7705,"answer":"In a new dose, for a novel duration, or by a new route of administration","answer_other":"","regimen":11259},{"id":7706,"answer":"In a novel population (e.g. pediatrics/neonates, pregnant women, immunosuppressed, etc.)","answer_other":"","regimen":11259}],"created":"2020-09-18T19:24:46.838697Z","updated":"2020-09-27T21:51:14.145089Z","dose":"2g/kg","frequency":"","route":"IV","severity":"ICU/Critical Care","severity_detail":"Pediatric ICU","comments":null,"report":5995},{"id":11260,"duration":{"id":5316,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6038,"name":"Aspirin","url":"cure-api2.ncats.io/v1/drugs/6038","rxNorm_id":null,"notes":null},"use_drug":[{"id":7707,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11260},{"id":7708,"answer":"In a novel combination with another drug","answer_other":"","regimen":11260},{"id":7709,"answer":"In a novel population (e.g. pediatrics/neonates, pregnant women, immunosuppressed, etc.)","answer_other":"","regimen":11260}],"created":"2020-09-18T19:24:46.844699Z","updated":"2020-09-27T21:51:14.150540Z","dose":"75 mg","frequency":"QD","route":"Oral","severity":"ICU/Critical Care","severity_detail":"Pediatric ICU","comments":null,"report":5995},{"id":11261,"duration":{"id":5317,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6675,"name":"Ceftriaxone","url":"cure-api2.ncats.io/v1/drugs/6675","rxNorm_id":null,"notes":null},"use_drug":[{"id":7710,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11261},{"id":7711,"answer":"In a novel combination with another drug","answer_other":"","regimen":11261},{"id":7712,"answer":"In a novel population (e.g. pediatrics/neonates, pregnant women, immunosuppressed, etc.)","answer_other":"","regimen":11261}],"created":"2020-09-18T19:24:46.850577Z","updated":"2020-09-27T21:51:14.156094Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"Pediatric ICU","comments":null,"report":5995},{"id":11262,"duration":{"id":5318,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":7713,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11262},{"id":7714,"answer":"In a novel combination with another drug","answer_other":"","regimen":11262},{"id":7715,"answer":"In a novel population (e.g. pediatrics/neonates, pregnant women, immunosuppressed, etc.)","answer_other":"","regimen":11262}],"created":"2020-09-18T19:30:18.547349Z","updated":"2020-09-27T21:51:14.162048Z","dose":"8mg/kg over two hours","frequency":"","route":"IV","severity":"ICU/Critical Care","severity_detail":"Pediatric ICU","comments":null,"report":5995}],"site_of_infection":[],"specific_site":[],"how_outcome":[],"how_diagnosis":[{"id":13373,"answer":"Imaging","answer_other":"","report":5995},{"id":13374,"answer":"PCR","answer_other":"","report":5995}],"author_username":"CURE ID Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":3947,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":5995}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-09-18T19:22:21.396206Z","updated":"2020-09-27T21:51:14.117780Z","title":"Hyper-inflammatory Syndrome in a Child With COVID-19 Treated Successfully With Intravenous Immunoglobulin and Tocilizumab.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32393681,"doi":"10.1007/s13312-020-1901-z","article_url":"https://pubmed.ncbi.nlm.nih.gov/32393681/","pub_year":2020,"published_authors":"Balasubramanian S\r\nNagendran TM\r\nRamachandran B\r\nRamanan AV","article_author_email":"nagupeds@gmail.com","journal":"Indian pediatrics","abstract":"No abstract available","article_type":"Original","study_type":"Case Report","number_of_patients":1,"article_patient_number":"","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"No","age":"6-10 years","sex":"Male","ethnicity":"Not Hispanic/Latino","country_contracted":"India","country_treated":"India","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Pneumonia","severity":"ICU/Critical Care","prev_treatment":"","unusual":"child with hyper-inflammatory syndrome","drug_treatment_features":"The initial differential diagnoses were pneumonia with septic shock,COVID-19 penumonitis, KD and TSS. High-flow nasal cannula (HFNC) support was started and antibiotics were modified to meropenem, vancomycin and clindamycin. Intravenous Immunoglobulin (IVIG) was given (2 g/kg) with aspirin (75 mg once-a-day). Echocardiogram did not show any abnormalities and repeat chest Xray showed increased right-sided infiltrates. Repeat nasopharyngeal COVID-19 RT-PCR was positive. Multiplex PCR of nasopharyngeal aspirate detected Coronavirus OC43 and Human Rhino/Enterovirus. As he improved, he was gradually weaned off HFNC. Blood cultures showed no growth and antibiotics were changed to ceftriaxone. In light of the persistent high-grade fever and elevated CRP (121 mg/L), 72 hours after IVIG infusion, he was given tocilizumab (8 mg/kg IV over 2 hours). Twelve hours later, his fever spikes settled, and inflammatory parameters rapidly decreased to baseline. Pt recovered after two weeks.","have_adverse_events":false,"adverse_events":"","when_outcome":"After a period of follow-up","follow_up_period":"2 weeks","relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"Reverse transcriptase polymerase chain reaction (RT-PCR) for severe acute respiratory illness novel coronavirus 2 (SARS-CoV-2) was negative. Treatment was empirically started with ceftriaxone and azithromycin. Despite treatment for three days, he continued to have high fever, worsening respiratory symptoms and was referred to our hospital. He was given a fluid bolus and treatment empirically\r\nstarted with piperacillin-tazobactam and doxycycline. When reassessed after 30 minutes, he was febrile,\r\nhypotensive and had increased work of breathing. He was shifted to the pediatric intensive care unit.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6038,6675,6928,8412,8971,10776,11121]},{"id":6000,"regimens":[{"id":11279,"duration":{"id":5334,"approximate_duration":"10 days","dates_unknown":true},"drug":{"id":11301,"name":"Remdesivir","url":"cure-api2.ncats.io/v1/drugs/11301","rxNorm_id":null,"notes":null},"use_drug":[{"id":7749,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11279}],"created":"2020-09-21T02:15:20.363637Z","updated":"2020-09-21T02:28:14.451824Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6000},{"id":11280,"duration":{"id":5335,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":7750,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11280},{"id":7751,"answer":"In a novel combination with another drug","answer_other":"","regimen":11280}],"created":"2020-09-21T02:15:20.371488Z","updated":"2020-09-21T02:28:14.458277Z","dose":"400 mg","frequency":"one-time dose","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6000},{"id":11281,"duration":{"id":5336,"approximate_duration":"5 days","dates_unknown":true},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":7752,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11281},{"id":7753,"answer":"In a novel combination with another drug","answer_other":"","regimen":11281}],"created":"2020-09-21T02:15:20.377950Z","updated":"2020-09-21T02:28:14.464145Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6000}],"site_of_infection":[],"specific_site":[],"how_outcome":[],"how_diagnosis":[{"id":13387,"answer":"Clinical assessment","answer_other":"","report":6000},{"id":13388,"answer":"Imaging","answer_other":"","report":6000},{"id":13389,"answer":"PCR","answer_other":"","report":6000}],"author_username":"Reema Charles","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":3954,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6000}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"},{"id":550,"name":"Respiratory Tract Infections"}],"races":[{"id":271,"answer":"American Indian or Alaskan Native","answer_other":""}],"created":"2020-09-21T02:13:46.697116Z","updated":"2020-09-21T02:28:14.444046Z","title":"Visualization of severe acute respiratory syndrome coronavirus 2 invading the human placenta using electron microscopy","status":"Approved","anonymous":false,"published":true,"pubmed_id":32405074,"doi":"10.1016/j.ajog.2020.05.023","article_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7219376/","pub_year":2020,"published_authors":"Gabriela N Algarroba, Patricia Rekawek, Sevan A Vahanian, et al","article_author_email":"Author email could not be found.","journal":"","abstract":"A 40-year-old Hispanic woman, G3P2002, at 28 weeks and 4 days of gestation, with no significant medical history, presented to the emergency department with worsening shortness of breath, cough, and hypoxia in the setting of a known COVID-19 infection, on day 2 of 5 of an azithromycin course. She was promptly admitted with the diagnosis of sepsis pneumonia secondary to COVID-19.","article_type":"Original","study_type":"Case Report","number_of_patients":1,"article_patient_number":"","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"31-40 years","sex":"Female","ethnicity":"Hispanic/Latino","country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"G3P2002, at 28 weeks and 4 days of gestation, with no significant medical history","pregnant":true,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Respiratory tract infection","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"She was intubated, sedated, and started on a norepinephrine infusion because of hypotension to maintain appropriate perfusion for the placenta. \r\n\r\nAntenatal corticosteroids for fetal lung maturity were administered in anticipation of a preterm delivery.\r\n\r\n Therapeutic anticoagulation with heparin was initiated because of the risk of venous thromboembolism in the setting of severe COVID-19 with elevated D-dimer. \r\n\r\nShe received a 4 g bolus dose of magnesium sulfate for fetal neuroprotection. An uncomplicated repeat cesarean delivery was performed in a negative pressure operating room with all personnel in personal protective equipment of a female infant weighing 2 lb and 15 oz (1340 g).\r\n\r\nThe infant had a negatve result for COVID-19 testing on day of life (DOL) 2 and 3.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6122,11301,10776]},{"id":6004,"regimens":[{"id":11293,"duration":{"id":5348,"approximate_duration":"1 day (2 single administrations on hospital day 7 and day 11)","dates_unknown":true},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":7770,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11293},{"id":8398,"answer":"In a novel combination with another drug","answer_other":"","regimen":11293}],"created":"2020-09-21T12:47:09.226868Z","updated":"2020-09-27T23:28:25.143242Z","dose":"400 mg (5mg/kg)","frequency":"QD","route":"IV","severity":"Inpatient","severity_detail":"IL-6 level prior to tocilizumab administration had reached 241 pg/mL and pt required 15 L/min of oxygen with worsening inflammatory markers and CXR infiltrates","comments":null,"report":6004},{"id":11294,"duration":{"id":5349,"approximate_duration":"4 days (Hospital Day 2-5)","dates_unknown":true},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":7771,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11294},{"id":8399,"answer":"In a novel combination with another drug","answer_other":"","regimen":11294}],"created":"2020-09-21T12:47:09.234426Z","updated":"2020-09-27T23:28:25.144101Z","dose":"400mg","frequency":"QD","route":"Oral","severity":"Inpatient","severity_detail":"Started upon PCR coming back positive; pt only required supplemental oxygen of 2 L/min at time of initiation. Remained afebrile and normotensive but had progressively increasing oxygen requirements and significantly elevated inflammatory markers on HCQ.","comments":null,"report":6004}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":7869,"answer":"Clinical assessment","answer_other":"","report":6004},{"id":7870,"answer":"Imaging","answer_other":"","report":6004},{"id":7871,"answer":"Other","answer_other":"Improvement in inflammatory markers","report":6004}],"how_diagnosis":[{"id":13399,"answer":"Clinical assessment","answer_other":"","report":6004},{"id":13400,"answer":"PCR","answer_other":"","report":6004},{"id":13401,"answer":"Imaging","answer_other":"","report":6004}],"author_username":"Heather Stone","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"FDA","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":3962,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6004},{"id":3963,"answer":"Co-Infection or Complex Co-morbidities","answer_other":"","report":6004}],"adverse_event_outcome":[{"id":46,"answer":"Other Serious or Important Medical Events","report":6004}],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-09-21T12:35:23.567623Z","updated":"2020-09-27T23:28:25.106475Z","title":"Interleukin-6 receptor antagonist therapy to treat SARS-CoV-2 driven inflammatory syndrome in a kidney transplant recipient.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32406985,"doi":"10.1111/tid.13326","article_url":"https://pubmed.ncbi.nlm.nih.gov/32406985/","pub_year":2020,"published_authors":"Allam SR\r\nDao A\r\nMadhrira MM\r\nAntiporta PB\r\nNair RR\r\nGuiteau JJ\r\nReyad AI","article_author_email":"Author email could not be found.","journal":"Transplant infectious disease : an official journal of the Transplantation Society","abstract":"Coronavirus disease 2019 (COVIDâ19) caused by severe acute respiratory syndrome coronavirus 2 (SARSâCoVâ2) is a pandemic that is evolving rapidly at present with unprecedented global health and societal implications. Herein, we report a case of successful treatment of SARSâCoVâ2 induced inflammatory syndrome by utilization of the interleukinâ6 receptor antagonist (ILâ6Ra) tocilizumab.          \r\nKeywords: COVID-19; SARS-CoV-2; kidney transplant; tocilizumab.","article_type":"Original","study_type":"Case Report","number_of_patients":1,"article_patient_number":"","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"61-70 years","sex":"Female","ethnicity":"Hispanic/Latino","country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":true,"hypertension":true,"cardiovascular_disease":false,"chronic_renal_disease":true,"chronic_liver_disease":false,"immunosuppressant_drugs":true,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":true,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"lungs","clinical_syndrome":"Hypoxemia, Pneumonia","severity":null,"prev_treatment":"","unusual":"Pt was a renal transplant recipient on an immunosuppressive regimen. Had two instances of inflammatory syndrome that improved after administration of Tocilizumab.","drug_treatment_features":"","have_adverse_events":true,"adverse_events":"Acute kidney injury (SCr 1.7 mg/dL, mild transaminitis (AST 73 units/L, ALT 47 units/L)","when_outcome":"After a period of follow-up","follow_up_period":"5 days","relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"Our case illustrated the utility of tocilizumab in treating SARS-CoV-2 induced inflammatory syndrome in a transplant recipient.\r\n\r\nPatient received Azithromycin and Ceftriaxone empirically on hospital Day 1-7. They had a positive PCR confirming SARS-CoV-2 infection on hospital day 2 and were started on Hydroxychloroquine. HCQ was continued through hospital day 5 and then was stopped. Due to worsening oxygen requirements and increased inflammatory markers and infiltrates on CXR, Tocilizumab was administered on hospital day 7. Improvement was seen for 2 days, followed by worsening oxygen requirements and inflammatory markers, and a second dose of Tocilizumab was administered on hospital day 11. Patient improved and was discharged from hospital on day 17. \r\n\r\nThe patient is a 65-year-old Hispanic female with history of end stage renal disease secondary to long\r\nstanding diabetes and hypertension who received a deceased donor renal transplant four years prior. She had uneventful post-transplant course with a baseline serum creatinine (SCr) of 1.2 mg/dL and maintained on triple immunosuppressive regimen of tacrolimus, mycophenolate and prednisone. She presented to the hospital with a 1-week history of worsening cough and shortness of breath. Upon presentation, patient was hypoxic with oxygen saturation of 91% on room air. Her examination was significant for crackles in both lung fields. \r\n\r\nLaboratory findings revealed WBC 4.9 k/mm3 with lymphopenia (0.6 k/mm3), procalcitonin 0.17 ng/mL,\r\ntroponin-I <0.040 ng/mL, BNP 68 pg/mL, SCr 1.3 mg/dL, AST 39 units/L and tacrolimus trough level 7.0 ng/mL. Chest X-ray (CXR) showed bilateral reticulonodular pulmonary opacities. Supplemental oxygen of 2 L/min by nasal cannula and an empiric antibiotic regimen of ceftriaxone and azithromycin were initiated. A nasal swab multiplex viral PCR panel and blood cultures were negative. \r\n\r\nOn hospital day 2, upon the COVID-19 nasal swab PCR resulting positive, hydroxychloroquine was initiated. Mycophenolate was discontinued and dosing of tacrolimus was lowered to target trough levels of 3-5 ng/mL. Despite remaining afebrile and normotensive throughout hospitalization, she had progressively increasing oxygen requirements. Inflammatory markers collected on hospital day 5 including CRP and ferritin were noted to be significantly elevated at 16.4 mg/dL and 2671 ng/mL respectively. Intravenous methylprednisolone 1 mg/kg daily was then initiated but no improvement was noted. She also developed acute kidney injury (AKI) with SCr of 1.7 mg/dL and mild transaminitis (AST 73 units/L, ALT 47 units/L). With increasing oxygen requirement to 15 L/min, worsening of inflammatory markers and CXR infiltrates, tocilizumab 400 mg (5 mg/kg) was administered on hospital day 7.\r\n\r\nAn IL-6 level obtained prior to tocilizumab administration was 241 pg/mL. Subsequently by hospital day 9,\r\noxygen requirements improved to 6 L/min along with improvements in inflammatory markers and CXR\r\ninfiltrates. On hospital day 11, patient again had increasing oxygen requirements to 11 L/min with up trending LDH and worsening CXR infiltrates. Given this, a second dose of tocilizumab 400 mg was administered. \r\n\r\nFollowing this dose, patient had progressive improvement in hypoxia, inflammatory markers, as well as\r\ninfiltrates on CXR. Patient was discharged on day 17 of hospitalization on 4 L/min of supplemental oxygen with resolved AKI and transaminitis. Figure 1 summarizes treatment therapies, oxygen requirement, and inflammatory markers during hospital course.\r\n\r\nOur case illustrated the utility of tocilizumab in treating SARS-CoV-2 induced inflammatory syndrome\r\nin a transplant recipient. Further randomized studies are necessary to confirm the benefit, optimal dosing,\r\nand timing of administration of IL-6Ra therapies in the management of COVID-19 in transplant recipients.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[8342,10776]},{"id":6005,"regimens":[{"id":11295,"duration":{"id":5350,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6675,"name":"Ceftriaxone","url":"cure-api2.ncats.io/v1/drugs/6675","rxNorm_id":null,"notes":null},"use_drug":[{"id":7773,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11295},{"id":7772,"answer":"In a novel combination with another drug","answer_other":"","regimen":11295}],"created":"2020-09-21T12:58:35.801274Z","updated":"2020-09-21T13:10:27.808377Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6005},{"id":11296,"duration":{"id":5351,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":7774,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11296},{"id":7775,"answer":"In a novel combination with another drug","answer_other":"","regimen":11296}],"created":"2020-09-21T12:58:35.808640Z","updated":"2020-09-21T13:10:27.814506Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6005},{"id":11297,"duration":{"id":5352,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":7776,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11297},{"id":7777,"answer":"In a novel combination with another drug","answer_other":"","regimen":11297}],"created":"2020-09-21T12:58:35.814781Z","updated":"2020-09-21T13:10:27.820108Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6005},{"id":11298,"duration":{"id":5353,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":7778,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11298},{"id":7779,"answer":"In a novel combination with another drug","answer_other":"","regimen":11298}],"created":"2020-09-21T12:58:35.820966Z","updated":"2020-09-21T13:10:27.825752Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6005}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":7868,"answer":"Clinical assessment","answer_other":"","report":6005}],"how_diagnosis":[{"id":13402,"answer":"Clinical assessment","answer_other":"","report":6005},{"id":13403,"answer":"Imaging","answer_other":"","report":6005},{"id":13404,"answer":"PCR","answer_other":"","report":6005}],"author_username":"Parvesh Paul","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"Christian Medical College, Ludhiana, Punjab, India.","author_country":"India","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":3964,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6005}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"},{"id":550,"name":"Respiratory Tract Infections"}],"races":[{"id":275,"answer":"White","answer_other":""}],"created":"2020-09-21T12:57:37.298328Z","updated":"2020-09-21T13:10:27.800187Z","title":"Rescue therapy for severe COVID-19-associated acute respiratory distress syndrome with tissue plasminogen activator: A case series. Case 1","status":"Approved","anonymous":false,"published":true,"pubmed_id":32427773,"doi":"10.1097/TA.0000000000002786","article_url":"https://pubmed.ncbi.nlm.nih.gov/32427773/","pub_year":2020,"published_authors":"Barrett CD\r\nOren-Grinberg A\r\nChao E\r\nMoraco AH\r\nMartin MJ\r\nReddy SH\r\nIlg AM\r\nJhunjhunwala R\r\nUribe M\r\nMoore HB\r\nMoore EE\r\nBaedorf-Kassis EN\r\nKrajewski ML\r\nTalmor DS\r\nShaefi S\r\nYaffe MB","article_author_email":"Author email could not be found.","journal":"The journal of trauma and acute care surgery","abstract":"The coronavirus disease 2019 (COVID-19) pandemic has led to unprecedented stresses on modern medical systems, overwhelming the resource infrastructure in numerous countries while presenting a unique series of pathophysiologic clinical findings. Thrombotic coagulopathy is common in critically ill patients suffering from COVID-19, with associated high rates of respiratory failure requiring prolonged periods of mechanical ventilation. Here, we report a case series of five patients suffering from profound, medically refractory COVID-19-associated respiratory failure who were treated with fibrinolytic therapy using tissue plasminogen activator (tPA; alteplase). All five patients appeared to have an improved respiratory status following tPA administration: one patient had an initial marked improvement that partially regressed after several hours, one patient had transient improvements that were not sustained, and three patients had sustained clinical improvements following tPA administration. LEVEL OF EVIDENCE: Therapeutic, Level V.","article_type":"Original","study_type":"Case Report","number_of_patients":5,"article_patient_number":"1","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"31-40 years","sex":"Male","ethnicity":"Not Hispanic/Latino","country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Respiratory tract infection","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"Mechanical ventilation + - Prone position\r\n\r\nRespiratory system and lung mechanics remained preserved throughout (static respiratory system compliance 35-45 mL/cmH2O and driving pressure <15cmH2O) despite severe hypoxemia and a large Alveolar-arterial oxygen gradient, consistent with pulmonary vascular occlusive phenomena as the primary pathophysiology - tPA \r\n\r\nSeven days post-tPA the patient was successfully extubated and neurologically intact with no apparent complications of tPA therapy.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6122,6675,8342,10776]},{"id":6018,"regimens":[{"id":11325,"duration":{"id":5380,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":7824,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11325},{"id":8686,"answer":"In a novel combination with another drug","answer_other":"","regimen":11325}],"created":"2020-09-21T17:51:31.596783Z","updated":"2020-10-01T06:17:33.287584Z","dose":"162mg","frequency":"Once","route":"SC","severity":"Inpatient","severity_detail":null,"comments":null,"report":6018},{"id":11651,"duration":{"id":5695,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":8687,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11651},{"id":8688,"answer":"In a novel combination with another drug","answer_other":"","regimen":11651}],"created":"2020-09-29T18:19:22.526862Z","updated":"2020-10-01T06:17:33.288389Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6018},{"id":11652,"duration":{"id":5696,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8783,"name":"Lopinavir-Ritonavir","url":"cure-api2.ncats.io/v1/drugs/8783","rxNorm_id":null,"notes":null},"use_drug":[{"id":8689,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11652},{"id":8690,"answer":"In a novel combination with another drug","answer_other":"","regimen":11652}],"created":"2020-09-29T18:19:22.533586Z","updated":"2020-10-01T06:17:33.289171Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6018},{"id":11653,"duration":{"id":5697,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":8691,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11653},{"id":8692,"answer":"In a novel combination with another drug","answer_other":"","regimen":11653}],"created":"2020-09-29T18:19:22.539548Z","updated":"2020-10-01T06:17:33.289948Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6018}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":7883,"answer":"Clinical assessment","answer_other":"","report":6018},{"id":7884,"answer":"Imaging","answer_other":"","report":6018}],"how_diagnosis":[{"id":13439,"answer":"Clinical assessment","answer_other":"","report":6018},{"id":13440,"answer":"Imaging","answer_other":"","report":6018},{"id":13441,"answer":"PCR","answer_other":"","report":6018}],"author_username":"Kate Borkowski","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Nurse","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"Armenian","why_new_way":[{"id":3983,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6018}],"adverse_event_outcome":[{"id":48,"answer":"Non-Serious Medical Event","report":6018}],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-09-21T17:50:41.900908Z","updated":"2020-10-01T06:17:33.229312Z","title":"Use of subcutaneous tocilizumab in patients with COVID-19 pneumonia. Case 1.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32410234,"doi":"10.1002/jmv.26016","article_url":"https://pubmed.ncbi.nlm.nih.gov/32410234/","pub_year":2020,"published_authors":"Mazzitelli M\r\nArrighi E\r\nSerapide F\r\nPelle MC\r\nTassone B\r\nLionello R\r\nMarrazzo G\r\nLaganÃ  D\r\nCostanzo FS\r\nMatera G\r\nTrecarichi EM\r\nTorti C\r\nIDTM UMG COVID-19 Group.","article_author_email":"Author email could not be found.","journal":"Journal of medical virology","abstract":"Over the last months, pandemic SARS-CoV-2 caused a significant challenge for clinicians. Unfortunately, no approved and validated treatments are available. Intravenous tocilizumab, an antirheumatic drug, seems to be promising in counteracting cytokine storm caused by SARS-CoV-2 infection with associated clinical improvements. We report herein a case series of patients with COVID-19 pneumonia who were treated with tocilizumab administrated, for the first time, subcutaneously with good clinical and radiological outcomes. This article is protected by copyright. All rights reserved.          \r\n        Keywords:      \r\n                  COVID-19; SARS-COV-2; pneumonia; subcutaneous; tocilizumab.","article_type":"Original","study_type":"Case Report","number_of_patients":3,"article_patient_number":"","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"61-70 years","sex":"Female","ethnicity":null,"country_contracted":"Italy","country_treated":"Italy","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"Hypercholesterolemia","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Pneumonia","severity":null,"prev_treatment":"Piperacillin-Tazobactam","unusual":"","drug_treatment_features":"","have_adverse_events":true,"adverse_events":"Mild increase of LFTs 2 days after SC tocilizumab.","when_outcome":"After a period of follow-up","follow_up_period":"12 days after TCZ administration","relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6122,8342,8783,10776]},{"id":6019,"regimens":[{"id":11326,"duration":{"id":5381,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":7825,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11326}],"created":"2020-09-21T18:05:07.898188Z","updated":"2020-09-29T18:21:36.830132Z","dose":"162 mg","frequency":"Once","route":"SC","severity":"Inpatient","severity_detail":"","comments":null,"report":6019}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":7885,"answer":"Imaging","answer_other":"","report":6019}],"how_diagnosis":[{"id":13442,"answer":"Clinical assessment","answer_other":"","report":6019},{"id":13443,"answer":"PCR","answer_other":"","report":6019}],"author_username":"Kate Borkowski","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Nurse","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":3984,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6019}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-09-21T17:58:23.645911Z","updated":"2020-09-29T18:21:36.821003Z","title":"Use of subcutaneous tocilizumab in patients with COVID-19 pneumonia. Case 2.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32410234,"doi":"10.1002/jmv.26016","article_url":"https://pubmed.ncbi.nlm.nih.gov/32410234/","pub_year":2020,"published_authors":"Mazzitelli M\r\nArrighi E\r\nSerapide F\r\nPelle MC\r\nTassone B\r\nLionello R\r\nMarrazzo G\r\nLaganÃ  D\r\nCostanzo FS\r\nMatera G\r\nTrecarichi EM\r\nTorti C\r\nIDTM UMG COVID-19 Group.","article_author_email":"Author email could not be found.","journal":"Journal of medical virology","abstract":"Over the last months, pandemic SARS-CoV-2 caused a significant challenge for clinicians. Unfortunately, no approved and validated treatments are available. Intravenous tocilizumab, an antirheumatic drug, seems to be promising in counteracting cytokine storm caused by SARS-CoV-2 infection with associated clinical improvements. We report herein a case series of patients with COVID-19 pneumonia who were treated with tocilizumab administrated, for the first time, subcutaneously with good clinical and radiological outcomes. This article is protected by copyright. All rights reserved.          \r\n        Keywords:      \r\n                  COVID-19; SARS-COV-2; pneumonia; subcutaneous; tocilizumab.","article_type":"Original","study_type":"Case Report","number_of_patients":3,"article_patient_number":"","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"51-60 years","sex":"Female","ethnicity":null,"country_contracted":"Italy","country_treated":"Italy","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":true,"hypertension":true,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"Depression","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Pneumonia","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"After a period of follow-up","follow_up_period":"1 week after tocilizumab administration","relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[10776]},{"id":6021,"regimens":[{"id":11329,"duration":{"id":5384,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":7830,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11329}],"created":"2020-09-21T18:17:15.595684Z","updated":"2020-09-28T20:36:57.812617Z","dose":"162 mg","frequency":"Once","route":"SC","severity":"Inpatient","severity_detail":"","comments":null,"report":6021},{"id":11625,"duration":{"id":5670,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":8486,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11625}],"created":"2020-09-28T20:34:07.632190Z","updated":"2020-09-28T20:36:57.821543Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6021},{"id":11626,"duration":{"id":5671,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":8487,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11626}],"created":"2020-09-28T20:34:07.638915Z","updated":"2020-09-28T20:36:57.829686Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6021},{"id":11627,"duration":{"id":5672,"approximate_duration":null,"dates_unknown":false},"drug":{"id":9780,"name":"Piperacillin-Tazobactam","url":"cure-api2.ncats.io/v1/drugs/9780","rxNorm_id":null,"notes":null},"use_drug":[{"id":8488,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11627}],"created":"2020-09-28T20:34:07.645096Z","updated":"2020-09-28T20:36:57.856928Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6021}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":7886,"answer":"Imaging","answer_other":"","report":6021},{"id":7887,"answer":"Clinical assessment","answer_other":"","report":6021}],"how_diagnosis":[{"id":13447,"answer":"Imaging","answer_other":"","report":6021},{"id":13448,"answer":"PCR","answer_other":"","report":6021}],"author_username":"Kate Borkowski","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Nurse","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"Armenian","why_new_way":[{"id":3987,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6021}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-09-21T18:16:26.222255Z","updated":"2020-09-28T20:36:57.803733Z","title":"Use of subcutaneous tocilizumab in patients with COVID-19 pneumonia. Case 3.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32410234,"doi":"10.1002/jmv.26016","article_url":"https://pubmed.ncbi.nlm.nih.gov/32410234/","pub_year":2020,"published_authors":"Mazzitelli M\r\nArrighi E\r\nSerapide F\r\nPelle MC\r\nTassone B\r\nLionello R\r\nMarrazzo G\r\nLaganÃ  D\r\nCostanzo FS\r\nMatera G\r\nTrecarichi EM\r\nTorti C\r\nIDTM UMG COVID-19 Group.","article_author_email":"Author email could not be found.","journal":"Journal of medical virology","abstract":"Over the last months, pandemic SARS-CoV-2 caused a significant challenge for clinicians. Unfortunately, no approved and validated treatments are available. Intravenous tocilizumab, an antirheumatic drug, seems to be promising in counteracting cytokine storm caused by SARS-CoV-2 infection with associated clinical improvements. We report herein a case series of patients with COVID-19 pneumonia who were treated with tocilizumab administrated, for the first time, subcutaneously with good clinical and radiological outcomes. This article is protected by copyright. All rights reserved.          \r\n        Keywords:      \r\n                  COVID-19; SARS-COV-2; pneumonia; subcutaneous; tocilizumab.","article_type":"Original","study_type":"Case Report","number_of_patients":3,"article_patient_number":"3","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"51-60 years","sex":"Male","ethnicity":"Not Hispanic/Latino","country_contracted":"Italy","country_treated":"Italy","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":true,"hypertension":true,"cardiovascular_disease":false,"chronic_renal_disease":true,"chronic_liver_disease":true,"immunosuppressant_drugs":false,"intellectual_disability":true,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"Stroke and meningoencephalitis during childhood","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Pneumonia","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"After a period of follow-up","follow_up_period":"3 weeks","relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"Antiviral treatment with hydroxychloroquine and azytromycin was started. Fever continued and respiratory parameters worsened (PaO2-to-FiO2 ratio from 110 to 96). Chest X rays showed pneumonia, so piperacillin/tazobactam was added to treatment. Respiratory function continued to worse, so SC tocilizumab was administered with no side effects recorded. Mild elevation of liver function tests was already present at baseline. After administration of SC tocilizumab, fever disappeared, and lung function progressively improved, with reduction of oxygen support and positioning of nasal oxygen flow with 4 l/min.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6122,8342,9780,10776]},{"id":6035,"regimens":[{"id":11355,"duration":{"id":5410,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":7870,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11355},{"id":8419,"answer":"In a novel combination with another drug","answer_other":"","regimen":11355}],"created":"2020-09-22T15:33:56.583469Z","updated":"2020-09-27T23:53:44.479637Z","dose":null,"frequency":"","route":"","severity":"Inpatient","severity_detail":null,"comments":null,"report":6035},{"id":11356,"duration":{"id":5411,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8783,"name":"Lopinavir-Ritonavir","url":"cure-api2.ncats.io/v1/drugs/8783","rxNorm_id":null,"notes":null},"use_drug":[{"id":7871,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11356},{"id":8420,"answer":"In a novel combination with another drug","answer_other":"","regimen":11356}],"created":"2020-09-22T15:33:56.591701Z","updated":"2020-09-27T23:53:44.480466Z","dose":null,"frequency":"","route":"","severity":"Inpatient","severity_detail":null,"comments":null,"report":6035},{"id":11357,"duration":{"id":5412,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":7872,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11357},{"id":8421,"answer":"In a novel combination with another drug","answer_other":"","regimen":11357}],"created":"2020-09-22T15:33:56.598035Z","updated":"2020-09-27T23:53:44.481249Z","dose":null,"frequency":"Once","route":"","severity":"Inpatient","severity_detail":null,"comments":null,"report":6035}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":7904,"answer":"Clinical assessment","answer_other":"","report":6035},{"id":7905,"answer":"Imaging","answer_other":"","report":6035}],"how_diagnosis":[{"id":13482,"answer":"PCR","answer_other":"","report":6035},{"id":13483,"answer":"Imaging","answer_other":"","report":6035},{"id":13484,"answer":"Clinical assessment","answer_other":"","report":6035}],"author_username":"Kate Borkowski","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Nurse","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4008,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6035}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-09-22T15:33:11.157369Z","updated":"2020-09-27T23:53:44.435626Z","title":"Abnormalities on chest computed tomography in patients with coronavirus disease 2019. Case 1.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32420708,"doi":"10.20452/pamw.15363","article_url":"https://pubmed.ncbi.nlm.nih.gov/32420708/","pub_year":2020,"published_authors":"Rogalska-PÅoÅska M\r\nKuÅºmicz A\r\nÅapiÅski TW\r\nFlisiak R","article_author_email":"robert.flisiak@umb.edu.pl","journal":"Polish archives of internal medicine","abstract":"No abstract available","article_type":"Original","study_type":"Case Report","number_of_patients":3,"article_patient_number":"1","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"No","age":"61-70 years","sex":"Female","ethnicity":"Not Hispanic/Latino","country_contracted":"Poland","country_treated":"Poland","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":true,"site_of_disease":"Lungs","clinical_syndrome":"Pneumonia","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[8342,8783,10776]},{"id":6036,"regimens":[{"id":11358,"duration":{"id":5413,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":7876,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11358},{"id":8415,"answer":"In a novel combination with another drug","answer_other":"","regimen":11358}],"created":"2020-09-22T15:38:22.807352Z","updated":"2020-09-27T23:50:47.484273Z","dose":"400mg","frequency":"BID","route":"oral","severity":"Inpatient","severity_detail":null,"comments":null,"report":6036},{"id":11359,"duration":{"id":5414,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":8416,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11359},{"id":8417,"answer":"In a novel combination with another drug","answer_other":"","regimen":11359}],"created":"2020-09-22T15:38:22.814673Z","updated":"2020-09-27T23:50:47.485106Z","dose":"500mg","frequency":"","route":"IV","severity":null,"severity_detail":null,"comments":null,"report":6036},{"id":11360,"duration":{"id":5415,"approximate_duration":"1 day","dates_unknown":true},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":7877,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11360},{"id":8418,"answer":"In a novel combination with another drug","answer_other":"","regimen":11360}],"created":"2020-09-22T15:38:22.821115Z","updated":"2020-09-27T23:50:47.485908Z","dose":"400mg","frequency":"once","route":"","severity":"Inpatient","severity_detail":null,"comments":null,"report":6036}],"site_of_infection":[{"id":91,"answer":"Lungs","report":6036}],"specific_site":[{"id":39,"answer":"Respiratory tract infection","report":6036}],"how_outcome":[{"id":7908,"answer":"Clinical assessment","answer_other":"","report":6036}],"how_diagnosis":[{"id":13485,"answer":"PCR","answer_other":"","report":6036},{"id":13486,"answer":"Imaging","answer_other":"","report":6036}],"author_username":"Belinda Nhundu","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"","outcome_computed":"Deteriorated","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4009,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6036}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-09-22T15:37:12.113769Z","updated":"2020-09-27T23:50:47.436995Z","title":"COVID-19 in a Hispanic Woman.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32422081,"doi":"10.5858/arpa.2020-0217-SA","article_url":"https://pubmed.ncbi.nlm.nih.gov/32422081/","pub_year":2020,"published_authors":"Yan L\r\nMir M\r\nSanchez P\r\nBeg M\r\nPeters J\r\nEnriquez O\r\nGilbert A","article_author_email":"Author email could not be found.","journal":"Archives of pathology & laboratory medicine","abstract":"Since making its debut on the global stage in December 2019, coronavirus disease 2019 (COVID-19) has afflicted nearly 4 million people and caused hundreds of thousands of deaths. Case reports and case series depicting the clinical effects of the causative virus-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-have been published, yet few demonstrate the cytopathologic alterations of this disease. We present a clinical-pathologic correlation report of a previously healthy Hispanic woman with laboratory-confirmed COVID-19 who had typical features of acute respiratory distress syndrome (ARDS) and also showed cardiac abnormalities thought to represent fulminant viral myocarditis. Congruent with the ARDS clinical impression, autopsy findings were remarkable for extensive and markedly severe acute lung injury consistent with viral pneumonia, characterized by diffuse alveolar damage, pulmonary infarction, severe pulmonary edema, desquamation of pneumocytes with intra-alveolar aggregation, and pneumocyte morphologic alterations suggestive of viral cytopathic effect. However, there was incongruence between the clinical impression and the cardiovascular pathology findings in that viral myocarditis was not detected on histopathologic evaluation. This case highlights the importance of pathologic corroboration of the clinical impression and, in addition, illuminates the key role autopsy plays during a pandemic by providing valuable insight into viral pathology in tissues.","article_type":"Original","study_type":"Case Report","number_of_patients":1,"article_patient_number":"1","full_text_available":true,"outcome":"Patient died","surgery":"No","age":"41-50 years","sex":"Female","ethnicity":"Hispanic/Latino","country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Respiratory tract infection","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"While the patient was still on treatment","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"Developed severe multiorgan failure and died.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6122,8342,10776]},{"id":6037,"regimens":[{"id":11361,"duration":{"id":5416,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":7873,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11361},{"id":8412,"answer":"In a novel combination with another drug","answer_other":"","regimen":11361}],"created":"2020-09-22T15:41:54.548091Z","updated":"2020-09-27T23:49:25.406106Z","dose":null,"frequency":"","route":"","severity":"Inpatient","severity_detail":null,"comments":null,"report":6037},{"id":11362,"duration":{"id":5417,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8783,"name":"Lopinavir-Ritonavir","url":"cure-api2.ncats.io/v1/drugs/8783","rxNorm_id":null,"notes":null},"use_drug":[{"id":7874,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11362},{"id":8413,"answer":"In a novel combination with another drug","answer_other":"","regimen":11362}],"created":"2020-09-22T15:41:54.555606Z","updated":"2020-09-27T23:49:25.406984Z","dose":null,"frequency":"","route":"","severity":"Inpatient","severity_detail":null,"comments":null,"report":6037},{"id":11363,"duration":{"id":5418,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":7875,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11363},{"id":8414,"answer":"In a novel combination with another drug","answer_other":"","regimen":11363}],"created":"2020-09-22T15:41:54.562623Z","updated":"2020-09-27T23:49:25.407803Z","dose":null,"frequency":"","route":"","severity":"Inpatient","severity_detail":null,"comments":null,"report":6037}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":7906,"answer":"Clinical assessment","answer_other":"","report":6037},{"id":7907,"answer":"Imaging","answer_other":"","report":6037}],"how_diagnosis":[{"id":13487,"answer":"Clinical assessment","answer_other":"","report":6037},{"id":13488,"answer":"PCR","answer_other":"","report":6037}],"author_username":"Kate Borkowski","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Nurse","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4010,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6037}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-09-22T15:41:23.931430Z","updated":"2020-09-27T23:49:25.359254Z","title":"Abnormalities on chest computed tomography in patients with coronavirus disease 2019. Case 2.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32420708,"doi":"10.20452/pamw.15363","article_url":"https://pubmed.ncbi.nlm.nih.gov/32420708/","pub_year":2020,"published_authors":"Rogalska-PÅoÅska M\r\nKuÅºmicz A\r\nÅapiÅski TW\r\nFlisiak R","article_author_email":"robert.flisiak@umb.edu.pl","journal":"Polish archives of internal medicine","abstract":"No abstract available","article_type":"Original","study_type":"Case Report","number_of_patients":3,"article_patient_number":"2","full_text_available":true,"outcome":"Patient improved","surgery":"","age":"61-70 years","sex":"Male","ethnicity":"Not Hispanic/Latino","country_contracted":"Poland","country_treated":"Poland","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":true,"site_of_disease":"Lungs","clinical_syndrome":"Pneumonia","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"After a period of follow-up","follow_up_period":"10 days","relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"Routine blood tests were performed and the serological test was positive for Mycoplasma pneumoniae. The patient was treated with hydroxychloroquine, lopinavir/ritonavir, and tocilizumab. Due to M. pneumoniae infection, doxycycline was introduced. We observed rapid improvement of the patientâs general condition.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[8342,8783,10776]},{"id":6085,"regimens":[{"id":11477,"duration":{"id":5532,"approximate_duration":null,"dates_unknown":false},"drug":{"id":9463,"name":"Oseltamivir","url":"cure-api2.ncats.io/v1/drugs/9463","rxNorm_id":null,"notes":null},"use_drug":[{"id":8086,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11477},{"id":8087,"answer":"In a novel combination with another drug","answer_other":"","regimen":11477}],"created":"2020-09-24T02:33:48.945282Z","updated":"2020-09-24T16:22:25.791522Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6085},{"id":11478,"duration":{"id":5533,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":8088,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11478},{"id":8089,"answer":"In a novel combination with another drug","answer_other":"","regimen":11478}],"created":"2020-09-24T02:33:48.952895Z","updated":"2020-09-24T16:22:25.797828Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6085},{"id":11479,"duration":{"id":5534,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":8090,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11479},{"id":8091,"answer":"In a novel combination with another drug","answer_other":"","regimen":11479}],"created":"2020-09-24T02:33:48.959013Z","updated":"2020-09-24T16:22:25.803330Z","dose":"400 mg","frequency":"Single dose","route":"IV","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6085},{"id":11480,"duration":{"id":5535,"approximate_duration":"3 days","dates_unknown":true},"drug":{"id":9077,"name":"Methylprednisolone","url":"cure-api2.ncats.io/v1/drugs/9077","rxNorm_id":null,"notes":null},"use_drug":[{"id":8092,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11480},{"id":8093,"answer":"In a novel combination with another drug","answer_other":"","regimen":11480}],"created":"2020-09-24T02:33:48.965207Z","updated":"2020-09-24T16:22:25.808889Z","dose":"60 mg","frequency":"OD","route":"IV","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6085}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":7989,"answer":"Clinical assessment","answer_other":"","report":6085},{"id":7990,"answer":"Imaging","answer_other":"","report":6085}],"how_diagnosis":[{"id":13596,"answer":"Clinical assessment","answer_other":"","report":6085},{"id":13597,"answer":"Imaging","answer_other":"","report":6085},{"id":13598,"answer":"PCR","answer_other":"","report":6085}],"author_username":"Parvesh Paul","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"Christian Medical College, Ludhiana, Punjab, India.","author_country":"India","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4076,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6085}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"},{"id":550,"name":"Respiratory Tract Infections"}],"races":[{"id":334,"answer":"White","answer_other":""}],"created":"2020-09-24T02:30:54.935300Z","updated":"2020-09-24T16:22:25.783760Z","title":"Effectiveness of Tocilizumab in a COVID-19 Patient with Cytokine Release Syndrome.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32523930,"doi":"10.12890/2020_001731","article_url":"https://pubmed.ncbi.nlm.nih.gov/32523930/","pub_year":2020,"published_authors":"Uslu S","article_author_email":"Author email could not be found.","journal":"European journal of case reports in internal medicine","abstract":"Cytokine release syndrome (CRS) is a systemic inflammatory response that can be triggered by many factors such as infections. CRS in patients with coronavirus disease 2019 (COVID-19) is life-threatening and can occur very rapidly after COVID-19 diagnosis. Tocilizumab (TCZ), an interleukin-6 (IL-6) inhibitor, may ameliorate the CRS associated with severe COVID-19 and thus improve clinical outcomes. We present a case of life-threatening CRS caused by COVID-19 infection successfully treated with TCZ.          \r\n        Learning points:      \r\n              Cytokine release syndrome (CRS) is a systemic inflammatory response that can be triggered by COVID-19.CRS can be life-threatening in severe COVID-19.Tocilizumab may have a role in treating severe COVID-19 patients with CRS.          \r\n        Keywords:      \r\n                  COVID-19; Tocilizumab; cytokine release syndrome.","article_type":"Original","study_type":"Case Report","number_of_patients":1,"article_patient_number":"","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"41-50 years","sex":"Female","ethnicity":"Not Hispanic/Latino","country_contracted":"Turkey","country_treated":"Turkey","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":true,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Respiratory tract infection","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"Mechanical ventilation + \r\nlow-molecular-weight heparin\r\nA chest x-ray showed that the lesions significantly improved within 3 days of TCZ administration\r\nThe patient was successfully extubated 5 days after treatment with TCZ. No adverse events were described.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[8342,9077,9463,10776]},{"id":6086,"regimens":[{"id":11505,"duration":{"id":5560,"approximate_duration":"one day","dates_unknown":true},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":8120,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11505},{"id":8609,"answer":"In a novel combination with another drug","answer_other":"","regimen":11505}],"created":"2020-09-25T00:20:55.210263Z","updated":"2020-09-30T00:36:57.246416Z","dose":"400mg","frequency":"once","route":"IV","severity":"Inpatient","severity_detail":null,"comments":null,"report":6086},{"id":11691,"duration":null,"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":8610,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11691},{"id":8611,"answer":"In a novel combination with another drug","answer_other":"","regimen":11691}],"created":"2020-09-30T00:36:57.232928Z","updated":"2020-09-30T00:36:57.247268Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6086},{"id":11692,"duration":null,"drug":{"id":6675,"name":"Ceftriaxone","url":"cure-api2.ncats.io/v1/drugs/6675","rxNorm_id":null,"notes":null},"use_drug":[{"id":8612,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11692},{"id":8613,"answer":"In a novel combination with another drug","answer_other":"","regimen":11692}],"created":"2020-09-30T00:36:57.237645Z","updated":"2020-09-30T00:36:57.248081Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6086},{"id":11693,"duration":null,"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":8614,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11693},{"id":8615,"answer":"In a novel combination with another drug","answer_other":"","regimen":11693}],"created":"2020-09-30T00:36:57.242166Z","updated":"2020-09-30T00:36:57.248880Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6086}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":7999,"answer":"Clinical assessment","answer_other":"","report":6086}],"how_diagnosis":[{"id":13622,"answer":"PCR","answer_other":"","report":6086}],"author_username":"Belinda Nhundu","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4089,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6086}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[],"races":[],"created":"2020-09-24T13:44:04.007896Z","updated":"2020-09-30T00:36:57.199515Z","title":"Utilizing tocilizumab for the treatment of cytokine release syndrome in COVID-19. Case 1.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32425661,"doi":"10.1016/j.jcv.2020.104443","article_url":"https://pubmed.ncbi.nlm.nih.gov/32425661/","pub_year":2020,"published_authors":"Hassoun A\r\nThottacherry ED\r\nMuklewicz J\r\nAziz QU\r\nEdwards J","article_author_email":"Author email could not be found.","journal":"Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology","abstract":"No abstract available","article_type":"Original","study_type":"Case Report","number_of_patients":9,"article_patient_number":"1","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"No","age":"31-40 years","sex":"Male","ethnicity":"Hispanic/Latino","country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"","clinical_syndrome":"","severity":"Inpatient","prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"After a period of follow-up","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"Patient went home with self-care after 13 days on being in the hospital. Patient was not intubated during his stay.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6122,6675,8342,10776]},{"id":6096,"regimens":[{"id":11506,"duration":{"id":3760,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":8121,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11506},{"id":8548,"answer":"In a novel combination with another drug","answer_other":"","regimen":11506}],"created":"2020-09-25T00:39:15.718280Z","updated":"2020-09-30T02:35:14.112815Z","dose":"162mg","frequency":"Once","route":"SC","severity":"Inpatient","severity_detail":null,"comments":null,"report":6096},{"id":11664,"duration":null,"drug":{"id":6642,"name":"Cefepime","url":"cure-api2.ncats.io/v1/drugs/6642","rxNorm_id":null,"notes":null},"use_drug":[{"id":8549,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11664},{"id":8550,"answer":"In a novel combination with another drug","answer_other":"","regimen":11664}],"created":"2020-09-29T23:46:38.075600Z","updated":"2020-09-30T02:35:14.117127Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6096},{"id":11665,"duration":null,"drug":{"id":6675,"name":"Ceftriaxone","url":"cure-api2.ncats.io/v1/drugs/6675","rxNorm_id":null,"notes":null},"use_drug":[{"id":8551,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11665},{"id":8552,"answer":"In a novel combination with another drug","answer_other":"","regimen":11665}],"created":"2020-09-29T23:46:38.080059Z","updated":"2020-09-30T02:35:14.120758Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6096},{"id":11666,"duration":null,"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":8553,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11666},{"id":8554,"answer":"In a novel combination with another drug","answer_other":"","regimen":11666}],"created":"2020-09-29T23:46:38.084343Z","updated":"2020-09-30T02:35:14.124281Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6096},{"id":11667,"duration":null,"drug":{"id":8745,"name":"Linezolid","url":"cure-api2.ncats.io/v1/drugs/8745","rxNorm_id":null,"notes":null},"use_drug":[{"id":8555,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11667},{"id":8556,"answer":"In a novel combination with another drug","answer_other":"","regimen":11667}],"created":"2020-09-29T23:46:38.088763Z","updated":"2020-09-30T02:35:14.127876Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6096},{"id":11668,"duration":null,"drug":{"id":11121,"name":"Vancomycin","url":"cure-api2.ncats.io/v1/drugs/11121","rxNorm_id":11124,"notes":""},"use_drug":[{"id":8557,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11668},{"id":8558,"answer":"In a novel combination with another drug","answer_other":"","regimen":11668}],"created":"2020-09-29T23:46:38.092990Z","updated":"2020-09-30T02:35:14.131418Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6096}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8000,"answer":"Clinical assessment","answer_other":"","report":6096}],"how_diagnosis":[{"id":13623,"answer":"PCR","answer_other":"","report":6096}],"author_username":"Belinda Nhundu","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4090,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6096}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[],"races":[{"id":339,"answer":"White","answer_other":""}],"created":"2020-09-25T00:38:46.200199Z","updated":"2020-09-30T02:35:14.105026Z","title":"Utilizing tocilizumab for the treatment of cytokine release syndrome in COVID-19.Case 2","status":"Approved","anonymous":false,"published":true,"pubmed_id":32425661,"doi":"10.1016/j.jcv.2020.104443","article_url":"https://pubmed.ncbi.nlm.nih.gov/32425661/","pub_year":2020,"published_authors":"Hassoun A\r\nThottacherry ED\r\nMuklewicz J\r\nAziz QU\r\nEdwards J","article_author_email":"Author email could not be found.","journal":"Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology","abstract":"No abstract available","article_type":"Original","study_type":"Case Report","number_of_patients":9,"article_patient_number":"2","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"No","age":"51-60 years","sex":"Female","ethnicity":"Not Hispanic/Latino","country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":true,"lung_disease":false,"diabetes_mellitus":false,"hypertension":true,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"GERD, Migraines","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"Patient was intubated for 11 days during their hospital stay,  and was discharged home with family care after 21 days in the hospital.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6642,6675,8342,8745,10776,11121]},{"id":6097,"regimens":[{"id":11507,"duration":{"id":5562,"approximate_duration":"one","dates_unknown":true},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":8122,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11507},{"id":8559,"answer":"In a novel combination with another drug","answer_other":"","regimen":11507}],"created":"2020-09-25T00:57:19.323021Z","updated":"2020-09-29T23:49:06.758926Z","dose":"400mg","frequency":"one","route":"IV","severity":"ICU/Critical Care","severity_detail":null,"comments":null,"report":6097},{"id":11669,"duration":null,"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":8560,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11669},{"id":8561,"answer":"In a novel combination with another drug","answer_other":"","regimen":11669}],"created":"2020-09-29T23:49:06.749617Z","updated":"2020-09-29T23:49:06.759787Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6097},{"id":11670,"duration":null,"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":8562,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11670},{"id":8563,"answer":"In a novel combination with another drug","answer_other":"","regimen":11670}],"created":"2020-09-29T23:49:06.754400Z","updated":"2020-09-29T23:49:06.760618Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6097}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8001,"answer":"Clinical assessment","answer_other":"","report":6097}],"how_diagnosis":[{"id":13624,"answer":"PCR","answer_other":"","report":6097}],"author_username":"Belinda Nhundu","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4091,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6097}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[],"races":[{"id":340,"answer":"White","answer_other":""}],"created":"2020-09-25T00:56:58.233653Z","updated":"2020-09-29T23:49:06.717296Z","title":"Utilizing tocilizumab for the treatment of cytokine release syndrome in COVID-19.Case 3","status":"Approved","anonymous":false,"published":true,"pubmed_id":32425661,"doi":"10.1016/j.jcv.2020.104443","article_url":"https://pubmed.ncbi.nlm.nih.gov/32425661/","pub_year":2020,"published_authors":"Hassoun A\r\nThottacherry ED\r\nMuklewicz J\r\nAziz QU\r\nEdwards J","article_author_email":"Author email could not be found.","journal":"Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology","abstract":"No abstract available","article_type":"Original","study_type":"Case Report","number_of_patients":9,"article_patient_number":"3","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"No","age":"61-70 years","sex":"Female","ethnicity":"Not Hispanic/Latino","country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":true,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"GERD","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"Case series. Patient 3. Patient was intubated for 9 days during their hospital stay. Patient was discharged to a rehab after 22 days in the hospital.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6122,8342,10776]},{"id":6098,"regimens":[{"id":11508,"duration":{"id":5423,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":8123,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11508},{"id":8564,"answer":"In a novel combination with another drug","answer_other":"","regimen":11508}],"created":"2020-09-25T01:11:26.864557Z","updated":"2020-09-29T23:52:02.174016Z","dose":"162mg","frequency":"Once","route":"SC","severity":"Inpatient","severity_detail":null,"comments":null,"report":6098},{"id":11671,"duration":null,"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":8565,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11671},{"id":8566,"answer":"In a novel combination with another drug","answer_other":"","regimen":11671}],"created":"2020-09-29T23:52:02.165479Z","updated":"2020-09-29T23:52:02.174851Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6098},{"id":11672,"duration":null,"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":8567,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11672},{"id":8568,"answer":"In a novel combination with another drug","answer_other":"","regimen":11672}],"created":"2020-09-29T23:52:02.169853Z","updated":"2020-09-29T23:52:02.175637Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6098}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8002,"answer":"Clinical assessment","answer_other":"","report":6098}],"how_diagnosis":[{"id":13625,"answer":"PCR","answer_other":"","report":6098}],"author_username":"Belinda Nhundu","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4092,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6098}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[],"races":[{"id":341,"answer":"Asian","answer_other":""}],"created":"2020-09-25T01:05:46.529938Z","updated":"2020-09-29T23:52:02.133325Z","title":"Utilizing tocilizumab for the treatment of cytokine release syndrome in COVID-19.Case 4","status":"Approved","anonymous":false,"published":true,"pubmed_id":32425661,"doi":"10.1016/j.jcv.2020.104443","article_url":"https://pubmed.ncbi.nlm.nih.gov/32425661/","pub_year":2020,"published_authors":"Hassoun A\r\nThottacherry ED\r\nMuklewicz J\r\nAziz QU\r\nEdwards J","article_author_email":"Author email could not be found.","journal":"Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology","abstract":"No abstract available","article_type":"Original","study_type":"Case Series","number_of_patients":9,"article_patient_number":"4","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"No","age":"51-60 years","sex":"Male","ethnicity":"Not Hispanic/Latino","country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":true,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"Obesity","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"Patient was discharged home with self-care after 8 days of being hospitalized.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6122,8342,10776]},{"id":6099,"regimens":[{"id":11509,"duration":{"id":5564,"approximate_duration":"2days","dates_unknown":true},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":8124,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11509},{"id":8569,"answer":"In a novel combination with another drug","answer_other":"","regimen":11509}],"created":"2020-09-25T01:18:02.924204Z","updated":"2020-09-29T23:56:32.698771Z","dose":"400mg","frequency":"once","route":"IV","severity":"ICU/Critical Care","severity_detail":"dosage changed to 162mg SC for second dosage","comments":null,"report":6099},{"id":11673,"duration":null,"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":8570,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11673},{"id":8571,"answer":"In a novel combination with another drug","answer_other":"","regimen":11673}],"created":"2020-09-29T23:56:32.677318Z","updated":"2020-09-29T23:56:32.699671Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6099},{"id":11674,"duration":null,"drug":{"id":8598,"name":"Ivermectin","url":"cure-api2.ncats.io/v1/drugs/8598","rxNorm_id":null,"notes":null},"use_drug":[{"id":8572,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11674},{"id":8573,"answer":"In a novel combination with another drug","answer_other":"","regimen":11674}],"created":"2020-09-29T23:56:32.681770Z","updated":"2020-09-29T23:56:32.700488Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6099},{"id":11675,"duration":null,"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":8574,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11675},{"id":8575,"answer":"In a novel combination with another drug","answer_other":"","regimen":11675}],"created":"2020-09-29T23:56:32.685952Z","updated":"2020-09-29T23:56:32.701284Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6099},{"id":11676,"duration":null,"drug":{"id":8745,"name":"Linezolid","url":"cure-api2.ncats.io/v1/drugs/8745","rxNorm_id":null,"notes":null},"use_drug":[{"id":8576,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11676},{"id":8577,"answer":"In a novel combination with another drug","answer_other":"","regimen":11676}],"created":"2020-09-29T23:56:32.690334Z","updated":"2020-09-29T23:56:32.702110Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6099},{"id":11677,"duration":null,"drug":{"id":8971,"name":"Meropenem","url":"cure-api2.ncats.io/v1/drugs/8971","rxNorm_id":null,"notes":null},"use_drug":[{"id":8578,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11677},{"id":8579,"answer":"In a novel combination with another drug","answer_other":"","regimen":11677}],"created":"2020-09-29T23:56:32.694606Z","updated":"2020-09-29T23:56:32.702905Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6099}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8003,"answer":"Clinical assessment","answer_other":"","report":6099}],"how_diagnosis":[{"id":13626,"answer":"PCR","answer_other":"","report":6099}],"author_username":"Belinda Nhundu","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4093,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6099}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[{"id":342,"answer":"White","answer_other":""}],"created":"2020-09-25T01:17:44.927327Z","updated":"2020-09-29T23:56:32.641516Z","title":"Utilizing tocilizumab for the treatment of cytokine release syndrome in COVID-19.Case 5","status":"Approved","anonymous":false,"published":true,"pubmed_id":32425661,"doi":"10.1016/j.jcv.2020.104443","article_url":"https://pubmed.ncbi.nlm.nih.gov/32425661/","pub_year":2020,"published_authors":"Hassoun A\r\nThottacherry ED\r\nMuklewicz J\r\nAziz QU\r\nEdwards J","article_author_email":"Author email could not be found.","journal":"Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology","abstract":"No abstract available","article_type":"Original","study_type":"Case Series","number_of_patients":9,"article_patient_number":"5","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"No","age":"61-70 years","sex":"Male","ethnicity":"Not Hispanic/Latino","country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6122,8342,8598,8745,8971,10776]},{"id":6100,"regimens":[{"id":11510,"duration":{"id":2520,"approximate_duration":"2 Days","dates_unknown":true},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":8125,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11510},{"id":8580,"answer":"In a novel combination with another drug","answer_other":"","regimen":11510}],"created":"2020-09-25T03:00:43.214378Z","updated":"2020-09-30T00:01:24.044626Z","dose":"400mg","frequency":"QD","route":"IV","severity":"Inpatient","severity_detail":null,"comments":null,"report":6100},{"id":11678,"duration":null,"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":8581,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11678},{"id":8582,"answer":"In a novel combination with another drug","answer_other":"","regimen":11678}],"created":"2020-09-30T00:01:24.022177Z","updated":"2020-09-30T00:01:24.045489Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6100},{"id":11679,"duration":null,"drug":{"id":6642,"name":"Cefepime","url":"cure-api2.ncats.io/v1/drugs/6642","rxNorm_id":null,"notes":null},"use_drug":[{"id":8583,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11679},{"id":8584,"answer":"In a novel combination with another drug","answer_other":"","regimen":11679}],"created":"2020-09-30T00:01:24.026890Z","updated":"2020-09-30T00:01:24.046326Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6100},{"id":11680,"duration":null,"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":8585,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11680},{"id":8586,"answer":"In a novel combination with another drug","answer_other":"","regimen":11680}],"created":"2020-09-30T00:01:24.031656Z","updated":"2020-09-30T00:01:24.047122Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6100},{"id":11681,"duration":null,"drug":{"id":9077,"name":"Methylprednisolone","url":"cure-api2.ncats.io/v1/drugs/9077","rxNorm_id":null,"notes":null},"use_drug":[{"id":8587,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11681},{"id":8588,"answer":"In a novel combination with another drug","answer_other":"","regimen":11681}],"created":"2020-09-30T00:01:24.036082Z","updated":"2020-09-30T00:01:24.047951Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6100},{"id":11682,"duration":null,"drug":{"id":11121,"name":"Vancomycin","url":"cure-api2.ncats.io/v1/drugs/11121","rxNorm_id":11124,"notes":""},"use_drug":[{"id":8589,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11682},{"id":8590,"answer":"In a novel combination with another drug","answer_other":"","regimen":11682}],"created":"2020-09-30T00:01:24.040283Z","updated":"2020-09-30T00:01:24.048720Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6100}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8004,"answer":"Clinical assessment","answer_other":"","report":6100}],"how_diagnosis":[{"id":13627,"answer":"PCR","answer_other":"","report":6100}],"author_username":"Belinda Nhundu","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"","outcome_computed":"Deteriorated","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4094,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6100}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[],"races":[{"id":343,"answer":"Black or African American","answer_other":""}],"created":"2020-09-25T03:00:08.713801Z","updated":"2020-09-30T00:01:23.985958Z","title":"Utilizing tocilizumab for the treatment of cytokine release syndrome in COVID-19.Case 6","status":"Approved","anonymous":false,"published":true,"pubmed_id":32425661,"doi":"10.1016/j.jcv.2020.104443","article_url":"https://pubmed.ncbi.nlm.nih.gov/32425661/","pub_year":2020,"published_authors":"Hassoun A\r\nThottacherry ED\r\nMuklewicz J\r\nAziz QU\r\nEdwards J","article_author_email":"Author email could not be found.","journal":"Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology","abstract":"No abstract available","article_type":"Original","study_type":"Case Series","number_of_patients":9,"article_patient_number":"6","full_text_available":true,"outcome":"Patient died","surgery":"No","age":"81-89 years","sex":"Male","ethnicity":"Not Hispanic/Latino","country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":true,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"Hyperlipidemia, dementia","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"Patient was not intubated during hospitalization, and expired after 12 days of being hospitalized.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6122,6642,8342,9077,10776,11121]},{"id":6101,"regimens":[{"id":11511,"duration":{"id":5555,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":8126,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11511},{"id":8591,"answer":"In a novel combination with another drug","answer_other":"","regimen":11511}],"created":"2020-09-25T03:09:14.659678Z","updated":"2020-09-30T01:20:52.526657Z","dose":"162mg","frequency":"Once","route":"SC","severity":"ICU/Critical Care","severity_detail":null,"comments":null,"report":6101},{"id":11683,"duration":null,"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":8592,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11683},{"id":8593,"answer":"In a novel combination with another drug","answer_other":"","regimen":11683}],"created":"2020-09-30T00:31:19.278190Z","updated":"2020-09-30T01:20:52.530984Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6101},{"id":11684,"duration":null,"drug":{"id":6642,"name":"Cefepime","url":"cure-api2.ncats.io/v1/drugs/6642","rxNorm_id":null,"notes":null},"use_drug":[{"id":8594,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11684},{"id":8595,"answer":"In a novel combination with another drug","answer_other":"","regimen":11684}],"created":"2020-09-30T00:31:19.282695Z","updated":"2020-09-30T01:20:52.534614Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6101},{"id":11685,"duration":null,"drug":{"id":6675,"name":"Ceftriaxone","url":"cure-api2.ncats.io/v1/drugs/6675","rxNorm_id":null,"notes":null},"use_drug":[{"id":8596,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11685},{"id":8597,"answer":"In a novel combination with another drug","answer_other":"","regimen":11685}],"created":"2020-09-30T00:31:19.286981Z","updated":"2020-09-30T01:20:52.538116Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6101},{"id":11686,"duration":null,"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":8598,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11686},{"id":8599,"answer":"In a novel combination with another drug","answer_other":"","regimen":11686}],"created":"2020-09-30T00:31:19.291135Z","updated":"2020-09-30T01:20:52.541674Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6101},{"id":11687,"duration":null,"drug":{"id":11121,"name":"Vancomycin","url":"cure-api2.ncats.io/v1/drugs/11121","rxNorm_id":11124,"notes":""},"use_drug":[{"id":8600,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11687},{"id":8601,"answer":"In a novel combination with another drug","answer_other":"","regimen":11687}],"created":"2020-09-30T00:31:19.295386Z","updated":"2020-09-30T01:20:52.545262Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6101}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8005,"answer":"Clinical assessment","answer_other":"","report":6101}],"how_diagnosis":[{"id":13628,"answer":"PCR","answer_other":"","report":6101}],"author_username":"Belinda Nhundu","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"","outcome_computed":"Deteriorated","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4095,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6101}],"adverse_event_outcome":[{"id":68,"answer":"Death","report":6101}],"is_author":false,"cross_linked_diseases":[],"races":[{"id":344,"answer":"Black or African American","answer_other":""}],"created":"2020-09-25T03:08:39.528484Z","updated":"2020-09-30T01:20:52.518668Z","title":"Utilizing tocilizumab for the treatment of cytokine release syndrome in COVID-19. Case 7","status":"Approved","anonymous":false,"published":true,"pubmed_id":32425661,"doi":"10.1016/j.jcv.2020.104443","article_url":null,"pub_year":2020,"published_authors":"","article_author_email":"Author email could not be found.","journal":"Journal of Clinical Virology","abstract":"","article_type":"Original","study_type":"Case Series","number_of_patients":9,"article_patient_number":"7","full_text_available":true,"outcome":"Patient died","surgery":"No","age":"61-70 years","sex":"Female","ethnicity":"Not Hispanic/Latino","country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":true,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":true,"adverse_events":"Patient 7 underwent cardiac arrest after tocilizumab therapy.","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"Patient died after 6 days of being hospitalized. Patient underwent cardiac arrest after tocilizumab therapy, making it impossible to interpret the effect of tocilizumab.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6122,6642,6675,8342,10776,11121]},{"id":6103,"regimens":[{"id":11513,"duration":{"id":5568,"approximate_duration":"2days","dates_unknown":true},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":8128,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11513},{"id":8602,"answer":"In a novel combination with another drug","answer_other":"","regimen":11513}],"created":"2020-09-25T09:44:05.428923Z","updated":"2020-09-30T00:34:19.252437Z","dose":"400mg","frequency":"QD","route":"IV","severity":"Inpatient","severity_detail":null,"comments":null,"report":6103},{"id":11688,"duration":null,"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":8603,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11688},{"id":8604,"answer":"In a novel combination with another drug","answer_other":"","regimen":11688}],"created":"2020-09-30T00:34:19.239217Z","updated":"2020-09-30T00:34:19.253297Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6103},{"id":11689,"duration":null,"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":8605,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11689},{"id":8606,"answer":"In a novel combination with another drug","answer_other":"","regimen":11689}],"created":"2020-09-30T00:34:19.243608Z","updated":"2020-09-30T00:34:19.254134Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6103},{"id":11690,"duration":null,"drug":{"id":9077,"name":"Methylprednisolone","url":"cure-api2.ncats.io/v1/drugs/9077","rxNorm_id":null,"notes":null},"use_drug":[{"id":8607,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11690},{"id":8608,"answer":"In a novel combination with another drug","answer_other":"","regimen":11690}],"created":"2020-09-30T00:34:19.247962Z","updated":"2020-09-30T00:34:19.254949Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6103}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8007,"answer":"Clinical assessment","answer_other":"","report":6103}],"how_diagnosis":[{"id":13630,"answer":"PCR","answer_other":"","report":6103}],"author_username":"Belinda Nhundu","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4097,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6103}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[],"races":[{"id":346,"answer":"White","answer_other":""}],"created":"2020-09-25T09:43:25.255354Z","updated":"2020-09-30T00:34:19.206857Z","title":"Utilizing tocilizumab for the treatment of cytokine release syndrome in COVID-19.Case 9","status":"Approved","anonymous":false,"published":true,"pubmed_id":32425661,"doi":"10.1016/j.jcv.2020.104443","article_url":"https://pubmed.ncbi.nlm.nih.gov/32425661/","pub_year":2020,"published_authors":"Hassoun A\r\nThottacherry ED\r\nMuklewicz J\r\nAziz QU\r\nEdwards J","article_author_email":"Author email could not be found.","journal":"Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology","abstract":"No abstract available","article_type":"Original","study_type":"Case Series","number_of_patients":9,"article_patient_number":"9","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"No","age":"61-70 years","sex":"Male","ethnicity":"Not Hispanic/Latino","country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":true,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"Patient was discharged home with self-care after 13 days of being hospitalized.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6122,8342,9077,10776]},{"id":6107,"regimens":[{"id":11522,"duration":{"id":5577,"approximate_duration":"one day","dates_unknown":true},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":8137,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11522},{"id":8438,"answer":"In a novel combination with another drug","answer_other":"","regimen":11522}],"created":"2020-09-25T11:42:12.408629Z","updated":"2020-09-28T03:36:12.493953Z","dose":"400mg","frequency":"once","route":"IV","severity":"Inpatient","severity_detail":null,"comments":null,"report":6107},{"id":11523,"duration":{"id":5578,"approximate_duration":"5days","dates_unknown":true},"drug":{"id":11165,"name":"Favipiravir","url":"cure-api2.ncats.io/v1/drugs/11165","rxNorm_id":null,"notes":null},"use_drug":[{"id":8138,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11523},{"id":8439,"answer":"In a novel combination with another drug","answer_other":"","regimen":11523}],"created":"2020-09-25T11:42:12.416745Z","updated":"2020-09-28T03:36:12.494896Z","dose":null,"frequency":"","route":"","severity":"Inpatient","severity_detail":null,"comments":null,"report":6107},{"id":11524,"duration":null,"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":8139,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11524},{"id":8440,"answer":"In a novel combination with another drug","answer_other":"","regimen":11524}],"created":"2020-09-25T11:53:24.655663Z","updated":"2020-09-28T03:36:12.495754Z","dose":null,"frequency":"","route":"","severity":"Inpatient","severity_detail":null,"comments":null,"report":6107},{"id":11525,"duration":null,"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":8140,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11525},{"id":8441,"answer":"In a novel combination with another drug","answer_other":"","regimen":11525}],"created":"2020-09-25T11:53:24.659845Z","updated":"2020-09-28T03:36:12.496534Z","dose":null,"frequency":"","route":"","severity":"Inpatient","severity_detail":null,"comments":null,"report":6107},{"id":11526,"duration":null,"drug":{"id":9463,"name":"Oseltamivir","url":"cure-api2.ncats.io/v1/drugs/9463","rxNorm_id":null,"notes":null},"use_drug":[{"id":8141,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11526},{"id":8442,"answer":"In a novel combination with another drug","answer_other":"","regimen":11526}],"created":"2020-09-25T11:53:24.663830Z","updated":"2020-09-28T03:36:12.497298Z","dose":null,"frequency":"","route":"","severity":"Inpatient","severity_detail":null,"comments":null,"report":6107}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8011,"answer":"Clinical assessment","answer_other":"","report":6107}],"how_diagnosis":[{"id":13634,"answer":"PCR","answer_other":"","report":6107}],"author_username":"Belinda Nhundu","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4101,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6107}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-09-25T10:33:29.984389Z","updated":"2020-09-28T03:36:12.438781Z","title":"Coronavirus 19 presenting with atypical Sweet's syndrome.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32452542,"doi":"10.1111/jdv.16662","article_url":"https://pubmed.ncbi.nlm.nih.gov/32452542/","pub_year":2020,"published_authors":"TaÅkÄ±n B\r\nVural S\r\nAltuÄ E\r\nDemirkesen C\r\nKocatÃ¼rk E\r\nÃelebi Ä°\r\nFerhanoÄlu B\r\nAlper S","article_author_email":"Author email could not be found.","journal":"Journal of the European Academy of Dermatology and Venereology : JEADV","abstract":"On March 11, 2020, the first case of the novel coronavirus 2019 disease (COVIDâ19) was officially confirmed in Turkey. The disease continues to spread, and the number of patients has risen to 120,000 by the end of April. In this observation, we report an atypical presentation of COVIDâ19 in a patient with indurated painful nodules. Aâ61âyearsâold woman with a oneâweek history of fever (axillary 38Â°C) and nodules on the cheek was admitted to the hospital with fatigue, arthralgia and myalgia.","article_type":"Original","study_type":"Case Report","number_of_patients":1,"article_patient_number":"1","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"No","age":"61-70 years","sex":"Female","ethnicity":null,"country_contracted":"Turkey","country_treated":"Turkey","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"Skin","clinical_syndrome":"skin nodules, fever, myalgia","severity":null,"prev_treatment":"","unusual":"dermatological manifestation of Covid without respiratory symptoms.","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"Concurrent dermatosis with Covid 19","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6122,11165,8342,9463,10776]},{"id":6120,"regimens":[{"id":11559,"duration":{"id":5611,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":8211,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11559},{"id":8218,"answer":"In a novel combination with another drug","answer_other":"","regimen":11559}],"created":"2020-09-25T19:38:18.285635Z","updated":"2020-09-25T19:50:36.434774Z","dose":null,"frequency":"2 doses","route":"","severity":"ICU/Critical Care","severity_detail":null,"comments":null,"report":6120},{"id":11563,"duration":null,"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":8219,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11563},{"id":8220,"answer":"In a novel combination with another drug","answer_other":"","regimen":11563}],"created":"2020-09-25T19:50:36.416894Z","updated":"2020-09-25T19:50:36.435668Z","dose":null,"frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":null,"comments":null,"report":6120},{"id":11564,"duration":null,"drug":{"id":9077,"name":"Methylprednisolone","url":"cure-api2.ncats.io/v1/drugs/9077","rxNorm_id":null,"notes":null},"use_drug":[{"id":8221,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11564},{"id":8222,"answer":"In a novel combination with another drug","answer_other":"","regimen":11564}],"created":"2020-09-25T19:50:36.421743Z","updated":"2020-09-25T19:50:36.436580Z","dose":null,"frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":null,"comments":null,"report":6120},{"id":11565,"duration":null,"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":8223,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11565},{"id":8224,"answer":"In a novel combination with another drug","answer_other":"","regimen":11565}],"created":"2020-09-25T19:50:36.426299Z","updated":"2020-09-25T19:50:36.437411Z","dose":null,"frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":null,"comments":null,"report":6120},{"id":11566,"duration":null,"drug":{"id":8783,"name":"Lopinavir-Ritonavir","url":"cure-api2.ncats.io/v1/drugs/8783","rxNorm_id":null,"notes":null},"use_drug":[{"id":8225,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11566},{"id":8226,"answer":"In a novel combination with another drug","answer_other":"","regimen":11566}],"created":"2020-09-25T19:50:36.430573Z","updated":"2020-09-25T19:50:36.438225Z","dose":null,"frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":null,"comments":null,"report":6120}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8030,"answer":"Clinical assessment","answer_other":"","report":6120},{"id":8031,"answer":"Imaging","answer_other":"","report":6120}],"how_diagnosis":[{"id":13666,"answer":"Clinical assessment","answer_other":"","report":6120},{"id":13667,"answer":"Imaging","answer_other":"","report":6120},{"id":13668,"answer":"PCR","answer_other":"","report":6120}],"author_username":"Parvesh Paul","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"Christian Medical College, Ludhiana, Punjab, India.","author_country":"India","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4114,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6120}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"},{"id":550,"name":"Respiratory Tract Infections"}],"races":[{"id":356,"answer":"White","answer_other":""}],"created":"2020-09-25T19:37:38.301160Z","updated":"2020-09-25T19:50:36.386846Z","title":"Severe SARS-CoV-2 Infection in Children With Suspected Acute Abdomen: A Case Series From a Tertiary Hospital in Spain. Case 1","status":"Approved","anonymous":false,"published":true,"pubmed_id":32467457,"doi":"10.1097/INF.0000000000002777","article_url":"https://pubmed.ncbi.nlm.nih.gov/32467457/","pub_year":2020,"published_authors":"Cabrero-HernÃ¡ndez M\r\nGarcÃ­a-Salido A\r\nLeoz-Gordillo I\r\nAlonso-Cadenas JA\r\nGochi-Valdovinos A\r\nGonzÃ¡lez Brabin A\r\nDe Lama Caro-PatÃ³n G\r\nNieto-Moro M\r\nde-Azagra-Garde AM\r\nSerrano-GonzÃ¡lez A","article_author_email":"Author email could not be found.","journal":"The Pediatric infectious disease journal","abstract":"We describe 5 children with severe SARS-CoV-2 infection, hemodynamic instability and suspected acute abdomen. This form of the disease has not been previously documented. Four of the cases were confirmed SARS-CoV-2 infection and 1 probable. All of them were previously healthy and needed a pediatric critical care unit admission. The respiratory symptoms were not dominant or were absent. Also, fever was observed. Laboratory testing revealed lymphopenia and high levels of C-reactive protein and procalcitonin with D-dimer, ferritin and interleukin-6 usually elevated. Respiratory support and inotropic support were almost always necessary. In all of them, deterioration occurred on the day of admission.","article_type":"Original","study_type":"Case Report","number_of_patients":5,"article_patient_number":"1","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"11-15 years","sex":"Male","ethnicity":"Hispanic/Latino","country_contracted":"Spain","country_treated":"Spain","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Respiratory tract infection with diarrhea","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"Findings from abdominal ultrasound and abdominal computed tomography (CT) showed signs of ileitis and colitis.\r\nInotropic medication (norepinephrine and adrenaline) were initiated on admission in addition to meropenem and amikacin.\r\nMechanical ventilation +\r\nLow molecular weight heparin +","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6122,8342,8783,9077,10776]},{"id":6126,"regimens":[{"id":11587,"duration":{"id":5635,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":8269,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11587},{"id":8270,"answer":"In a novel combination with another drug","answer_other":"","regimen":11587}],"created":"2020-09-26T18:09:14.778557Z","updated":"2020-09-26T18:23:18.312825Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6126},{"id":11588,"duration":{"id":5636,"approximate_duration":null,"dates_unknown":false},"drug":{"id":9077,"name":"Methylprednisolone","url":"cure-api2.ncats.io/v1/drugs/9077","rxNorm_id":null,"notes":null},"use_drug":[{"id":8271,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11588},{"id":8272,"answer":"In a novel combination with another drug","answer_other":"","regimen":11588}],"created":"2020-09-26T18:09:14.786532Z","updated":"2020-09-26T18:23:18.318950Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6126},{"id":11589,"duration":{"id":5637,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":8274,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11589},{"id":8273,"answer":"In a novel combination with another drug","answer_other":"","regimen":11589}],"created":"2020-09-26T18:09:14.792767Z","updated":"2020-09-26T18:23:18.324677Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6126},{"id":11590,"duration":{"id":5638,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8783,"name":"Lopinavir-Ritonavir","url":"cure-api2.ncats.io/v1/drugs/8783","rxNorm_id":null,"notes":null},"use_drug":[{"id":8275,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11590},{"id":8276,"answer":"In a novel combination with another drug","answer_other":"","regimen":11590}],"created":"2020-09-26T18:09:14.799227Z","updated":"2020-09-26T18:23:18.329962Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6126},{"id":11591,"duration":{"id":5639,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":8277,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11591},{"id":8278,"answer":"In a novel combination with another drug","answer_other":"","regimen":11591}],"created":"2020-09-26T18:09:14.805107Z","updated":"2020-09-26T18:23:18.335639Z","dose":"single dose","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6126}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8036,"answer":"Clinical assessment","answer_other":"","report":6126}],"how_diagnosis":[{"id":13678,"answer":"Clinical assessment","answer_other":"","report":6126},{"id":13679,"answer":"PCR","answer_other":"","report":6126},{"id":13680,"answer":"Imaging","answer_other":"","report":6126}],"author_username":"Parvesh Paul","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"Christian Medical College, Ludhiana, Punjab, India.","author_country":"India","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4120,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6126}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[{"id":359,"answer":"White","answer_other":""}],"created":"2020-09-26T18:06:58.870379Z","updated":"2020-09-26T18:23:18.304900Z","title":"Severe SARS-CoV-2 Infection in Children With Suspected Acute Abdomen: A Case Series From a Tertiary Hospital in Spain. Case 3","status":"Approved","anonymous":false,"published":true,"pubmed_id":32467457,"doi":"10.1097/INF.0000000000002777","article_url":"https://pubmed.ncbi.nlm.nih.gov/32467457/","pub_year":2020,"published_authors":"Cabrero-HernÃ¡ndez M\r\nGarcÃ­a-Salido A\r\nLeoz-Gordillo I\r\nAlonso-Cadenas JA\r\nGochi-Valdovinos A\r\nGonzÃ¡lez Brabin A\r\nDe Lama Caro-PatÃ³n G\r\nNieto-Moro M\r\nde-Azagra-Garde AM\r\nSerrano-GonzÃ¡lez A","article_author_email":"Author email could not be found.","journal":"The Pediatric infectious disease journal","abstract":"We describe 5 children with severe SARS-CoV-2 infection, hemodynamic instability and suspected acute abdomen. This form of the disease has not been previously documented. Four of the cases were confirmed SARS-CoV-2 infection and 1 probable. All of them were previously healthy and needed a pediatric critical care unit admission. The respiratory symptoms were not dominant or were absent. Also, fever was observed. Laboratory testing revealed lymphopenia and high levels of C-reactive protein and procalcitonin with D-dimer, ferritin and interleukin-6 usually elevated. Respiratory support and inotropic support were almost always necessary. In all of them, deterioration occurred on the day of admission.","article_type":"Original","study_type":"Case Report","number_of_patients":5,"article_patient_number":"3","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"6-10 years","sex":"Female","ethnicity":"Hispanic/Latino","country_contracted":"Spain","country_treated":"Spain","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Respiratory tract infection with diarrhea and vomiting","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"On examination, she was hemodynamically stable but showed signs of dehydration. Elevation of acute phase reactants was observed on blood testing; as a result, treatment with intravenous cefotaxime was initiated, and a COVID-19 PCR was performed on nasal swab samples, with positive results. \r\nAfter volume expansion with crystalloids, she was admitted to the PICU. Inotropic support with norepinephrine was administered. An abdominal ultrasound scan was performed, revealing signs of intestinal inflammation. She received respiratory support with HFNC for tachypnea, and a right pulmonary infiltrate was visible on the chest radiograph.\r\nLow molecular weight Heparin - Prophlactic dose","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6122,8342,8783,9077,10776]},{"id":6127,"regimens":[{"id":11592,"duration":{"id":5640,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":8279,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11592},{"id":8280,"answer":"In a novel combination with another drug","answer_other":"","regimen":11592}],"created":"2020-09-26T18:32:27.143233Z","updated":"2020-09-26T18:47:39.128509Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6127},{"id":11593,"duration":{"id":5641,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":8281,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11593},{"id":8282,"answer":"In a novel combination with another drug","answer_other":"","regimen":11593}],"created":"2020-09-26T18:32:27.150815Z","updated":"2020-09-26T18:47:39.134747Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6127},{"id":11594,"duration":{"id":5642,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8783,"name":"Lopinavir-Ritonavir","url":"cure-api2.ncats.io/v1/drugs/8783","rxNorm_id":null,"notes":null},"use_drug":[{"id":8283,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11594},{"id":8284,"answer":"In a novel combination with another drug","answer_other":"","regimen":11594}],"created":"2020-09-26T18:32:27.157020Z","updated":"2020-09-26T18:47:39.140249Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6127},{"id":11595,"duration":{"id":5643,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":8285,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11595},{"id":8286,"answer":"In a novel combination with another drug","answer_other":"","regimen":11595}],"created":"2020-09-26T18:32:27.162939Z","updated":"2020-09-26T18:47:39.145745Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6127},{"id":11596,"duration":{"id":5644,"approximate_duration":null,"dates_unknown":false},"drug":{"id":9077,"name":"Methylprednisolone","url":"cure-api2.ncats.io/v1/drugs/9077","rxNorm_id":null,"notes":null},"use_drug":[{"id":8287,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11596},{"id":8288,"answer":"In a novel combination with another drug","answer_other":"","regimen":11596}],"created":"2020-09-26T18:32:27.168869Z","updated":"2020-09-26T18:47:39.151614Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6127}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8037,"answer":"Clinical assessment","answer_other":"","report":6127}],"how_diagnosis":[{"id":13681,"answer":"Clinical assessment","answer_other":"","report":6127},{"id":13682,"answer":"Serology","answer_other":"","report":6127}],"author_username":"Parvesh Paul","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"Christian Medical College, Ludhiana, Punjab, India.","author_country":"India","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4121,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6127}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[{"id":360,"answer":"White","answer_other":""}],"created":"2020-09-26T18:30:29.521731Z","updated":"2020-09-26T18:47:39.120719Z","title":"Severe SARS-CoV-2 Infection in Children With Suspected Acute Abdomen: A Case Series From a Tertiary Hospital in Spain. Case 4","status":"Approved","anonymous":false,"published":true,"pubmed_id":32467457,"doi":"10.1097/INF.0000000000002777","article_url":"https://pubmed.ncbi.nlm.nih.gov/32467457/","pub_year":2020,"published_authors":"Cabrero-HernÃ¡ndez M\r\nGarcÃ­a-Salido A\r\nLeoz-Gordillo I\r\nAlonso-Cadenas JA\r\nGochi-Valdovinos A\r\nGonzÃ¡lez Brabin A\r\nDe Lama Caro-PatÃ³n G\r\nNieto-Moro M\r\nde-Azagra-Garde AM\r\nSerrano-GonzÃ¡lez A","article_author_email":"Author email could not be found.","journal":"The Pediatric infectious disease journal","abstract":"We describe 5 children with severe SARS-CoV-2 infection, hemodynamic instability and suspected acute abdomen. This form of the disease has not been previously documented. Four of the cases were confirmed SARS-CoV-2 infection and 1 probable. All of them were previously healthy and needed a pediatric critical care unit admission. The respiratory symptoms were not dominant or were absent. Also, fever was observed. Laboratory testing revealed lymphopenia and high levels of C-reactive protein and procalcitonin with D-dimer, ferritin and interleukin-6 usually elevated. Respiratory support and inotropic support were almost always necessary. In all of them, deterioration occurred on the day of admission.","article_type":"Original","study_type":"Case Report","number_of_patients":5,"article_patient_number":"4","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"6-10 years","sex":"Male","ethnicity":"Hispanic/Latino","country_contracted":"Spain","country_treated":"Spain","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Respiratory tract infection with abdominal pain","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"He received volume expansion, and she did not require inotropic support. \r\nHe was treated with meropenem.\r\nProphylactic heparinization was also performed.\r\nHe was discharged from the PICU after 5 days.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6122,8342,8783,9077,10776]},{"id":6138,"regimens":[{"id":11619,"duration":{"id":5664,"approximate_duration":"5 days","dates_unknown":true},"drug":{"id":8412,"name":"Immunoglobulins, Intravenous","url":"cure-api2.ncats.io/v1/drugs/8412","rxNorm_id":null,"notes":null},"use_drug":[{"id":8480,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11619},{"id":8709,"answer":"In a novel combination with another drug","answer_other":"","regimen":11619}],"created":"2020-09-28T19:38:46.842174Z","updated":"2020-10-05T03:00:31.636424Z","dose":"0.4 grams/kg/day","frequency":"","route":"IV","severity":"ICU/Critical Care","severity_detail":null,"comments":null,"report":6138},{"id":11739,"duration":null,"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":8710,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11739},{"id":8711,"answer":"In a novel combination with another drug","answer_other":"","regimen":11739}],"created":"2020-10-01T07:09:17.104968Z","updated":"2020-10-05T03:00:31.640775Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6138},{"id":11740,"duration":null,"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":8712,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11740},{"id":8713,"answer":"In a novel combination with another drug","answer_other":"","regimen":11740}],"created":"2020-10-01T07:09:17.109446Z","updated":"2020-10-05T03:00:31.644544Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6138}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8049,"answer":"Clinical assessment","answer_other":"","report":6138}],"how_diagnosis":[{"id":13705,"answer":"Clinical assessment","answer_other":"","report":6138},{"id":13706,"answer":"Imaging","answer_other":"","report":6138},{"id":13707,"answer":"PCR","answer_other":"","report":6138}],"author_username":"Kate Borkowski","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Nurse","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4137,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6138}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"},{"id":550,"name":"Respiratory Tract Infections"}],"races":[],"created":"2020-09-28T19:37:30.491548Z","updated":"2020-10-05T03:00:31.627998Z","title":"New clinical manifestation of COVID-19 related Guillain-BarrÃ¨ syndrome highly responsive to intravenous immunoglobulins: two Italian cases. Case 2.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32468450,"doi":"10.1007/s10072-020-04484-5","article_url":"https://pubmed.ncbi.nlm.nih.gov/32468450/","pub_year":2020,"published_authors":"Assini A\r\nBenedetti L\r\nDi Maio S\r\nSchirinzi E\r\nDel Sette M","article_author_email":"massimo.del.sette@galliera.it","journal":"Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","abstract":"Recently, some cases of Guillain-BarrÃ© syndrome (GBS) and Miller Fisher (MF) have been reported, following COVID-19 infection. We report two different clinical manifestations of COVID-19 related GBS; one is a GBS/MF overlap syndrome, the other one an Acute Motor Sensory Axonal Neuropathy (AMSAN) with massive vegetative impairment, both highly responsive to intravenous immunoglobulins.","article_type":"Original","study_type":"Case Report","number_of_patients":2,"article_patient_number":"2","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"51-60 years","sex":"Male","ethnicity":"Not Hispanic/Latino","country_contracted":"Italy","country_treated":"Italy","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":true,"site_of_disease":"Lungs","clinical_syndrome":"Pneumonia","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"At admission, blood tests showed lymphocytopenia, increased LDH and GGT, and leukocytosis. The patient performed pharyngeal nose swab and thoracic CT scan, positive for severe COVID-related interstitial pneumonia. Three days after, he showed worsening of respiratory functions with the need for tracheostomy and assisted ventilation.\r\n20 days after admission, the patient presented acute weakness in lower limbs with distal distribution and foot drop on the right side. Simultaneously, massive disorders of the vegetative nervous system, consisting of gastroplegia, paralytic ileus, and loss of blood pressure control occurred. Neurological examination showed distal weakness at four limbs, with foot drop. Deep tendon reflexes were absent. Electroneurography showed severe sensory-motor axonal polyneuropathy with relative sparing of conduction velocities. The amplitudes of sensory and motor action potentials were significantly reduced. The EMG showed neurogenic changes on the muscles of the 4 limbs, without myogenic pattern. CSF and serum examination showed presence of oligoclonal bands both in CSF and serum, with increased ratio IgG/albumin in CSF (170); total protein level in CSF was normal, yet the patient had low serum albumin level (2.6 mg/dl): Direct research for the RNA virus on CSF was negative. The search for anti-ganglioside antibodies was negative. Three days after the onset of symptoms, intravenous immunoglobulin therapy was started at the standard dosage of 0.4 g/kg/day. After 5 days, the vegetative symptomatology significantly improved, with the remission of gastroplegia and recovery of intestinal functions. A subsequent neurological evaluation showed persistence of osteotendinous hyporeflexia but slight improvement in the right foot drop.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[8342,8412,10776]},{"id":6141,"regimens":[{"id":11628,"duration":{"id":5673,"approximate_duration":null,"dates_unknown":false},"drug":{"id":7262,"name":"Dexmedetomidine","url":"cure-api2.ncats.io/v1/drugs/7262","rxNorm_id":null,"notes":null},"use_drug":[{"id":8493,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11628},{"id":8849,"answer":"In a novel combination with another drug","answer_other":"","regimen":11628}],"created":"2020-09-28T21:28:54.587097Z","updated":"2020-10-05T02:50:33.557231Z","dose":null,"frequency":"","route":"","severity":"Inpatient","severity_detail":"After about a week of care the patient's SpO2 dropped, she became agitated and at risk of dislodging her oxygen devices. Intubation was delayed and drug was admitted instead.","comments":null,"report":6141},{"id":11629,"duration":{"id":5674,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":8494,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11629},{"id":8850,"answer":"In a novel combination with another drug","answer_other":"","regimen":11629}],"created":"2020-09-28T21:28:54.595059Z","updated":"2020-10-05T02:50:33.558114Z","dose":null,"frequency":"","route":"","severity":"Inpatient","severity_detail":"Initial standard medical therapy","comments":null,"report":6141},{"id":11630,"duration":{"id":5675,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":8495,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11630},{"id":8851,"answer":"In a novel combination with another drug","answer_other":"","regimen":11630}],"created":"2020-09-28T21:28:54.601175Z","updated":"2020-10-05T02:50:33.559053Z","dose":null,"frequency":"","route":"","severity":"Inpatient","severity_detail":"Initial standard medical therapy","comments":null,"report":6141}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8052,"answer":"Clinical assessment","answer_other":"","report":6141}],"how_diagnosis":[{"id":13715,"answer":"Imaging","answer_other":"","report":6141},{"id":13716,"answer":"Clinical assessment","answer_other":"","report":6141}],"author_username":"Paige Evans","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Nurse","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4143,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6141}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[],"races":[{"id":368,"answer":"White","answer_other":""}],"created":"2020-09-28T21:18:16.189541Z","updated":"2020-10-05T02:50:33.512625Z","title":"Dexmedetomidine and worsening hypoxemia in the setting of COVID-19: A case report.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32475761,"doi":"10.1016/j.ajem.2020.05.066","article_url":"https://pubmed.ncbi.nlm.nih.gov/32475761/","pub_year":2020,"published_authors":"Stockton J\r\nKyle-Sidell C","article_author_email":"jstockton@maimonidesmed.org","journal":"The American journal of emergency medicine","abstract":"Emergency department management of hypoxemia in the setting of COVID-19 is riddled with uncertainty. The lack of high-quality research has translated to an absence of clarity at the bedside. With disease spread outpacing treatment consensus, provider discretion has taken on a heightened role. Here, we report a case of dexmedetomidine use in the setting of worsening hypoxemia, whereby oxygenation improved and intubation was avoided. Well known pharmacologic properties of the drug, namely the lack of respiratory depression and its anti-delirium effects, as well as other possible physiologic effects, suggest potential benefit for patients being managed with a delayed intubation approach. If dexmedetomidine can improve compliance with non-invasive oxygen support (the current recommended first-line therapy) while promoting better oxygenation, it may also decrease the need for mechanical ventilation and thus improve mortality.","article_type":"Original","study_type":"Case Report","number_of_patients":1,"article_patient_number":"1","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"51-60 years","sex":"Female","ethnicity":"Not Hispanic/Latino","country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":true,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"","clinical_syndrome":"","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"While the patient was still on treatment","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"Patient received the standard medical therapy endorsed by our department at the time of her care: supplemental oxygen, azithromycin, anticoagulation and corticosteroids. She was placed in trials for tocilizumab and convalescent plasma and received chest physical therapy and awake intermittent proning.\r\n\r\nThereafter, dexmedetomidine was administered. \r\n\r\nGiven the context of gradually worsening hypoxemia, timing of administration, subsequent improvement in SpO2 and observed change in mental status (from agitated to calm), dexmedetomidine appeared to play a significant role. The patient avoided intubation, now has a stable SpO2 on nasal cannula and is not in multi-system organ failure.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6122,7262,10776]},{"id":6142,"regimens":[{"id":11637,"duration":{"id":5681,"approximate_duration":"Two Doses 2 Days Apart","dates_unknown":true},"drug":{"id":11339,"name":"Convalescent plasma","url":"cure-api2.ncats.io/v1/drugs/11339","rxNorm_id":null,"notes":null},"use_drug":[{"id":8526,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11637},{"id":8845,"answer":"In a novel combination with another drug","answer_other":"","regimen":11637}],"created":"2020-09-29T17:23:17.172662Z","updated":"2020-10-05T02:46:02.245441Z","dose":"200ml","frequency":"","route":"IV","severity":"ICU/Critical Care","severity_detail":"Initial 200ml dose was on inpatient day 1, second 200ml dose in the ICU on day 3 after clinical deterioration progressed","comments":null,"report":6142},{"id":11638,"duration":{"id":5682,"approximate_duration":"7 Days","dates_unknown":true},"drug":{"id":11165,"name":"Favipiravir","url":"cure-api2.ncats.io/v1/drugs/11165","rxNorm_id":null,"notes":null},"use_drug":[{"id":8530,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11638},{"id":8846,"answer":"In a novel combination with another drug","answer_other":"","regimen":11638}],"created":"2020-09-29T17:23:17.180487Z","updated":"2020-10-05T02:46:02.251908Z","dose":null,"frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"Clinical/respiratory symptoms improved and drug was terminated on 7th day","comments":null,"report":6142},{"id":11639,"duration":{"id":5683,"approximate_duration":"","dates_unknown":true},"drug":{"id":8971,"name":"Meropenem","url":"cure-api2.ncats.io/v1/drugs/8971","rxNorm_id":null,"notes":null},"use_drug":[{"id":8531,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11639},{"id":8847,"answer":"In a novel combination with another drug","answer_other":"","regimen":11639}],"created":"2020-09-29T17:23:17.187055Z","updated":"2020-10-05T02:46:02.257740Z","dose":null,"frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"A high neutrophil count and procalcitonin level meant bacterial infection could not be ruled so drug was added day 2 and continued up to a week after clinical improvement","comments":null,"report":6142},{"id":11640,"duration":{"id":5684,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":8532,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11640},{"id":8848,"answer":"In a novel combination with another drug","answer_other":"","regimen":11640}],"created":"2020-09-29T17:23:17.193333Z","updated":"2020-10-05T02:46:02.263405Z","dose":"400mg","frequency":"Single Dose","route":"","severity":"ICU/Critical Care","severity_detail":"Drug was added to manage the MAS status on the fourth day of antiviral treatment","comments":null,"report":6142}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8060,"answer":"PCR","answer_other":"","report":6142},{"id":8061,"answer":"Clinical assessment","answer_other":"","report":6142}],"how_diagnosis":[{"id":13717,"answer":"Imaging","answer_other":"","report":6142},{"id":13718,"answer":"PCR","answer_other":"","report":6142},{"id":13719,"answer":"Clinical assessment","answer_other":"","report":6142}],"author_username":"Paige Evans","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Nurse","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4144,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6142},{"id":4145,"answer":"Co-Infection or Complex Co-morbidities","answer_other":"","report":6142}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[{"id":373,"answer":"White","answer_other":""}],"created":"2020-09-29T03:25:21.829144Z","updated":"2020-10-05T02:46:02.236762Z","title":"Convalescent (immune) plasma treatment in a myelodysplastic COVID-19 patient with disseminated tuberculosis.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32487513,"doi":"10.1016/j.transci.2020.102821","article_url":"https://pubmed.ncbi.nlm.nih.gov/32487513/","pub_year":2020,"published_authors":"ÃÄ±nar OE\r\nSayÄ±nalp B\r\nAladaÄ Karakulak E\r\nAvÅar KarataÅ A\r\nVelet M\r\nÄ°nkaya AÃ\r\nErsoy OrtaÃ§ NE\r\nÃcal S\r\nAksu S\r\nHaznedaroÄlu Ä°C\r\nSayÄ±nalp N\r\nÃzcebe OÄ°","article_author_email":"drerkincinar@gmail.com","journal":"Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis","abstract":"During the ongoing COVID-19 pandemic due to the SARS-CoV-2 virus of which evidence-based medical paradigms cannot be easily applied; difficult clinical decisions shall be required particularly in the 'difficult-to-treat' cases of high risk group with associated comorbidities. Convalescent immune plasma therapy is a promising option as a sort of 'rescue' treatment in COVID-19 immune syndrome, where miraculous antiviral drugs are not available yet. In this report, we aim to convey our experience of multi-task treatment approach with convalescent immune plasma and anti-cytokine drug combination in a COVID-19 patient with extremely challenging comorbidities including active myeloid malignancy, disseminated tuberculosis and kidney failure.          \r\n        Keywords:      \r\n                  COVID-19; Convalescent; Myelodysplastic; Plasmapheresis; Tuberculosis.","article_type":"Original","study_type":"Case Report","number_of_patients":1,"article_patient_number":"1","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"No","age":"51-60 years","sex":"Male","ethnicity":"Not Hispanic/Latino","country_contracted":"Turkey","country_treated":"Turkey","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":true,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"Recently Disseminated Tuberculosis","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Pneumonia, Macrophage Activation Syndrome","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"Patient had been previously released from the hospital for follow up of disseminated tuberculosis and was still on a four drug regimen of isoniazid, rifampin, pyrazinamide, and ethambutol throughout treatment.\r\n\r\nFavipiravir was the only anti-viral prescribed during treatment due to the prolonged basal QTc.\r\n\r\nTocilizumab treatment was added despite the risk of Tuberculosis reactivation, because patient had received tuberculosis treatment for over a month. Written consent was still obtained from the patient.","previously_treated":"","flagged":false,"other_coinfections":"Myelodysplastic Syndrome (MDS)","disease":630,"drugs":[11339,11165,8971,10776]},{"id":6152,"regimens":[{"id":11755,"duration":{"id":5756,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":8750,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11755},{"id":8751,"answer":"In a novel combination with another drug","answer_other":"","regimen":11755}],"created":"2020-10-01T16:57:10.167291Z","updated":"2020-10-05T16:52:44.329198Z","dose":"80mg","frequency":"Singe Dose","route":"","severity":"Inpatient","severity_detail":"Administered after patient was stabilized upon initial arrival","comments":null,"report":6152},{"id":11756,"duration":{"id":5757,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":8838,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11756},{"id":8839,"answer":"In a novel combination with another drug","answer_other":"","regimen":11756}],"created":"2020-10-01T16:57:10.173742Z","updated":"2020-10-05T16:52:44.338137Z","dose":"400mg, 200mg","frequency":"","route":"","severity":"Inpatient","severity_detail":"Administered after patient was stabilized upon initial arrival","comments":null,"report":6152}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8109,"answer":"PCR","answer_other":"","report":6152},{"id":8110,"answer":"Clinical assessment","answer_other":"","report":6152},{"id":8111,"answer":"Imaging","answer_other":"","report":6152}],"how_diagnosis":[{"id":13744,"answer":"Clinical assessment","answer_other":"","report":6152},{"id":13745,"answer":"Imaging","answer_other":"","report":6152},{"id":13746,"answer":"PCR","answer_other":"","report":6152}],"author_username":"Paige Evans","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Nurse","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"Armenian","why_new_way":[{"id":4157,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6152}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[],"races":[{"id":383,"answer":"Other","answer_other":""}],"created":"2020-09-29T22:41:09.781869Z","updated":"2020-10-05T16:52:44.321162Z","title":"As the COVID-19 pandemic drags on, where have all the STEMIs gone?","status":"Approved","anonymous":false,"published":true,"pubmed_id":32550258,"doi":"10.1016/j.ijcha.2020.100550","article_url":"https://pubmed.ncbi.nlm.nih.gov/32550258/","pub_year":2020,"published_authors":"Ullah W\r\nSattar Y\r\nSaeed R\r\nAhmad A\r\nBoigon MI\r\nHaas DC\r\nAlraies MC","article_author_email":"Waqasullah.dr@gmail.com","journal":"International journal of cardiology. Heart & vasculature","abstract":"No abstract available","article_type":"Original","study_type":"Case Report","number_of_patients":1,"article_patient_number":"1","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"31-40 years","sex":"Male","ethnicity":"Not Hispanic/Latino","country_contracted":"","country_treated":"","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"STEMI, Hypoxia","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[8342,10776]},{"id":6158,"regimens":[{"id":11706,"duration":{"id":5720,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":8636,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11706},{"id":8835,"answer":"In a novel combination with another drug","answer_other":"","regimen":11706}],"created":"2020-09-30T16:23:20.796891Z","updated":"2020-10-04T23:03:16.985305Z","dose":"600 mg","frequency":"","route":"IV","severity":"ICU/Critical Care","severity_detail":null,"comments":null,"report":6158},{"id":11808,"duration":null,"drug":{"id":8783,"name":"Lopinavir-Ritonavir","url":"cure-api2.ncats.io/v1/drugs/8783","rxNorm_id":null,"notes":null},"use_drug":[{"id":8836,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11808},{"id":8837,"answer":"In a novel combination with another drug","answer_other":"","regimen":11808}],"created":"2020-10-04T23:03:16.980517Z","updated":"2020-10-04T23:03:16.986210Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6158}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8073,"answer":"Clinical assessment","answer_other":"","report":6158},{"id":8074,"answer":"Serology","answer_other":"","report":6158}],"how_diagnosis":[{"id":13760,"answer":"Clinical assessment","answer_other":"","report":6158},{"id":13761,"answer":"Imaging","answer_other":"","report":6158},{"id":13762,"answer":"Serology","answer_other":"","report":6158},{"id":13763,"answer":"PCR","answer_other":"","report":6158}],"author_username":"Eleanor McCartney","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4164,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6158}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[{"id":378,"answer":"Asian","answer_other":""}],"created":"2020-09-30T16:22:59.249063Z","updated":"2020-10-04T23:03:16.948157Z","title":"Interleukin-6 blockade treatment for COVID-19 associated cytokine release syndrome in a patient with poorly controlled chronic myeloid leukaemia.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32480422,"doi":"10.1111/bjh.16901","article_url":"https://pubmed.ncbi.nlm.nih.gov/32480422/","pub_year":2020,"published_authors":"Ranger A\r\nHaji R\r\nKaczmarski R\r\nDanga A","article_author_email":"Author email could not be found.","journal":"British journal of haematology","abstract":"In December 2019, a novel coronavirus pneumonia, coronavirus disease 2019 (COVIDâ19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARSâCoVâ2) was reported in Wuhan, China. A hyperinflammatory immune response, or cytokine release syndrome (CRS) is observed in critically unwell patients with SARSâCoVâ2 globally. Severe lymphopenia, hyperactivated proâinflammatory T cells\r\n1 and decreased regulatory T cells 2 are seen in these critically ill patients, suggesting dysregulated immune responses.          \r\n        Keywords:      \r\n                  chronic myeloid leukaemia; coronavirus; tocilizumab.","article_type":"Original","study_type":"Case Report","number_of_patients":1,"article_patient_number":"","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"51-60 years","sex":"Male","ethnicity":"Not Hispanic/Latino","country_contracted":"United Kingdom","country_treated":"United Kingdom","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"chronic myeloid leukemia","pregnant":false,"unknown":false,"site_of_disease":"lungs","clinical_syndrome":"pneumonia","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"The patient took tyrosine kinase inhibitor (Tki) Imatinib which was discontinued because of poor hematological response. He was initially assessed in an outpatient review and prescribed oral antibiotics. 48 hours later, he reported to the emergency department and was randomized into the liponavir and ritonavir antiviral therapy arm of the RECOVERY trial and began broad-spectrum IV antibiotics. On hospital day 11 the patient required non-invasive ventilation support.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[8783,10776]},{"id":6159,"regimens":[{"id":11709,"duration":{"id":5723,"approximate_duration":"17 days","dates_unknown":true},"drug":{"id":8783,"name":"Lopinavir-Ritonavir","url":"cure-api2.ncats.io/v1/drugs/8783","rxNorm_id":null,"notes":null},"use_drug":[{"id":8641,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11709},{"id":8642,"answer":"In a novel combination with another drug","answer_other":"","regimen":11709}],"created":"2020-09-30T16:30:55.965719Z","updated":"2020-10-04T22:55:44.348468Z","dose":"200/50 mg","frequency":"BID","route":"Oral","severity":"Inpatient","severity_detail":"oxygen saturation 92%","comments":null,"report":6159},{"id":11710,"duration":{"id":5724,"approximate_duration":"9 days","dates_unknown":true},"drug":{"id":8466,"name":"Interferon Beta-1A","url":"cure-api2.ncats.io/v1/drugs/8466","rxNorm_id":null,"notes":null},"use_drug":[{"id":8643,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11710},{"id":8644,"answer":"In a novel combination with another drug","answer_other":"","regimen":11710}],"created":"2020-09-30T16:30:55.971692Z","updated":"2020-10-04T22:55:44.354749Z","dose":"12 millions units","frequency":"Every other day","route":"Subcutaneous","severity":"Inpatient","severity_detail":"oxygen saturation 92%","comments":null,"report":6159},{"id":11711,"duration":{"id":5725,"approximate_duration":"12 days","dates_unknown":true},"drug":{"id":10130,"name":"Ribavirin","url":"cure-api2.ncats.io/v1/drugs/10130","rxNorm_id":null,"notes":null},"use_drug":[{"id":8650,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11711},{"id":8651,"answer":"In a novel combination with another drug","answer_other":"","regimen":11711}],"created":"2020-09-30T16:30:55.977700Z","updated":"2020-10-04T22:55:44.360654Z","dose":"1200 mg","frequency":"BID","route":"Oral","severity":"Inpatient","severity_detail":"deteriorated, oxygen saturation 85%","comments":null,"report":6159},{"id":11712,"duration":{"id":5726,"approximate_duration":"12 days","dates_unknown":true},"drug":{"id":8412,"name":"Immunoglobulins, Intravenous","url":"cure-api2.ncats.io/v1/drugs/8412","rxNorm_id":null,"notes":null},"use_drug":[{"id":8652,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11712},{"id":8653,"answer":"In a novel combination with another drug","answer_other":"","regimen":11712}],"created":"2020-09-30T16:30:55.983735Z","updated":"2020-10-04T22:55:44.366331Z","dose":"20 mg","frequency":"daily","route":"IV","severity":"Inpatient","severity_detail":"deteriorated, oxygen saturation 85%","comments":null,"report":6159},{"id":11715,"duration":{"id":5729,"approximate_duration":"1 day","dates_unknown":true},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":8658,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11715},{"id":8659,"answer":"In a novel combination with another drug","answer_other":"","regimen":11715}],"created":"2020-09-30T16:30:56.001630Z","updated":"2020-10-04T22:55:44.371899Z","dose":"400 mg","frequency":"single dose infused over 2 hours","route":"","severity":"Inpatient","severity_detail":"dyspnea, oxygen saturation 83%","comments":null,"report":6159},{"id":11723,"duration":{"id":5737,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":8668,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11723},{"id":8669,"answer":"In a novel combination with another drug","answer_other":"","regimen":11723}],"created":"2020-09-30T18:53:40.280206Z","updated":"2020-10-04T22:55:44.377399Z","dose":"200 mg","frequency":"BID","route":"Oral","severity":"Inpatient","severity_detail":"oxygen saturation 92%","comments":null,"report":6159},{"id":11724,"duration":{"id":5738,"approximate_duration":null,"dates_unknown":false},"drug":{"id":9463,"name":"Oseltamivir","url":"cure-api2.ncats.io/v1/drugs/9463","rxNorm_id":null,"notes":null},"use_drug":[{"id":8670,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11724},{"id":8671,"answer":"In a novel combination with another drug","answer_other":"","regimen":11724}],"created":"2020-09-30T18:53:40.286863Z","updated":"2020-10-04T22:55:44.383403Z","dose":"75 mg","frequency":"BID","route":"Oral","severity":"Inpatient","severity_detail":"oxygen saturation 92%","comments":null,"report":6159}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8079,"answer":"PCR","answer_other":"","report":6159},{"id":8080,"answer":"Imaging","answer_other":"","report":6159},{"id":8081,"answer":"Clinical assessment","answer_other":"","report":6159}],"how_diagnosis":[{"id":13764,"answer":"PCR","answer_other":"","report":6159},{"id":13765,"answer":"Imaging","answer_other":"","report":6159}],"author_username":"Mili Duggal","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"United States","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4165,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6159}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-09-30T16:28:54.473385Z","updated":"2020-10-04T22:55:44.339842Z","title":"Tocilizumab administration in a refractory case of COVID-19.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32502524,"doi":"10.1016/j.ijantimicag.2020.106043","article_url":"https://pubmed.ncbi.nlm.nih.gov/32502524/","pub_year":2020,"published_authors":"Dastan F\r\nNadji SA\r\nSaffaei A\r\nTabarsi P","article_author_email":"fzh.dastan@gmail.com","journal":"International journal of antimicrobial agents","abstract":"Pathophysiological studies have demonstrated the role of inflammatory mediators in COVID-19 pneumonia.In some COVID-19 cases, especially those with impaired immune function, an uncontrolled immune response that triggers an overproduction of immune cells and their signaling molecules occurs.\r\nCytokine release syndrome may be the underlying pathophysiology of refractory cases.Tocilizumab, as an IL-6 antagonist, may have a promising role in the cytokine release syndrome that occurs in COVID-19.\r\nClinicians should be aware of the precautions and contraindications of tocilizumab.","article_type":"Original","study_type":"Case Report","number_of_patients":1,"article_patient_number":"","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"No","age":"31-40 years","sex":"Male","ethnicity":null,"country_contracted":"Iran, Islamic Republic of","country_treated":"Iran, Islamic Republic of","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Pneumonia","severity":null,"prev_treatment":"","unusual":"The current case was a refractory COVID-19 case who did not respond to conventional therapeutic agents and had tocilizumab administered as salvage therapy. In contrast to hydroxychloroquine, tocilizumab may be a useful agent in severe cases who have not responded to conventional therapy","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"3-day history of fever and dry cough. The patient was a physician with a history of close contact with COVID-19 cases. The following were commenced: hydroxychloroquine 200 mg p.o. twice a day, oseltamivir 75 mg p.o. twice a day, lopinavir/ritonavir 200/50 mg p.o. in two tablets twice a day, and interferon Î²-1a 12 million units s.c. every other day. On 08 March 2020 the clinical condition of the patient deteriorated, and he exhibited dyspnea with an oxygen saturation of 85%. Fever and cough were persistent, and new chest X-ray imaging revealed progression of bilateral infiltration in the lower and upper lobes. It was decided to initiate ribavirin 1,200 mg p.o. b.i.d. and immunoglobulin 20 mg i.v. daily. Meropenem and teicoplanin were also started to cover any probable bacterial sources. After 2 days, on 10 March 2020, his clinical condition worsened. Dyspnea continued with greater severity and he had an oxygen saturation of 83%.the patient was a candidate for intubation and invasive mechanical ventilation. However, this did not happen. Tocilizumab was considered as a last-chance therapy.Hence, tocilizumab (Actemra Hoffmann-La Roche Limited) at a single dose of 400 mg was infused over 2 hours. After 2 days, the patient's dyspnea had gradually improved and his oxygen saturation increased to 90%.Recovery was observed over the next few days, and dyspnea and oxygen saturation significantly improved.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[8342,8412,8466,8783,9463,10130,10776]},{"id":6165,"regimens":[{"id":11729,"duration":{"id":5742,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":8679,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11729},{"id":8680,"answer":"In a novel combination with another drug","answer_other":"","regimen":11729}],"created":"2020-09-30T21:58:22.061599Z","updated":"2020-10-05T03:37:35.667499Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6165},{"id":11730,"duration":{"id":687,"approximate_duration":"4 days","dates_unknown":true},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":8681,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11730},{"id":8682,"answer":"In a novel combination with another drug","answer_other":"","regimen":11730}],"created":"2020-09-30T21:58:22.069494Z","updated":"2020-10-05T03:37:35.675046Z","dose":"500mg","frequency":"LD","route":"oral","severity":"Outpatient","severity_detail":"switched to 250mg QD day 2-4","comments":null,"report":6165},{"id":11731,"duration":{"id":111,"approximate_duration":"4 Days","dates_unknown":true},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":8856,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11731},{"id":8857,"answer":"In a novel combination with another drug","answer_other":"","regimen":11731}],"created":"2020-09-30T22:50:34.123745Z","updated":"2020-10-05T03:37:35.704818Z","dose":"800mg","frequency":"LD","route":"oral","severity":"Outpatient","severity_detail":"switch to 400mg QD day 2-4","comments":null,"report":6165}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8089,"answer":"Clinical assessment","answer_other":"","report":6165},{"id":8090,"answer":"Imaging","answer_other":"","report":6165}],"how_diagnosis":[{"id":13777,"answer":"PCR","answer_other":"","report":6165}],"author_username":"Belinda Nhundu","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4173,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6165}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-09-30T21:43:00.830596Z","updated":"2020-10-05T03:37:35.659568Z","title":"Remdesivir and tocilizumab: Mix or match.Case 1","status":"Approved","anonymous":false,"published":true,"pubmed_id":32492200,"doi":"10.1002/jmv.26117","article_url":"https://pubmed.ncbi.nlm.nih.gov/32492200/","pub_year":2020,"published_authors":"Akinosoglou K\r\nVelissaris D\r\nZiazias D\r\nDavoulos C\r\nTousis A\r\nTsiotsios K\r\nKalogeropoulou C\r\nSpyridonidis A\r\nMarangos M\r\nFligkou F\r\nGogos C","article_author_email":"Author email could not be found.","journal":"Journal of medical virology","abstract":"To date, no therapy has demonstrated definite efficacy for patients with COVIDâ19. Antiviral, as well as, antiâinflammatory approaches, as these represented by remdesivir (RDV) and tocilizumab (TCZ) use, have been recently put forward. However, data upon optimal choice of one over the other, or potential need for regimen combination, remains an open question. We hereby report two wellâmatched cases of SARSâCoVâ2 (+) patients, developing respiratory failure, both receiving TCZ following severe inflammatory response, with or without RDV. We argue that, RDV administration is pivotal early in the course of the disease, since TCZ use alone cannot ensure inflammation control.","article_type":"Original","study_type":"Case Report","number_of_patients":2,"article_patient_number":"1","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"No","age":"41-50 years","sex":"","ethnicity":null,"country_contracted":"Greece","country_treated":"Greece","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"dyspnea","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"While the patient was still on treatment","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6122,8342,10776]},{"id":6166,"regimens":[{"id":11760,"duration":{"id":5761,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":8753,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11760},{"id":8754,"answer":"In a novel combination with another drug","answer_other":"","regimen":11760}],"created":"2020-10-01T18:46:39.383810Z","updated":"2020-10-05T03:36:48.906097Z","dose":"800mg LD/400mg","frequency":"QD","route":"oral","severity":"Outpatient","severity_detail":"","comments":null,"report":6166},{"id":11761,"duration":{"id":5762,"approximate_duration":"4days","dates_unknown":true},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":8755,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11761},{"id":8756,"answer":"In a novel combination with another drug","answer_other":"","regimen":11761}],"created":"2020-10-01T18:46:39.391350Z","updated":"2020-10-05T03:36:48.912928Z","dose":"500mg LD/250mg","frequency":"QD","route":"oral","severity":"Outpatient","severity_detail":"","comments":null,"report":6166},{"id":11762,"duration":{"id":5763,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":8757,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11762},{"id":8758,"answer":"In a novel combination with another drug","answer_other":"","regimen":11762}],"created":"2020-10-01T18:46:39.397859Z","updated":"2020-10-05T03:36:48.918478Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6166},{"id":11763,"duration":{"id":5764,"approximate_duration":null,"dates_unknown":false},"drug":{"id":11301,"name":"Remdesivir","url":"cure-api2.ncats.io/v1/drugs/11301","rxNorm_id":null,"notes":null},"use_drug":[{"id":8759,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11763},{"id":8760,"answer":"In a novel combination with another drug","answer_other":"","regimen":11763}],"created":"2020-10-01T18:46:39.404329Z","updated":"2020-10-05T03:36:48.923938Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6166}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8094,"answer":"Clinical assessment","answer_other":"","report":6166},{"id":8095,"answer":"Imaging","answer_other":"","report":6166}],"how_diagnosis":[{"id":13784,"answer":"PCR","answer_other":"","report":6166}],"author_username":"Belinda Nhundu","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4179,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6166}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-10-01T02:57:36.988822Z","updated":"2020-10-05T03:36:48.898276Z","title":"Remdesivir and tocilizumab: Mix or match.Case 2","status":"Approved","anonymous":false,"published":true,"pubmed_id":32492200,"doi":"10.1002/jmv.26117","article_url":"https://pubmed.ncbi.nlm.nih.gov/32492200/","pub_year":2020,"published_authors":"Akinosoglou K\r\nVelissaris D\r\nZiazias D\r\nDavoulos C\r\nTousis A\r\nTsiotsios K\r\nKalogeropoulou C\r\nSpyridonidis A\r\nMarangos M\r\nFligkou F\r\nGogos C","article_author_email":"Author email could not be found.","journal":"Journal of medical virology","abstract":"To date, no therapy has demonstrated definite efficacy for patients with COVIDâ19. Antiviral, as well as, antiâinflammatory approaches, as these represented by remdesivir (RDV) and tocilizumab (TCZ) use, have been recently put forward. However, data upon optimal choice of one over the other, or potential need for regimen combination, remains an open question. We hereby report two wellâmatched cases of SARSâCoVâ2 (+) patients, developing respiratory failure, both receiving TCZ following severe inflammatory response, with or without RDV. We argue that, RDV administration is pivotal early in the course of the disease, since TCZ use alone cannot ensure inflammation control.","article_type":"Original","study_type":"Case Report","number_of_patients":2,"article_patient_number":"2","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"No","age":"41-50 years","sex":"","ethnicity":"Not Hispanic/Latino","country_contracted":"Greece","country_treated":"Greece","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"Lung","clinical_syndrome":"fever, dyspnea","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6122,8342,11301,10776]},{"id":6178,"regimens":[{"id":11782,"duration":{"id":5783,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":8795,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11782},{"id":8796,"answer":"In a novel combination with another drug","answer_other":"","regimen":11782}],"created":"2020-10-02T01:28:48.424179Z","updated":"2020-10-05T03:26:23.740549Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6178},{"id":11783,"duration":{"id":5784,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":8797,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11783},{"id":8798,"answer":"In a novel combination with another drug","answer_other":"","regimen":11783}],"created":"2020-10-02T01:28:48.431846Z","updated":"2020-10-05T03:26:23.747184Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6178},{"id":11784,"duration":{"id":5785,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6675,"name":"Ceftriaxone","url":"cure-api2.ncats.io/v1/drugs/6675","rxNorm_id":null,"notes":null},"use_drug":[{"id":8799,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11784},{"id":8800,"answer":"In a novel combination with another drug","answer_other":"","regimen":11784}],"created":"2020-10-02T01:28:48.438300Z","updated":"2020-10-05T03:26:23.752800Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6178},{"id":11785,"duration":{"id":5786,"approximate_duration":"once","dates_unknown":true},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":8801,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11785},{"id":8802,"answer":"In a novel combination with another drug","answer_other":"","regimen":11785}],"created":"2020-10-02T01:28:48.444417Z","updated":"2020-10-05T03:26:23.758383Z","dose":"400mg","frequency":"","route":"IV","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6178},{"id":11786,"duration":{"id":5787,"approximate_duration":"14days","dates_unknown":true},"drug":{"id":11386,"name":"AT- 001","url":"cure-api2.ncats.io/v1/drugs/11386","rxNorm_id":null,"notes":null},"use_drug":[{"id":8803,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11786},{"id":8804,"answer":"In a novel combination with another drug","answer_other":"","regimen":11786}],"created":"2020-10-02T01:28:48.450615Z","updated":"2020-10-05T03:26:23.763883Z","dose":"1500mg","frequency":"BID","route":"oral","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6178}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8102,"answer":"Clinical assessment","answer_other":"","report":6178}],"how_diagnosis":[{"id":13799,"answer":"PCR","answer_other":"","report":6178}],"author_username":"Belinda Nhundu","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4190,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6178}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":521,"name":"Myocarditis"},{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-10-02T01:23:51.297170Z","updated":"2020-10-05T03:26:23.732874Z","title":"A Recovered Case of COVID-19 Myocarditis and ARDS Treated With Corticosteroids, Tocilizumab, and Experimental AT-001.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32368755,"doi":"10.1016/j.jaccas.2020.04.025","article_url":"https://pubmed.ncbi.nlm.nih.gov/32368755/","pub_year":2020,"published_authors":"Coyle J\r\nIgbinomwanhia E\r\nSanchez-Nadales A\r\nDanciu S\r\nChu C\r\nShah N","article_author_email":"Author email could not be found.","journal":"JACC. Case reports","abstract":"We describes a case of a critically ill patient with myocarditis and severe acute respiratory distress syndrome related to coronavirus disease-2019. This case highlights management strategies, including the use of corticosteroids, an interleukin-6 inhibitor, and an aldose reductase inhibitor, resulting in complete clinical recovery.","article_type":"Original","study_type":"Case Report","number_of_patients":1,"article_patient_number":"1","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"51-60 years","sex":"Male","ethnicity":null,"country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":true,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"Lung/ Gastrointestinal","clinical_syndrome":"respiratory tract infection, nausea, diarrhea","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"Covid19 patient with myocarditis. Treated with experimental drug AT-001.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[11386,6122,6675,8342,10776]},{"id":6185,"regimens":[{"id":11809,"duration":{"id":5807,"approximate_duration":"1 Day","dates_unknown":true},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":8861,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11809}],"created":"2020-10-05T17:13:15.960980Z","updated":"2020-10-08T18:19:13.169867Z","dose":"800mg","frequency":"2 doses, 12 hours apart","route":"IV","severity":"Inpatient","severity_detail":"Admitted after a three day history of CSR like syndromes and respiratory failure. Symptoms were not sever enough to be admitted to the ICU.","comments":null,"report":6185}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8113,"answer":"Clinical assessment","answer_other":"","report":6185},{"id":8114,"answer":"Imaging","answer_other":"","report":6185}],"how_diagnosis":[{"id":13816,"answer":"Clinical assessment","answer_other":"","report":6185},{"id":13817,"answer":"Imaging","answer_other":"","report":6185}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4202,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6185},{"id":4203,"answer":"Co-Infection or Complex Co-morbidities","answer_other":"","report":6185}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-10-05T17:12:26.476160Z","updated":"2020-10-08T18:19:13.161887Z","title":"Interleukin 6-blockade treatment for severe COVID-19 in two patients with multiple myeloma. Case 1.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32369612,"doi":"10.1111/bjh.16787","article_url":"https://pubmed.ncbi.nlm.nih.gov/32369612/","pub_year":2020,"published_authors":"Chaidos A\r\nKatsarou A\r\nMustafa C\r\nMilojkovic D\r\nKaradimitris A","article_author_email":"a.chaidos@imperial.ac.uk","journal":"British journal of haematology","abstract":"No abstract available","article_type":"Original","study_type":"Case Report","number_of_patients":2,"article_patient_number":"1","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"No","age":"61-70 years","sex":"Male","ethnicity":null,"country_contracted":"United Kingdom","country_treated":"United Kingdom","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":true,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"Relapsing myeloma, on thirdâline lenalidomideâbased therapy","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Hypoxia, Acute Hyperinflammatory Syndrome","severity":"Inpatient","prev_treatment":"","unusual":"Patients with myeloma are usually older with complex humoral and cellular immunodeficiency and comprise a particularly vulnerable population. Additionally, most COVID-19 treatment studies exclude patients with cancer.","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"The patient had relapsing Myeloma and was on third-line lenalidomline-based therapy upon admittance for COVID-19 symptoms.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[10776]},{"id":6188,"regimens":[{"id":11814,"duration":{"id":5812,"approximate_duration":"1 Day","dates_unknown":true},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":8862,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11814}],"created":"2020-10-05T17:40:56.968460Z","updated":"2020-10-08T18:20:55.946909Z","dose":"2 doses of 800mg, given 12 hours apart","frequency":"q12h","route":"IV","severity":"ICU/Critical Care","severity_detail":"The patient was intubated and ventilated upon treatment","comments":null,"report":6188}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8115,"answer":"Clinical assessment","answer_other":"","report":6188},{"id":8116,"answer":"Imaging","answer_other":"","report":6188}],"how_diagnosis":[{"id":13822,"answer":"Clinical assessment","answer_other":"","report":6188},{"id":13823,"answer":"Imaging","answer_other":"","report":6188}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4209,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6188},{"id":4210,"answer":"Co-Infection or Complex Co-morbidities","answer_other":"","report":6188}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-10-05T17:40:19.051558Z","updated":"2020-10-08T18:20:55.939297Z","title":"Interleukin 6-blockade treatment for severe COVID-19 in two patients with multiple myeloma. Case 2.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32369612,"doi":"10.1111/bjh.16787","article_url":"https://pubmed.ncbi.nlm.nih.gov/32369612/","pub_year":2020,"published_authors":"Chaidos A\r\nKatsarou A\r\nMustafa C\r\nMilojkovic D\r\nKaradimitris A","article_author_email":"a.chaidos@imperial.ac.uk","journal":"British journal of haematology","abstract":"No abstract available","article_type":"Original","study_type":"Case Report","number_of_patients":2,"article_patient_number":"2","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"51-60 years","sex":"Male","ethnicity":null,"country_contracted":"United Kingdom","country_treated":"United Kingdom","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":true,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"Relapsing myeloma on fourthâline therapy with bortezomib and panobinostat.","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Hypoxia, cytokine release syndrome","severity":"Inpatient","prev_treatment":"","unusual":"Patients with myeloma are usually older with complex humoral and cellular immunodeficiency and comprise a particularly vulnerable population. Additionally, most COVID-19 treatment studies exclude patients with cancer.","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"While the patient was still on treatment","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"The patient experienced relapsing Myeloma and was on fourth-line therapy with Bortezomib and Panobinostat.\r\n\r\nThis patient #2 experienced slower improvement of respiratory improvement than patient #1 from drug therapy. The patient received a tracheostomy after mechanical ventilation for 24 days and remains in ICU with reducing organ support requirements.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[10776]},{"id":6194,"regimens":[{"id":11827,"duration":{"id":5825,"approximate_duration":"100 ml/h over 60 minutes","dates_unknown":true},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":8892,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11827},{"id":8893,"answer":"In a novel combination with another drug","answer_other":"","regimen":11827}],"created":"2020-10-06T00:07:00.540785Z","updated":"2020-10-08T20:27:27.129286Z","dose":"680 mg","frequency":"single dose","route":"IV","severity":"Inpatient","severity_detail":"","comments":null,"report":6194},{"id":11828,"duration":{"id":5826,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8233,"name":"Heparin","url":"cure-api2.ncats.io/v1/drugs/8233","rxNorm_id":null,"notes":null},"use_drug":[{"id":8894,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11828}],"created":"2020-10-06T00:07:56.967176Z","updated":"2020-10-08T20:27:27.135673Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6194},{"id":11829,"duration":{"id":5827,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6038,"name":"Aspirin","url":"cure-api2.ncats.io/v1/drugs/6038","rxNorm_id":null,"notes":null},"use_drug":[{"id":8895,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11829},{"id":8896,"answer":"In a novel combination with another drug","answer_other":"","regimen":11829}],"created":"2020-10-06T00:07:56.974630Z","updated":"2020-10-08T20:27:27.141247Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6194}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8127,"answer":"Clinical assessment","answer_other":"","report":6194},{"id":8128,"answer":"Imaging","answer_other":"","report":6194}],"how_diagnosis":[{"id":13835,"answer":"Clinical assessment","answer_other":"","report":6194},{"id":13836,"answer":"Imaging","answer_other":"","report":6194},{"id":13837,"answer":"PCR","answer_other":"","report":6194}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Improved","previous_drugs":[{"id":8342,"name":"Hydroxychloroquine"},{"id":11390,"name":"Lenzilumab"}],"comments":[],"article_language":"English","why_new_way":[{"id":4218,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6194},{"id":4219,"answer":"Patient failed previous therapy","answer_other":"","report":6194}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-10-06T00:06:26.611915Z","updated":"2020-10-08T20:27:27.121469Z","title":"Case report: use of lenzilumab and tocilizumab for the treatment of coronavirus disease 2019.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32546029,"doi":"10.2217/imt-2020-0136","article_url":"https://pubmed.ncbi.nlm.nih.gov/32546029/","pub_year":2020,"published_authors":"Melody M\r\nNelson J\r\nHastings J\r\nPropst J\r\nSmerina M\r\nMendez J\r\nGuru P","article_author_email":"Guru.Pramod@mayo.edu","journal":"Immunotherapy","abstract":"Coronavirus disease 2019 (COVID-19) is a novel disease associated with a cytokine-mediated, severe, acute respiratory syndrome. Tocilizumab and lenzilumab are recombinant monoclonal antibodies against IL-6 and granulocyte macrophage colony-stimulating factor, respectively, and have been proposed as a potential treatment for acute, hypoxic respiratory failure associated with COVID-19.","article_type":"Original","study_type":"Case Report","number_of_patients":1,"article_patient_number":"","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"No","age":"61-70 years","sex":"Male","ethnicity":null,"country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":true,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Respiratory Tract Infection","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"After a period of follow-up","follow_up_period":"13 days from discharge","relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6038,8233,10776]},{"id":6211,"regimens":[{"id":11875,"duration":{"id":5873,"approximate_duration":null,"dates_unknown":false},"drug":{"id":9077,"name":"Methylprednisolone","url":"cure-api2.ncats.io/v1/drugs/9077","rxNorm_id":null,"notes":null},"use_drug":[{"id":9003,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11875},{"id":9002,"answer":"In a novel combination with another drug","answer_other":"","regimen":11875}],"created":"2020-10-07T19:21:24.425361Z","updated":"2020-11-05T18:09:53.032101Z","dose":"","frequency":"QD","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6211},{"id":11876,"duration":{"id":5874,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":9004,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11876},{"id":9005,"answer":"In a novel combination with another drug","answer_other":"","regimen":11876}],"created":"2020-10-07T19:21:24.433515Z","updated":"2020-11-05T18:09:53.039397Z","dose":"400mg","frequency":"Once","route":"IV","severity":"Inpatient","severity_detail":"","comments":null,"report":6211},{"id":12469,"duration":null,"drug":{"id":7629,"name":"Enoxaparin","url":"cure-api2.ncats.io/v1/drugs/7629","rxNorm_id":null,"notes":null},"use_drug":[{"id":10105,"answer":"It was not used in a new way","answer_other":"","regimen":12469}],"created":"2020-11-05T18:09:53.061309Z","updated":"2020-11-05T18:09:53.069125Z","dose":"40mg","frequency":"BD","route":"SC","severity":null,"severity_detail":null,"comments":null,"report":6211},{"id":12470,"duration":null,"drug":{"id":11408,"name":"Tissue plasminogen activator","url":"cure-api2.ncats.io/v1/drugs/11408","rxNorm_id":19,"notes":""},"use_drug":[{"id":10106,"answer":"It was not used in a new way","answer_other":"","regimen":12470}],"created":"2020-11-05T18:09:53.065465Z","updated":"2020-11-05T18:09:53.069928Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6211}],"site_of_infection":[],"specific_site":[],"how_outcome":[],"how_diagnosis":[{"id":13880,"answer":"Clinical assessment","answer_other":"","report":6211},{"id":13881,"answer":"PCR","answer_other":"","report":6211}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Deteriorated","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4245,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6211}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":550,"name":"Respiratory Tract Infections"}],"races":[],"created":"2020-10-07T19:20:07.808320Z","updated":"2020-11-05T18:09:53.024053Z","title":"Arterial thromboembolic complications in COVID-19 in low-risk patients despite prophylaxis. Case 1.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32374029,"doi":"10.1111/bjh.16792","article_url":"https://pubmed.ncbi.nlm.nih.gov/32374029/","pub_year":2020,"published_authors":"Griffin DO\r\nJensen A\r\nKhan M\r\nChin J\r\nChin K\r\nParnell R\r\nAwwad C\r\nPatel D","article_author_email":"dg2810@cumc.columbia.edu","journal":"British journal of haematology","abstract":"We present a case series of three patients with coronavirus disease 2019 (COVIDâ19) who developed arterial vascular complications, one who developed an acute cerebrovascular accident, one who developed popliteal artery occlusion and one who developed both during their hospital course.","article_type":"Original","study_type":"Case Report","number_of_patients":3,"article_patient_number":"","full_text_available":true,"outcome":"Patient died","surgery":"No","age":"41-50 years","sex":"Male","ethnicity":null,"country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":true,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"Hyperlipidemia","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"","severity":"ICU/Critical Care","prev_treatment":"","unusual":"The patient was found to have arterial thrombosis as a complication of COVIDâ19.","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"The patient presented with dyspnoea on day 14 of symptoms. His deep vein thrombosis (DVT) prophylaxis was increased to enoxaparin 40 mg subcutaneously twice a day. On day 23 of symptoms, the patient was noted to have left upper extremity weakness, code âstrokeâ was called. Serial computed tomography (CT) showed a nonâhaemorrhagic right parietal infarct and the patient was given tissue plasminogen activator (tPA). The patientâs neurological deficits resolved after tPA, but then he had an acute mental status change and was intubated to protect his airway. The patient was started on a full dose of enoxaparin for new onset rapid atrial fibrillation. On day 25 of symptoms, the patient developed a cool left lower extremity. Arterial Doppler showed no flow distal to the popliteal artery while on enoxaparin 1 mg/kg twice a day. He was transferred for surgical intervention, but did not undergo any surgical intervention and ultimately died.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[7629,9077,11408,10776]},{"id":6212,"regimens":[{"id":11877,"duration":{"id":5875,"approximate_duration":null,"dates_unknown":false},"drug":{"id":9077,"name":"Methylprednisolone","url":"cure-api2.ncats.io/v1/drugs/9077","rxNorm_id":null,"notes":null},"use_drug":[{"id":9006,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11877},{"id":9007,"answer":"In a novel combination with another drug","answer_other":"","regimen":11877}],"created":"2020-10-07T19:28:53.656477Z","updated":"2020-11-05T18:16:06.287236Z","dose":"","frequency":"QD","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6212},{"id":11878,"duration":{"id":5876,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":9008,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11878},{"id":9009,"answer":"In a novel combination with another drug","answer_other":"","regimen":11878}],"created":"2020-10-07T19:28:53.664950Z","updated":"2020-11-05T18:16:06.293421Z","dose":"400 mg","frequency":"Once","route":"IV","severity":"Inpatient","severity_detail":"","comments":null,"report":6212},{"id":12471,"duration":null,"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":10107,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12471},{"id":10108,"answer":"In a novel combination with another drug","answer_other":"","regimen":12471}],"created":"2020-11-05T18:16:06.313461Z","updated":"2020-11-05T18:16:06.317922Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6212}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8154,"answer":"Clinical assessment","answer_other":"","report":6212}],"how_diagnosis":[{"id":13882,"answer":"Clinical assessment","answer_other":"","report":6212},{"id":13883,"answer":"PCR","answer_other":"","report":6212}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4246,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6212}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[],"races":[],"created":"2020-10-07T19:27:38.364555Z","updated":"2020-11-05T18:16:06.279616Z","title":"Arterial thromboembolic complications in COVID-19 in low-risk patients despite prophylaxis. Case 3.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32374029,"doi":"10.1111/bjh.16792","article_url":"https://pubmed.ncbi.nlm.nih.gov/32374029/","pub_year":2020,"published_authors":"Griffin DO\r\nJensen A\r\nKhan M\r\nChin J\r\nChin K\r\nParnell R\r\nAwwad C\r\nPatel D","article_author_email":"dg2810@cumc.columbia.edu","journal":"British journal of haematology","abstract":"We present a case series of three patients with coronavirus disease 2019 (COVIDâ19) who developed arterial vascular complications, one who developed an acute cerebrovascular accident, one who developed popliteal artery occlusion and one who developed both during their hospital course.","article_type":"Original","study_type":"Case Report","number_of_patients":3,"article_patient_number":"","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"No","age":"61-70 years","sex":"Male","ethnicity":null,"country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":true,"hypertension":true,"cardiovascular_disease":true,"chronic_renal_disease":true,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"Lungs, GI","clinical_syndrome":"Dyspnea, profuse watery diarrhea","severity":"ICU/Critical Care","prev_treatment":"","unusual":"On day 11 of symptoms, the patient was intubated for acute hypoxic respiratory failure. The patient remained intubated for 7 days. On day 23 of symptoms, the patient had a syncopal event for which a CT head showed an illâdefined lowâdensity focus within the left thalamus, suspicious for acute infarct. Magnetic resonance imaging showed a hyperâintense signal within the left thalamus, with a small amount of associated enhancement, interpreted as likely a subacute infarct.","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"The patient was discharged on aspirin, clopidogrel and statin therapy. The patient initially did well, but 1 day after finishing a taper of steroids he was readmitted with laryngeal oedema. He did well after additional steroids were given.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[8342,9077,10776]},{"id":6284,"regimens":[{"id":12106,"duration":{"id":6104,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":9433,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12106},{"id":9434,"answer":"In a novel combination with another drug","answer_other":"","regimen":12106}],"created":"2020-10-21T14:57:59.166613Z","updated":"2020-10-21T18:07:31.973887Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6284},{"id":12107,"duration":{"id":6105,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":9435,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12107},{"id":9436,"answer":"In a novel combination with another drug","answer_other":"","regimen":12107}],"created":"2020-10-21T14:57:59.175634Z","updated":"2020-10-21T18:07:31.984091Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6284},{"id":12108,"duration":{"id":6106,"approximate_duration":null,"dates_unknown":false},"drug":{"id":5600,"name":"Acetaminophen","url":"cure-api2.ncats.io/v1/drugs/5600","rxNorm_id":null,"notes":null},"use_drug":[{"id":9437,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12108},{"id":9438,"answer":"In a novel combination with another drug","answer_other":"","regimen":12108}],"created":"2020-10-21T14:57:59.182827Z","updated":"2020-10-21T18:07:31.992887Z","dose":"","frequency":"","route":"","severity":"Outpatient","severity_detail":"","comments":null,"report":6284},{"id":12110,"duration":{"id":6108,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":9441,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12110}],"created":"2020-10-21T14:57:59.196581Z","updated":"2020-10-21T18:07:32.001296Z","dose":"600 mg","frequency":"1 dose","route":"IV","severity":"ICU/Critical Care","severity_detail":"Patient was intubated and while in the ICU, also required hemodynamic support with vasopressors","comments":null,"report":6284}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8270,"answer":"Clinical assessment","answer_other":"","report":6284}],"how_diagnosis":[{"id":14072,"answer":"PCR","answer_other":"","report":6284},{"id":14073,"answer":"Clinical assessment","answer_other":"","report":6284},{"id":14074,"answer":"Imaging","answer_other":"","report":6284}],"author_username":"Maggie McCoy","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"","why_new_way":[{"id":4345,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6284},{"id":4346,"answer":"Co-Infection or Complex Co-morbidities","answer_other":"","report":6284}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[],"races":[],"created":"2020-10-21T14:55:37.137231Z","updated":"2020-10-21T18:07:31.927031Z","title":null,"status":"Approved","anonymous":false,"published":false,"pubmed_id":null,"doi":"","article_url":null,"pub_year":null,"published_authors":"","article_author_email":"wingerchuk.dean@mayo.edu","journal":"","abstract":"","article_type":"","study_type":"Case Report","number_of_patients":null,"article_patient_number":"","full_text_available":false,"outcome":"Patient improved","surgery":"No","age":"51-60 years","sex":"Female","ethnicity":null,"country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":true,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"Multiple Sclerosis","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Pneumonia, respiratory tract infection","severity":null,"prev_treatment":null,"unusual":"This case describes a patient with MS who developed COVID-19 while treated with fingolimod, which she had been taking for nine years to treat her MS. After suspension of fingolimod, she developed CRS and acute respiratory distress syndrome (ARDS) and was successfully treated with tocilizumab.","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"","reminder":false,"when_reminder":"1 week","additional_info":"Patient was diagnosed with SARS-CoV-2 and advised to self-isolate at home, taking acetaminophen. She returned several days later with worsening dyspnea and multifocal pneumonia. Fingolimod was discontinued when she was admitted. Hydroxychloroquine and azithromycin were initiated and after five days, her condition worsened. The patient then received one dose of intravenous tocilizumab and did not receive corticosteroids. Fingolimod was reinitiated prior to discharge, 18 days after discontinuation. At the follow up video visit one week after discharge, the patient continued self-isolation, and she reported hyposmia and dysgeusia.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[5600,6122,8342,10776]},{"id":6294,"regimens":[{"id":12141,"duration":{"id":6139,"approximate_duration":"8 days","dates_unknown":true},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":9498,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12141},{"id":9499,"answer":"In a novel combination with another drug","answer_other":"","regimen":12141}],"created":"2020-10-23T14:27:48.479863Z","updated":"2020-10-23T14:41:43.273825Z","dose":"200 mg","frequency":"daily","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6294},{"id":12142,"duration":{"id":6140,"approximate_duration":"8 days","dates_unknown":true},"drug":{"id":11396,"name":"Darunavir-Ritonavir","url":"cure-api2.ncats.io/v1/drugs/11396","rxNorm_id":null,"notes":null},"use_drug":[{"id":9500,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12142},{"id":9501,"answer":"In a novel combination with another drug","answer_other":"","regimen":12142}],"created":"2020-10-23T14:27:48.488304Z","updated":"2020-10-23T14:41:43.280580Z","dose":"800/100 mg","frequency":"QD","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6294},{"id":12143,"duration":{"id":6141,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6642,"name":"Cefepime","url":"cure-api2.ncats.io/v1/drugs/6642","rxNorm_id":null,"notes":null},"use_drug":[{"id":9502,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12143},{"id":9503,"answer":"In a novel combination with another drug","answer_other":"","regimen":12143}],"created":"2020-10-23T14:27:48.495607Z","updated":"2020-10-23T14:41:43.286308Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6294},{"id":12144,"duration":{"id":6142,"approximate_duration":"2 days","dates_unknown":true},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":9504,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12144},{"id":9505,"answer":"In a novel combination with another drug","answer_other":"","regimen":12144}],"created":"2020-10-23T14:27:48.502402Z","updated":"2020-10-23T14:41:43.291794Z","dose":"8 mg/Kg","frequency":"QD","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6294}],"site_of_infection":[],"specific_site":[],"how_outcome":[],"how_diagnosis":[{"id":14103,"answer":"Clinical assessment","answer_other":"","report":6294},{"id":14104,"answer":"PCR","answer_other":"","report":6294}],"author_username":"Eleanor McCartney","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"","outcome_computed":"Deteriorated","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4362,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6294}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"},{"id":550,"name":"Respiratory Tract Infections"}],"races":[],"created":"2020-10-23T14:26:29.341053Z","updated":"2020-10-23T14:41:43.265548Z","title":"Case series of six kidney transplanted patients with COVID-19 pneumonia treated with tocilizumab. Case 1.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32500936,"doi":"10.1111/tid.13348","article_url":"https://pubmed.ncbi.nlm.nih.gov/32500936/","pub_year":2020,"published_authors":"Mella A\r\nMingozzi S\r\nGallo E\r\nLavacca A\r\nRossetti M\r\nClari R\r\nRandone O\r\nMaffei S\r\nSalomone M\r\nImperiale D\r\nBiancone L","article_author_email":"Author email could not be found.","journal":"Transplant infectious disease : an official journal of the Transplantation Society","abstract":"Few reports described the outcome of kidney transplanted patients (KTs) affected by COVID-19 treated with interleukin-6 receptor inhibitor tocilizumab (TCZ). We report our case series of 6 KTs with COVID-19 pneumonia who received TCZ: All were of male gender, with a mean age of 55.5 Â± 8.4 years, a median time from transplantation of 3611 days (1465-5757); 5/6 had cardiovascular comorbidities, 1/6 had diabetes, and 3/6 have one or more previous KTs. Four out of six patients died, at an average time of 9.75 Â± 2.4 days after tocilizumab administration, 3/6 due to a coexistent septic shock. Two patients improved after TCZ and were discharged at 20 and 21 days, respectively; in both patient, a significant increase of total lymphocyte count was observed. In conclusion, KTs, where the role of peculiar factors such as chronic immunosuppression is still undetermined, represent a high-risk group with significant COVID-19-associated mortality. The evaluation of the TCZ effect in COVID-19 pneumonia requires controlled studies (ideally RCTs) in this specific population.          \r\n        Keywords:      \r\n                  COVID-19; Tocilizumab; kidney transplant.","article_type":"Original","study_type":"Case Report","number_of_patients":6,"article_patient_number":"1","full_text_available":true,"outcome":"Patient died","surgery":"No","age":"41-50 years","sex":"","ethnicity":null,"country_contracted":"Italy","country_treated":"Italy","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":true,"cardiovascular_disease":false,"chronic_renal_disease":true,"chronic_liver_disease":false,"immunosuppressant_drugs":true,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"lungs, kidney","clinical_syndrome":"respiratory and renal failure","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"","additional_info":"This patient had received a kidney transplant from a  deceased donor 15 years prior to contracting COVID-19. The patient medical history included hypertension and was on ongoing immunosuppressive therapy composed of tacrolimus and prednisolone. The patient was put on azithromycin for antibiotic therapy.  The patient underwent continuous renal-replacement therapy and mechanical ventilation prior to death.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6642,11396,8342,10776]},{"id":6295,"regimens":[{"id":12145,"duration":{"id":6143,"approximate_duration":"7 days","dates_unknown":true},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":9506,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12145},{"id":9507,"answer":"In a novel combination with another drug","answer_other":"","regimen":12145}],"created":"2020-10-23T14:44:20.390286Z","updated":"2020-10-23T15:01:31.024157Z","dose":"200 mg","frequency":"QD","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6295},{"id":12146,"duration":{"id":6144,"approximate_duration":"7 days","dates_unknown":true},"drug":{"id":11396,"name":"Darunavir-Ritonavir","url":"cure-api2.ncats.io/v1/drugs/11396","rxNorm_id":null,"notes":null},"use_drug":[{"id":9508,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12146},{"id":9509,"answer":"In a novel combination with another drug","answer_other":"","regimen":12146}],"created":"2020-10-23T14:44:20.398687Z","updated":"2020-10-23T15:01:31.030469Z","dose":"800/100 mg","frequency":"QD","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6295},{"id":12147,"duration":{"id":6145,"approximate_duration":"2 days","dates_unknown":true},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":9510,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12147},{"id":9511,"answer":"In a novel combination with another drug","answer_other":"","regimen":12147}],"created":"2020-10-23T14:44:20.405263Z","updated":"2020-10-23T15:01:31.036239Z","dose":"8 mg/Kg","frequency":"QD","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6295}],"site_of_infection":[],"specific_site":[],"how_outcome":[],"how_diagnosis":[{"id":14105,"answer":"Clinical assessment","answer_other":"","report":6295},{"id":14106,"answer":"PCR","answer_other":"","report":6295}],"author_username":"Eleanor McCartney","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"","outcome_computed":"Deteriorated","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4363,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6295}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":253,"name":"Enterococcal Infection"},{"id":282,"name":"Klebsiella"},{"id":396,"name":"Pneumonia"},{"id":550,"name":"Respiratory Tract Infections"}],"races":[],"created":"2020-10-23T14:43:05.816900Z","updated":"2020-10-23T15:01:31.015734Z","title":"Case series of six kidney transplanted patients with COVID-19 pneumonia treated with tocilizumab. Case 2.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32500936,"doi":"10.1111/tid.13348","article_url":"https://pubmed.ncbi.nlm.nih.gov/32500936/","pub_year":2020,"published_authors":"Mella A\r\nMingozzi S\r\nGallo E\r\nLavacca A\r\nRossetti M\r\nClari R\r\nRandone O\r\nMaffei S\r\nSalomone M\r\nImperiale D\r\nBiancone L","article_author_email":"Author email could not be found.","journal":"Transplant infectious disease : an official journal of the Transplantation Society","abstract":"Few reports described the outcome of kidney transplanted patients (KTs) affected by COVID-19 treated with interleukin-6 receptor inhibitor tocilizumab (TCZ). We report our case series of 6 KTs with COVID-19 pneumonia who received TCZ: All were of male gender, with a mean age of 55.5 Â± 8.4 years, a median time from transplantation of 3611 days (1465-5757); 5/6 had cardiovascular comorbidities, 1/6 had diabetes, and 3/6 have one or more previous KTs. Four out of six patients died, at an average time of 9.75 Â± 2.4 days after tocilizumab administration, 3/6 due to a coexistent septic shock. Two patients improved after TCZ and were discharged at 20 and 21 days, respectively; in both patient, a significant increase of total lymphocyte count was observed. In conclusion, KTs, where the role of peculiar factors such as chronic immunosuppression is still undetermined, represent a high-risk group with significant COVID-19-associated mortality. The evaluation of the TCZ effect in COVID-19 pneumonia requires controlled studies (ideally RCTs) in this specific population.          \r\n        Keywords:      \r\n                  COVID-19; Tocilizumab; kidney transplant.","article_type":"Original","study_type":"Case Report","number_of_patients":2,"article_patient_number":"2","full_text_available":true,"outcome":"Patient died","surgery":"No","age":"61-70 years","sex":"Male","ethnicity":"Not Hispanic/Latino","country_contracted":"Italy","country_treated":"Italy","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":true,"hypertension":true,"cardiovascular_disease":true,"chronic_renal_disease":true,"chronic_liver_disease":false,"immunosuppressant_drugs":true,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"lungs, kidney","clinical_syndrome":"respiratory failure, oliguria","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"Patient has received a kidney translate 8 days prior to positive COVID-19 test. Immunosuppressive therapy composed of thyroglobulin (for 3 days) and methylprednisolone and maintenance therapy included tacrolimus (levels 10-12 ng/mL), mycophenolate mofetil, and prednisone. Patient also received ganciclovir. Patient underwent mechanical ventilation and had positive blood and urine cultures for Klebsiella Pneumoniae for which they were administered amoxicillin/clavulanic acid, cefepime, gentamicin, piperacillin/tazobactam, and daptomycin. Patient eventually became oliguric.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[11396,8342,10776]},{"id":6296,"regimens":[{"id":12148,"duration":{"id":6146,"approximate_duration":"7 days","dates_unknown":true},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":9512,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12148},{"id":9513,"answer":"In a novel combination with another drug","answer_other":"","regimen":12148}],"created":"2020-10-23T15:02:44.389568Z","updated":"2020-10-23T15:09:39.099002Z","dose":"200 mg","frequency":"QD","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6296},{"id":12149,"duration":{"id":6147,"approximate_duration":"2 days","dates_unknown":true},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":9514,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12149},{"id":9515,"answer":"In a novel combination with another drug","answer_other":"","regimen":12149}],"created":"2020-10-23T15:02:44.397335Z","updated":"2020-10-23T15:09:39.105403Z","dose":"8 mg/Kg","frequency":"QD","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6296}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8285,"answer":"Clinical assessment","answer_other":"","report":6296}],"how_diagnosis":[{"id":14107,"answer":"Clinical assessment","answer_other":"","report":6296},{"id":14108,"answer":"PCR","answer_other":"","report":6296}],"author_username":"Eleanor McCartney","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4364,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6296}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":550,"name":"Respiratory Tract Infections"}],"races":[],"created":"2020-10-23T15:02:09.028488Z","updated":"2020-10-23T15:09:39.090782Z","title":"Case series of six kidney transplanted patients with COVID-19 pneumonia treated with tocilizumab. Case 3.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32500936,"doi":"10.1111/tid.13348","article_url":"https://pubmed.ncbi.nlm.nih.gov/32500936/","pub_year":2020,"published_authors":"Mella A\r\nMingozzi S\r\nGallo E\r\nLavacca A\r\nRossetti M\r\nClari R\r\nRandone O\r\nMaffei S\r\nSalomone M\r\nImperiale D\r\nBiancone L","article_author_email":"Author email could not be found.","journal":"Transplant infectious disease : an official journal of the Transplantation Society","abstract":"Few reports described the outcome of kidney transplanted patients (KTs) affected by COVID-19 treated with interleukin-6 receptor inhibitor tocilizumab (TCZ). We report our case series of 6 KTs with COVID-19 pneumonia who received TCZ: All were of male gender, with a mean age of 55.5 Â± 8.4 years, a median time from transplantation of 3611 days (1465-5757); 5/6 had cardiovascular comorbidities, 1/6 had diabetes, and 3/6 have one or more previous KTs. Four out of six patients died, at an average time of 9.75 Â± 2.4 days after tocilizumab administration, 3/6 due to a coexistent septic shock. Two patients improved after TCZ and were discharged at 20 and 21 days, respectively; in both patient, a significant increase of total lymphocyte count was observed. In conclusion, KTs, where the role of peculiar factors such as chronic immunosuppression is still undetermined, represent a high-risk group with significant COVID-19-associated mortality. The evaluation of the TCZ effect in COVID-19 pneumonia requires controlled studies (ideally RCTs) in this specific population.          \r\n        Keywords:      \r\n                  COVID-19; Tocilizumab; kidney transplant.","article_type":"Original","study_type":"Case Report","number_of_patients":6,"article_patient_number":"3","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"No","age":"51-60 years","sex":"Male","ethnicity":null,"country_contracted":"Italy","country_treated":"Italy","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":true,"chronic_renal_disease":true,"chronic_liver_disease":false,"immunosuppressant_drugs":true,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"lungs","clinical_syndrome":"respiratory tract infection","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"After a period of follow-up","follow_up_period":"26 days after discharge","relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"This patient underwent their third kidney transplant in 2014, 6 years prior to positive COVID-19 test. Immunospressive regimen was composed of tacrolimus and glucocorticoids. Patient was treated with low-molecular-weight heparin and non-invasive ventilation.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[8342,10776]},{"id":6297,"regimens":[{"id":12150,"duration":{"id":6148,"approximate_duration":"14 days","dates_unknown":true},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":9516,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12150},{"id":9517,"answer":"In a novel combination with another drug","answer_other":"","regimen":12150}],"created":"2020-10-23T15:11:21.056441Z","updated":"2020-10-23T15:22:33.894523Z","dose":"200 mg","frequency":"QD","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6297},{"id":12154,"duration":{"id":6152,"approximate_duration":"2 days","dates_unknown":true},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":9518,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12154},{"id":9519,"answer":"In a novel combination with another drug","answer_other":"","regimen":12154}],"created":"2020-10-23T15:11:21.083111Z","updated":"2020-10-23T15:22:33.901180Z","dose":"8 mg/Kg","frequency":"QD","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6297}],"site_of_infection":[],"specific_site":[],"how_outcome":[],"how_diagnosis":[{"id":14109,"answer":"Clinical assessment","answer_other":"","report":6297},{"id":14110,"answer":"PCR","answer_other":"","report":6297}],"author_username":"Eleanor McCartney","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"","outcome_computed":"Deteriorated","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4365,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6297}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":501,"name":"Hepatitis C"},{"id":396,"name":"Pneumonia"},{"id":550,"name":"Respiratory Tract Infections"}],"races":[],"created":"2020-10-23T15:10:16.136835Z","updated":"2020-10-23T15:22:33.886591Z","title":"Case series of six kidney transplanted patients with COVID-19 pneumonia treated with tocilizumab. Case 4.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32500936,"doi":"10.1111/tid.13348","article_url":"https://pubmed.ncbi.nlm.nih.gov/32500936/","pub_year":2020,"published_authors":"Mella A\r\nMingozzi S\r\nGallo E\r\nLavacca A\r\nRossetti M\r\nClari R\r\nRandone O\r\nMaffei S\r\nSalomone M\r\nImperiale D\r\nBiancone L","article_author_email":"Author email could not be found.","journal":"Transplant infectious disease : an official journal of the Transplantation Society","abstract":"Few reports described the outcome of kidney transplanted patients (KTs) affected by COVID-19 treated with interleukin-6 receptor inhibitor tocilizumab (TCZ). We report our case series of 6 KTs with COVID-19 pneumonia who received TCZ: All were of male gender, with a mean age of 55.5 Â± 8.4 years, a median time from transplantation of 3611 days (1465-5757); 5/6 had cardiovascular comorbidities, 1/6 had diabetes, and 3/6 have one or more previous KTs. Four out of six patients died, at an average time of 9.75 Â± 2.4 days after tocilizumab administration, 3/6 due to a coexistent septic shock. Two patients improved after TCZ and were discharged at 20 and 21 days, respectively; in both patient, a significant increase of total lymphocyte count was observed. In conclusion, KTs, where the role of peculiar factors such as chronic immunosuppression is still undetermined, represent a high-risk group with significant COVID-19-associated mortality. The evaluation of the TCZ effect in COVID-19 pneumonia requires controlled studies (ideally RCTs) in this specific population.          \r\n        Keywords:      \r\n                  COVID-19; Tocilizumab; kidney transplant.","article_type":"Original","study_type":"Case Report","number_of_patients":6,"article_patient_number":"4","full_text_available":true,"outcome":"Patient died","surgery":"No","age":"61-70 years","sex":"Male","ethnicity":null,"country_contracted":"Italy","country_treated":"Italy","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":true,"cardiovascular_disease":true,"chronic_renal_disease":true,"chronic_liver_disease":false,"immunosuppressant_drugs":true,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"lungs","clinical_syndrome":"respiratory failure","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"This patient had a second kidney transplant in 2007. Immunosuppressive therapy composed of tacrolimus, mycophenolate mofetil, and steroids. Patient was administered methylprednisolone 20 mg daily, and piperacillin-tazobactum in association to fluconazole. Patient required mechanical ventilation and aided 26 days after admission.","previously_treated":"","flagged":false,"other_coinfections":"Hepatitis C Infection","disease":630,"drugs":[8342,10776]},{"id":6298,"regimens":[{"id":12155,"duration":{"id":6153,"approximate_duration":"14 days","dates_unknown":true},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":9520,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12155},{"id":9521,"answer":"In a novel combination with another drug","answer_other":"","regimen":12155}],"created":"2020-10-23T15:23:53.790732Z","updated":"2020-10-23T15:36:40.255027Z","dose":"200 mg","frequency":"QD","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6298},{"id":12156,"duration":{"id":6154,"approximate_duration":"2 days","dates_unknown":true},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":9522,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12156},{"id":9523,"answer":"In a novel combination with another drug","answer_other":"","regimen":12156}],"created":"2020-10-23T15:23:53.799048Z","updated":"2020-10-23T15:36:40.261430Z","dose":"8 mg/Kg","frequency":"QD","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6298},{"id":12157,"duration":{"id":6155,"approximate_duration":"4 days","dates_unknown":true},"drug":{"id":11148,"name":"Immunoglobulin G (IgG)","url":"cure-api2.ncats.io/v1/drugs/11148","rxNorm_id":null,"notes":null},"use_drug":[{"id":9524,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12157},{"id":9525,"answer":"In a novel combination with another drug","answer_other":"","regimen":12157}],"created":"2020-10-23T15:29:53.899278Z","updated":"2020-10-23T15:36:40.267110Z","dose":"0.2g/Kg/Day","frequency":"QD","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6298},{"id":12158,"duration":{"id":6156,"approximate_duration":"14 days","dates_unknown":true},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":9526,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12158},{"id":9527,"answer":"In a novel combination with another drug","answer_other":"","regimen":12158}],"created":"2020-10-23T15:29:53.906886Z","updated":"2020-10-23T15:36:40.272654Z","dose":"200 mg","frequency":"QD","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6298},{"id":12159,"duration":{"id":6157,"approximate_duration":"2 days","dates_unknown":true},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":9528,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12159},{"id":9529,"answer":"In a novel combination with another drug","answer_other":"","regimen":12159}],"created":"2020-10-23T15:29:53.913160Z","updated":"2020-10-23T15:36:40.278658Z","dose":"8 mg/Kg","frequency":"QD","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6298}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8286,"answer":"Clinical assessment","answer_other":"","report":6298}],"how_diagnosis":[{"id":14111,"answer":"Clinical assessment","answer_other":"","report":6298},{"id":14112,"answer":"PCR","answer_other":"","report":6298}],"author_username":"Eleanor McCartney","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4366,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6298}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":501,"name":"Hepatitis C"},{"id":396,"name":"Pneumonia"},{"id":550,"name":"Respiratory Tract Infections"}],"races":[],"created":"2020-10-23T15:22:58.438878Z","updated":"2020-10-23T15:36:40.247010Z","title":"Case series of six kidney transplanted patients with COVID-19 pneumonia treated with tocilizumab. Case 5.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32500936,"doi":"10.1111/tid.13348","article_url":"https://pubmed.ncbi.nlm.nih.gov/32500936/","pub_year":2020,"published_authors":"Mella A\r\nMingozzi S\r\nGallo E\r\nLavacca A\r\nRossetti M\r\nClari R\r\nRandone O\r\nMaffei S\r\nSalomone M\r\nImperiale D\r\nBiancone L","article_author_email":"Author email could not be found.","journal":"Transplant infectious disease : an official journal of the Transplantation Society","abstract":"Few reports described the outcome of kidney transplanted patients (KTs) affected by COVID-19 treated with interleukin-6 receptor inhibitor tocilizumab (TCZ). We report our case series of 6 KTs with COVID-19 pneumonia who received TCZ: All were of male gender, with a mean age of 55.5 Â± 8.4 years, a median time from transplantation of 3611 days (1465-5757); 5/6 had cardiovascular comorbidities, 1/6 had diabetes, and 3/6 have one or more previous KTs. Four out of six patients died, at an average time of 9.75 Â± 2.4 days after tocilizumab administration, 3/6 due to a coexistent septic shock. Two patients improved after TCZ and were discharged at 20 and 21 days, respectively; in both patient, a significant increase of total lymphocyte count was observed. In conclusion, KTs, where the role of peculiar factors such as chronic immunosuppression is still undetermined, represent a high-risk group with significant COVID-19-associated mortality. The evaluation of the TCZ effect in COVID-19 pneumonia requires controlled studies (ideally RCTs) in this specific population.          \r\n        Keywords:      \r\n                  COVID-19; Tocilizumab; kidney transplant.","article_type":"Original","study_type":"Case Report","number_of_patients":6,"article_patient_number":"5","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"No","age":"41-50 years","sex":"","ethnicity":null,"country_contracted":"Italy","country_treated":"Italy","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":true,"chronic_renal_disease":true,"chronic_liver_disease":false,"immunosuppressant_drugs":true,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"lungs","clinical_syndrome":"respiratory tract infection","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"After a period of follow-up","follow_up_period":"12 days after discharge","relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"This patient receieved a kidney transplant 18 years ago. Immunosuppressive therapy included tacromilus, mycophenolate mofetil, and glucocorticoids. Patient was also given antibiotic therapy ceftaroline and was discharged after 21 days.","previously_treated":"","flagged":false,"other_coinfections":"Hepatitis C infection","disease":630,"drugs":[8342,8342,11148,10776,10776]},{"id":6304,"regimens":[{"id":12170,"duration":{"id":6168,"approximate_duration":"1day","dates_unknown":true},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":9545,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12170}],"created":"2020-10-23T16:58:30.795940Z","updated":"2020-10-23T17:11:02.321709Z","dose":"8mg/kg","frequency":"once","route":"IV","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6304}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8291,"answer":"Clinical assessment","answer_other":"","report":6304}],"how_diagnosis":[{"id":14127,"answer":"PCR","answer_other":"","report":6304},{"id":14128,"answer":"Clinical assessment","answer_other":"","report":6304}],"author_username":"Belinda Nhundu","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4373,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6304},{"id":4374,"answer":"Co-Infection or Complex Co-morbidities","answer_other":"","report":6304}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[],"races":[{"id":447,"answer":"White","answer_other":""}],"created":"2020-10-23T16:52:30.053721Z","updated":"2020-10-23T17:11:02.314141Z","title":"Rapid resolution of cytokine release syndrome and favorable clinical course of severe COVID-19 in a kidney transplant recipient treated with tocilizumab.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32505467,"doi":"10.1016/j.kint.2020.05.022","article_url":"https://pubmed.ncbi.nlm.nih.gov/32505467/","pub_year":2020,"published_authors":"Gautier-Vargas G\r\nBaldacini C\r\nBenotmane I\r\nKeller N\r\nPerrin P\r\nMoulin B\r\nCaillard S","article_author_email":"ste-phan.kemmner@med.uni-muenchen.de","journal":"Kidney international","abstract":"No abstract available","article_type":"Original","study_type":"Case Report","number_of_patients":1,"article_patient_number":"1","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"61-70 years","sex":"Female","ethnicity":null,"country_contracted":"Germany","country_treated":"Germany","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":true,"cardiovascular_disease":false,"chronic_renal_disease":true,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"Lung","clinical_syndrome":"Respiratory tract infection","severity":null,"prev_treatment":"","unusual":"kidney transplant patient with Covid19 treated for cytokine release syndrome.","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[10776]},{"id":6306,"regimens":[{"id":12171,"duration":{"id":6169,"approximate_duration":"7 days","dates_unknown":true},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":9546,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12171},{"id":9547,"answer":"In a novel combination with another drug","answer_other":"","regimen":12171}],"created":"2020-10-23T17:11:21.581096Z","updated":"2020-10-23T17:17:41.248540Z","dose":"200 mg","frequency":"QD","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6306},{"id":12172,"duration":{"id":6170,"approximate_duration":"2 days","dates_unknown":true},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":9548,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12172},{"id":9549,"answer":"In a novel combination with another drug","answer_other":"","regimen":12172}],"created":"2020-10-23T17:11:21.588618Z","updated":"2020-10-23T17:17:41.254916Z","dose":"8 mg/Kg","frequency":"QD","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6306}],"site_of_infection":[],"specific_site":[],"how_outcome":[],"how_diagnosis":[{"id":14129,"answer":"Clinical assessment","answer_other":"","report":6306},{"id":14130,"answer":"PCR","answer_other":"","report":6306}],"author_username":"Eleanor McCartney","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"","outcome_computed":"Deteriorated","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4375,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6306}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"},{"id":550,"name":"Respiratory Tract Infections"}],"races":[],"created":"2020-10-23T17:10:50.324883Z","updated":"2020-10-23T17:17:41.238876Z","title":"Case series of six kidney transplanted patients with COVID-19 pneumonia treated with tocilizumab. Case 6.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32500936,"doi":"10.1111/tid.13348","article_url":"https://pubmed.ncbi.nlm.nih.gov/32500936/","pub_year":2020,"published_authors":"Mella A\r\nMingozzi S\r\nGallo E\r\nLavacca A\r\nRossetti M\r\nClari R\r\nRandone O\r\nMaffei S\r\nSalomone M\r\nImperiale D\r\nBiancone L","article_author_email":"Author email could not be found.","journal":"Transplant infectious disease : an official journal of the Transplantation Society","abstract":"Few reports described the outcome of kidney transplanted patients (KTs) affected by COVID-19 treated with interleukin-6 receptor inhibitor tocilizumab (TCZ). We report our case series of 6 KTs with COVID-19 pneumonia who received TCZ: All were of male gender, with a mean age of 55.5 Â± 8.4 years, a median time from transplantation of 3611 days (1465-5757); 5/6 had cardiovascular comorbidities, 1/6 had diabetes, and 3/6 have one or more previous KTs. Four out of six patients died, at an average time of 9.75 Â± 2.4 days after tocilizumab administration, 3/6 due to a coexistent septic shock. Two patients improved after TCZ and were discharged at 20 and 21 days, respectively; in both patient, a significant increase of total lymphocyte count was observed. In conclusion, KTs, where the role of peculiar factors such as chronic immunosuppression is still undetermined, represent a high-risk group with significant COVID-19-associated mortality. The evaluation of the TCZ effect in COVID-19 pneumonia requires controlled studies (ideally RCTs) in this specific population.          \r\n        Keywords:      \r\n                  COVID-19; Tocilizumab; kidney transplant.","article_type":"Original","study_type":"Case Report","number_of_patients":6,"article_patient_number":"6","full_text_available":true,"outcome":"Patient died","surgery":"No","age":"61-70 years","sex":"Male","ethnicity":null,"country_contracted":"Italy","country_treated":"Italy","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":true,"cardiovascular_disease":true,"chronic_renal_disease":true,"chronic_liver_disease":false,"immunosuppressant_drugs":true,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"lungs","clinical_syndrome":"respiratory failure","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"Patient had a kidney transplant in 2011. ongoing immunosuppressive thereby included glucocorticoids and tacrolimus. Pneumonia was treated with amoxicillin-clavulanic acid (1g BID). Patient underwent mechanical ventilation and deceased 8 days after diagnosis.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[8342,10776]},{"id":6319,"regimens":[{"id":12203,"duration":{"id":6201,"approximate_duration":"16 Days","dates_unknown":true},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":9604,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12203},{"id":9605,"answer":"In a novel combination with another drug","answer_other":"","regimen":12203}],"created":"2020-10-26T18:44:46.299647Z","updated":"2020-10-26T18:58:52.151480Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"Under mechanical ventilation","comments":null,"report":6319},{"id":12204,"duration":{"id":6202,"approximate_duration":"16 Days","dates_unknown":true},"drug":{"id":8783,"name":"Lopinavir-Ritonavir","url":"cure-api2.ncats.io/v1/drugs/8783","rxNorm_id":null,"notes":null},"use_drug":[{"id":9606,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12204},{"id":9607,"answer":"In a novel combination with another drug","answer_other":"","regimen":12204}],"created":"2020-10-26T18:44:46.307696Z","updated":"2020-10-26T18:58:52.158080Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"Under mechanical ventilation","comments":null,"report":6319},{"id":12205,"duration":{"id":6203,"approximate_duration":"9 Days","dates_unknown":true},"drug":{"id":7066,"name":"Corticosteroids","url":"cure-api2.ncats.io/v1/drugs/7066","rxNorm_id":null,"notes":null},"use_drug":[{"id":9608,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12205},{"id":9609,"answer":"In a novel combination with another drug","answer_other":"","regimen":12205}],"created":"2020-10-26T18:44:46.314274Z","updated":"2020-10-26T18:58:52.163794Z","dose":"1mg/kg","frequency":"","route":"","severity":"Inpatient","severity_detail":"Under mechanical ventilation","comments":null,"report":6319},{"id":12206,"duration":{"id":6204,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":9610,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12206},{"id":9611,"answer":"In a novel combination with another drug","answer_other":"","regimen":12206}],"created":"2020-10-26T18:44:46.320850Z","updated":"2020-10-26T18:58:52.169513Z","dose":"600mg","frequency":"2 Doses","route":"","severity":"Inpatient","severity_detail":"Under mechanical ventilation","comments":null,"report":6319}],"site_of_infection":[],"specific_site":[],"how_outcome":[],"how_diagnosis":[{"id":14158,"answer":"Clinical assessment","answer_other":"","report":6319},{"id":14159,"answer":"Imaging","answer_other":"","report":6319},{"id":14160,"answer":"PCR","answer_other":"","report":6319}],"author_username":"Paige Evans","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Nurse","author_affiliation":"None","author_country":"","outcome_computed":"Deteriorated","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4391,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6319},{"id":4392,"answer":"Co-Infection or Complex Co-morbidities","answer_other":"","report":6319}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[{"id":451,"answer":"Other","answer_other":""}],"created":"2020-10-26T18:43:04.659049Z","updated":"2020-10-26T18:58:52.143732Z","title":"Poor outcome in patients with acute leukemia on intensive chemotherapy and COVID-19. Case 1.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32499538,"doi":"10.1038/s41409-020-0961-y","article_url":"https://pubmed.ncbi.nlm.nih.gov/32499538/","pub_year":2020,"published_authors":"NÃºÃ±ez-TorrÃ³n C\r\nGarcÃ­a-GutiÃ©rrez V\r\nTenorio-NÃºÃ±ez MC\r\nMoreno-JimÃ©nez G\r\nLÃ³pez-JimÃ©nez FJ\r\nHerrera-Puente P","article_author_email":"jvalentingg@gmail.com","journal":"Bone marrow transplantation","abstract":"We reviewed eight patients with AML that received a total of nine intensive AML chemotherapy\r\ncycles in a tertiary care hospital of which four were confirmed cases. To our knowledge, there are no current data evaluating the impact of concomitant COVID-19 in AML patients candidates to intensive therapy, and thus recommendations of expert panels are followed based on the available data in\r\nnonhematological population.","article_type":"Original","study_type":"Case Report","number_of_patients":4,"article_patient_number":"1","full_text_available":true,"outcome":"Patient died","surgery":"No","age":"","sex":"","ethnicity":null,"country_contracted":"Spain","country_treated":"Spain","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"Acute Myeloid Leukemia","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Pneumonia","severity":null,"prev_treatment":"","unusual":"Patient was undergoing chemotherapy for AML when COVID-19 was contracted.","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"Patient had undergone 9 intensive AML chemotherapy cycles in a tertiary care hospital where COVID-19 was acquired.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[7066,8342,8783,10776]},{"id":6321,"regimens":[{"id":12210,"duration":{"id":6208,"approximate_duration":"5 Days","dates_unknown":true},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":9618,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12210},{"id":9619,"answer":"In a novel combination with another drug","answer_other":"","regimen":12210}],"created":"2020-10-26T19:27:18.519075Z","updated":"2020-10-26T19:39:35.263875Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"Under mechanical ventilation","comments":null,"report":6321},{"id":12211,"duration":{"id":6209,"approximate_duration":"4 Days","dates_unknown":true},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":9620,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12211},{"id":9621,"answer":"In a novel combination with another drug","answer_other":"","regimen":12211}],"created":"2020-10-26T19:27:49.024588Z","updated":"2020-10-26T19:39:35.270272Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"Under mechanical ventilation","comments":null,"report":6321},{"id":12212,"duration":{"id":6210,"approximate_duration":"6 Days","dates_unknown":true},"drug":{"id":7066,"name":"Corticosteroids","url":"cure-api2.ncats.io/v1/drugs/7066","rxNorm_id":null,"notes":null},"use_drug":[{"id":9622,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12212},{"id":9623,"answer":"In a novel combination with another drug","answer_other":"","regimen":12212}],"created":"2020-10-26T19:27:49.031507Z","updated":"2020-10-26T19:39:35.276310Z","dose":"1mg/kg","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"Under mechanical ventilation","comments":null,"report":6321},{"id":12213,"duration":{"id":6211,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":9624,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12213},{"id":9625,"answer":"In a novel combination with another drug","answer_other":"","regimen":12213}],"created":"2020-10-26T19:27:49.037842Z","updated":"2020-10-26T19:39:35.281843Z","dose":"600mg first dose, 400mg second dose","frequency":"2 Doses","route":"","severity":"ICU/Critical Care","severity_detail":"Under mechanical ventilation","comments":null,"report":6321}],"site_of_infection":[],"specific_site":[],"how_outcome":[],"how_diagnosis":[{"id":14164,"answer":"Clinical assessment","answer_other":"","report":6321},{"id":14165,"answer":"Imaging","answer_other":"","report":6321},{"id":14166,"answer":"PCR","answer_other":"","report":6321}],"author_username":"Paige Evans","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Nurse","author_affiliation":"None","author_country":"","outcome_computed":"Deteriorated","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4395,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6321},{"id":4396,"answer":"Co-Infection or Complex Co-morbidities","answer_other":"","report":6321}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-10-26T19:25:23.886918Z","updated":"2020-10-26T19:39:35.256299Z","title":"Poor outcome in patients with acute leukemia on intensive chemotherapy and COVID-19. Case 3.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32499538,"doi":"10.1038/s41409-020-0961-y","article_url":"https://pubmed.ncbi.nlm.nih.gov/32499538/","pub_year":2020,"published_authors":"NÃºÃ±ez-TorrÃ³n C\r\nGarcÃ­a-GutiÃ©rrez V\r\nTenorio-NÃºÃ±ez MC\r\nMoreno-JimÃ©nez G\r\nLÃ³pez-JimÃ©nez FJ\r\nHerrera-Puente P","article_author_email":"jvalentingg@gmail.com","journal":"Bone marrow transplantation","abstract":"We reviewed eight patients with AML that received a total of nine intensive AML chemotherapy cycles in a tertiary care hospital of which four were confirmed cases. To our knowledge, there are no current data evaluating the impact of concomitant COVID-19 in AML patients candidates to intensive therapy, and thus recommendations of expert panels are followed based on the available data in nonhematological population.","article_type":"Original","study_type":"Case Report","number_of_patients":4,"article_patient_number":"3","full_text_available":true,"outcome":"Patient died","surgery":"No","age":"","sex":"","ethnicity":null,"country_contracted":"Spain","country_treated":"Spain","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"Acute Myeloid Leukemia","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Pneumonia","severity":null,"prev_treatment":"","unusual":"Patient was undergoing chemotherapy for AML when COVID-19 was contracted.","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"Patient had undergone 9 intensive AML chemotherapy cycles in a tertiary care hospital where COVID-19 was acquired.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6122,7066,8342,10776]},{"id":6331,"regimens":[{"id":12227,"duration":{"id":6225,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":9641,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12227},{"id":9642,"answer":"In a novel combination with another drug","answer_other":"","regimen":12227}],"created":"2020-10-27T00:45:54.069378Z","updated":"2020-10-27T00:58:46.465945Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6331},{"id":12228,"duration":{"id":6226,"approximate_duration":"8 doses","dates_unknown":true},"drug":{"id":5926,"name":"Anakinra","url":"cure-api2.ncats.io/v1/drugs/5926","rxNorm_id":null,"notes":null},"use_drug":[{"id":9645,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12228},{"id":9646,"answer":"In a novel combination with another drug","answer_other":"","regimen":12228}],"created":"2020-10-27T00:45:54.076507Z","updated":"2020-10-27T00:58:46.472414Z","dose":"100 mg","frequency":"q6H","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6331},{"id":12229,"duration":{"id":6227,"approximate_duration":"2 doses","dates_unknown":true},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":9647,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12229},{"id":9648,"answer":"In a novel combination with another drug","answer_other":"","regimen":12229}],"created":"2020-10-27T00:45:54.082885Z","updated":"2020-10-27T00:58:46.478244Z","dose":"400 mg","frequency":"","route":"IV","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6331},{"id":12230,"duration":{"id":6228,"approximate_duration":null,"dates_unknown":false},"drug":{"id":11339,"name":"Convalescent plasma","url":"cure-api2.ncats.io/v1/drugs/11339","rxNorm_id":null,"notes":null},"use_drug":[{"id":9649,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12230},{"id":9650,"answer":"In a novel combination with another drug","answer_other":"","regimen":12230}],"created":"2020-10-27T00:45:54.089273Z","updated":"2020-10-27T00:58:46.483765Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6331},{"id":12231,"duration":{"id":6229,"approximate_duration":"1 dose","dates_unknown":true},"drug":{"id":7561,"name":"Eculizumab","url":"cure-api2.ncats.io/v1/drugs/7561","rxNorm_id":null,"notes":null},"use_drug":[{"id":9651,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12231},{"id":9652,"answer":"In a novel combination with another drug","answer_other":"","regimen":12231}],"created":"2020-10-27T00:45:54.095538Z","updated":"2020-10-27T00:58:46.489579Z","dose":"900 mg","frequency":"","route":"IV","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6331}],"site_of_infection":[],"specific_site":[],"how_outcome":[],"how_diagnosis":[{"id":14184,"answer":"Clinical assessment","answer_other":"","report":6331},{"id":14185,"answer":"Imaging","answer_other":"","report":6331},{"id":14186,"answer":"PCR","answer_other":"","report":6331}],"author_username":"Reema Charles","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"","outcome_computed":"Deteriorated","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4409,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6331}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"},{"id":550,"name":"Respiratory Tract Infections"}],"races":[{"id":453,"answer":"White","answer_other":""}],"created":"2020-10-27T00:43:29.191486Z","updated":"2020-10-27T00:58:46.457497Z","title":"Thrombotic microangiopathy inÂ aÂ patient with COVID-19.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32525010,"doi":"10.1016/j.kint.2020.05.025","article_url":"https://pubmed.ncbi.nlm.nih.gov/32525010/","pub_year":2020,"published_authors":"Jhaveri KD\r\nMeir LR\r\nFlores Chang BS\r\nParikh R\r\nWanchoo R\r\nBarilla-LaBarca ML\r\nBijol V\r\nHajizadeh N","article_author_email":"Author email could not be found.","journal":"Kidney international","abstract":"A Caucasian female in 60s with a past medical history of asthma presented to the emergency department with productive cough, fever, and shortness of breath of 2 weeksâ duration. In the emergency room, she was afebrile, with a respiratory rate of 22 breaths per minute, and oxygen saturation of 89% on room air. Initial laboratory tests showed a normal white blood cell count, hemoglobin level, and platelet count. Inflammatory lab parameters were elevated (Table 1 ). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was confirmed in the patient by reverse-transcriptase polymerase chain reaction assay or serologic testing at our center. A chest X-ray showed bilateral diffuse patchy opacities.","article_type":"Original","study_type":"Case Report","number_of_patients":1,"article_patient_number":"","full_text_available":true,"outcome":"Patient died","surgery":"No","age":"61-70 years","sex":"Female","ethnicity":"Not Hispanic/Latino","country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":true,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Pneumonia","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"","follow_up_period":null,"relapse":"","reminder":false,"when_reminder":"1 week","additional_info":"low-molecular-weight heparin, and oxygen  +\r\nMechanical ventilation +\r\nUrinalysis showed hematuria\r\nThe patientâs kidney function worsened, requiring initiation of continuous renal replacement therapy. \r\nOn day 20, the patient underwent a kidney biopsy that revealed severe acute thrombotic microangiopathy with cortical necrosis. Although beta 2 glycoprotein-1 IgM levels were elevated, other laboratory and clinical features of antiphospholipid antibody were absent. The disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) level was not low. Complement 3 and 4 were in the normal range. Heparin-induced antibody testing was negative. Coagulation parameters were normal.\r\nA kidney sonogram was negative for renal vein thrombosis and arterial clots. \r\nThe patient did not have any other systemic findings of macro thrombi. \r\nSubsequent detailed complement testing revealed a low factor H complement antigen, and elevated plasma CBb complement and plasma SC5b-9 complement levels, suggesting an activation of the alternative complement pathway","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[5926,11339,7561,8342,10776]},{"id":6357,"regimens":[{"id":12291,"duration":{"id":6290,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":9771,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12291},{"id":9772,"answer":"In a novel combination with another drug","answer_other":"","regimen":12291}],"created":"2020-10-27T18:37:19.482346Z","updated":"2020-10-27T19:11:28.803814Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6357},{"id":12292,"duration":{"id":6291,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":9773,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12292},{"id":9774,"answer":"In a novel combination with another drug","answer_other":"","regimen":12292}],"created":"2020-10-27T18:37:19.489790Z","updated":"2020-10-27T19:11:28.810140Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6357}],"site_of_infection":[],"specific_site":[],"how_outcome":[],"how_diagnosis":[{"id":14245,"answer":"Clinical assessment","answer_other":"","report":6357},{"id":14246,"answer":"PCR","answer_other":"","report":6357}],"author_username":"Kate Borkowski","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Nurse","author_affiliation":"None","author_country":"","outcome_computed":"Deteriorated","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4443,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6357}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[],"races":[{"id":461,"answer":"White","answer_other":""}],"created":"2020-10-27T18:37:00.413155Z","updated":"2020-10-27T19:11:28.795426Z","title":"SARS-CoV-2 and Stroke in a New York Healthcare System. Case 16.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32432996,"doi":"10.1161/STROKEAHA.120.030335","article_url":"https://pubmed.ncbi.nlm.nih.gov/32432996/","pub_year":2020,"published_authors":"Yaghi S\r\nIshida K\r\nTorres J\r\nMac Grory B\r\nRaz E\r\nHumbert K\r\nHenninger N\r\nTrivedi T\r\nLillemoe K\r\nAlam S\r\nSanger M\r\nKim S\r\nScher E\r\nDehkharghani S\r\nWachs M\r\nTanweer O\r\nVolpicelli F\r\nBosworth B\r\nLord A\r\nFrontera J","article_author_email":"shadiyaghi@yahoo.com","journal":"Stroke","abstract":"Background and purpose:      \r\n              With the spread of coronavirus disease 2019 (COVID-19) during the current worldwide pandemic, there is mounting evidence that patients affected by the illness may develop clinically significant coagulopathy with thromboembolic complications including ischemic stroke. However, there is limited data on the clinical characteristics, stroke mechanism, and outcomes of patients who have a stroke and COVID-19.          \r\n        Methods:      \r\n              We conducted a retrospective cohort study of consecutive patients with ischemic stroke who were hospitalized between March 15, 2020, and April 19, 2020, within a major health system in New York, the current global epicenter of the pandemic. We compared the clinical characteristics of stroke patients with a concurrent diagnosis of COVID-19 to stroke patients without COVID-19 (contemporary controls). In addition, we compared patients to a historical cohort of patients with ischemic stroke discharged from our hospital system between March 15, 2019, and April 15, 2019 (historical controls).          \r\n        Results:      \r\n              During the study period in 2020, out of 3556 hospitalized patients with diagnosis of COVID-19 infection, 32 patients (0.9%) had imaging proven ischemic stroke. Cryptogenic stroke was more common in patients with COVID-19 (65.6%) as compared to contemporary controls (30.4%, \r\nP\r\n=0.003) and historical controls (25.0%, \r\nP\r\n<0.001). When compared with contemporary controls, COVID-19 positive patients had higher admission National Institutes of Health Stroke Scale score and higher peak D-dimer levels. When compared with historical controls, COVID-19 positive patients were more likely to be younger men with elevated troponin, higher admission National Institutes of Health Stroke Scale score, and higher erythrocyte sedimentation rate. Patients with COVID-19 and stroke had significantly higher mortality than historical and contemporary controls.          \r\n        Conclusions:      \r\n              We observed a low rate of imaging-confirmed ischemic stroke in hospitalized patients with COVID-19. Most strokes were cryptogenic, possibly related to an acquired hypercoagulability, and mortality was increased. Studies are needed to determine the utility of therapeutic anticoagulation for stroke and other thrombotic event prevention in patients with COVID-19.          \r\n        Keywords:      \r\n                  COVID-19; coronavirus; diagnosis; pandemic; troponin.","article_type":"Original","study_type":"Case Report","number_of_patients":32,"article_patient_number":"","full_text_available":true,"outcome":"Patient died","surgery":"","age":"71-80 years","sex":"","ethnicity":null,"country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":true,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"A-fib, hyperlipidemia","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Fever, cough, hypoxia","severity":null,"prev_treatment":"","unusual":"24 days after the start of COVID-19 symptoms, patient experienced cardioembolic stroke.","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"","follow_up_period":null,"relapse":"","reminder":false,"when_reminder":"1 week","additional_info":"","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[8342,10776]},{"id":6359,"regimens":[{"id":12301,"duration":{"id":6300,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":9753,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12301},{"id":9754,"answer":"In a novel combination with another drug","answer_other":"","regimen":12301}],"created":"2020-10-27T18:47:47.779901Z","updated":"2020-12-17T19:23:40.233200Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"Intubation and ventilation","comments":null,"report":6359},{"id":12302,"duration":{"id":6301,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[],"created":"2020-10-27T18:47:47.787060Z","updated":"2020-12-17T19:23:40.240085Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"Intubation and ventilation","comments":null,"report":6359},{"id":12303,"duration":{"id":6302,"approximate_duration":null,"dates_unknown":false},"drug":{"id":11091,"name":"Zinc","url":"cure-api2.ncats.io/v1/drugs/11091","rxNorm_id":null,"notes":null},"use_drug":[{"id":9755,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12303},{"id":9756,"answer":"In a novel combination with another drug","answer_other":"","regimen":12303}],"created":"2020-10-27T18:47:47.793389Z","updated":"2020-12-17T19:23:40.245445Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"Intubation and ventilation","comments":null,"report":6359},{"id":12304,"duration":{"id":6303,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":9757,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12304},{"id":9758,"answer":"In a novel combination with another drug","answer_other":"","regimen":12304}],"created":"2020-10-27T18:47:47.799891Z","updated":"2020-12-17T19:23:40.250844Z","dose":"","frequency":"3 Doses","route":"","severity":"ICU/Critical Care","severity_detail":"Intubation and ventilation","comments":null,"report":6359},{"id":12305,"duration":{"id":6304,"approximate_duration":null,"dates_unknown":false},"drug":{"id":9905,"name":"Prednisolone","url":"cure-api2.ncats.io/v1/drugs/9905","rxNorm_id":null,"notes":null},"use_drug":[{"id":9759,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12305},{"id":9760,"answer":"In a novel combination with another drug","answer_other":"","regimen":12305}],"created":"2020-10-27T18:47:47.806169Z","updated":"2020-12-17T19:23:40.256335Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"Intubation and ventilation","comments":null,"report":6359},{"id":12306,"duration":{"id":6305,"approximate_duration":null,"dates_unknown":false},"drug":{"id":11339,"name":"Convalescent plasma","url":"cure-api2.ncats.io/v1/drugs/11339","rxNorm_id":null,"notes":null},"use_drug":[{"id":9761,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12306},{"id":9762,"answer":"In a novel combination with another drug","answer_other":"","regimen":12306}],"created":"2020-10-27T18:47:47.812317Z","updated":"2020-12-17T19:23:40.261935Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"Intubation and ventilation","comments":null,"report":6359}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8354,"answer":"Clinical assessment","answer_other":"","report":6359},{"id":8355,"answer":"Imaging","answer_other":"","report":6359},{"id":8356,"answer":"PCR","answer_other":"","report":6359}],"how_diagnosis":[{"id":14250,"answer":"Clinical assessment","answer_other":"","report":6359},{"id":14251,"answer":"Imaging","answer_other":"","report":6359},{"id":14252,"answer":"PCR","answer_other":"","report":6359}],"author_username":"Paige Evans","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Nurse","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"Armenian","why_new_way":[{"id":4445,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6359},{"id":4446,"answer":"Co-Infection or Complex Co-morbidities","answer_other":"","report":6359}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-10-27T18:45:47.742566Z","updated":"2020-12-17T19:23:40.225436Z","title":"Response to \"COVID-19 in persons with haematological cancers\". Case 2.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32528043,"doi":"10.1038/s41375-020-0914-x","article_url":"https://pubmed.ncbi.nlm.nih.gov/32528043/","pub_year":2020,"published_authors":"Hatzl S\r\nEisner F\r\nSchilcher G\r\nKreuzer P\r\nGornicec M\r\nEller P\r\nBrodmann M\r\nSchlenke P\r\nStradner MH\r\nKrause R\r\nGreinix H\r\nSchulz E","article_author_email":"eduard.shulz@medunigraz.at","journal":"Leukemia","abstract":"","article_type":"Original","study_type":"Case Report","number_of_patients":8,"article_patient_number":"3","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"51-60 years","sex":"Male","ethnicity":null,"country_contracted":"Austria","country_treated":"Austria","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"Diffuse large B cell lymphoma (DLBCL)","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Severe ARDS, cytokine release syndrome, ventilator associated pneumonia","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"While the patient was still on treatment","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"IL-6 and serum ferritin decreased dramatically, and patient was off the ventilator 5 and 4 days after CP therapy, respectively achieving a negative NAT.","previously_treated":"","flagged":false,"other_coinfections":"Obesity","disease":630,"drugs":[6122,11339,8342,9905,10776,11091]},{"id":6360,"regimens":[{"id":12307,"duration":{"id":6306,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":9765,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12307},{"id":9766,"answer":"In a novel combination with another drug","answer_other":"","regimen":12307}],"created":"2020-10-27T19:01:16.982722Z","updated":"2020-10-27T19:11:49.233339Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"Intubation and mechanical ventilation","comments":null,"report":6360},{"id":12308,"duration":{"id":6307,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":9767,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12308},{"id":9768,"answer":"In a novel combination with another drug","answer_other":"","regimen":12308}],"created":"2020-10-27T19:01:16.991443Z","updated":"2020-10-27T19:11:49.239506Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"Intubation and mechanical ventilation","comments":null,"report":6360},{"id":12309,"duration":{"id":6308,"approximate_duration":null,"dates_unknown":false},"drug":{"id":11091,"name":"Zinc","url":"cure-api2.ncats.io/v1/drugs/11091","rxNorm_id":null,"notes":null},"use_drug":[{"id":9769,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12309},{"id":9770,"answer":"In a novel combination with another drug","answer_other":"","regimen":12309}],"created":"2020-10-27T19:01:16.997703Z","updated":"2020-10-27T19:11:49.245275Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"Intubation and mechanical ventilation","comments":null,"report":6360},{"id":12310,"duration":{"id":6309,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":9775,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12310},{"id":9776,"answer":"In a novel combination with another drug","answer_other":"","regimen":12310}],"created":"2020-10-27T19:01:17.004236Z","updated":"2020-10-27T19:11:49.250820Z","dose":"","frequency":"3 Doses","route":"","severity":"ICU/Critical Care","severity_detail":"Intubation and mechanical ventilation","comments":null,"report":6360},{"id":12315,"duration":{"id":6314,"approximate_duration":null,"dates_unknown":false},"drug":{"id":7230,"name":"Dexamethasone","url":"cure-api2.ncats.io/v1/drugs/7230","rxNorm_id":null,"notes":null},"use_drug":[{"id":9777,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12315},{"id":9778,"answer":"In a novel combination with another drug","answer_other":"","regimen":12315}],"created":"2020-10-27T19:03:54.814162Z","updated":"2020-10-27T19:11:49.256578Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"Intubation and mechanical ventilation","comments":null,"report":6360}],"site_of_infection":[],"specific_site":[],"how_outcome":[],"how_diagnosis":[{"id":14253,"answer":"Clinical assessment","answer_other":"","report":6360},{"id":14254,"answer":"Imaging","answer_other":"","report":6360},{"id":14255,"answer":"PCR","answer_other":"","report":6360}],"author_username":"Paige Evans","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Nurse","author_affiliation":"None","author_country":"","outcome_computed":"Deteriorated","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4447,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6360},{"id":4448,"answer":"Co-Infection or Complex Co-morbidities","answer_other":"","report":6360}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-10-27T18:59:58.081453Z","updated":"2020-10-27T19:11:49.225681Z","title":"Response to \"COVID-19 in persons with haematological cancers\". Case 3.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32528043,"doi":"10.1038/s41375-020-0914-x","article_url":"https://pubmed.ncbi.nlm.nih.gov/32528043/","pub_year":2020,"published_authors":"Hatzl S\r\nEisner F\r\nSchilcher G\r\nKreuzer P\r\nGornicec M\r\nEller P\r\nBrodmann M\r\nSchlenke P\r\nStradner MH\r\nKrause R\r\nGreinix H\r\nSchulz E","article_author_email":"eduard.shulz@medunigraz.at","journal":"Leukemia","abstract":"","article_type":"Original","study_type":"Case Report","number_of_patients":8,"article_patient_number":"5","full_text_available":true,"outcome":"Patient died","surgery":"No","age":"51-60 years","sex":"Male","ethnicity":null,"country_contracted":"Austria","country_treated":"Austria","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":true,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"AML-MRC","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Pneumonia, Severe ARDS, cytokine release","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"","previously_treated":"","flagged":false,"other_coinfections":"CRi (severe pancytopenia)","disease":630,"drugs":[6122,7230,8342,10776,11091]},{"id":6369,"regimens":[{"id":12334,"duration":{"id":6333,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":9826,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12334},{"id":9827,"answer":"In a novel combination with another drug","answer_other":"","regimen":12334}],"created":"2020-10-27T20:17:50.360496Z","updated":"2020-10-27T20:28:06.112456Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6369},{"id":12335,"duration":{"id":6334,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":9828,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12335},{"id":9829,"answer":"In a novel combination with another drug","answer_other":"","regimen":12335}],"created":"2020-10-27T20:17:50.367598Z","updated":"2020-10-27T20:28:06.119009Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6369}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8364,"answer":"Clinical assessment","answer_other":"","report":6369}],"how_diagnosis":[{"id":14274,"answer":"Clinical assessment","answer_other":"","report":6369},{"id":14275,"answer":"PCR","answer_other":"","report":6369}],"author_username":"Kate Borkowski","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Nurse","author_affiliation":"None","author_country":"","outcome_computed":"Deteriorated","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4457,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6369}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[],"races":[{"id":467,"answer":"White","answer_other":""}],"created":"2020-10-27T20:16:48.727377Z","updated":"2020-10-27T20:28:06.104188Z","title":"SARS-CoV-2 and Stroke in a New York Healthcare System. Case 27.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32432996,"doi":"10.1161/STROKEAHA.120.030335","article_url":"https://pubmed.ncbi.nlm.nih.gov/32432996/","pub_year":2020,"published_authors":"Yaghi S\r\nIshida K\r\nTorres J\r\nMac Grory B\r\nRaz E\r\nHumbert K\r\nHenninger N\r\nTrivedi T\r\nLillemoe K\r\nAlam S\r\nSanger M\r\nKim S\r\nScher E\r\nDehkharghani S\r\nWachs M\r\nTanweer O\r\nVolpicelli F\r\nBosworth B\r\nLord A\r\nFrontera J","article_author_email":"shadiyaghi@yahoo.com","journal":"Stroke","abstract":"Background and purpose:      \r\n              With the spread of coronavirus disease 2019 (COVID-19) during the current worldwide pandemic, there is mounting evidence that patients affected by the illness may develop clinically significant coagulopathy with thromboembolic complications including ischemic stroke. However, there is limited data on the clinical characteristics, stroke mechanism, and outcomes of patients who have a stroke and COVID-19.          \r\n        Methods:      \r\n              We conducted a retrospective cohort study of consecutive patients with ischemic stroke who were hospitalized between March 15, 2020, and April 19, 2020, within a major health system in New York, the current global epicenter of the pandemic. We compared the clinical characteristics of stroke patients with a concurrent diagnosis of COVID-19 to stroke patients without COVID-19 (contemporary controls). In addition, we compared patients to a historical cohort of patients with ischemic stroke discharged from our hospital system between March 15, 2019, and April 15, 2019 (historical controls).          \r\n        Results:      \r\n              During the study period in 2020, out of 3556 hospitalized patients with diagnosis of COVID-19 infection, 32 patients (0.9%) had imaging proven ischemic stroke. Cryptogenic stroke was more common in patients with COVID-19 (65.6%) as compared to contemporary controls (30.4%, \r\nP\r\n=0.003) and historical controls (25.0%, \r\nP\r\n<0.001). When compared with contemporary controls, COVID-19 positive patients had higher admission National Institutes of Health Stroke Scale score and higher peak D-dimer levels. When compared with historical controls, COVID-19 positive patients were more likely to be younger men with elevated troponin, higher admission National Institutes of Health Stroke Scale score, and higher erythrocyte sedimentation rate. Patients with COVID-19 and stroke had significantly higher mortality than historical and contemporary controls.          \r\n        Conclusions:      \r\n              We observed a low rate of imaging-confirmed ischemic stroke in hospitalized patients with COVID-19. Most strokes were cryptogenic, possibly related to an acquired hypercoagulability, and mortality was increased. Studies are needed to determine the utility of therapeutic anticoagulation for stroke and other thrombotic event prevention in patients with COVID-19.          \r\n        Keywords:      \r\n                  COVID-19; coronavirus; diagnosis; pandemic; troponin.","article_type":"Original","study_type":"Case Report","number_of_patients":32,"article_patient_number":"","full_text_available":true,"outcome":"Patient deteriorated","surgery":"No","age":"61-70 years","sex":"","ethnicity":null,"country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":true,"site_of_disease":"Lungs","clinical_syndrome":"Fever, cough, hypoxia","severity":null,"prev_treatment":"","unusual":"17 days after the start of COVID-19 symptoms, the patient experienced a cryptogenic stroke.","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"","follow_up_period":null,"relapse":"","reminder":false,"when_reminder":"1 week","additional_info":"","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[8342,10776]},{"id":6373,"regimens":[{"id":12339,"duration":{"id":6338,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":9833,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12339},{"id":9834,"answer":"In a novel combination with another drug","answer_other":"","regimen":12339}],"created":"2020-10-27T21:42:19.767486Z","updated":"2020-12-17T19:22:32.893823Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"Intubation and mechanical ventilation","comments":null,"report":6373},{"id":12340,"duration":{"id":6339,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":9835,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12340},{"id":9836,"answer":"In a novel combination with another drug","answer_other":"","regimen":12340}],"created":"2020-10-27T21:42:19.775182Z","updated":"2020-12-17T19:22:32.900236Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"Intubation and mechanical ventilation","comments":null,"report":6373},{"id":12341,"duration":{"id":6340,"approximate_duration":null,"dates_unknown":false},"drug":{"id":11091,"name":"Zinc","url":"cure-api2.ncats.io/v1/drugs/11091","rxNorm_id":null,"notes":null},"use_drug":[{"id":9838,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12341},{"id":9837,"answer":"In a novel combination with another drug","answer_other":"","regimen":12341}],"created":"2020-10-27T21:42:19.781528Z","updated":"2020-12-17T19:22:32.906155Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"Intubation and mechanical ventilation","comments":null,"report":6373},{"id":12342,"duration":{"id":6341,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":9839,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12342},{"id":9840,"answer":"In a novel combination with another drug","answer_other":"","regimen":12342}],"created":"2020-10-27T21:42:19.787788Z","updated":"2020-12-17T19:22:32.911620Z","dose":"","frequency":"2 Doses","route":"","severity":"ICU/Critical Care","severity_detail":"Intubation and mechanical ventilation","comments":null,"report":6373},{"id":12343,"duration":{"id":6342,"approximate_duration":null,"dates_unknown":false},"drug":{"id":11339,"name":"Convalescent plasma","url":"cure-api2.ncats.io/v1/drugs/11339","rxNorm_id":null,"notes":null},"use_drug":[{"id":9841,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12343},{"id":9842,"answer":"In a novel combination with another drug","answer_other":"","regimen":12343}],"created":"2020-10-27T21:42:19.794146Z","updated":"2020-12-17T19:22:32.946458Z","dose":null,"frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"Intubation and mechanical ventilation","comments":null,"report":6373},{"id":13604,"duration":null,"drug":{"id":9905,"name":"Prednisolone","url":"cure-api2.ncats.io/v1/drugs/9905","rxNorm_id":null,"notes":null},"use_drug":[{"id":12330,"answer":"It was not used in a new way","answer_other":"","regimen":13604}],"created":"2020-12-17T19:22:32.942534Z","updated":"2020-12-17T19:22:32.947325Z","dose":null,"frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":null,"comments":null,"report":6373}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8368,"answer":"Clinical assessment","answer_other":"","report":6373},{"id":8369,"answer":"Imaging","answer_other":"","report":6373},{"id":8370,"answer":"PCR","answer_other":"","report":6373}],"how_diagnosis":[{"id":14282,"answer":"Clinical assessment","answer_other":"","report":6373},{"id":14283,"answer":"Imaging","answer_other":"","report":6373},{"id":14284,"answer":"PCR","answer_other":"","report":6373}],"author_username":"Paige Evans","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Nurse","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"Armenian","why_new_way":[{"id":4461,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6373},{"id":4462,"answer":"Co-Infection or Complex Co-morbidities","answer_other":"","report":6373}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-10-27T21:41:06.871389Z","updated":"2020-12-17T19:22:32.885931Z","title":"Response to \"COVID-19 in persons with haematological cancers\". Case 4.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32528043,"doi":"10.1038/s41375-020-0914-x","article_url":"https://pubmed.ncbi.nlm.nih.gov/32528043/","pub_year":2020,"published_authors":"Hatzl S\r\nEisner F\r\nSchilcher G\r\nKreuzer P\r\nGornicec M\r\nEller P\r\nBrodmann M\r\nSchlenke P\r\nStradner MH\r\nKrause R\r\nGreinix H\r\nSchulz E","article_author_email":"eduard.shulz@medunigraz.at","journal":"Leukemia","abstract":"","article_type":"Original","study_type":"Case Report","number_of_patients":8,"article_patient_number":"6","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"51-60 years","sex":"Male","ethnicity":null,"country_contracted":"Austria","country_treated":"Austria","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":true,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"Follicular Lymphoma","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Pneumonia","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"IL-6 and serum ferritin decreased dramatically, and patient was off the ventilator 5 and 4 days after CP therapy, respectively achieving a negative NAT.","previously_treated":"","flagged":false,"other_coinfections":"COPD","disease":630,"drugs":[6122,11339,8342,9905,10776,11091]},{"id":6391,"regimens":[{"id":12374,"duration":{"id":6373,"approximate_duration":null,"dates_unknown":false},"drug":{"id":7230,"name":"Dexamethasone","url":"cure-api2.ncats.io/v1/drugs/7230","rxNorm_id":null,"notes":null},"use_drug":[{"id":9909,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12374},{"id":9910,"answer":"In a novel combination with another drug","answer_other":"","regimen":12374}],"created":"2020-10-29T19:19:23.564147Z","updated":"2020-10-29T19:48:37.227300Z","dose":"5mg","frequency":"BID","route":"","severity":"ICU/Critical Care","severity_detail":"Intubation and mechanical ventilation, prone positioning","comments":null,"report":6391},{"id":12375,"duration":{"id":6374,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6675,"name":"Ceftriaxone","url":"cure-api2.ncats.io/v1/drugs/6675","rxNorm_id":null,"notes":null},"use_drug":[{"id":9911,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12375},{"id":9912,"answer":"In a novel combination with another drug","answer_other":"","regimen":12375}],"created":"2020-10-29T19:19:23.571849Z","updated":"2020-10-29T19:48:37.233733Z","dose":"2g","frequency":"Per Day","route":"","severity":"ICU/Critical Care","severity_detail":"Intubation and mechanical ventilation, prone positioning","comments":null,"report":6391},{"id":12376,"duration":{"id":6375,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10399,"name":"Spiramycin","url":"cure-api2.ncats.io/v1/drugs/10399","rxNorm_id":null,"notes":null},"use_drug":[{"id":9913,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12376},{"id":9914,"answer":"In a novel combination with another drug","answer_other":"","regimen":12376}],"created":"2020-10-29T19:19:23.577865Z","updated":"2020-10-29T19:48:37.239305Z","dose":"1.5 million units","frequency":"q3d","route":"","severity":"ICU/Critical Care","severity_detail":"Intubation and mechanical ventilation, prone positioning","comments":null,"report":6391},{"id":12377,"duration":{"id":6376,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":9915,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12377},{"id":9916,"answer":"In a novel combination with another drug","answer_other":"","regimen":12377}],"created":"2020-10-29T19:19:23.584087Z","updated":"2020-10-29T19:48:37.245460Z","dose":"8mg/kg","frequency":"Once","route":"IV","severity":"ICU/Critical Care","severity_detail":"Multi organ failure, intubation and mechanical ventilation, prone positioning","comments":null,"report":6391}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8394,"answer":"Clinical assessment","answer_other":"","report":6391}],"how_diagnosis":[{"id":14331,"answer":"Clinical assessment","answer_other":"","report":6391},{"id":14332,"answer":"PCR","answer_other":"","report":6391}],"author_username":"Paige Evans","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Nurse","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4490,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6391},{"id":4491,"answer":"Co-Infection or Complex Co-morbidities","answer_other":"","report":6391}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[],"races":[],"created":"2020-10-29T19:17:28.852274Z","updated":"2020-10-29T19:48:37.219440Z","title":"Tocilizumab for Hemophagocytic Syndrome in a Kidney Transplant Recipient With COVID-19.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32432518,"doi":"10.7326/L20-0419","article_url":"https://pubmed.ncbi.nlm.nih.gov/32432518/","pub_year":2020,"published_authors":"Faguer S\r\nDel Bello A\r\nAbravanel F\r\nNicolau-Travers ML\r\nKamar N","article_author_email":"faguer.s@chu-toulouse.fr.","journal":"Annals of internal medicine","abstract":"To describe a patient with COVID-19 and overt hemophagocytic syndrome whose response to treatment was consistent with this hypothesis.","article_type":"Original","study_type":"Case Report","number_of_patients":1,"article_patient_number":"","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"No","age":"51-60 years","sex":"Male","ethnicity":null,"country_contracted":"France","country_treated":"France","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":true,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"Lungs, heart, kidney","clinical_syndrome":"Multi-organ failure, acute respiratory failure","severity":null,"prev_treatment":"","unusual":"Unusual disease manifestation- hemophagocytic syndrome in a kidney transplant recipient with COVID-19","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"While the patient was still on treatment","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"Tocilizumab administration was followed by dramatic improvement of the respiratory, hemodynamic, and liver conditions and correction of the ferritin levels.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6675,7230,10399,10776]},{"id":6416,"regimens":[{"id":12442,"duration":{"id":6441,"approximate_duration":null,"dates_unknown":false},"drug":{"id":11165,"name":"Favipiravir","url":"cure-api2.ncats.io/v1/drugs/11165","rxNorm_id":null,"notes":null},"use_drug":[{"id":10054,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12442},{"id":10055,"answer":"In a novel combination with another drug","answer_other":"","regimen":12442}],"created":"2020-11-01T21:35:45.807496Z","updated":"2020-12-17T20:37:30.713660Z","dose":"loading dose 1600 mg twice on the first day, maintenance dose 600 mg twice daily","frequency":"BD","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6416},{"id":12443,"duration":{"id":6442,"approximate_duration":null,"dates_unknown":false},"drug":{"id":9463,"name":"Oseltamivir","url":"cure-api2.ncats.io/v1/drugs/9463","rxNorm_id":null,"notes":null},"use_drug":[{"id":10056,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12443},{"id":10057,"answer":"In a novel combination with another drug","answer_other":"","regimen":12443}],"created":"2020-11-01T21:35:45.816053Z","updated":"2020-12-17T20:37:30.720124Z","dose":"75mg","frequency":"BD","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6416},{"id":12444,"duration":{"id":6443,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":10058,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12444},{"id":10059,"answer":"In a novel combination with another drug","answer_other":"","regimen":12444}],"created":"2020-11-01T21:35:45.822502Z","updated":"2020-12-17T20:37:30.725904Z","dose":"loading dose 400 mg twice on the first day, maintenance dose 200 mg twice daily","frequency":"BD","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6416},{"id":12445,"duration":{"id":6444,"approximate_duration":null,"dates_unknown":false},"drug":{"id":9905,"name":"Prednisolone","url":"cure-api2.ncats.io/v1/drugs/9905","rxNorm_id":null,"notes":null},"use_drug":[{"id":10060,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12445},{"id":10061,"answer":"In a novel combination with another drug","answer_other":"","regimen":12445}],"created":"2020-11-01T21:35:45.828531Z","updated":"2020-12-17T20:37:30.731767Z","dose":"40 mg","frequency":"OD","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6416},{"id":12446,"duration":{"id":6447,"approximate_duration":"2 weeks","dates_unknown":true},"drug":{"id":7629,"name":"Enoxaparin","url":"cure-api2.ncats.io/v1/drugs/7629","rxNorm_id":null,"notes":null},"use_drug":[{"id":10062,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12446},{"id":10063,"answer":"In a novel combination with another drug","answer_other":"","regimen":12446}],"created":"2020-11-01T21:35:45.835042Z","updated":"2020-12-17T20:37:30.771816Z","dose":"60mg","frequency":"","route":"","severity":"Inpatient","severity_detail":null,"comments":null,"report":6416},{"id":12447,"duration":{"id":6446,"approximate_duration":"Single dose","dates_unknown":true},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":10064,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12447},{"id":10065,"answer":"In a novel combination with another drug","answer_other":"","regimen":12447}],"created":"2020-11-01T21:35:45.841450Z","updated":"2020-12-17T20:37:30.743452Z","dose":"400mg","frequency":"","route":"IV","severity":"Inpatient","severity_detail":"","comments":null,"report":6416}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8424,"answer":"Clinical assessment","answer_other":"","report":6416},{"id":8425,"answer":"PCR","answer_other":"","report":6416},{"id":8474,"answer":"Serology","answer_other":"","report":6416}],"how_diagnosis":[{"id":14392,"answer":"Clinical assessment","answer_other":"","report":6416},{"id":14393,"answer":"Imaging","answer_other":"","report":6416},{"id":14394,"answer":"PCR","answer_other":"","report":6416}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4529,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6416}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"},{"id":550,"name":"Respiratory Tract Infections"}],"races":[{"id":481,"answer":"White","answer_other":""}],"created":"2020-11-01T21:27:21.411545Z","updated":"2020-12-17T20:37:30.704298Z","title":"Coronavirus disease 2019 (COVID-19) in a patient with ankylosing spondylitis treated with secukinumab: a case-based review.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32591970,"doi":"10.1007/s00296-020-04635-z","article_url":"https://pubmed.ncbi.nlm.nih.gov/32591970/","pub_year":2020,"published_authors":"Coskun Benlidayi I\r\nKurtaran B\r\nTirasci E\r\nGuzel R","article_author_email":"Author email could not be found.","journal":"Rheumatology international","abstract":"Severe acute respiratory syndrome coranovirus-2 (SARS-CoV-2) infection has become an important health-care issue worldwide. The coronavirus disease 2019 (COVID-19) has also raised concerns among patients with inflammatory rheumatic conditions and their treating physicians. There are emerging data regarding the potential risks of SARS-CoV-2 for this particular patient group. However, less is known with regard to the course of COVID-19 among patients receiving IL-17 inhibitors. The aim of the current article is to review the growing body of knowledge on the course/management of COVID-19 in patients with inflammatory rheumatic diseases by presenting a SARS-CoV-2 infected case with ankylosing spondylitis under secukinumab therapy. A 61-year old patient with ankylosing spondylitis who was on secukinumab therapy for 5 months admitted with newly onset fever and gastrointestinal complaints. After being hospitalized, she developed respiratory manifestations with focal pulmonary ground-glass opacities and multiple nodular densities in both lungs. The patient was tested positive for SARS-CoV-2 infection. Substantial clinical improvement was obtained following a management plan, which included tocilizumab, hydroxychloroquine, prednisolone and enoxaparin sodium. PubMed/MEDLINE and Scopus databases were searched by using relevant keywords and their combinations. The literature search revealed four articles reporting the clinical course of COVID-19 in seven rheumatic patients on secukinumab. The clinical course of SARS-CoV-2 infection was mild in most of these patients, while one of them experienced severe COVID-19. Interleukin-17 has been related to the hyperinflammatory state in COVID-19 and IL-17 inhibitors were presented as promising targets for the prevention of aberrant inflammation and acute respiratory distress in COVID-19. However, this hypothesis still remains to be proved. Further studies are warranted in order to test the benefits and risks of IL-inhibitors in SARS-CoV-2 infected individuals.          \r\n        Keywords:      \r\n                  Ankylosing spondylitis; Biological drugs; COVID-19; Interleukin-17; Rheumatic diseases; Secukinumab; Spondyloarthritis.","article_type":"Original","study_type":"Case Report","number_of_patients":1,"article_patient_number":"","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"61-70 years","sex":"Female","ethnicity":"Not Hispanic/Latino","country_contracted":"Turkey","country_treated":"Turkey","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"Ankylosing spondylitis on secukinumab","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Pneumonia","severity":"Inpatient","prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"While the patient was still on treatment","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"She had a history of ankylosing spondylitis dated back 11 years and over the past 5 months, she had been treated with secukinumab with a good clinical response. The patient has taken the last dose of secukinumab 5 days ago. Given the two negative RT-PCR test results for SARS-CoV-2 and complete clinical recovery, secukinumab infusion was performed just after the second follow-up visit.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[7629,11165,8342,9463,9905,10776]},{"id":6418,"regimens":[{"id":12449,"duration":{"id":6449,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":10067,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12449},{"id":10068,"answer":"In a novel combination with another drug","answer_other":"","regimen":12449}],"created":"2020-11-02T20:53:24.063295Z","updated":"2020-11-12T15:52:10.540170Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"Intubation and mechanical ventilation","comments":null,"report":6418},{"id":12450,"duration":{"id":6450,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8783,"name":"Lopinavir-Ritonavir","url":"cure-api2.ncats.io/v1/drugs/8783","rxNorm_id":null,"notes":null},"use_drug":[{"id":10069,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12450},{"id":10070,"answer":"In a novel combination with another drug","answer_other":"","regimen":12450}],"created":"2020-11-02T20:53:24.071340Z","updated":"2020-11-12T15:52:10.546914Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"Intubation and mechanical ventilation","comments":null,"report":6418},{"id":12451,"duration":{"id":6451,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6675,"name":"Ceftriaxone","url":"cure-api2.ncats.io/v1/drugs/6675","rxNorm_id":null,"notes":null},"use_drug":[{"id":10287,"answer":"It was not used in a new way","answer_other":"","regimen":12451},{"id":10288,"answer":"Other","answer_other":"Likely given for bacterial cover","regimen":12451}],"created":"2020-11-02T20:53:24.077302Z","updated":"2020-11-12T15:52:10.595619Z","dose":null,"frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"Intubation and mechanical ventilation","comments":null,"report":6418},{"id":12452,"duration":{"id":6452,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8233,"name":"Heparin","url":"cure-api2.ncats.io/v1/drugs/8233","rxNorm_id":null,"notes":null},"use_drug":[{"id":10289,"answer":"It was not used in a new way","answer_other":"","regimen":12452}],"created":"2020-11-02T20:53:24.083536Z","updated":"2020-11-12T15:52:10.596486Z","dose":null,"frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"Intubation and mechanical ventilation","comments":null,"report":6418},{"id":12453,"duration":{"id":6453,"approximate_duration":"1 Day","dates_unknown":true},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":10075,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12453},{"id":10076,"answer":"In a novel combination with another drug","answer_other":"","regimen":12453}],"created":"2020-11-02T20:53:24.089672Z","updated":"2020-11-12T15:52:10.563404Z","dose":"8mg/kg","frequency":"q12h","route":"IV","severity":"ICU/Critical Care","severity_detail":"Five days into initial drug treatment the patientâs clinical conditions deteriorated and intravenous tocilizumab was administered, intubation and mechanical ventilation","comments":null,"report":6418}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8428,"answer":"Clinical assessment","answer_other":"","report":6418},{"id":8429,"answer":"Imaging","answer_other":"","report":6418}],"how_diagnosis":[{"id":14397,"answer":"Clinical assessment","answer_other":"","report":6418},{"id":14398,"answer":"Imaging","answer_other":"","report":6418},{"id":14399,"answer":"PCR","answer_other":"","report":6418}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4531,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6418}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-11-02T20:51:59.833512Z","updated":"2020-11-12T15:52:10.532011Z","title":"Rapid radiological improvement of COVID-19 pneumonia after treatment with tocilizumab.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32557206,"doi":"10.1007/s15010-020-01449-w","article_url":"https://pubmed.ncbi.nlm.nih.gov/32557206/","pub_year":2020,"published_authors":"Comel AC\r\nMosaner W\r\nBragantini D\r\nLanzafame M","article_author_email":"lanzafame.massimiliano@gmail.com","journal":"Infection","abstract":"A 50-some-old man, without comorbidities and not smoker, was admitted to our intensive care unit with fever (39Â°) and dyspnea lasting for 5 days. The chest CT (computed tomography) scan\r\nshowed a bilateral interstitial pneumonia and he was positive for Sars-Cov-2 (nasopharyngeal swab). After initial drug treatment patient continued to deteriorate until treatment with tocilizumab.","article_type":"Original","study_type":"Case Report","number_of_patients":1,"article_patient_number":"","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"No","age":"51-60 years","sex":"Male","ethnicity":null,"country_contracted":"Italy","country_treated":"Italy","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Pneumonia, fever, dyspnea","severity":"ICU/Critical Care","prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"Five days into initial drug treatment the patient deteriorated. After tocilizumab treatment,  ventilation conditions improved day by day. One day after infusion of tocilizumab,\r\nCPR, LDH, ferritin and D-dimer levels went down. After 3 days, we repeated CT chest scan that showed an impressive improvement. Two days later, the patient was extubated and was transferred to pulmonary medicine unit.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6675,8233,8342,8783,10776]},{"id":6425,"regimens":[{"id":12488,"duration":{"id":6485,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8233,"name":"Heparin","url":"cure-api2.ncats.io/v1/drugs/8233","rxNorm_id":null,"notes":null},"use_drug":[{"id":10133,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12488},{"id":10134,"answer":"In a novel combination with another drug","answer_other":"","regimen":12488}],"created":"2020-11-06T23:31:22.811269Z","updated":"2020-11-09T18:10:35.076461Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6425},{"id":12489,"duration":{"id":6486,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":10135,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12489},{"id":10136,"answer":"In a novel combination with another drug","answer_other":"","regimen":12489}],"created":"2020-11-06T23:31:22.819030Z","updated":"2020-11-09T18:10:35.083173Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6425},{"id":12490,"duration":{"id":6487,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":10137,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12490},{"id":10138,"answer":"In a novel combination with another drug","answer_other":"","regimen":12490}],"created":"2020-11-06T23:31:22.825304Z","updated":"2020-11-09T18:10:35.088684Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6425}],"site_of_infection":[],"specific_site":[],"how_outcome":[],"how_diagnosis":[{"id":14417,"answer":"Clinical assessment","answer_other":"","report":6425},{"id":14418,"answer":"PCR","answer_other":"","report":6425}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Deteriorated","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4543,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6425},{"id":4544,"answer":"Co-Infection or Complex Co-morbidities","answer_other":"","report":6425}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-11-06T23:11:42.051704Z","updated":"2020-11-09T18:10:35.068439Z","title":"Acute coronary syndrome and shock in the context of acute COVID-19 infection.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32586778,"doi":"10.1016/j.rec.2020.05.023","article_url":"https://pubmed.ncbi.nlm.nih.gov/32586778/","pub_year":2020,"published_authors":"CÃ¡rdenes LeÃ³n A\r\nHernÃ¡ndez Meneses B\r\nSÃ¡nchez PÃ©rez A\r\nNovoa Medina JM\r\nBujanda MorÃºn PF\r\nMartÃ­n Lorenzo P","article_author_email":"Author email could not be found.","journal":"Revista espanola de cardiologia (English ed.)","abstract":"The cardiac manifestations of coronavirus disease 2019 (COVID-19) are not well established, but there have been reports of cardiovascular complications.\r\n\r\nWe describe the case of a 74-year-old man with a past history of hypertension, type 2 diabetes mellitus, and ischemic stroke who underwent a thrombectomy in 2017. He had been in solitary confinement since returning from a trip to a COVID-19 risk area 13 days earlier. He presented at the emergency room with general malaise and shortness of breath. He had had flu-like symptoms and fever for 2 days before admission, as well as self-limiting chest pain.","article_type":"Original","study_type":"Case Report","number_of_patients":1,"article_patient_number":"1","full_text_available":true,"outcome":"Patient died","surgery":"No","age":"71-80 years","sex":"Male","ethnicity":null,"country_contracted":"Spain","country_treated":"Spain","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":true,"hypertension":true,"cardiovascular_disease":true,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"Lung","clinical_syndrome":"respiratory tract infection , shock","severity":"ICU/Critical Care","prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"While the patient was still on treatment","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"Case of an elderly patient who developed acute coronary syndrome, mixed shock, and shortness of breath during the course of SARS-CoV-2 infection.\r\nThe patient was administered dual antiplatelet therapy (aspirin and clopidogrel) and anticoagulation with sodium heparin. He was also started on hydroxychloroquine and tocilizumab. His condition progressed slowly over the following hours, with further hemodynamic deterioration. We therefore decided to perform a computed tomography scan of the chest and abdomen, which showed multiple arterial thrombosis and findings consistent with mesenteric ischemia , splenic infarction, and pulmonary thromboembolism. The patient died 72 hours after admission.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[8233,8342,10776]},{"id":6427,"regimens":[{"id":12492,"duration":{"id":6489,"approximate_duration":"6 days","dates_unknown":true},"drug":{"id":7023,"name":"Colchicine","url":"cure-api2.ncats.io/v1/drugs/7023","rxNorm_id":null,"notes":null},"use_drug":[{"id":10140,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12492},{"id":10141,"answer":"In a novel combination with another drug","answer_other":"","regimen":12492}],"created":"2020-11-08T17:22:24.520756Z","updated":"2020-11-09T19:27:19.842485Z","dose":"1 mg/kg/day","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6427},{"id":12493,"duration":{"id":6490,"approximate_duration":"3 days","dates_unknown":true},"drug":{"id":9077,"name":"Methylprednisolone","url":"cure-api2.ncats.io/v1/drugs/9077","rxNorm_id":null,"notes":null},"use_drug":[{"id":10142,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12493},{"id":10143,"answer":"In a novel combination with another drug","answer_other":"","regimen":12493}],"created":"2020-11-08T17:22:24.528560Z","updated":"2020-11-09T19:27:19.848857Z","dose":"40 mg","frequency":"BID","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6427},{"id":12494,"duration":{"id":6491,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":10144,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12494},{"id":10145,"answer":"In a novel combination with another drug","answer_other":"","regimen":12494}],"created":"2020-11-08T17:22:24.534893Z","updated":"2020-11-09T19:27:19.854592Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6427},{"id":12507,"duration":null,"drug":{"id":8233,"name":"Heparin","url":"cure-api2.ncats.io/v1/drugs/8233","rxNorm_id":null,"notes":null},"use_drug":[{"id":10178,"answer":"It was not used in a new way","answer_other":"","regimen":12507}],"created":"2020-11-09T19:04:39.171484Z","updated":"2020-11-09T19:27:19.858367Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6427}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8436,"answer":"Clinical assessment","answer_other":"","report":6427}],"how_diagnosis":[{"id":14422,"answer":"Clinical assessment","answer_other":"","report":6427},{"id":14423,"answer":"PCR","answer_other":"","report":6427}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4546,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6427}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"},{"id":550,"name":"Respiratory Tract Infections"}],"races":[],"created":"2020-11-08T17:21:39.641706Z","updated":"2020-11-09T19:27:19.834044Z","title":"Takotsubo cardiomyopathy triggered by SARS-CoV-2 infection in a critically ill patient.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32540884,"doi":"10.1136/bcr-2020-236561","article_url":"https://pubmed.ncbi.nlm.nih.gov/32540884/","pub_year":2020,"published_authors":"Taza F\r\nZulty M\r\nKanwal A\r\nGrove D","article_author_email":"Author email could not be found.","journal":"BMJ case reports","abstract":"COVID-19 became a global pandemic in early 2020. While well known for its pulmonary manifestations, the virus also has a number of cardiac manifestations as well. Takotsubo syndrome has scarcely been reported in patients with COVID-19, but it is possible that the cytokine storm associated with the infection can trigger Takotsubo syndrome in patients with underlying risk factors for Takotsubo (emotional distress, physical distress, history of psychiatric disorders).          \r\n        Keywords:      \r\n                  adult intensive care; cardiovascular medicine; heart failure; infectious diseases.","article_type":"Original","study_type":"Case Report","number_of_patients":1,"article_patient_number":"1","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"No","age":"51-60 years","sex":"Male","ethnicity":null,"country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":true,"hypertension":true,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":true,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"history of schizophrenia","pregnant":false,"unknown":false,"site_of_disease":"lungs, brain, heart","clinical_syndrome":"respiratory failure, pneumonia, respiratory tract infection, altered mental status, acute inferior wall infarction, pericarditis, myocarditis, Prinzmental's syndromes, Taskotsubo syndrome","severity":"ICU/Critical Care","prev_treatment":"","unusual":"Takotsubo syndrome","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"ECG revealed ST segment elevations in the inferior leads. Laboratory testing demonstrated normal levels of cardiac troponin I (<0.015âng/L; reference range (RR) <0.045âng/L). He underwent emergent coronary angiography due to haemodynamic instability, which revealed non-obstructive coronary arteries and apical ballooning on ventriculography, consistent with Takotsubo syndrome. The estimated left ventricular (LV) ejection fraction was 45%.\r\nBased on the ECG changes, acute myocardial infarction was possible. The patient had ST elevations in II, III, aVF, signalling a right coronary artery infarct. Pericarditis was possible, however, less likely given the distributional pattern of ST segment elevations, rather than a diffuse pattern. The patient never had cardiac MRI; however, myocarditis was unlikely given ventriculogram findings and negative troponin. The most likely diagnosis remains Takotsubo syndrome based on the patients apical ballooning on ventriculogram and patent coronary arteries on angiography.\r\nThis patient was intubated upon admission to the hospital. They were administered colchicine and methylprednisolone 1/mg/kg/day, IV continuous heparin for anticoagulation and extubated after 6 days after which he received methylprednisolone (40 mg, BID). Patient was discharged to outpatient rehabilitation without medical symptoms.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[7023,8233,9077,10776]},{"id":6428,"regimens":[{"id":12495,"duration":{"id":6492,"approximate_duration":"5 days","dates_unknown":true},"drug":{"id":9077,"name":"Methylprednisolone","url":"cure-api2.ncats.io/v1/drugs/9077","rxNorm_id":null,"notes":null},"use_drug":[{"id":10146,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12495},{"id":10147,"answer":"In a novel combination with another drug","answer_other":"","regimen":12495}],"created":"2020-11-08T18:01:37.234355Z","updated":"2020-11-09T19:13:22.136779Z","dose":"1000 mg","frequency":"","route":"IV","severity":"Inpatient","severity_detail":"","comments":null,"report":6428},{"id":12496,"duration":{"id":6493,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":10148,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12496},{"id":10149,"answer":"In a novel combination with another drug","answer_other":"","regimen":12496}],"created":"2020-11-08T18:01:37.242152Z","updated":"2020-11-09T19:13:22.143205Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6428},{"id":12497,"duration":{"id":6494,"approximate_duration":"5 days","dates_unknown":true},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":10150,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12497},{"id":10151,"answer":"In a novel combination with another drug","answer_other":"","regimen":12497}],"created":"2020-11-08T18:01:37.248574Z","updated":"2020-11-09T19:13:22.148955Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6428},{"id":12498,"duration":{"id":6495,"approximate_duration":"5 days","dates_unknown":true},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":10152,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12498},{"id":10153,"answer":"In a novel combination with another drug","answer_other":"","regimen":12498}],"created":"2020-11-08T18:01:37.255494Z","updated":"2020-11-09T19:13:22.154555Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6428}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8437,"answer":"Clinical assessment","answer_other":"","report":6428}],"how_diagnosis":[{"id":14424,"answer":"Clinical assessment","answer_other":"","report":6428},{"id":14425,"answer":"PCR","answer_other":"","report":6428}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4547,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6428}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":550,"name":"Respiratory Tract Infections"}],"races":[],"created":"2020-11-08T18:00:47.114948Z","updated":"2020-11-09T19:13:22.128113Z","title":"COVID-19-associated myositis with severe proximal and bulbar weakness.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32535934,"doi":"10.1002/mus.27003","article_url":"https://pubmed.ncbi.nlm.nih.gov/32535934/","pub_year":2020,"published_authors":"Zhang H\r\nCharmchi Z\r\nSeidman RJ\r\nAnziska Y\r\nVelayudhan V\r\nPerk J","article_author_email":"Author email could not be found.","journal":"Muscle & nerve","abstract":"A 58-year-old woman presented with cough, dyspnea, and myalgia. Vital signs were stable and her physical exam was unremarkable. Initial polymerase chain reaction (PCR) testing for SARS-CoV-2 was negative and the patient was discharged home. She returned three weeks later with more severe dyspnea, cough, dysarthria, dysphagia, odynophagia and severe generalized weakness with inability to ambulate. She had no sensory symptoms or bowel or bladder dysfunction.","article_type":"Original","study_type":"Case Report","number_of_patients":1,"article_patient_number":"1","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"51-60 years","sex":"Female","ethnicity":null,"country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"lungs, nervous system, skeletal muscle","clinical_syndrome":"respiratory tract infection, inflammatory myopathy, facial, bulbar, and proximal limb weakness","severity":"Inpatient","prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"This patient presented to the ER three weeks prior with cough, dyspnea, and myalgia, however vital signs were stable, her physical exam was unremarkable, and her SARS_coV-2 PCR test was negative. She returned three weeks later complaining of more severe symptoms including onset of severe generalized weakness. She had bilateral ptosis, facial weakness, hypernasal dysarthria, profound symmetric proximal limb weakness, and symmetrically diminished reflexes. Repeated SARS-CoV-2 PCR test was positive. MRI revealed diffuse muscle edema and enhancement, with a region of myonecrosis. Needle electromyography of the right vests laterals, ilipsoas, and deltoid muscles revealed sparse fibrillation potentials, no motor units could be activated. Muscle biopsy showed perivascular inflammatory infiltration with endomysial extension, regenerating fibers and up regulation of HLA Class ABC expression on non-necrotic fibers. Patient had a percutaneous endoscopic gastronomy tube inserted and received anticoagulation therapy.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6122,8342,9077,10776]},{"id":6430,"regimens":[{"id":12502,"duration":{"id":6499,"approximate_duration":"5 days","dates_unknown":true},"drug":{"id":8783,"name":"Lopinavir-Ritonavir","url":"cure-api2.ncats.io/v1/drugs/8783","rxNorm_id":null,"notes":null},"use_drug":[{"id":10160,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12502},{"id":10161,"answer":"In a novel combination with another drug","answer_other":"","regimen":12502}],"created":"2020-11-08T19:08:54.117417Z","updated":"2020-11-09T20:00:42.833790Z","dose":"400/100 mg","frequency":"","route":"PO","severity":"Inpatient","severity_detail":"","comments":null,"report":6430},{"id":12503,"duration":{"id":6500,"approximate_duration":"2 doses","dates_unknown":true},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":10162,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12503},{"id":10163,"answer":"In a novel combination with another drug","answer_other":"","regimen":12503}],"created":"2020-11-08T19:08:54.125482Z","updated":"2020-11-09T20:00:42.840132Z","dose":"8 mg/kg","frequency":"q8h","route":"IV","severity":"Inpatient","severity_detail":"","comments":null,"report":6430}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8440,"answer":"Clinical assessment","answer_other":"","report":6430},{"id":8441,"answer":"Imaging","answer_other":"","report":6430}],"how_diagnosis":[{"id":14429,"answer":"Clinical assessment","answer_other":"","report":6430},{"id":14430,"answer":"Imaging","answer_other":"","report":6430},{"id":14431,"answer":"PCR","answer_other":"","report":6430}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Improved","previous_drugs":[{"id":6675,"name":"Ceftriaxone"}],"comments":[],"article_language":"English","why_new_way":[{"id":4549,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6430}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"},{"id":550,"name":"Respiratory Tract Infections"}],"races":[],"created":"2020-11-08T19:08:12.301009Z","updated":"2020-11-09T20:00:42.825692Z","title":"Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32247642,"doi":"10.1016/j.annonc.2020.03.300","article_url":"https://pubmed.ncbi.nlm.nih.gov/32247642/","pub_year":2020,"published_authors":"Michot JM\r\nAlbiges L\r\nChaput N\r\nSaada V\r\nPommeret F\r\nGriscelli F\r\nBalleyguier C\r\nBesse B\r\nMarabelle A\r\nNetzer F\r\nMerad M\r\nRobert C\r\nBarlesi F\r\nGachot B\r\nStoclin A","article_author_email":"Author email could not be found.","journal":"Annals of oncology : official journal of the European Society for Medical Oncology","abstract":"The pathogenesis of coronavirus disease 2019 (COVID-19) remains unclear and there is presently no evidence for efficient therapeutics. The pathogenesis of severe acute respiratory syndrome (SARS) related to coronavirus involves a cytokine storm with high serum levels of proinflammatory cytokines and chemokines interleukin 6 (IL-6), tumor necrosis factor-alpha (TNF-Î±), interferon-Î³, IL-1 and IL-12, and IL-8. Similarly, in COVID-19, higher plasma levels of cytokines IL-6, IL-2, IL-7, IL-10, interferon-Î³ inducible protein (IP10), monocyte chemoattractant protein (MCP1), macrophage inflammatory protein (MIP1A), and TNF-Î± have been found in patients admitted to intensive care units, and the cytokine storm syndrome was proportional to the severity of disease. The proinflammatory IL-6 appears as one of the key cytokines leading to the inflammatory storm, which may result in increased alveolarâcapillary bloodâgas exchange dysfunction. The proinflammatory cytokine IL-6 seems to have a prominent role in this inflammatory cascade.","article_type":"Original","study_type":"Case Report","number_of_patients":1,"article_patient_number":"1","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"No","age":"41-50 years","sex":"Male","ethnicity":null,"country_contracted":"France","country_treated":"France","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"metastatic sarcomatoid clear cell renal cell carcinoma","pregnant":false,"unknown":false,"site_of_disease":"lungs","clinical_syndrome":"respiratory tract infection, pneumonia","severity":"Inpatient","prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"This patient was recently diagnosed with metastatic sarcomatous clear cell renal cell carcinoma and had been hospitalized for fever, symptomatic bone metastases pain management, and first-line systemic treatment decisions. Patient was initially treated with ceftriazone for an isolated fever but developed symptoms of COVID-19 after 6 days, was admitted, and began treatment for COVID-19.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[8783,10776]},{"id":6444,"regimens":[{"id":12539,"duration":{"id":6534,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":10243,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12539},{"id":10244,"answer":"In a novel combination with another drug","answer_other":"","regimen":12539}],"created":"2020-11-10T17:51:06.939594Z","updated":"2020-11-10T20:43:06.802754Z","dose":"200mg","frequency":"BID","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6444},{"id":12540,"duration":{"id":6535,"approximate_duration":null,"dates_unknown":false},"drug":{"id":7629,"name":"Enoxaparin","url":"cure-api2.ncats.io/v1/drugs/7629","rxNorm_id":null,"notes":null},"use_drug":[{"id":10245,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12540},{"id":10246,"answer":"In a novel combination with another drug","answer_other":"","regimen":12540}],"created":"2020-11-10T17:51:06.947555Z","updated":"2020-11-10T20:43:06.809305Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6444},{"id":12541,"duration":{"id":6536,"approximate_duration":null,"dates_unknown":false},"drug":{"id":9780,"name":"Piperacillin-Tazobactam","url":"cure-api2.ncats.io/v1/drugs/9780","rxNorm_id":null,"notes":null},"use_drug":[{"id":10248,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12541},{"id":10247,"answer":"In a novel combination with another drug","answer_other":"","regimen":12541}],"created":"2020-11-10T17:51:06.953966Z","updated":"2020-11-10T20:43:06.814859Z","dose":"4.5g","frequency":"q8h","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6444},{"id":12542,"duration":{"id":6537,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":10249,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12542},{"id":10250,"answer":"In a novel combination with another drug","answer_other":"","regimen":12542}],"created":"2020-11-10T17:51:06.960170Z","updated":"2020-11-10T20:43:06.821593Z","dose":"8mg/kg","frequency":"Single Dose","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6444},{"id":12543,"duration":{"id":6538,"approximate_duration":"7 Days","dates_unknown":true},"drug":{"id":9077,"name":"Methylprednisolone","url":"cure-api2.ncats.io/v1/drugs/9077","rxNorm_id":null,"notes":null},"use_drug":[{"id":10251,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12543},{"id":10252,"answer":"In a novel combination with another drug","answer_other":"","regimen":12543}],"created":"2020-11-10T17:51:06.966411Z","updated":"2020-11-10T20:43:06.827671Z","dose":"0.75 mg/kg","frequency":"q1d","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6444}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8468,"answer":"Clinical assessment","answer_other":"","report":6444},{"id":8469,"answer":"Imaging","answer_other":"","report":6444}],"how_diagnosis":[{"id":14469,"answer":"Clinical assessment","answer_other":"","report":6444},{"id":14470,"answer":"Imaging","answer_other":"","report":6444},{"id":14471,"answer":"PCR","answer_other":"","report":6444}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4568,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6444},{"id":4569,"answer":"Unusual disease presentation","answer_other":"","report":6444}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":399,"name":"Diarrhea (Infectious)"},{"id":550,"name":"Respiratory Tract Infections"}],"races":[{"id":488,"answer":"White","answer_other":""}],"created":"2020-11-10T17:47:07.914541Z","updated":"2020-11-10T20:43:06.794550Z","title":"Heart transplant recipient patient with COVID-19 treated with tocilizumab.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32573990,"doi":"10.1111/tid.13380","article_url":"https://pubmed.ncbi.nlm.nih.gov/32573990/","pub_year":2020,"published_authors":"Mattioli M\r\nFustini E\r\nGennarini S","article_author_email":"mattio87@libero.it","journal":"Transplant infectious disease : an official journal of the Transplantation Society","abstract":"A heart transplant 60-some-old patient referred for coronavirus-19 disease (COVID-19) pneumonia. At admission, he was febrile, tachypnoeic, and mild hypoxic with dry cough; during hospitalization, a diffuse morbilliform skin rash appeared. He was treated with tocilizumab with symptoms improvement, without a complete pulmonary function recovery. Skin rash, highly suggestive for COVID-19 cutaneous involvement, persisted for ten days despite tocilizumab administration.          \r\n        Keywords:      \r\n                  COVID-19; heart transplant; pneumonia; tocilizumab.","article_type":"Original","study_type":"Case Report","number_of_patients":1,"article_patient_number":"","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"61-70 years","sex":"Male","ethnicity":"Not Hispanic/Latino","country_contracted":"Italy","country_treated":"Italy","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":true,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":true,"chronic_renal_disease":true,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"COPD, post-myocarditis dilated cardiomyopathy, who underwent a heart transplant in 2011","pregnant":false,"unknown":false,"site_of_disease":"Lungs, Skin","clinical_syndrome":"Nausea, diarrhea, hypoxia, respiratory tract infection, morbilliform eruption of trunk and abdomen appeared, with mild pruritus and dermographism","severity":"Inpatient","prev_treatment":"","unusual":"This is the first case reported in which tocilizumab was successfully administered,\r\nalthough without complete resolution of symptoms. Unusual disease manifestation through morbilliform rash on abdomen.","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"As recommended by the reference transplant center, and according to the literature, mycophenolate mofetil and tacrolimus were withdrawal, monitoring the serum level of tacrolimus, and keeping a low dose of prednisone. Along with his usual therapy (pantoprazole, fluticasone furoate/vilanterol.\r\n\r\n22 days after admission, mild shortness of breath remained, and long-term oxygen therapy was prescribed (1 L/min 24 h/d); echocardiographic findings were unchanged.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[7629,8342,9077,9780,10776]},{"id":6451,"regimens":[{"id":12572,"duration":{"id":6566,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6665,"name":"Ceftaroline","url":"cure-api2.ncats.io/v1/drugs/6665","rxNorm_id":null,"notes":null},"use_drug":[{"id":12890,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12572},{"id":12891,"answer":"In a novel combination with another drug","answer_other":"","regimen":12572}],"created":"2020-11-13T16:39:10.136754Z","updated":"2021-01-10T20:33:07.317159Z","dose":null,"frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":null,"comments":null,"report":6451},{"id":12573,"duration":{"id":6567,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6928,"name":"Clindamycin","url":"cure-api2.ncats.io/v1/drugs/6928","rxNorm_id":null,"notes":null},"use_drug":[{"id":12892,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12573},{"id":12893,"answer":"In a novel combination with another drug","answer_other":"","regimen":12573}],"created":"2020-11-13T16:39:10.143097Z","updated":"2021-01-10T20:33:07.318050Z","dose":null,"frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":null,"comments":null,"report":6451},{"id":12574,"duration":{"id":6568,"approximate_duration":null,"dates_unknown":false},"drug":{"id":9780,"name":"Piperacillin-Tazobactam","url":"cure-api2.ncats.io/v1/drugs/9780","rxNorm_id":null,"notes":null},"use_drug":[{"id":12894,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12574},{"id":12895,"answer":"In a novel combination with another drug","answer_other":"","regimen":12574}],"created":"2020-11-13T16:39:10.149288Z","updated":"2021-01-10T20:33:07.318972Z","dose":null,"frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":null,"comments":null,"report":6451},{"id":12577,"duration":{"id":6571,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":10352,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12577},{"id":10351,"answer":"In a novel combination with another drug","answer_other":"","regimen":12577},{"id":10367,"answer":"In a novel population (e.g. pediatrics/neonates, pregnant women, immunosuppressed, etc.)","answer_other":"","regimen":12577}],"created":"2020-11-13T16:39:10.167437Z","updated":"2021-01-10T20:33:07.237513Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6451},{"id":12578,"duration":{"id":6572,"approximate_duration":null,"dates_unknown":false},"drug":{"id":11339,"name":"Convalescent plasma","url":"cure-api2.ncats.io/v1/drugs/11339","rxNorm_id":null,"notes":null},"use_drug":[{"id":10353,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12578},{"id":10354,"answer":"In a novel combination with another drug","answer_other":"","regimen":12578},{"id":10368,"answer":"In a novel population (e.g. pediatrics/neonates, pregnant women, immunosuppressed, etc.)","answer_other":"","regimen":12578}],"created":"2020-11-13T16:39:10.173265Z","updated":"2021-01-10T20:33:07.243249Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6451},{"id":12579,"duration":{"id":6573,"approximate_duration":null,"dates_unknown":false},"drug":{"id":11301,"name":"Remdesivir","url":"cure-api2.ncats.io/v1/drugs/11301","rxNorm_id":null,"notes":null},"use_drug":[{"id":10355,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12579},{"id":10356,"answer":"In a novel combination with another drug","answer_other":"","regimen":12579},{"id":10369,"answer":"In a novel population (e.g. pediatrics/neonates, pregnant women, immunosuppressed, etc.)","answer_other":"","regimen":12579}],"created":"2020-11-13T16:39:10.179385Z","updated":"2021-01-10T20:33:07.249063Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6451},{"id":12580,"duration":{"id":6574,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8412,"name":"Immunoglobulins, Intravenous","url":"cure-api2.ncats.io/v1/drugs/8412","rxNorm_id":null,"notes":null},"use_drug":[{"id":10357,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12580},{"id":10358,"answer":"In a novel combination with another drug","answer_other":"","regimen":12580},{"id":10370,"answer":"In a novel population (e.g. pediatrics/neonates, pregnant women, immunosuppressed, etc.)","answer_other":"","regimen":12580}],"created":"2020-11-13T16:39:10.185574Z","updated":"2021-01-10T20:33:07.254784Z","dose":"","frequency":"","route":"IV","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6451}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8479,"answer":"Clinical assessment","answer_other":"","report":6451}],"how_diagnosis":[{"id":14490,"answer":"Clinical assessment","answer_other":"","report":6451},{"id":14491,"answer":"Imaging","answer_other":"","report":6451},{"id":14492,"answer":"PCR","answer_other":"","report":6451}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4582,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6451},{"id":4583,"answer":"Unusual disease presentation","answer_other":"","report":6451}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":550,"name":"Respiratory Tract Infections"}],"races":[],"created":"2020-11-13T15:56:15.789731Z","updated":"2021-01-10T20:33:07.171042Z","title":"Toxic shock-like syndrome and COVID-19: A case report of multisystem inflammatory syndrome in children (MIS-C).","status":"Approved","anonymous":false,"published":true,"pubmed_id":32532619,"doi":"10.1016/j.ajem.2020.05.117","article_url":"https://pubmed.ncbi.nlm.nih.gov/32532619/","pub_year":2020,"published_authors":"Greene AG\r\nSaleh M\r\nRoseman E\r\nSinert R","article_author_email":"andrea.greene@downstate.edu","journal":"The American journal of emergency medicine","abstract":"Early reports of COVID-19 in pediatric populations emphasized a mild course of disease with severe cases disproportionately affecting infant and comorbid pediatric patients. After the peak of the epidemic in New York City, in late April to early May, cases of severe illness associated with COVID-19 were reported among mostly previously healthy children ages 5-19. Many of these cases feature a toxic shock-like syndrome or Kawasaki-like syndrome in the setting of SARS-CoV-2 positive diagnostic testing and the CDC has termed this presentation Multisystem Inflammatory Syndrome (MIS-C). It is essential to disseminate information among the medical community regarding severe and atypical presentations of COVID-19 as prior knowledge can help communities with increasing caseloads prepare to quickly identify and treat these patients as they present in the emergency department. We describe a case of MIS-C in a child who presented to our Emergency Department (ED) twice and on the second visit was found to have signs of distributive shock, multi-organ injury and systemic inflammation associated with COVID-19. The case describes two ED visits by a SARS-CoV-2-positive female child who initially presented with fever, rash and pharyngitis and returned within 48 hours with evidence of cardiac and renal dysfunction and fluid-refractory hypotension requiring vasopressors and PICU admission.          \r\n        Keywords:      \r\n                  COVID-19; Child; Coronavirus; Enoxaparin; Pediatric; Remdesivir; Septic; Shock; Tocilizumab.","article_type":"Original","study_type":"Case Report","number_of_patients":1,"article_patient_number":"","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"No","age":"11-15 years","sex":"Female","ethnicity":null,"country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"Lungs, Multi-Organ","clinical_syndrome":"Toxic shock syndrome, multi-organ injury, systemic inflammation, fever, rash, abdomen pain, malaise","severity":"ICU/Critical Care","prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6665,6928,11339,8412,9780,11301,10776]},{"id":6453,"regimens":[{"id":12583,"duration":{"id":6577,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":10375,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12583},{"id":10376,"answer":"In a novel combination with another drug","answer_other":"","regimen":12583}],"created":"2020-11-13T18:53:55.060449Z","updated":"2020-11-13T22:41:02.950906Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6453},{"id":12584,"duration":{"id":6578,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":10377,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12584},{"id":10378,"answer":"In a novel combination with another drug","answer_other":"","regimen":12584}],"created":"2020-11-13T18:53:55.068575Z","updated":"2020-11-13T22:41:02.957520Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6453},{"id":12585,"duration":{"id":6579,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":10379,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12585},{"id":10380,"answer":"In a novel combination with another drug","answer_other":"","regimen":12585}],"created":"2020-11-13T18:53:55.074680Z","updated":"2020-11-13T22:41:02.963004Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6453}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8482,"answer":"Clinical assessment","answer_other":"","report":6453},{"id":8483,"answer":"Imaging","answer_other":"","report":6453}],"how_diagnosis":[{"id":14495,"answer":"Clinical assessment","answer_other":"","report":6453},{"id":14496,"answer":"Imaging","answer_other":"","report":6453},{"id":14497,"answer":"PCR","answer_other":"","report":6453}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Deteriorated","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4585,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6453}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"},{"id":550,"name":"Respiratory Tract Infections"}],"races":[],"created":"2020-11-13T18:53:20.911727Z","updated":"2020-11-13T22:41:02.943172Z","title":"[18F]-FDG PET/CT for suspected lymphoma relapse in a patient with concomitant pneumococcal pneumonia during COVID-19 outbreak: unexpected SARS-Cov-2 co-infection despite double RT-PCR negativity.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32430579,"doi":"10.1007/s00259-020-04838-3","article_url":"https://pubmed.ncbi.nlm.nih.gov/32430579/","pub_year":2020,"published_authors":"Zanoni L\r\nMosconi C\r\nCervati V\r\nDiegoli M\r\nMonteduro F\r\nGolfieri R\r\nFanti S","article_author_email":"Author email could not be found.","journal":"European journal of nuclear medicine and molecular imaging","abstract":"No abstract available","article_type":"Original","study_type":"Case Report","number_of_patients":1,"article_patient_number":"1","full_text_available":true,"outcome":"Patient deteriorated","surgery":"No","age":"71-80 years","sex":"Male","ethnicity":null,"country_contracted":"Italy","country_treated":"Italy","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":true,"other_comorbid":"Prior treated non-Hodgkin lymphoma which eventually progressed in current admission","pregnant":false,"unknown":false,"site_of_disease":"lungs","clinical_syndrome":"pneumonia, respiratory tract infection,","severity":"Inpatient","prev_treatment":"","unusual":"Streptococcus pneumoniae urinary antigen was found positive; therefore, the patient was immediately referred to high-dose antibiotics administration for pneumonia","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"While the patient was still on treatment","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"This patient has a history of non-Hodgkin lymphoma. High-resolution computer tomography revealed enlarged axillary and mediastinal lymphadenopathies. Patient had concurrent streptococcus pneumoniae (determined by a urine test). Patient required CPAP.","previously_treated":"","flagged":false,"other_coinfections":"Streptococcus pneumoniae","disease":630,"drugs":[6122,8342,10776]},{"id":6461,"regimens":[{"id":12612,"duration":{"id":6606,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":10416,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12612},{"id":10417,"answer":"In a novel combination with another drug","answer_other":"","regimen":12612}],"created":"2020-11-13T21:19:36.202660Z","updated":"2020-11-16T19:43:50.592430Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6461},{"id":12613,"duration":{"id":6607,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":10418,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12613},{"id":10419,"answer":"In a novel combination with another drug","answer_other":"","regimen":12613}],"created":"2020-11-13T21:19:36.209948Z","updated":"2020-11-16T19:43:50.598769Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6461},{"id":12614,"duration":{"id":6608,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":10420,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12614},{"id":10421,"answer":"In a novel combination with another drug","answer_other":"","regimen":12614}],"created":"2020-11-13T21:19:36.215888Z","updated":"2020-11-16T19:43:50.604822Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6461},{"id":12615,"duration":{"id":6609,"approximate_duration":null,"dates_unknown":false},"drug":{"id":9077,"name":"Methylprednisolone","url":"cure-api2.ncats.io/v1/drugs/9077","rxNorm_id":null,"notes":null},"use_drug":[{"id":10422,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12615},{"id":10423,"answer":"In a novel combination with another drug","answer_other":"","regimen":12615}],"created":"2020-11-13T21:19:36.221868Z","updated":"2020-11-16T19:43:50.610595Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6461}],"site_of_infection":[],"specific_site":[],"how_outcome":[],"how_diagnosis":[{"id":14516,"answer":"Clinical assessment","answer_other":"","report":6461},{"id":14517,"answer":"PCR","answer_other":"","report":6461},{"id":14518,"answer":"Imaging","answer_other":"","report":6461}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Deteriorated","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4597,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6461}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"},{"id":550,"name":"Respiratory Tract Infections"}],"races":[],"created":"2020-11-13T21:18:48.690676Z","updated":"2020-11-16T19:43:50.583530Z","title":"Pneumomediastinum and spontaneous pneumothorax as an extrapulmonary complication of COVID-19 disease. Case 3.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32524296,"doi":"10.1007/s10140-020-01806-0","article_url":"https://pubmed.ncbi.nlm.nih.gov/32524296/","pub_year":2020,"published_authors":"LÃ³pez Vega JM\r\nParra Gordo ML\r\nDiez TascÃ³n A\r\nOssaba VÃ©lez S","article_author_email":"Author email could not be found.","journal":"Emergency radiology","abstract":"The new disease outbreak that causes atypical pneumonia named COVID-19, which started in China's Wuhan province, has quickly spread to a pandemic. Although the imaging test of choice for the initial study is plain chest radiograph, CT has proven useful in characterizing better the complications associated with this new infection. We describe the evolution of 3 patients presenting pneumomediastinum and spontaneous pneumothorax as a very rare complication of COVID-19 and their particular interest as a probable prognostic factor.          \r\n        Keywords:      \r\n                  COVID-19; Complications; Pneumomediastinum; Pneumothorax.","article_type":"Original","study_type":"Case Report","number_of_patients":3,"article_patient_number":"3","full_text_available":true,"outcome":"Patient died","surgery":"No","age":"71-80 years","sex":"Male","ethnicity":null,"country_contracted":"Spain","country_treated":"Spain","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":true,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"history of basal cell epithelioma, obstructive sleep apnea, obesity, and depression under pharmacological treatment","pregnant":false,"unknown":false,"site_of_disease":"lungs","clinical_syndrome":"pneumonia, respiratory tract infection","severity":"ICU/Critical Care","prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"While the patient was still on treatment","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"This patient had a history of basal cell epithelium, obstructive sleep apnea, obesity, and depression under pharmacological treatment. This patient received oxygen and support with CPAP. CT scan found a pneumomediastinum.\r\nGiven the torpid evolution of the disease, it was decided to perform a chest CT with contrast, suspecting pulmonary thromboembolism.\r\n\r\nIn the study, filling defects were identified in the segmental arteries of both upper lobes, extensive bilateral involvement by coronavirus, and, as an incidental finding, a minimal chamber of pneumomediastinum (Fig. 4). Anticoagulant therapy and non-invasive ventilatory support with CPAP were started. The patient presented progressive deterioration until his death 15 days after admission.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6122,8342,9077,10776]},{"id":6482,"regimens":[{"id":12671,"duration":{"id":6656,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":10559,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12671},{"id":10560,"answer":"In a novel combination with another drug","answer_other":"","regimen":12671}],"created":"2020-11-16T23:02:58.374161Z","updated":"2020-11-18T17:17:08.898216Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"Assisted ventilation","comments":null,"report":6482},{"id":12672,"duration":{"id":6657,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":10561,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12672},{"id":10562,"answer":"In a novel combination with another drug","answer_other":"","regimen":12672}],"created":"2020-11-16T23:02:58.382174Z","updated":"2020-11-18T17:17:08.904867Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"Assisted ventilation","comments":null,"report":6482},{"id":12673,"duration":{"id":6658,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8711,"name":"Levofloxacin","url":"cure-api2.ncats.io/v1/drugs/8711","rxNorm_id":null,"notes":null},"use_drug":[{"id":10563,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12673},{"id":10564,"answer":"In a novel combination with another drug","answer_other":"","regimen":12673}],"created":"2020-11-16T23:02:58.388348Z","updated":"2020-11-18T17:17:08.910824Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"Assisted ventilation","comments":null,"report":6482},{"id":12674,"duration":{"id":6659,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":10565,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12674},{"id":10566,"answer":"In a novel combination with another drug","answer_other":"","regimen":12674}],"created":"2020-11-16T23:02:58.394471Z","updated":"2020-11-18T17:17:08.916709Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"Assisted ventilation","comments":null,"report":6482},{"id":12675,"duration":{"id":6660,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8233,"name":"Heparin","url":"cure-api2.ncats.io/v1/drugs/8233","rxNorm_id":null,"notes":null},"use_drug":[{"id":10567,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12675},{"id":10568,"answer":"In a novel combination with another drug","answer_other":"","regimen":12675}],"created":"2020-11-16T23:02:58.400514Z","updated":"2020-11-18T17:17:08.922250Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"Assisted ventilation","comments":null,"report":6482},{"id":12676,"duration":{"id":6661,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8783,"name":"Lopinavir-Ritonavir","url":"cure-api2.ncats.io/v1/drugs/8783","rxNorm_id":null,"notes":null},"use_drug":[{"id":10569,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12676},{"id":10570,"answer":"In a novel combination with another drug","answer_other":"","regimen":12676}],"created":"2020-11-16T23:02:58.406797Z","updated":"2020-11-18T17:17:08.927879Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"Assisted ventilation","comments":null,"report":6482}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8521,"answer":"Clinical assessment","answer_other":"","report":6482}],"how_diagnosis":[{"id":14577,"answer":"Clinical assessment","answer_other":"","report":6482},{"id":14578,"answer":"Imaging","answer_other":"","report":6482},{"id":14579,"answer":"PCR","answer_other":"","report":6482}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4630,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6482},{"id":4631,"answer":"Co-Infection or Complex Co-morbidities","answer_other":"","report":6482}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-11-16T22:59:50.725697Z","updated":"2020-11-18T17:17:08.890398Z","title":"Atypical Presentation of COVID-19 Incidentally Detected at 18F-FDG PET/CT in an Asymptomatic Oncological Patient.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32520513,"doi":"10.1097/RLU.0000000000003175","article_url":"https://pubmed.ncbi.nlm.nih.gov/32520513/","pub_year":2020,"published_authors":"Mattoli MV\r\nTaralli S\r\nPennese E\r\nD'Angelo C\r\nAngrilli F\r\nVillano C","article_author_email":"mvittoriamattoli@yahoo.it.","journal":"Clinical nuclear medicine","abstract":"The incidence of COVID-19, a severe acute respiratory syndrome caused by SARS-CoV-2, is rapidly growing worldwide. In this pandemic period, the chance of incidental pulmonary findings suggestive of COVID-19 at F-FDG PET/CT in asymptomatic oncological patients is not negligible. To suspect COVID-19 is more demanding whether its presentation is atypical. We describe the incidental PET/CT detection of an F-FDG-avid isolated centrilobular pulmonary consolidation in an asymptomatic lymphoma patient, which later resulted in an unexpected and atypical COVID-19 presentation. The nuclear medicine physicians should be prepared to suspect COVID-19 even in asymptomatic patients presenting with a \"far-from-COVID-19\" finding at PET/CT.","article_type":"Original","study_type":"Case Report","number_of_patients":1,"article_patient_number":"","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"51-60 years","sex":"Male","ethnicity":null,"country_contracted":"Italy","country_treated":"Italy","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":true,"other_comorbid":"Diffuse Large B-cell Lymphoma","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Pneumonia, fever, cough","severity":"ICU/Critical Care","prev_treatment":"","unusual":"To the best of our knowledge, this is the first reported case of an atypical presentation of a confirmed COVID-19 pneumonia as unilateral isolated and relatively small 18F-FDGâavid consolidation in an asymptomatic oncological patient incidentally detected at PET/CT.","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"While the patient was still on treatment","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"Patient was also treated for infection with and unidentified antiplatelet and steroids.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6122,8233,8342,8711,8783,10776]},{"id":6487,"regimens":[{"id":12688,"duration":{"id":6673,"approximate_duration":"1 week","dates_unknown":true},"drug":{"id":8783,"name":"Lopinavir-Ritonavir","url":"cure-api2.ncats.io/v1/drugs/8783","rxNorm_id":null,"notes":null},"use_drug":[{"id":10593,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12688},{"id":10594,"answer":"In a novel combination with another drug","answer_other":"","regimen":12688}],"created":"2020-11-17T15:07:04.437623Z","updated":"2020-11-18T17:52:19.609536Z","dose":"200/50 mg","frequency":"BID","route":"PO","severity":"Inpatient","severity_detail":"","comments":null,"report":6487},{"id":12689,"duration":{"id":6674,"approximate_duration":"6 days","dates_unknown":true},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":10595,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12689},{"id":10596,"answer":"In a novel combination with another drug","answer_other":"","regimen":12689}],"created":"2020-11-17T15:07:04.445583Z","updated":"2020-11-18T17:52:19.615916Z","dose":"200 mg","frequency":"BID","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6487},{"id":12690,"duration":{"id":6675,"approximate_duration":"4 days","dates_unknown":true},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":10597,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12690},{"id":10598,"answer":"In a novel combination with another drug","answer_other":"","regimen":12690}],"created":"2020-11-17T15:07:04.451907Z","updated":"2020-11-18T17:52:19.621494Z","dose":"250 mg","frequency":"QD","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6487},{"id":12691,"duration":{"id":6676,"approximate_duration":"1 day","dates_unknown":true},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":10599,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12691},{"id":10600,"answer":"In a novel combination with another drug","answer_other":"","regimen":12691}],"created":"2020-11-17T15:07:04.458272Z","updated":"2020-11-18T17:52:19.627396Z","dose":"400 mg","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6487},{"id":12692,"duration":{"id":6677,"approximate_duration":"2 days","dates_unknown":true},"drug":{"id":5926,"name":"Anakinra","url":"cure-api2.ncats.io/v1/drugs/5926","rxNorm_id":null,"notes":null},"use_drug":[{"id":10601,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12692},{"id":10602,"answer":"In a novel combination with another drug","answer_other":"","regimen":12692}],"created":"2020-11-17T15:07:04.464380Z","updated":"2020-11-18T17:52:19.632913Z","dose":"200 mg","frequency":"QD","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6487},{"id":12742,"duration":null,"drug":{"id":6675,"name":"Ceftriaxone","url":"cure-api2.ncats.io/v1/drugs/6675","rxNorm_id":null,"notes":null},"use_drug":[{"id":10697,"answer":"It was not used in a new way","answer_other":"","regimen":12742},{"id":10698,"answer":"Other","answer_other":"Treatment of S. pneumoniae","regimen":12742}],"created":"2020-11-18T17:52:19.659065Z","updated":"2020-11-18T17:52:19.667677Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6487},{"id":12743,"duration":null,"drug":{"id":6665,"name":"Ceftaroline","url":"cure-api2.ncats.io/v1/drugs/6665","rxNorm_id":null,"notes":null},"use_drug":[{"id":10699,"answer":"It was not used in a new way","answer_other":"","regimen":12743},{"id":10700,"answer":"Other","answer_other":"Treatment of S. pneumoniae","regimen":12743}],"created":"2020-11-18T17:52:19.663539Z","updated":"2020-11-18T17:52:19.668535Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6487}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8530,"answer":"Clinical assessment","answer_other":"","report":6487}],"how_diagnosis":[{"id":14590,"answer":"Clinical assessment","answer_other":"","report":6487},{"id":14591,"answer":"Imaging","answer_other":"","report":6487},{"id":14592,"answer":"PCR","answer_other":"","report":6487}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4636,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6487}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":331,"name":"Pneumococcal Infection (Streptococcus Pneumoniae)"},{"id":396,"name":"Pneumonia"},{"id":550,"name":"Respiratory Tract Infections"}],"races":[],"created":"2020-11-17T15:05:47.260445Z","updated":"2020-11-18T17:52:19.601127Z","title":"Pneumococcal superinfection in COVID-19 patients: A series of 5 cases. Case 1.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32591180,"doi":"10.1016/j.medcli.2020.05.022","article_url":"https://pubmed.ncbi.nlm.nih.gov/32591180/","pub_year":2020,"published_authors":"Cucchiari D\r\nPericÃ s JM\r\nRiera J\r\nGumucio R\r\nMd EC\r\nNicolÃ¡s D\r\nHospital ClÃ­nic 4H Team.","article_author_email":"Author email could not be found.","journal":"Medicina clinica","abstract":"Background:      \r\n              In the context of the COVID-19 pandemic the risk of misdiagnosis of other causes of respiratory infection is likely. In this work we aim to describe the clinical characteristics, treatment and outcome of pneumococcal infection in COVID-19 patients.          \r\n        Patients and methods:      \r\n              Every COVID-19 patient presenting with concomitant pneumococcal pneumonia during March 2020 in a tertiary teaching Hospital In Barcelona, Spain.          \r\n        Results:      \r\n              Five patients with PCR confirmed COVID19 or clinical and radiological suspicion were diagnosed of pneumococcal infection. In all cases chest X-ray were abnormal, with unilateral or bilateral infiltrates. Procalcitonin showed to be not sensitive enough to detect pneumococcal infection. Antibiotherapy was promptly started in all five cases with subsequent satisfactory evolution.          \r\n        Conclusion:      \r\n              International guidelines do not include the universal screening for bacterial co-infection. Radiological pattern of COVID-19 can be indistinguishable from that of pneumococcus pneumonia and frequency of co-infection is not well stablished, therefore clinicians should be aware of the possible SARS-CoV-2-pneumococcus association to avoid misdiagnosis and delay antibiotic therapy.          \r\n        IntroducciÃ³n:      \r\n              En el contexto de la pandemia por COVID-19 el riesgo de errores en el diagnÃ³stico de otras causas de infecciÃ³n respiratoria es elevado. En este trabajo describimos las caracterÃ­sticas clÃ­nicas, el tratamiento y la evoluciÃ³n de los pacientes con coinfecciÃ³n por COVID-19 y neumococo.          \r\n        Pacientes y mÃ©todos:      \r\n              Todos los pacientes con COVID-19 que presentaron neumonÃ­a neumocÃ³cica durante marzo 2020 en un hospital universitario de Barcelona, EspaÃ±a.          \r\n        Resultados:      \r\n              Cinco pacientes con COVID-19 confirmada por PCR o sospecha radiolÃ³gica fueron diagnosticados de infecciÃ³n por neumococo. En todos los casos la radiografÃ­a de tÃ³rax era patolÃ³gica con infiltrado unilateral o bilateral. La procalcitonina demostrÃ³ no ser suficientemente sensible para detectar la infecciÃ³n neumocÃ³cica. La antibioterapia fue iniciada de manera precoz en los 5 casos con evoluciÃ³n satisfactoria.          \r\n        Conclusiones:      \r\n              Las guÃ­as internacionales no incluyen el cribado universal para coinfecciÃ³n bacteriana. El patrÃ³n radiolÃ³gico del COVID-19 puede ser indistinguible de la neumonÃ­a neumocÃ³cica, y la frecuencia de la coinfecciÃ³n no ha sido establecida. Los clÃ­nicos deben de ser conscientes de la posible asociaciÃ³n de SARS-CoV-2 y neumococo para evitar errores diagnÃ³sticos y retrasos en el tratamiento antibiÃ³tico.          \r\n        Keywords:      \r\n                  COVID-19; CoinfecciÃ³n; Diagnosis; DiagnÃ³stico; S. pneumoniae; Tratamiento; Treatment; co-infection.","article_type":"Original","study_type":"Case Report","number_of_patients":5,"article_patient_number":"1","full_text_available":true,"outcome":"Patient improved","surgery":"Yes","age":"81-89 years","sex":"Male","ethnicity":null,"country_contracted":"Spain","country_treated":"Spain","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":true,"hypertension":true,"cardiovascular_disease":true,"chronic_renal_disease":true,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"Ischemic Heart Disease\r\nAortic Stenosis","pregnant":false,"unknown":false,"site_of_disease":"lungs","clinical_syndrome":"respiratory tract infection, pneumonia","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"This patient has a medical history including diabetes, hypertension (treated with ARBs), Ischemic heart disease, aortic stenosis, and chronic kidney disease. This patient was found to have a S. pneumonia infection for which they were treated with ceftriaxone (1g, QD) and was upgraded to ceftaroline (600 mg, BID). This patient received the S. pneumonia vaccination in 2007.","previously_treated":"","flagged":false,"other_coinfections":"S. pneumoniae","disease":630,"drugs":[5926,6122,6665,6675,8342,8783,10776]},{"id":6489,"regimens":[{"id":12694,"duration":{"id":6679,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":10605,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12694},{"id":10606,"answer":"In a novel combination with another drug","answer_other":"","regimen":12694}],"created":"2020-11-17T16:17:06.159123Z","updated":"2020-11-18T17:38:50.600827Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6489},{"id":12695,"duration":{"id":6680,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":10607,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12695},{"id":10608,"answer":"In a novel combination with another drug","answer_other":"","regimen":12695}],"created":"2020-11-17T16:17:06.166898Z","updated":"2020-11-18T17:38:50.607079Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6489},{"id":12696,"duration":{"id":6681,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":10609,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12696},{"id":10610,"answer":"In a novel combination with another drug","answer_other":"","regimen":12696}],"created":"2020-11-17T16:17:06.172987Z","updated":"2020-11-18T17:38:50.612538Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6489}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8533,"answer":"Clinical assessment","answer_other":"","report":6489},{"id":8534,"answer":"Imaging","answer_other":"","report":6489}],"how_diagnosis":[{"id":14597,"answer":"Clinical assessment","answer_other":"","report":6489},{"id":14598,"answer":"Imaging","answer_other":"","report":6489},{"id":14599,"answer":"PCR","answer_other":"","report":6489}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4638,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6489}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"},{"id":550,"name":"Respiratory Tract Infections"}],"races":[],"created":"2020-11-17T16:16:39.873489Z","updated":"2020-11-18T17:38:50.593036Z","title":"Unique case of central retinal artery occlusion secondary to COVID-19 disease.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32572363,"doi":"10.1016/j.idcr.2020.e00867","article_url":"https://pubmed.ncbi.nlm.nih.gov/32572363/","pub_year":2020,"published_authors":"Acharya S\r\nDiamond M\r\nAnwar S\r\nGlaser A\r\nTyagi P","article_author_email":"Author email could not be found.","journal":"IDCases","abstract":"SARS-COVID-2 has been noted to be associated with neurological symptoms and complications including stroke. Hypercoagulability associated with COVID-19 has been described as a \"sepsis-induced coagulopathy\" and may predispose to spectrum of thromboembolic events. We present a unique article of isolated central retinal artery occlusion secondary to SARS-COV 2.          \r\n        Keywords:      \r\n                  COVID-19; Infectious disease; Sepsis.","article_type":"Original","study_type":"Case Report","number_of_patients":1,"article_patient_number":"1","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"51-60 years","sex":"Male","ethnicity":"Hispanic/Latino","country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":true,"diabetes_mellitus":false,"hypertension":true,"cardiovascular_disease":true,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"dyslipidemia, stable coronary artery disease and chronic obstructive pulmonary disease","pregnant":false,"unknown":false,"site_of_disease":"lungs, eye","clinical_syndrome":"respiratory tract infection, pneumonia, acute respiratory distress syndrome, cytokine release syndrome, loss of vision","severity":"ICU/Critical Care","prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"While the patient was still on treatment","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"This patient has a history of hypertension, dyslipidemia, stable coronary artery disease and chronic obstructive pulmonary disease. This patient wa intubated and admitted to the ICU. On the twelfth day of admission, the patine experienced painless loss of vision int he right eye. CT and angiogram were unremarkable. Ophthalmology performed at the bedside revealed central retinal after occlusion.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6122,8342,10776]},{"id":6498,"regimens":[{"id":12730,"duration":{"id":6701,"approximate_duration":"7 days","dates_unknown":true},"drug":{"id":8783,"name":"Lopinavir-Ritonavir","url":"cure-api2.ncats.io/v1/drugs/8783","rxNorm_id":null,"notes":null},"use_drug":[{"id":10669,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12730},{"id":10670,"answer":"In a novel combination with another drug","answer_other":"","regimen":12730}],"created":"2020-11-17T20:34:54.359137Z","updated":"2020-11-18T18:01:06.311306Z","dose":"200/50 mg","frequency":"BID","route":"PO","severity":"Inpatient","severity_detail":"","comments":null,"report":6498},{"id":12731,"duration":{"id":6702,"approximate_duration":"6 days","dates_unknown":true},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":10671,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12731},{"id":10672,"answer":"In a novel combination with another drug","answer_other":"","regimen":12731}],"created":"2020-11-17T20:34:54.366384Z","updated":"2020-11-18T18:01:06.317802Z","dose":"200 mg","frequency":"BID","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6498},{"id":12732,"duration":{"id":6703,"approximate_duration":"4 days","dates_unknown":true},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":10673,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12732},{"id":10674,"answer":"In a novel combination with another drug","answer_other":"","regimen":12732}],"created":"2020-11-17T20:34:54.372463Z","updated":"2020-11-18T18:01:06.324292Z","dose":"250 mg","frequency":"QD","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6498},{"id":12734,"duration":{"id":6705,"approximate_duration":"1 day","dates_unknown":true},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":10677,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12734},{"id":10678,"answer":"In a novel combination with another drug","answer_other":"","regimen":12734}],"created":"2020-11-17T20:44:49.747307Z","updated":"2020-11-18T18:01:06.330132Z","dose":"400 mg","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6498},{"id":12746,"duration":null,"drug":{"id":6675,"name":"Ceftriaxone","url":"cure-api2.ncats.io/v1/drugs/6675","rxNorm_id":null,"notes":null},"use_drug":[{"id":10705,"answer":"It was not used in a new way","answer_other":"","regimen":12746},{"id":10706,"answer":"Other","answer_other":"Treatment of S. pneumoniae","regimen":12746}],"created":"2020-11-18T18:01:06.354744Z","updated":"2020-11-18T18:01:06.363881Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6498},{"id":12747,"duration":null,"drug":{"id":8711,"name":"Levofloxacin","url":"cure-api2.ncats.io/v1/drugs/8711","rxNorm_id":null,"notes":null},"use_drug":[{"id":10707,"answer":"It was not used in a new way","answer_other":"","regimen":12747},{"id":10708,"answer":"Other","answer_other":"Treatment of S. pneumoniae","regimen":12747}],"created":"2020-11-18T18:01:06.359545Z","updated":"2020-11-18T18:01:06.364766Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6498}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8546,"answer":"Clinical assessment","answer_other":"","report":6498}],"how_diagnosis":[{"id":14618,"answer":"Clinical assessment","answer_other":"","report":6498},{"id":14619,"answer":"Imaging","answer_other":"","report":6498},{"id":14620,"answer":"PCR","answer_other":"","report":6498}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4649,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6498}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":331,"name":"Pneumococcal Infection (Streptococcus Pneumoniae)"},{"id":396,"name":"Pneumonia"},{"id":550,"name":"Respiratory Tract Infections"}],"races":[],"created":"2020-11-17T20:34:19.683863Z","updated":"2020-11-18T18:01:06.302733Z","title":"Pneumococcal superinfection in COVID-19 patients: A series of 5 cases. Case 3.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32591180,"doi":"10.1016/j.medcli.2020.05.022","article_url":"https://pubmed.ncbi.nlm.nih.gov/32591180/","pub_year":2020,"published_authors":"Cucchiari D\r\nPericÃ s JM\r\nRiera J\r\nGumucio R\r\nMd EC\r\nNicolÃ¡s D\r\nHospital ClÃ­nic 4H Team.","article_author_email":"Author email could not be found.","journal":"Medicina clinica","abstract":"Background:      \r\n              In the context of the COVID-19 pandemic the risk of misdiagnosis of other causes of respiratory infection is likely. In this work we aim to describe the clinical characteristics, treatment and outcome of pneumococcal infection in COVID-19 patients.          \r\n        Patients and methods:      \r\n              Every COVID-19 patient presenting with concomitant pneumococcal pneumonia during March 2020 in a tertiary teaching Hospital In Barcelona, Spain.          \r\n        Results:      \r\n              Five patients with PCR confirmed COVID19 or clinical and radiological suspicion were diagnosed of pneumococcal infection. In all cases chest X-ray were abnormal, with unilateral or bilateral infiltrates. Procalcitonin showed to be not sensitive enough to detect pneumococcal infection. Antibiotherapy was promptly started in all five cases with subsequent satisfactory evolution.          \r\n        Conclusion:      \r\n              International guidelines do not include the universal screening for bacterial co-infection. Radiological pattern of COVID-19 can be indistinguishable from that of pneumococcus pneumonia and frequency of co-infection is not well stablished, therefore clinicians should be aware of the possible SARS-CoV-2-pneumococcus association to avoid misdiagnosis and delay antibiotic therapy.          \r\n        IntroducciÃ³n:      \r\n              En el contexto de la pandemia por COVID-19 el riesgo de errores en el diagnÃ³stico de otras causas de infecciÃ³n respiratoria es elevado. En este trabajo describimos las caracterÃ­sticas clÃ­nicas, el tratamiento y la evoluciÃ³n de los pacientes con coinfecciÃ³n por COVID-19 y neumococo.          \r\n        Pacientes y mÃ©todos:      \r\n              Todos los pacientes con COVID-19 que presentaron neumonÃ­a neumocÃ³cica durante marzo 2020 en un hospital universitario de Barcelona, EspaÃ±a.          \r\n        Resultados:      \r\n              Cinco pacientes con COVID-19 confirmada por PCR o sospecha radiolÃ³gica fueron diagnosticados de infecciÃ³n por neumococo. En todos los casos la radiografÃ­a de tÃ³rax era patolÃ³gica con infiltrado unilateral o bilateral. La procalcitonina demostrÃ³ no ser suficientemente sensible para detectar la infecciÃ³n neumocÃ³cica. La antibioterapia fue iniciada de manera precoz en los 5 casos con evoluciÃ³n satisfactoria.          \r\n        Conclusiones:      \r\n              Las guÃ­as internacionales no incluyen el cribado universal para coinfecciÃ³n bacteriana. El patrÃ³n radiolÃ³gico del COVID-19 puede ser indistinguible de la neumonÃ­a neumocÃ³cica, y la frecuencia de la coinfecciÃ³n no ha sido establecida. Los clÃ­nicos deben de ser conscientes de la posible asociaciÃ³n de SARS-CoV-2 y neumococo para evitar errores diagnÃ³sticos y retrasos en el tratamiento antibiÃ³tico.          \r\n        Keywords:      \r\n                  COVID-19; CoinfecciÃ³n; Diagnosis; DiagnÃ³stico; S. pneumoniae; Tratamiento; Treatment; co-infection.","article_type":"Original","study_type":"Case Report","number_of_patients":5,"article_patient_number":"3","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"61-70 years","sex":"Male","ethnicity":null,"country_contracted":"Spain","country_treated":"Spain","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"Depression","pregnant":false,"unknown":false,"site_of_disease":"lungs","clinical_syndrome":"respiratory tract infection, pneumonia","severity":"Inpatient","prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"This patient has a history of depression. They were also found to have a S. pneumoniae infection that was treated with ceftriaxone (1g, QD) and levofloxin (500 mg, QD, PO) upon discharge.","previously_treated":"","flagged":false,"other_coinfections":"S. pneumoniae infection","disease":630,"drugs":[6122,6675,8342,8711,8783,10776]},{"id":6510,"regimens":[{"id":12780,"duration":{"id":6742,"approximate_duration":"7 days","dates_unknown":true},"drug":{"id":8783,"name":"Lopinavir-Ritonavir","url":"cure-api2.ncats.io/v1/drugs/8783","rxNorm_id":null,"notes":null},"use_drug":[{"id":10783,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12780},{"id":10784,"answer":"In a novel combination with another drug","answer_other":"","regimen":12780}],"created":"2020-11-20T12:04:15.256829Z","updated":"2020-11-24T02:27:47.716498Z","dose":"200/50 mg","frequency":"BID","route":"PO","severity":"Inpatient","severity_detail":"","comments":null,"report":6510},{"id":12781,"duration":{"id":6743,"approximate_duration":"6 days","dates_unknown":true},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":10785,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12781},{"id":10786,"answer":"In a novel combination with another drug","answer_other":"","regimen":12781}],"created":"2020-11-20T12:04:15.264567Z","updated":"2020-11-24T02:27:47.723118Z","dose":"200 mg","frequency":"BID","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6510},{"id":12782,"duration":{"id":6744,"approximate_duration":"4 days","dates_unknown":true},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":10787,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12782},{"id":10788,"answer":"In a novel combination with another drug","answer_other":"","regimen":12782}],"created":"2020-11-20T12:04:15.270850Z","updated":"2020-11-24T02:27:47.728722Z","dose":"250 mg","frequency":"QD","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6510},{"id":12783,"duration":{"id":6745,"approximate_duration":"1 day","dates_unknown":true},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":10789,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12783},{"id":10790,"answer":"In a novel combination with another drug","answer_other":"","regimen":12783}],"created":"2020-11-20T12:04:15.276835Z","updated":"2020-11-24T02:27:47.735025Z","dose":"400 mg","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6510}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8564,"answer":"Clinical assessment","answer_other":"","report":6510}],"how_diagnosis":[{"id":14648,"answer":"Clinical assessment","answer_other":"","report":6510},{"id":14649,"answer":"Imaging","answer_other":"","report":6510}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4670,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6510}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"},{"id":550,"name":"Respiratory Tract Infections"}],"races":[],"created":"2020-11-20T12:03:34.034431Z","updated":"2020-11-24T02:27:47.708076Z","title":"Pneumococcal superinfection in COVID-19 patients: A series of 5 cases. Case 4.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32591180,"doi":"10.1016/j.medcli.2020.05.022","article_url":"https://pubmed.ncbi.nlm.nih.gov/32591180/","pub_year":2020,"published_authors":"Cucchiari D\r\nPericÃ s JM\r\nRiera J\r\nGumucio R\r\nMd EC\r\nNicolÃ¡s D\r\nHospital ClÃ­nic 4H Team.","article_author_email":"Author email could not be found.","journal":"Medicina clinica","abstract":"Background:      \r\n              In the context of the COVID-19 pandemic the risk of misdiagnosis of other causes of respiratory infection is likely. In this work we aim to describe the clinical characteristics, treatment and outcome of pneumococcal infection in COVID-19 patients.          \r\n        Patients and methods:      \r\n              Every COVID-19 patient presenting with concomitant pneumococcal pneumonia during March 2020 in a tertiary teaching Hospital In Barcelona, Spain.          \r\n        Results:      \r\n              Five patients with PCR confirmed COVID19 or clinical and radiological suspicion were diagnosed of pneumococcal infection. In all cases chest X-ray were abnormal, with unilateral or bilateral infiltrates. Procalcitonin showed to be not sensitive enough to detect pneumococcal infection. Antibiotherapy was promptly started in all five cases with subsequent satisfactory evolution.          \r\n        Conclusion:      \r\n              International guidelines do not include the universal screening for bacterial co-infection. Radiological pattern of COVID-19 can be indistinguishable from that of pneumococcus pneumonia and frequency of co-infection is not well stablished, therefore clinicians should be aware of the possible SARS-CoV-2-pneumococcus association to avoid misdiagnosis and delay antibiotic therapy.          \r\n        IntroducciÃ³n:      \r\n              En el contexto de la pandemia por COVID-19 el riesgo de errores en el diagnÃ³stico de otras causas de infecciÃ³n respiratoria es elevado. En este trabajo describimos las caracterÃ­sticas clÃ­nicas, el tratamiento y la evoluciÃ³n de los pacientes con coinfecciÃ³n por COVID-19 y neumococo.          \r\n        Pacientes y mÃ©todos:      \r\n              Todos los pacientes con COVID-19 que presentaron neumonÃ­a neumocÃ³cica durante marzo 2020 en un hospital universitario de Barcelona, EspaÃ±a.          \r\n        Resultados:      \r\n              Cinco pacientes con COVID-19 confirmada por PCR o sospecha radiolÃ³gica fueron diagnosticados de infecciÃ³n por neumococo. En todos los casos la radiografÃ­a de tÃ³rax era patolÃ³gica con infiltrado unilateral o bilateral. La procalcitonina demostrÃ³ no ser suficientemente sensible para detectar la infecciÃ³n neumocÃ³cica. La antibioterapia fue iniciada de manera precoz en los 5 casos con evoluciÃ³n satisfactoria.          \r\n        Conclusiones:      \r\n              Las guÃ­as internacionales no incluyen el cribado universal para coinfecciÃ³n bacteriana. El patrÃ³n radiolÃ³gico del COVID-19 puede ser indistinguible de la neumonÃ­a neumocÃ³cica, y la frecuencia de la coinfecciÃ³n no ha sido establecida. Los clÃ­nicos deben de ser conscientes de la posible asociaciÃ³n de SARS-CoV-2 y neumococo para evitar errores diagnÃ³sticos y retrasos en el tratamiento antibiÃ³tico.          \r\n        Keywords:      \r\n                  COVID-19; CoinfecciÃ³n; Diagnosis; DiagnÃ³stico; S. pneumoniae; Tratamiento; Treatment; co-infection.","article_type":"Original","study_type":"Case Report","number_of_patients":5,"article_patient_number":"4","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"71-80 years","sex":"Female","ethnicity":null,"country_contracted":"Spain","country_treated":"Spain","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":true,"cardiovascular_disease":false,"chronic_renal_disease":true,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"anemia","pregnant":false,"unknown":false,"site_of_disease":"lungs","clinical_syndrome":"respiratory tract infection, pneumonia","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"This patient has a medical history including hypertension (treated with ARBs and diuretic), chronic kidney disease, and chronic anemia. They received a 12-valent S. pneumoniae vaccination in 2008. Their S. pneumoniae infection was treated with ceftriaxone (1g, daily) and teicoplanin (6 mg/kg, daily). This patient received a 400 mg loading dose of hydroxycloroquine and a 500 mg loading dose of azithromycin.","previously_treated":"","flagged":false,"other_coinfections":"S. pneumoniae","disease":630,"drugs":[6122,8342,8783,10776]},{"id":6518,"regimens":[{"id":12798,"duration":{"id":6760,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":10813,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12798},{"id":10814,"answer":"In a novel combination with another drug","answer_other":"","regimen":12798}],"created":"2020-11-20T17:59:30.920105Z","updated":"2020-11-24T17:59:00.274994Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6518},{"id":12799,"duration":{"id":6761,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":10815,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12799},{"id":10816,"answer":"In a novel combination with another drug","answer_other":"","regimen":12799}],"created":"2020-11-20T17:59:30.928599Z","updated":"2020-11-24T17:59:00.281279Z","dose":"","frequency":"","route":"Intramuscular Injection","severity":"Inpatient","severity_detail":"","comments":null,"report":6518}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8573,"answer":"Clinical assessment","answer_other":"","report":6518}],"how_diagnosis":[{"id":14667,"answer":"Clinical assessment","answer_other":"","report":6518},{"id":14799,"answer":"PCR","answer_other":"","report":6518}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Improved","previous_drugs":[{"id":5600,"name":"Acetaminophen"}],"comments":[],"article_language":"English","why_new_way":[{"id":4678,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6518},{"id":4679,"answer":"Unusual disease presentation","answer_other":"","report":6518}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":550,"name":"Respiratory Tract Infections"}],"races":[],"created":"2020-11-20T17:57:38.034657Z","updated":"2020-11-24T17:59:00.267067Z","title":"Acute maculopapular eruption in Covid-19 patient: A case report.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32526051,"doi":"10.1111/dth.13812","article_url":"https://pubmed.ncbi.nlm.nih.gov/32526051/","pub_year":2020,"published_authors":"Rossi E\r\nLasagni C\r\nTrakatelli M\r\nWertzberger Rowan S\r\nMagnoni C","article_author_email":"dr.elenarossi@gmail.com","journal":"Dermatologic therapy","abstract":"We report the case of a positive COVID-19 patient who presented to our hospital for a maculopapular skin rash which appeared 7 days after the onset of COVID-19 symptoms. He was 30 some years old and nothing relevant was recorded at his previous anamnesis. The patient was hospitalized for 3 days and received systemic therapy with steroid, antihistamines, tocilizumab, and hydroxicloroquine. On the third day of the hospitalization the cutaneous rash had almost completely disappeared.          \r\n        Keywords:      \r\n                  Covid-19; acetaminophen; drug reaction; exhantem; skin rash.","article_type":"Original","study_type":"Case Report","number_of_patients":3,"article_patient_number":"1","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"No","age":"31-40 years","sex":"Male","ethnicity":null,"country_contracted":"Italy","country_treated":"Italy","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"Lungs, Skin","clinical_syndrome":"Maculopapular skin rash, respiratory tract infection","severity":"Inpatient","prev_treatment":"","unusual":"Unusual clinical manifestation by a generalized maculopapular eruption observed on the trunk, upper limbs, legs, and face without involvement of the palmoplantar\r\nareas.","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"The maculopapular eruptions were treated with undisclosed antihistamines and intravenous steroid bolus. \r\n\r\nThe patient was also discharged with an antihistamine and hydroxychloroquine 200mg/2 tablets per day prescription.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[8342,10776]},{"id":6520,"regimens":[{"id":12802,"duration":{"id":6764,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":10821,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12802},{"id":10822,"answer":"In a novel combination with another drug","answer_other":"","regimen":12802}],"created":"2020-11-20T19:28:10.100811Z","updated":"2020-11-25T13:20:11.056148Z","dose":"200 mg","frequency":"BID","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6520},{"id":12803,"duration":{"id":6765,"approximate_duration":"4 days","dates_unknown":true},"drug":{"id":9077,"name":"Methylprednisolone","url":"cure-api2.ncats.io/v1/drugs/9077","rxNorm_id":null,"notes":null},"use_drug":[{"id":10823,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12803},{"id":10824,"answer":"In a novel combination with another drug","answer_other":"","regimen":12803}],"created":"2020-11-20T19:28:10.108698Z","updated":"2020-11-25T13:20:11.062482Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6520},{"id":12804,"duration":{"id":6766,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":10825,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12804},{"id":10826,"answer":"In a novel combination with another drug","answer_other":"","regimen":12804}],"created":"2020-11-20T19:28:10.115566Z","updated":"2020-11-25T13:20:11.068403Z","dose":"1200 mg","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6520},{"id":12943,"duration":null,"drug":{"id":10521,"name":"Tacrolimus","url":"cure-api2.ncats.io/v1/drugs/10521","rxNorm_id":null,"notes":null},"use_drug":[{"id":11094,"answer":"Other","answer_other":"Low dose as immuno suppressive therapy","regimen":12943}],"created":"2020-11-25T13:20:11.091605Z","updated":"2020-11-25T13:20:11.095658Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6520}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8574,"answer":"Clinical assessment","answer_other":"","report":6520}],"how_diagnosis":[{"id":14671,"answer":"Clinical assessment","answer_other":"","report":6520},{"id":14673,"answer":"PCR","answer_other":"","report":6520}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4681,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6520}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":550,"name":"Respiratory Tract Infections"}],"races":[],"created":"2020-11-20T19:24:13.636329Z","updated":"2020-11-25T13:20:11.047985Z","title":"Should cyclosporine be useful in renal transplant recipients affected by SARS-CoV-2? Case 2.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32529737,"doi":"10.1111/ajt.16141","article_url":"https://pubmed.ncbi.nlm.nih.gov/32529737/","pub_year":2020,"published_authors":"Rodriguez-Cubillo B\r\nde la Higuera MAM\r\nLucena R\r\nFranci EV\r\nHurtado M\r\nRomero NC\r\nMoreno AR\r\nValencia D\r\nVelo M\r\nFornie IS\r\nSanchez-Fructuoso AI","article_author_email":"Author email could not be found.","journal":"American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons","abstract":"Minimization of immunosuppression and administration of antiretrovirals have been recommended for kidney transplant recipients (KTRs) with coronavirus disease 2019 (COVID-19). However, outcomes remain poor. Given the likely benefit of cyclosporine because of its antiviral and immunomodulatory effect, we have been using it as a strategy in KTRs diagnosed with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We studied 29 kidney transplant recipients (KTRs) who were admitted to our institution with COVID-19 between March 15and April, 24, 2020. Mycophenolate and/or mammalian target of rapamycin inhibitors (mTORi) were discontinued in all patients. Two therapeutic strategies were compared: Group 1, minimization of calcineurin inhibitors (N = 6); and Group 2, cyclosporine-based therapy (N = 23), with 15 patients switched from tacrolimus. Hydroxychloroquine was considered in both strategies but antivirals in none. Six patients died after respiratory distress (20.6%). Five required mechanical ventilation (17.2%), and 3 could be weaned. Nineteen patients had an uneventful recovery (65.5%). In group 1, 3 of 6 patients died (50%) and 1 of 6 required invasive mechanical ventilation (16.7%). In group 2, 3 of 23 patients died (12.5%). Renal function did not deteriorate and signs of rejection were not observed in any patient on the second treatment regime. In conclusion, immunosuppressant treatment based on cyclosporine could be safe and effective for KTRs diagnosed with COVID-19.          \r\n        Keywords:      \r\n                  clinical research/practice; health services and outcomes research; immunosuppressant; kidney disease: infectious; kidney transplantation / nephrology.","article_type":"Original","study_type":"Case Report","number_of_patients":1,"article_patient_number":"2","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"41-50 years","sex":"Male","ethnicity":null,"country_contracted":"Spain","country_treated":"Spain","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":true,"cardiovascular_disease":true,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"Status renal transplant in 2003 on tacrolimus and mycophenolate, dyslipidemia","pregnant":false,"unknown":false,"site_of_disease":"lungs","clinical_syndrome":"respiratory tract infection, fever, myalgia","severity":"ICU/Critical Care","prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"After a period of follow-up","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"This patient has a medical history of high blood pressure, dyslipemia, and a kidney transplant in 2003. Their immunosuppression regimen ad admission included tacrolimus and sodium mycophenolate and was adjusted to only include low dose tacrolimus. 24 days after admission, they were switched to cyclosporin and tacrolimus was discontinued. This patient received anticoagulants, was in the ICU and had invasive mechanical ventilation.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[8342,9077,10521,10776]},{"id":6521,"regimens":[{"id":12805,"duration":{"id":6767,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":10827,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12805},{"id":10828,"answer":"In a novel combination with another drug","answer_other":"","regimen":12805}],"created":"2020-11-20T19:49:31.152978Z","updated":"2020-11-25T13:21:10.132538Z","dose":"200 mg","frequency":"BID","route":"PO","severity":"Inpatient","severity_detail":"","comments":null,"report":6521},{"id":12806,"duration":{"id":6768,"approximate_duration":null,"dates_unknown":false},"drug":{"id":9077,"name":"Methylprednisolone","url":"cure-api2.ncats.io/v1/drugs/9077","rxNorm_id":null,"notes":null},"use_drug":[{"id":10829,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12806},{"id":10830,"answer":"In a novel combination with another drug","answer_other":"","regimen":12806}],"created":"2020-11-20T19:49:31.160656Z","updated":"2020-11-25T13:21:10.139133Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6521},{"id":12808,"duration":{"id":6770,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":10831,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12808},{"id":10832,"answer":"In a novel combination with another drug","answer_other":"","regimen":12808}],"created":"2020-11-20T19:55:23.193201Z","updated":"2020-11-25T13:21:10.144984Z","dose":"1200 mg","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6521},{"id":12944,"duration":null,"drug":{"id":9905,"name":"Prednisolone","url":"cure-api2.ncats.io/v1/drugs/9905","rxNorm_id":null,"notes":null},"use_drug":[{"id":11095,"answer":"Other","answer_other":"As immunosuppressive therapy","regimen":12944}],"created":"2020-11-25T13:21:10.168468Z","updated":"2020-11-25T13:21:10.172721Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6521}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8575,"answer":"Clinical assessment","answer_other":"","report":6521}],"how_diagnosis":[{"id":14674,"answer":"Clinical assessment","answer_other":"","report":6521},{"id":14675,"answer":"PCR","answer_other":"","report":6521}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4682,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6521}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":550,"name":"Respiratory Tract Infections"}],"races":[],"created":"2020-11-20T19:47:59.148888Z","updated":"2020-11-25T13:21:10.124483Z","title":"Should cyclosporine be useful in renal transplant recipients affected by SARS-CoV-2? Case 3.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32529737,"doi":"10.1111/ajt.16141","article_url":"https://pubmed.ncbi.nlm.nih.gov/32529737/","pub_year":2020,"published_authors":"Rodriguez-Cubillo B\r\nde la Higuera MAM\r\nLucena R\r\nFranci EV\r\nHurtado M\r\nRomero NC\r\nMoreno AR\r\nValencia D\r\nVelo M\r\nFornie IS\r\nSanchez-Fructuoso AI","article_author_email":"Author email could not be found.","journal":"American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons","abstract":"Minimization of immunosuppression and administration of antiretrovirals have been recommended for kidney transplant recipients (KTRs) with coronavirus disease 2019 (COVID-19). However, outcomes remain poor. Given the likely benefit of cyclosporine because of its antiviral and immunomodulatory effect, we have been using it as a strategy in KTRs diagnosed with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We studied 29 kidney transplant recipients (KTRs) who were admitted to our institution with COVID-19 between March 15and April, 24, 2020. Mycophenolate and/or mammalian target of rapamycin inhibitors (mTORi) were discontinued in all patients. Two therapeutic strategies were compared: Group 1, minimization of calcineurin inhibitors (N = 6); and Group 2, cyclosporine-based therapy (N = 23), with 15 patients switched from tacrolimus. Hydroxychloroquine was considered in both strategies but antivirals in none. Six patients died after respiratory distress (20.6%). Five required mechanical ventilation (17.2%), and 3 could be weaned. Nineteen patients had an uneventful recovery (65.5%). In group 1, 3 of 6 patients died (50%) and 1 of 6 required invasive mechanical ventilation (16.7%). In group 2, 3 of 23 patients died (12.5%). Renal function did not deteriorate and signs of rejection were not observed in any patient on the second treatment regime. In conclusion, immunosuppressant treatment based on cyclosporine could be safe and effective for KTRs diagnosed with COVID-19.          \r\n        Keywords:      \r\n                  clinical research/practice; health services and outcomes research; immunosuppressant; kidney disease: infectious; kidney transplantation / nephrology.","article_type":"Original","study_type":"Case Report","number_of_patients":29,"article_patient_number":"3","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"71-80 years","sex":"Male","ethnicity":null,"country_contracted":"Spain","country_treated":"Spain","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":true,"cardiovascular_disease":true,"chronic_renal_disease":true,"chronic_liver_disease":false,"immunosuppressant_drugs":true,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"Post renal transplant in 2012 on tacrolimus, rapamycin and prednisolone, dyslipidemia","pregnant":false,"unknown":false,"site_of_disease":"lungs","clinical_syndrome":"respiratory tract infection, fever, myalgia, diarrhea, cough","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"After a period of follow-up","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"This patient has a medical history including high blood pressure, dyslipemia, and they had a second kidney transplant in 2012. At the time of admission, their immunosuppression regimen included tacrolimus, prednisone, and rapamycin, upon admission it was changes to only prednisone, and switched to cyclosporin 15 days after admission. They also received anticoagulation therapy.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[8342,9077,9905,10776]},{"id":6523,"regimens":[{"id":12879,"duration":{"id":6841,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6916,"name":"Clarithromycin","url":"cure-api2.ncats.io/v1/drugs/6916","rxNorm_id":null,"notes":null},"use_drug":[{"id":10966,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12879},{"id":10967,"answer":"In a novel combination with another drug","answer_other":"","regimen":12879}],"created":"2020-11-23T18:08:45.330465Z","updated":"2020-11-24T18:45:24.191069Z","dose":"1000mg","frequency":"","route":"PO","severity":"Inpatient","severity_detail":"Low flow oxygen therapy","comments":null,"report":6523},{"id":12880,"duration":{"id":6842,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":10968,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12880},{"id":10969,"answer":"In a novel combination with another drug","answer_other":"","regimen":12880}],"created":"2020-11-23T18:08:45.338026Z","updated":"2020-11-24T18:45:24.197260Z","dose":"800mg loading dose, then 400mg daily","frequency":"q1d","route":"PO","severity":"Inpatient","severity_detail":"Low flow oxygen therapy","comments":null,"report":6523},{"id":12881,"duration":{"id":6843,"approximate_duration":null,"dates_unknown":false},"drug":{"id":11417,"name":"Tilorone","url":"cure-api2.ncats.io/v1/drugs/11417","rxNorm_id":null,"notes":null},"use_drug":[{"id":10970,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12881},{"id":10971,"answer":"In a novel combination with another drug","answer_other":"","regimen":12881}],"created":"2020-11-23T18:08:45.344327Z","updated":"2020-11-24T18:45:24.202819Z","dose":"125 mg","frequency":"q1d","route":"PO","severity":"Inpatient","severity_detail":"Low flow oxygen therapy","comments":null,"report":6523},{"id":12882,"duration":{"id":6844,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6675,"name":"Ceftriaxone","url":"cure-api2.ncats.io/v1/drugs/6675","rxNorm_id":null,"notes":null},"use_drug":[{"id":11081,"answer":"Other","answer_other":"Likely given for bacterial cover","regimen":12882}],"created":"2020-11-23T18:08:45.351230Z","updated":"2020-11-24T18:45:24.291095Z","dose":"2000mg/day","frequency":"","route":"IV","severity":"Inpatient","severity_detail":"Low flow oxygen therapy","comments":null,"report":6523},{"id":12883,"duration":{"id":6845,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8783,"name":"Lopinavir-Ritonavir","url":"cure-api2.ncats.io/v1/drugs/8783","rxNorm_id":null,"notes":null},"use_drug":[{"id":10982,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12883},{"id":10983,"answer":"In a novel combination with another drug","answer_other":"","regimen":12883}],"created":"2020-11-23T18:08:45.357133Z","updated":"2020-11-24T18:45:24.291957Z","dose":"800mg/200mg","frequency":"OD","route":"PO","severity":"Inpatient","severity_detail":"Low flow oxygen therapy","comments":null,"report":6523},{"id":12885,"duration":{"id":6847,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10942,"name":"Umifenovir","url":"cure-api2.ncats.io/v1/drugs/10942","rxNorm_id":null,"notes":null},"use_drug":[{"id":10986,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12885},{"id":10987,"answer":"In a novel combination with another drug","answer_other":"","regimen":12885}],"created":"2020-11-23T18:08:45.370473Z","updated":"2020-11-24T18:45:24.224676Z","dose":"400mg/daily","frequency":"","route":"PO","severity":"Inpatient","severity_detail":"Low flow oxygen therapy","comments":null,"report":6523},{"id":12886,"duration":{"id":6848,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8971,"name":"Meropenem","url":"cure-api2.ncats.io/v1/drugs/8971","rxNorm_id":null,"notes":null},"use_drug":[{"id":11082,"answer":"Other","answer_other":"Given for bacterial cover","regimen":12886}],"created":"2020-11-23T18:08:45.376678Z","updated":"2020-11-24T18:45:24.295028Z","dose":"3000mg/daily","frequency":"","route":"IV","severity":"Inpatient","severity_detail":"Low flow oxygen therapy","comments":null,"report":6523},{"id":12887,"duration":{"id":6849,"approximate_duration":"4 Days, 3 Days","dates_unknown":true},"drug":{"id":9077,"name":"Methylprednisolone","url":"cure-api2.ncats.io/v1/drugs/9077","rxNorm_id":null,"notes":null},"use_drug":[{"id":10990,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12887},{"id":10991,"answer":"In a novel combination with another drug","answer_other":"","regimen":12887}],"created":"2020-11-23T18:08:45.383024Z","updated":"2020-11-24T18:45:24.235424Z","dose":"125mg, later 1000mg daily","frequency":"","route":"IV","severity":"ICU/Critical Care","severity_detail":"High flow oxygen therapy","comments":null,"report":6523},{"id":12888,"duration":{"id":6850,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":10992,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12888},{"id":10993,"answer":"In a novel combination with another drug","answer_other":"","regimen":12888}],"created":"2020-11-23T18:08:45.388588Z","updated":"2020-11-24T18:45:24.240878Z","dose":"400mg","frequency":"1qd","route":"IV","severity":"ICU/Critical Care","severity_detail":"High flow oxygen therapy","comments":null,"report":6523},{"id":12889,"duration":{"id":6851,"approximate_duration":"3 Days","dates_unknown":true},"drug":{"id":8412,"name":"Immunoglobulins, Intravenous","url":"cure-api2.ncats.io/v1/drugs/8412","rxNorm_id":null,"notes":null},"use_drug":[{"id":10996,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12889},{"id":10997,"answer":"In a novel combination with another drug","answer_other":"","regimen":12889}],"created":"2020-11-23T18:08:45.396216Z","updated":"2020-11-24T18:45:24.246575Z","dose":"20g/day","frequency":"","route":"IV","severity":"ICU/Critical Care","severity_detail":"High flow oxygen therapy","comments":null,"report":6523}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8613,"answer":"Clinical assessment","answer_other":"","report":6523},{"id":8614,"answer":"Imaging","answer_other":"","report":6523},{"id":8615,"answer":"PCR","answer_other":"","report":6523}],"how_diagnosis":[{"id":14679,"answer":"Clinical assessment","answer_other":"","report":6523},{"id":14680,"answer":"Imaging","answer_other":"","report":6523},{"id":14681,"answer":"PCR","answer_other":"","report":6523}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4685,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6523}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-11-21T00:05:22.565748Z","updated":"2020-11-24T18:45:24.182959Z","title":"Pulse Therapy With Corticosteroids and Intravenous Immunoglobulin in the Management of Severe Tocilizumab-Resistant COVID-19: A Report of Three Clinical Cases. Case 1.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32656044,"doi":"10.7759/cureus.9038","article_url":"https://pubmed.ncbi.nlm.nih.gov/32656044/","pub_year":2020,"published_authors":"Sheianov MV\r\nUdalov YD\r\nOchkin SS\r\nBashkov AN\r\nSamoilov AS","article_author_email":"msheyanov@mail.ru","journal":"Cureus","abstract":"We present the cases of three patients with severe, life-threatening coronavirus disease 2019 (COVID-19) who had failed to achieve substantial improvement on intial treatment. They subsequently received pulse therapy with methylprednisolone [1,000 mg/day intravenously (IV) for three consecutive days] and IV immunoglobulin (20 g/day). This treatment regimen was associated with a prompt resolution of respiratory failure, elimination of clinical manifestations of the cytokine release syndrome (CRS), and reversal of pulmonary CT changes. The treatment was generally safe and well-tolerated. There was no evidence of protracted persistence of the virus in the patients. Further randomized controlled trials are required to better understand the efficacy and safety of high-dose methylprednisolone and IV immunoglobulin, separately or in combination with each other, in the treatment of severe, life-threatening COVID-19.          \r\n        Keywords:      \r\n                  corticosteroids; covid-19; cytokine release syndrome; immunoglobulin; methylprednisolone; pulse therapy; sars-cov-2.","article_type":"Original","study_type":"Case Report","number_of_patients":3,"article_patient_number":"","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"No","age":"61-70 years","sex":"Female","ethnicity":null,"country_contracted":"Russian Federation","country_treated":"Russian Federation","began_treatment_year":"2020","hiv":false,"asthma":true,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"Obesity","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Bilateral multilobar pneumonia, acute respiratory failure","severity":"ICU/Critical Care","prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"The first SARS-CoV-2-negative nasopharyngeal swab was obtained on day 20 and confirmed two days later.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6675,6916,8342,8412,8783,8971,9077,11417,10776,10942]},{"id":6530,"regimens":[{"id":12824,"duration":{"id":6786,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":10861,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12824},{"id":10862,"answer":"In a novel combination with another drug","answer_other":"","regimen":12824}],"created":"2020-11-21T19:32:21.065179Z","updated":"2020-11-25T17:18:45.776804Z","dose":"200 mg","frequency":"BID","route":"PO","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6530},{"id":12825,"duration":{"id":6787,"approximate_duration":null,"dates_unknown":false},"drug":{"id":9077,"name":"Methylprednisolone","url":"cure-api2.ncats.io/v1/drugs/9077","rxNorm_id":null,"notes":null},"use_drug":[{"id":10863,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12825},{"id":10864,"answer":"In a novel combination with another drug","answer_other":"","regimen":12825}],"created":"2020-11-21T19:32:21.073530Z","updated":"2020-11-25T17:18:45.783601Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6530},{"id":12826,"duration":{"id":6788,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":10865,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12826},{"id":10866,"answer":"In a novel combination with another drug","answer_other":"","regimen":12826}],"created":"2020-11-21T19:32:21.079948Z","updated":"2020-11-25T17:18:45.789621Z","dose":"600 mg","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6530},{"id":12954,"duration":null,"drug":{"id":7117,"name":"Cyclosporine","url":"cure-api2.ncats.io/v1/drugs/7117","rxNorm_id":null,"notes":null},"use_drug":[{"id":11105,"answer":"Other","answer_other":"Immunosupression","regimen":12954}],"created":"2020-11-25T17:18:45.812304Z","updated":"2020-11-25T17:18:45.820373Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6530},{"id":12955,"duration":null,"drug":{"id":9905,"name":"Prednisolone","url":"cure-api2.ncats.io/v1/drugs/9905","rxNorm_id":null,"notes":null},"use_drug":[{"id":11106,"answer":"Other","answer_other":"Immunosuppression","regimen":12955}],"created":"2020-11-25T17:18:45.816545Z","updated":"2020-11-25T17:18:45.821207Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6530}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8582,"answer":"Clinical assessment","answer_other":"","report":6530}],"how_diagnosis":[{"id":14696,"answer":"Clinical assessment","answer_other":"","report":6530},{"id":14697,"answer":"Imaging","answer_other":"","report":6530},{"id":14698,"answer":"PCR","answer_other":"","report":6530}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4692,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6530}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"},{"id":550,"name":"Respiratory Tract Infections"}],"races":[{"id":513,"answer":"Native Hawaiian or Other Pacific Islander","answer_other":""}],"created":"2020-11-21T19:30:28.613952Z","updated":"2020-11-25T17:18:45.768345Z","title":"Should cyclosporine be useful in renal transplant recipients affected by SARS-CoV-2? Case 10.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32529737,"doi":"10.1111/ajt.16141","article_url":"https://pubmed.ncbi.nlm.nih.gov/32529737/","pub_year":2020,"published_authors":"Rodriguez-Cubillo B\r\nde la Higuera MAM\r\nLucena R\r\nFranci EV\r\nHurtado M\r\nRomero NC\r\nMoreno AR\r\nValencia D\r\nVelo M\r\nFornie IS\r\nSanchez-Fructuoso AI","article_author_email":"Author email could not be found.","journal":"American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons","abstract":"Minimization of immunosuppression and administration of antiretrovirals have been recommended for kidney transplant recipients (KTRs) with coronavirus disease 2019 (COVID-19). However, outcomes remain poor. Given the likely benefit of cyclosporine because of its antiviral and immunomodulatory effect, we have been using it as a strategy in KTRs diagnosed with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We studied 29 kidney transplant recipients (KTRs) who were admitted to our institution with COVID-19 between March 15and April, 24, 2020. Mycophenolate and/or mammalian target of rapamycin inhibitors (mTORi) were discontinued in all patients. Two therapeutic strategies were compared: Group 1, minimization of calcineurin inhibitors (N = 6); and Group 2, cyclosporine-based therapy (N = 23), with 15 patients switched from tacrolimus. Hydroxychloroquine was considered in both strategies but antivirals in none. Six patients died after respiratory distress (20.6%). Five required mechanical ventilation (17.2%), and 3 could be weaned. Nineteen patients had an uneventful recovery (65.5%). In group 1, 3 of 6 patients died (50%) and 1 of 6 required invasive mechanical ventilation (16.7%). In group 2, 3 of 23 patients died (12.5%). Renal function did not deteriorate and signs of rejection were not observed in any patient on the second treatment regime. In conclusion, immunosuppressant treatment based on cyclosporine could be safe and effective for KTRs diagnosed with COVID-19.          \r\n        Keywords:      \r\n                  clinical research/practice; health services and outcomes research; immunosuppressant; kidney disease: infectious; kidney transplantation / nephrology.","article_type":"Original","study_type":"Case Report","number_of_patients":29,"article_patient_number":"10","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"61-70 years","sex":"Male","ethnicity":null,"country_contracted":"Spain","country_treated":"Spain","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":true,"hypertension":true,"cardiovascular_disease":false,"chronic_renal_disease":true,"chronic_liver_disease":false,"immunosuppressant_drugs":true,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"kidney transplant recipient in 2006 on tacrolimus, mycophenolate and pednisolone. Dyslipidemia.","pregnant":false,"unknown":false,"site_of_disease":"lungs","clinical_syndrome":"respiratory tract infection, fever, myalgia, diarrhea, dyspnea","severity":"ICU/Critical Care","prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"After a period of follow-up","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"This patient has a medical history including a kidney transplant in 2006, high blood pressure, and diabetes. At the time of admission, their immunosuppression treatment included tacrolimus, sodium mycophenolate, and prednisone. It was changes to cyclosporin and prednisone five days after admission. This patient received anti-coagulation treatment, supplemental oxygen via nasal glasses, and invasive mechanical ventilation.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[7117,8342,9077,9905,10776]},{"id":6531,"regimens":[{"id":12827,"duration":{"id":6789,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":10867,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12827},{"id":10868,"answer":"In a novel combination with another drug","answer_other":"","regimen":12827}],"created":"2020-11-21T19:53:36.208197Z","updated":"2020-11-25T17:24:09.911934Z","dose":"200 mg","frequency":"BID","route":"PO","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6531},{"id":12828,"duration":{"id":6790,"approximate_duration":null,"dates_unknown":false},"drug":{"id":9077,"name":"Methylprednisolone","url":"cure-api2.ncats.io/v1/drugs/9077","rxNorm_id":null,"notes":null},"use_drug":[{"id":10869,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12828},{"id":10870,"answer":"In a novel combination with another drug","answer_other":"","regimen":12828}],"created":"2020-11-21T19:53:36.216231Z","updated":"2020-11-25T17:24:09.918768Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6531},{"id":12829,"duration":{"id":6791,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":10871,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12829},{"id":10872,"answer":"In a novel combination with another drug","answer_other":"","regimen":12829}],"created":"2020-11-21T19:53:36.222700Z","updated":"2020-11-25T17:24:09.924359Z","dose":"600 mg","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6531},{"id":12956,"duration":null,"drug":{"id":7117,"name":"Cyclosporine","url":"cure-api2.ncats.io/v1/drugs/7117","rxNorm_id":null,"notes":null},"use_drug":[{"id":11107,"answer":"Other","answer_other":"Immuno suppression","regimen":12956}],"created":"2020-11-25T17:24:09.947708Z","updated":"2020-11-25T17:24:09.956098Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6531},{"id":12957,"duration":null,"drug":{"id":9905,"name":"Prednisolone","url":"cure-api2.ncats.io/v1/drugs/9905","rxNorm_id":null,"notes":null},"use_drug":[{"id":11108,"answer":"Other","answer_other":"Immuno suppression","regimen":12957}],"created":"2020-11-25T17:24:09.952023Z","updated":"2020-11-25T17:24:09.956976Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6531}],"site_of_infection":[],"specific_site":[],"how_outcome":[],"how_diagnosis":[{"id":14699,"answer":"Clinical assessment","answer_other":"","report":6531},{"id":14700,"answer":"PCR","answer_other":"","report":6531},{"id":14701,"answer":"Imaging","answer_other":"","report":6531}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Deteriorated","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4693,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6531}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"},{"id":550,"name":"Respiratory Tract Infections"}],"races":[],"created":"2020-11-21T19:52:19.978571Z","updated":"2020-11-25T17:24:09.903059Z","title":"Should cyclosporine be useful in renal transplant recipients affected by SARS-CoV-2? Case 11.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32529737,"doi":"10.1111/ajt.16141","article_url":"https://pubmed.ncbi.nlm.nih.gov/32529737/","pub_year":2020,"published_authors":"Rodriguez-Cubillo B\r\nde la Higuera MAM\r\nLucena R\r\nFranci EV\r\nHurtado M\r\nRomero NC\r\nMoreno AR\r\nValencia D\r\nVelo M\r\nFornie IS\r\nSanchez-Fructuoso AI","article_author_email":"Author email could not be found.","journal":"American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons","abstract":"Minimization of immunosuppression and administration of antiretrovirals have been recommended for kidney transplant recipients (KTRs) with coronavirus disease 2019 (COVID-19). However, outcomes remain poor. Given the likely benefit of cyclosporine because of its antiviral and immunomodulatory effect, we have been using it as a strategy in KTRs diagnosed with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We studied 29 kidney transplant recipients (KTRs) who were admitted to our institution with COVID-19 between March 15and April, 24, 2020. Mycophenolate and/or mammalian target of rapamycin inhibitors (mTORi) were discontinued in all patients. Two therapeutic strategies were compared: Group 1, minimization of calcineurin inhibitors (N = 6); and Group 2, cyclosporine-based therapy (N = 23), with 15 patients switched from tacrolimus. Hydroxychloroquine was considered in both strategies but antivirals in none. Six patients died after respiratory distress (20.6%). Five required mechanical ventilation (17.2%), and 3 could be weaned. Nineteen patients had an uneventful recovery (65.5%). In group 1, 3 of 6 patients died (50%) and 1 of 6 required invasive mechanical ventilation (16.7%). In group 2, 3 of 23 patients died (12.5%). Renal function did not deteriorate and signs of rejection were not observed in any patient on the second treatment regime. In conclusion, immunosuppressant treatment based on cyclosporine could be safe and effective for KTRs diagnosed with COVID-19.          \r\n        Keywords:      \r\n                  clinical research/practice; health services and outcomes research; immunosuppressant; kidney disease: infectious; kidney transplantation / nephrology.","article_type":"Original","study_type":"Case Report","number_of_patients":29,"article_patient_number":"11","full_text_available":true,"outcome":"Patient died","surgery":"No","age":"41-50 years","sex":"Male","ethnicity":null,"country_contracted":"Spain","country_treated":"Spain","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":true,"cardiovascular_disease":false,"chronic_renal_disease":true,"chronic_liver_disease":false,"immunosuppressant_drugs":true,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"Dyslipidemia, kidney transplant recipient in 2005 on mycophenolate, cyclosporine, and prednisolone.","pregnant":false,"unknown":false,"site_of_disease":"lungs","clinical_syndrome":"pneumonia, respiratory tact infection, fever, myalgia, dyspnea, diarrhea","severity":"ICU/Critical Care","prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"While the patient was still on treatment","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"This patient has a medical history including a kidney transplant in 2005, high blood pressure, and dyslipidemia. At the time of admission, their immunosuppression treatment included cyclosporin, sodium mycophenolate, prednisolone. It was changed to only cyclosporin and prednisone upon admission. They received supplemental oxygen via venturi mask, underwent invasive mechanical ventilation, and anti-coagulation treatment. This patient suffered from an acute kidney injury and underwent hemodialysis starting on the first day after admission.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[7117,8342,9077,9905,10776]},{"id":6532,"regimens":[{"id":12830,"duration":{"id":6792,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":10873,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12830},{"id":10874,"answer":"In a novel combination with another drug","answer_other":"","regimen":12830}],"created":"2020-11-21T20:20:55.073816Z","updated":"2020-11-25T17:28:52.552322Z","dose":"200 mg","frequency":"BID","route":"PO","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6532},{"id":12831,"duration":{"id":6793,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8412,"name":"Immunoglobulins, Intravenous","url":"cure-api2.ncats.io/v1/drugs/8412","rxNorm_id":null,"notes":null},"use_drug":[{"id":10875,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12831},{"id":10876,"answer":"In a novel combination with another drug","answer_other":"","regimen":12831}],"created":"2020-11-21T20:20:55.081696Z","updated":"2020-11-25T17:28:52.558836Z","dose":"10 g/kg","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6532},{"id":12832,"duration":{"id":6794,"approximate_duration":null,"dates_unknown":false},"drug":{"id":9077,"name":"Methylprednisolone","url":"cure-api2.ncats.io/v1/drugs/9077","rxNorm_id":null,"notes":null},"use_drug":[{"id":10877,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12832},{"id":10878,"answer":"In a novel combination with another drug","answer_other":"","regimen":12832}],"created":"2020-11-21T20:20:55.087992Z","updated":"2020-11-25T17:28:52.564771Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6532},{"id":12833,"duration":{"id":6795,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":10879,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12833},{"id":10880,"answer":"In a novel combination with another drug","answer_other":"","regimen":12833}],"created":"2020-11-21T20:20:55.094170Z","updated":"2020-11-25T17:28:52.570516Z","dose":"600 mg","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6532},{"id":12958,"duration":null,"drug":{"id":7117,"name":"Cyclosporine","url":"cure-api2.ncats.io/v1/drugs/7117","rxNorm_id":null,"notes":null},"use_drug":[{"id":11109,"answer":"Other","answer_other":"Immunosuppression","regimen":12958}],"created":"2020-11-25T17:28:52.594987Z","updated":"2020-11-25T17:28:52.602739Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6532},{"id":12959,"duration":null,"drug":{"id":9905,"name":"Prednisolone","url":"cure-api2.ncats.io/v1/drugs/9905","rxNorm_id":null,"notes":null},"use_drug":[{"id":11110,"answer":"Other","answer_other":"Immunosuppression","regimen":12959}],"created":"2020-11-25T17:28:52.599044Z","updated":"2020-11-25T17:28:52.603584Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6532}],"site_of_infection":[],"specific_site":[],"how_outcome":[],"how_diagnosis":[{"id":14702,"answer":"Clinical assessment","answer_other":"","report":6532},{"id":14703,"answer":"PCR","answer_other":"","report":6532},{"id":14704,"answer":"Imaging","answer_other":"","report":6532}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Deteriorated","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4694,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6532}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"},{"id":550,"name":"Respiratory Tract Infections"}],"races":[],"created":"2020-11-21T20:19:26.456388Z","updated":"2020-11-25T17:28:52.543958Z","title":"Should cyclosporine be useful in renal transplant recipients affected by SARS-CoV-2? Case 12.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32529737,"doi":"10.1111/ajt.16141","article_url":"https://pubmed.ncbi.nlm.nih.gov/32529737/","pub_year":2020,"published_authors":"Rodriguez-Cubillo B\r\nde la Higuera MAM\r\nLucena R\r\nFranci EV\r\nHurtado M\r\nRomero NC\r\nMoreno AR\r\nValencia D\r\nVelo M\r\nFornie IS\r\nSanchez-Fructuoso AI","article_author_email":"Author email could not be found.","journal":"American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons","abstract":"Minimization of immunosuppression and administration of antiretrovirals have been recommended for kidney transplant recipients (KTRs) with coronavirus disease 2019 (COVID-19). However, outcomes remain poor. Given the likely benefit of cyclosporine because of its antiviral and immunomodulatory effect, we have been using it as a strategy in KTRs diagnosed with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We studied 29 kidney transplant recipients (KTRs) who were admitted to our institution with COVID-19 between March 15and April, 24, 2020. Mycophenolate and/or mammalian target of rapamycin inhibitors (mTORi) were discontinued in all patients. Two therapeutic strategies were compared: Group 1, minimization of calcineurin inhibitors (N = 6); and Group 2, cyclosporine-based therapy (N = 23), with 15 patients switched from tacrolimus. Hydroxychloroquine was considered in both strategies but antivirals in none. Six patients died after respiratory distress (20.6%). Five required mechanical ventilation (17.2%), and 3 could be weaned. Nineteen patients had an uneventful recovery (65.5%). In group 1, 3 of 6 patients died (50%) and 1 of 6 required invasive mechanical ventilation (16.7%). In group 2, 3 of 23 patients died (12.5%). Renal function did not deteriorate and signs of rejection were not observed in any patient on the second treatment regime. In conclusion, immunosuppressant treatment based on cyclosporine could be safe and effective for KTRs diagnosed with COVID-19.          \r\n        Keywords:      \r\n                  clinical research/practice; health services and outcomes research; immunosuppressant; kidney disease: infectious; kidney transplantation / nephrology.","article_type":"Original","study_type":"Case Report","number_of_patients":29,"article_patient_number":"12","full_text_available":true,"outcome":"Patient died","surgery":"No","age":"61-70 years","sex":"Male","ethnicity":null,"country_contracted":"Spain","country_treated":"Spain","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":true,"hypertension":true,"cardiovascular_disease":false,"chronic_renal_disease":true,"chronic_liver_disease":false,"immunosuppressant_drugs":true,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"kidney transplant recipient in 2020 on tacrolimus, mycophenolate and prednisolone. Dyslipidemia.","pregnant":false,"unknown":false,"site_of_disease":"lungs","clinical_syndrome":"respiratory tract infection, pneumonia, fever, dyspnea, myalgia, diarrhea","severity":"ICU/Critical Care","prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"While the patient was still on treatment","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"This patient has a medical history including a kidney transplant in 2020, high blood pressure, dyslipidemia, and diabetes. Their immunosuppression treatment includes tacrolimus, sodium mycophenolate, and prednisone. It was changed to cyclosporin and prednisone on the third day after admission. This patient received supplemental oxygen via venturi mask, invasive mechanical ventilation, anti-coagulation treatment, hemodialysis starting three days after admission. This patient suffered from an acute kidney injury.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[7117,8342,8412,9077,9905,10776]},{"id":6536,"regimens":[{"id":12839,"duration":{"id":6801,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":10890,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12839},{"id":10891,"answer":"In a novel combination with another drug","answer_other":"","regimen":12839}],"created":"2020-11-21T21:23:59.910734Z","updated":"2020-11-25T17:48:39.659073Z","dose":"200 mg","frequency":"BID","route":"PO","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6536},{"id":12840,"duration":{"id":6802,"approximate_duration":null,"dates_unknown":false},"drug":{"id":9077,"name":"Methylprednisolone","url":"cure-api2.ncats.io/v1/drugs/9077","rxNorm_id":null,"notes":null},"use_drug":[{"id":10893,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12840},{"id":10892,"answer":"In a novel combination with another drug","answer_other":"","regimen":12840}],"created":"2020-11-21T21:23:59.918690Z","updated":"2020-11-25T17:48:39.665843Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6536},{"id":12841,"duration":{"id":6803,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":10894,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12841},{"id":10895,"answer":"In a novel combination with another drug","answer_other":"","regimen":12841}],"created":"2020-11-21T21:23:59.925230Z","updated":"2020-11-25T17:48:39.671802Z","dose":"400 mg","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6536},{"id":12968,"duration":null,"drug":{"id":9905,"name":"Prednisolone","url":"cure-api2.ncats.io/v1/drugs/9905","rxNorm_id":null,"notes":null},"use_drug":[{"id":11121,"answer":"Other","answer_other":"Immune suppression","regimen":12968}],"created":"2020-11-25T17:48:39.694600Z","updated":"2020-11-25T17:48:39.702619Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6536},{"id":12969,"duration":null,"drug":{"id":7117,"name":"Cyclosporine","url":"cure-api2.ncats.io/v1/drugs/7117","rxNorm_id":null,"notes":null},"use_drug":[{"id":11122,"answer":"Other","answer_other":"Immune suppression","regimen":12969}],"created":"2020-11-25T17:48:39.698716Z","updated":"2020-11-25T17:48:39.703474Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6536}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8586,"answer":"Clinical assessment","answer_other":"","report":6536}],"how_diagnosis":[{"id":14713,"answer":"Clinical assessment","answer_other":"","report":6536},{"id":14714,"answer":"PCR","answer_other":"","report":6536},{"id":14715,"answer":"Imaging","answer_other":"","report":6536}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4698,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6536}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"},{"id":550,"name":"Respiratory Tract Infections"}],"races":[],"created":"2020-11-21T21:22:12.661650Z","updated":"2020-11-25T17:48:39.650674Z","title":"Should cyclosporine be useful in renal transplant recipients affected by SARS-CoV-2? Case 16.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32529737,"doi":"10.1111/ajt.16141","article_url":"https://pubmed.ncbi.nlm.nih.gov/32529737/","pub_year":2020,"published_authors":"Rodriguez-Cubillo B\r\nde la Higuera MAM\r\nLucena R\r\nFranci EV\r\nHurtado M\r\nRomero NC\r\nMoreno AR\r\nValencia D\r\nVelo M\r\nFornie IS\r\nSanchez-Fructuoso AI","article_author_email":"Author email could not be found.","journal":"American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons","abstract":"Minimization of immunosuppression and administration of antiretrovirals have been recommended for kidney transplant recipients (KTRs) with coronavirus disease 2019 (COVID-19). However, outcomes remain poor. Given the likely benefit of cyclosporine because of its antiviral and immunomodulatory effect, we have been using it as a strategy in KTRs diagnosed with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We studied 29 kidney transplant recipients (KTRs) who were admitted to our institution with COVID-19 between March 15and April, 24, 2020. Mycophenolate and/or mammalian target of rapamycin inhibitors (mTORi) were discontinued in all patients. Two therapeutic strategies were compared: Group 1, minimization of calcineurin inhibitors (N = 6); and Group 2, cyclosporine-based therapy (N = 23), with 15 patients switched from tacrolimus. Hydroxychloroquine was considered in both strategies but antivirals in none. Six patients died after respiratory distress (20.6%). Five required mechanical ventilation (17.2%), and 3 could be weaned. Nineteen patients had an uneventful recovery (65.5%). In group 1, 3 of 6 patients died (50%) and 1 of 6 required invasive mechanical ventilation (16.7%). In group 2, 3 of 23 patients died (12.5%). Renal function did not deteriorate and signs of rejection were not observed in any patient on the second treatment regime. In conclusion, immunosuppressant treatment based on cyclosporine could be safe and effective for KTRs diagnosed with COVID-19.          \r\n        Keywords:      \r\n                  clinical research/practice; health services and outcomes research; immunosuppressant; kidney disease: infectious; kidney transplantation / nephrology.","article_type":"Original","study_type":"Case Report","number_of_patients":29,"article_patient_number":"16","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"31-40 years","sex":"Female","ethnicity":null,"country_contracted":"Spain","country_treated":"Spain","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":true,"cardiovascular_disease":false,"chronic_renal_disease":true,"chronic_liver_disease":false,"immunosuppressant_drugs":true,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"Dyslipidemia, kidney transplant recipient in 2015 on tacrolimus, rapamycin and prednisolone.","pregnant":false,"unknown":false,"site_of_disease":"lungs","clinical_syndrome":"respiratory tract infection, pneumonia, fever, myalgia, dyspnea","severity":"ICU/Critical Care","prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"After a period of follow-up","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"This patient has a medical history including four kidney transplants, the most recent one in 2015, high blood pressure, and dyslipidemia. Upon admission, their immunosuppressive treatment included tacrolimus, rapamycin, and prednisone. It was changed to only cyclosporin and prednisone one day after admission. They suffered an acute kidney injury from which they recovered. They received anti-coagulation treatment and invasive mechanical ventilation. \r\n\r\nThey suffered from acute kidney injury.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[7117,8342,9077,9905,10776]},{"id":6538,"regimens":[{"id":12844,"duration":{"id":6806,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":10900,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12844},{"id":10901,"answer":"In a novel combination with another drug","answer_other":"","regimen":12844}],"created":"2020-11-21T21:47:35.676825Z","updated":"2020-11-25T18:16:55.251329Z","dose":"200 mg","frequency":"BID","route":"PO","severity":"Inpatient","severity_detail":"","comments":null,"report":6538},{"id":12845,"duration":{"id":6807,"approximate_duration":null,"dates_unknown":false},"drug":{"id":9077,"name":"Methylprednisolone","url":"cure-api2.ncats.io/v1/drugs/9077","rxNorm_id":null,"notes":null},"use_drug":[{"id":10902,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12845},{"id":10903,"answer":"In a novel combination with another drug","answer_other":"","regimen":12845}],"created":"2020-11-21T21:47:35.684071Z","updated":"2020-11-25T18:16:55.258964Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6538},{"id":12846,"duration":{"id":6808,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":10904,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12846},{"id":10905,"answer":"In a novel combination with another drug","answer_other":"","regimen":12846}],"created":"2020-11-21T21:47:35.690133Z","updated":"2020-11-25T18:16:55.264949Z","dose":"600 mg","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6538},{"id":12972,"duration":null,"drug":{"id":7117,"name":"Cyclosporine","url":"cure-api2.ncats.io/v1/drugs/7117","rxNorm_id":null,"notes":null},"use_drug":[{"id":11126,"answer":"Other","answer_other":"Immune suppression","regimen":12972}],"created":"2020-11-25T18:16:55.287872Z","updated":"2020-11-25T18:16:55.296039Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6538},{"id":12973,"duration":null,"drug":{"id":9905,"name":"Prednisolone","url":"cure-api2.ncats.io/v1/drugs/9905","rxNorm_id":null,"notes":null},"use_drug":[{"id":11127,"answer":"Other","answer_other":"Immune suppression","regimen":12973}],"created":"2020-11-25T18:16:55.292129Z","updated":"2020-11-25T18:16:55.296862Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6538}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8588,"answer":"Clinical assessment","answer_other":"","report":6538}],"how_diagnosis":[{"id":14719,"answer":"Clinical assessment","answer_other":"","report":6538},{"id":14720,"answer":"PCR","answer_other":"","report":6538},{"id":14721,"answer":"Imaging","answer_other":"","report":6538}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4700,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6538}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"},{"id":550,"name":"Respiratory Tract Infections"}],"races":[],"created":"2020-11-21T21:46:23.675286Z","updated":"2020-11-25T18:16:55.241685Z","title":"Should cyclosporine be useful in renal transplant recipients affected by SARS-CoV-2? Case 18.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32529737,"doi":"10.1111/ajt.16141","article_url":"https://pubmed.ncbi.nlm.nih.gov/32529737/","pub_year":2020,"published_authors":"Rodriguez-Cubillo B\r\nde la Higuera MAM\r\nLucena R\r\nFranci EV\r\nHurtado M\r\nRomero NC\r\nMoreno AR\r\nValencia D\r\nVelo M\r\nFornie IS\r\nSanchez-Fructuoso AI","article_author_email":"Author email could not be found.","journal":"American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons","abstract":"Minimization of immunosuppression and administration of antiretrovirals have been recommended for kidney transplant recipients (KTRs) with coronavirus disease 2019 (COVID-19). However, outcomes remain poor. Given the likely benefit of cyclosporine because of its antiviral and immunomodulatory effect, we have been using it as a strategy in KTRs diagnosed with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We studied 29 kidney transplant recipients (KTRs) who were admitted to our institution with COVID-19 between March 15and April, 24, 2020. Mycophenolate and/or mammalian target of rapamycin inhibitors (mTORi) were discontinued in all patients. Two therapeutic strategies were compared: Group 1, minimization of calcineurin inhibitors (N = 6); and Group 2, cyclosporine-based therapy (N = 23), with 15 patients switched from tacrolimus. Hydroxychloroquine was considered in both strategies but antivirals in none. Six patients died after respiratory distress (20.6%). Five required mechanical ventilation (17.2%), and 3 could be weaned. Nineteen patients had an uneventful recovery (65.5%). In group 1, 3 of 6 patients died (50%) and 1 of 6 required invasive mechanical ventilation (16.7%). In group 2, 3 of 23 patients died (12.5%). Renal function did not deteriorate and signs of rejection were not observed in any patient on the second treatment regime. In conclusion, immunosuppressant treatment based on cyclosporine could be safe and effective for KTRs diagnosed with COVID-19.          \r\n        Keywords:      \r\n                  clinical research/practice; health services and outcomes research; immunosuppressant; kidney disease: infectious; kidney transplantation / nephrology.","article_type":"Original","study_type":"Case Report","number_of_patients":29,"article_patient_number":"18","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"61-70 years","sex":"Male","ethnicity":null,"country_contracted":"Spain","country_treated":"Spain","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":true,"hypertension":true,"cardiovascular_disease":false,"chronic_renal_disease":true,"chronic_liver_disease":false,"immunosuppressant_drugs":true,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"Dyslipidemia, obesity, kidney transplant recipient on tacrolimus, mycophenolate and prednisolone.","pregnant":false,"unknown":false,"site_of_disease":"lungs","clinical_syndrome":"pneumonia, respiratory tract infection, fever, diarrhea, dyspnea","severity":"Inpatient","prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"After a period of follow-up","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"This patient has a medical history including a kidney transplant in 2011, high blood pressure, dyslipidemia, obesity, diabetes. At the time of admission, this patients immunosuppressive treatment included tacrolimus, sodium mycophenolate, and prednisone. It was changed to cyclosporin and prednisone one day after admission. This patient suffered an acute kidney injury from which they recovered. This patient received anti-coagulation treatment.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[7117,8342,9077,9905,10776]},{"id":6540,"regimens":[{"id":12849,"duration":{"id":6811,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":10910,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12849},{"id":10911,"answer":"In a novel combination with another drug","answer_other":"","regimen":12849}],"created":"2020-11-21T22:14:38.213889Z","updated":"2020-11-25T19:19:24.243454Z","dose":"200 mg","frequency":"BID","route":"PO","severity":"Inpatient","severity_detail":"","comments":null,"report":6540},{"id":12850,"duration":{"id":6812,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8412,"name":"Immunoglobulins, Intravenous","url":"cure-api2.ncats.io/v1/drugs/8412","rxNorm_id":null,"notes":null},"use_drug":[{"id":10912,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12850},{"id":10913,"answer":"In a novel combination with another drug","answer_other":"","regimen":12850}],"created":"2020-11-21T22:14:38.221213Z","updated":"2020-11-25T19:19:24.249655Z","dose":"10 g/kg","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6540},{"id":12851,"duration":{"id":6813,"approximate_duration":null,"dates_unknown":false},"drug":{"id":9077,"name":"Methylprednisolone","url":"cure-api2.ncats.io/v1/drugs/9077","rxNorm_id":null,"notes":null},"use_drug":[{"id":10914,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12851},{"id":10915,"answer":"In a novel combination with another drug","answer_other":"","regimen":12851}],"created":"2020-11-21T22:14:38.227823Z","updated":"2020-11-25T19:19:24.255279Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6540},{"id":12852,"duration":{"id":6814,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":10916,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12852},{"id":10917,"answer":"In a novel combination with another drug","answer_other":"","regimen":12852}],"created":"2020-11-21T22:14:38.234624Z","updated":"2020-11-25T19:19:24.261889Z","dose":"600 mg","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6540},{"id":12980,"duration":null,"drug":{"id":7117,"name":"Cyclosporine","url":"cure-api2.ncats.io/v1/drugs/7117","rxNorm_id":null,"notes":null},"use_drug":[{"id":11137,"answer":"Other","answer_other":"Immune suppresion","regimen":12980}],"created":"2020-11-25T19:19:24.285953Z","updated":"2020-11-25T19:19:24.293601Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6540},{"id":12981,"duration":null,"drug":{"id":9905,"name":"Prednisolone","url":"cure-api2.ncats.io/v1/drugs/9905","rxNorm_id":null,"notes":null},"use_drug":[{"id":11138,"answer":"Other","answer_other":"Immune suppression","regimen":12981}],"created":"2020-11-25T19:19:24.289891Z","updated":"2020-11-25T19:19:24.295301Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6540}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8590,"answer":"Clinical assessment","answer_other":"","report":6540}],"how_diagnosis":[{"id":14725,"answer":"Clinical assessment","answer_other":"","report":6540},{"id":14726,"answer":"PCR","answer_other":"","report":6540},{"id":14727,"answer":"Imaging","answer_other":"","report":6540}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4702,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6540}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"},{"id":550,"name":"Respiratory Tract Infections"}],"races":[],"created":"2020-11-21T22:13:25.910257Z","updated":"2020-11-25T19:19:24.235295Z","title":"Should cyclosporine be useful in renal transplant recipients affected by SARS-CoV-2? Case 20.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32529737,"doi":"10.1111/ajt.16141","article_url":"https://pubmed.ncbi.nlm.nih.gov/32529737/","pub_year":2020,"published_authors":"Rodriguez-Cubillo B\r\nde la Higuera MAM\r\nLucena R\r\nFranci EV\r\nHurtado M\r\nRomero NC\r\nMoreno AR\r\nValencia D\r\nVelo M\r\nFornie IS\r\nSanchez-Fructuoso AI","article_author_email":"Author email could not be found.","journal":"American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons","abstract":"Minimization of immunosuppression and administration of antiretrovirals have been recommended for kidney transplant recipients (KTRs) with coronavirus disease 2019 (COVID-19). However, outcomes remain poor. Given the likely benefit of cyclosporine because of its antiviral and immunomodulatory effect, we have been using it as a strategy in KTRs diagnosed with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We studied 29 kidney transplant recipients (KTRs) who were admitted to our institution with COVID-19 between March 15and April, 24, 2020. Mycophenolate and/or mammalian target of rapamycin inhibitors (mTORi) were discontinued in all patients. Two therapeutic strategies were compared: Group 1, minimization of calcineurin inhibitors (N = 6); and Group 2, cyclosporine-based therapy (N = 23), with 15 patients switched from tacrolimus. Hydroxychloroquine was considered in both strategies but antivirals in none. Six patients died after respiratory distress (20.6%). Five required mechanical ventilation (17.2%), and 3 could be weaned. Nineteen patients had an uneventful recovery (65.5%). In group 1, 3 of 6 patients died (50%) and 1 of 6 required invasive mechanical ventilation (16.7%). In group 2, 3 of 23 patients died (12.5%). Renal function did not deteriorate and signs of rejection were not observed in any patient on the second treatment regime. In conclusion, immunosuppressant treatment based on cyclosporine could be safe and effective for KTRs diagnosed with COVID-19.          \r\n        Keywords:      \r\n                  clinical research/practice; health services and outcomes research; immunosuppressant; kidney disease: infectious; kidney transplantation / nephrology.","article_type":"Original","study_type":"Case Report","number_of_patients":29,"article_patient_number":"20","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"61-70 years","sex":"Male","ethnicity":null,"country_contracted":"Spain","country_treated":"Spain","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":true,"hypertension":true,"cardiovascular_disease":false,"chronic_renal_disease":true,"chronic_liver_disease":false,"immunosuppressant_drugs":true,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"Obesity, kidney transplant recipient in 2019 tacrolimus, mycophenolate, prednisolone.","pregnant":false,"unknown":false,"site_of_disease":"lungs","clinical_syndrome":"respiratory tract infection, pneumonia, fever, diarrhea","severity":"Inpatient","prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"After a period of follow-up","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"This patient has a medical history including a kidney transplant in 2019, obesity, and diabetes. At the time of admission, the patients immunosuppressive treatment included tacrolimus, sodium mycophenolate, and prednisone. It was changed to cyclosporin and prednisone one day after admission. They were administer anti-coagulation treatment and supplemental oxygen via nasal glasses.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[7117,8342,8412,9077,9905,10776]},{"id":6541,"regimens":[{"id":12853,"duration":{"id":6815,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":10918,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12853},{"id":10919,"answer":"In a novel combination with another drug","answer_other":"","regimen":12853}],"created":"2020-11-21T22:25:18.174688Z","updated":"2020-11-25T19:22:41.113312Z","dose":"200 mg","frequency":"BID","route":"PO","severity":"Inpatient","severity_detail":"","comments":null,"report":6541},{"id":12854,"duration":{"id":6816,"approximate_duration":null,"dates_unknown":false},"drug":{"id":9077,"name":"Methylprednisolone","url":"cure-api2.ncats.io/v1/drugs/9077","rxNorm_id":null,"notes":null},"use_drug":[{"id":10920,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12854},{"id":10921,"answer":"In a novel combination with another drug","answer_other":"","regimen":12854}],"created":"2020-11-21T22:25:18.183257Z","updated":"2020-11-25T19:22:41.119893Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6541},{"id":12855,"duration":{"id":6817,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":10922,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12855},{"id":10923,"answer":"In a novel combination with another drug","answer_other":"","regimen":12855}],"created":"2020-11-21T22:25:18.189925Z","updated":"2020-11-25T19:22:41.125656Z","dose":"600 mg","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6541},{"id":12982,"duration":null,"drug":{"id":7117,"name":"Cyclosporine","url":"cure-api2.ncats.io/v1/drugs/7117","rxNorm_id":null,"notes":null},"use_drug":[{"id":11139,"answer":"Other","answer_other":"Immune suppression","regimen":12982}],"created":"2020-11-25T19:22:41.148799Z","updated":"2020-11-25T19:22:41.156782Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6541},{"id":12983,"duration":null,"drug":{"id":9905,"name":"Prednisolone","url":"cure-api2.ncats.io/v1/drugs/9905","rxNorm_id":null,"notes":null},"use_drug":[{"id":11140,"answer":"Other","answer_other":"Immune suppression","regimen":12983}],"created":"2020-11-25T19:22:41.152918Z","updated":"2020-11-25T19:22:41.157694Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6541}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8591,"answer":"Clinical assessment","answer_other":"","report":6541}],"how_diagnosis":[{"id":14728,"answer":"Clinical assessment","answer_other":"","report":6541},{"id":14729,"answer":"PCR","answer_other":"","report":6541},{"id":14730,"answer":"Imaging","answer_other":"","report":6541}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4703,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6541}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"},{"id":550,"name":"Respiratory Tract Infections"}],"races":[],"created":"2020-11-21T22:23:12.869221Z","updated":"2020-11-25T19:22:41.104684Z","title":"Should cyclosporine be useful in renal transplant recipients affected by SARS-CoV-2? Case 21.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32529737,"doi":"10.1111/ajt.16141","article_url":"https://pubmed.ncbi.nlm.nih.gov/32529737/","pub_year":2020,"published_authors":"Rodriguez-Cubillo B\r\nde la Higuera MAM\r\nLucena R\r\nFranci EV\r\nHurtado M\r\nRomero NC\r\nMoreno AR\r\nValencia D\r\nVelo M\r\nFornie IS\r\nSanchez-Fructuoso AI","article_author_email":"Author email could not be found.","journal":"American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons","abstract":"Minimization of immunosuppression and administration of antiretrovirals have been recommended for kidney transplant recipients (KTRs) with coronavirus disease 2019 (COVID-19). However, outcomes remain poor. Given the likely benefit of cyclosporine because of its antiviral and immunomodulatory effect, we have been using it as a strategy in KTRs diagnosed with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We studied 29 kidney transplant recipients (KTRs) who were admitted to our institution with COVID-19 between March 15and April, 24, 2020. Mycophenolate and/or mammalian target of rapamycin inhibitors (mTORi) were discontinued in all patients. Two therapeutic strategies were compared: Group 1, minimization of calcineurin inhibitors (N = 6); and Group 2, cyclosporine-based therapy (N = 23), with 15 patients switched from tacrolimus. Hydroxychloroquine was considered in both strategies but antivirals in none. Six patients died after respiratory distress (20.6%). Five required mechanical ventilation (17.2%), and 3 could be weaned. Nineteen patients had an uneventful recovery (65.5%). In group 1, 3 of 6 patients died (50%) and 1 of 6 required invasive mechanical ventilation (16.7%). In group 2, 3 of 23 patients died (12.5%). Renal function did not deteriorate and signs of rejection were not observed in any patient on the second treatment regime. In conclusion, immunosuppressant treatment based on cyclosporine could be safe and effective for KTRs diagnosed with COVID-19.          \r\n        Keywords:      \r\n                  clinical research/practice; health services and outcomes research; immunosuppressant; kidney disease: infectious; kidney transplantation / nephrology.","article_type":"Original","study_type":"Case Report","number_of_patients":29,"article_patient_number":"21","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"51-60 years","sex":"Female","ethnicity":null,"country_contracted":"Spain","country_treated":"Spain","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":true,"cardiovascular_disease":false,"chronic_renal_disease":true,"chronic_liver_disease":false,"immunosuppressant_drugs":true,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"Dyslipidemia, obesity, kidney transplant recipient in 2006 on tacrolimus, mycophenolate, prednisolone.","pregnant":false,"unknown":false,"site_of_disease":"lungs","clinical_syndrome":"respiratory tract infection, pneumonia, myalgia, diarrhea","severity":"Inpatient","prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"After a period of follow-up","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"This patient has a medical history including a kidney transplant in 2006, high blood pressure, obesity, and dyslipidemia. At the time of admission, their immunosuppressive treatment included tacrolimus, sodium mycophenolate, and prednisone. It was changed to cyclosporin and prednisone one day after admission. They received anti-coagulation therapy.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[7117,8342,9077,9905,10776]},{"id":6560,"regimens":[{"id":12904,"duration":{"id":6866,"approximate_duration":null,"dates_unknown":false},"drug":{"id":9077,"name":"Methylprednisolone","url":"cure-api2.ncats.io/v1/drugs/9077","rxNorm_id":null,"notes":null},"use_drug":[{"id":11020,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12904},{"id":11021,"answer":"In a novel combination with another drug","answer_other":"","regimen":12904}],"created":"2020-11-23T19:32:08.250195Z","updated":"2020-11-24T18:59:11.234237Z","dose":"125mg/day, then 1000mg/day","frequency":"","route":"IV","severity":"Inpatient","severity_detail":"","comments":null,"report":6560},{"id":12905,"duration":{"id":6867,"approximate_duration":null,"dates_unknown":false},"drug":{"id":7629,"name":"Enoxaparin","url":"cure-api2.ncats.io/v1/drugs/7629","rxNorm_id":null,"notes":null},"use_drug":[{"id":11083,"answer":"Other","answer_other":"for thromboprophylaxis","regimen":12905}],"created":"2020-11-23T19:32:08.257834Z","updated":"2020-11-24T18:59:11.313425Z","dose":"40mg","frequency":"BID","route":"Subcutaneous","severity":"Inpatient","severity_detail":null,"comments":null,"report":6560},{"id":12906,"duration":{"id":6868,"approximate_duration":"3 Days","dates_unknown":true},"drug":{"id":8412,"name":"Immunoglobulins, Intravenous","url":"cure-api2.ncats.io/v1/drugs/8412","rxNorm_id":null,"notes":null},"use_drug":[{"id":11024,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12906},{"id":11025,"answer":"In a novel combination with another drug","answer_other":"","regimen":12906}],"created":"2020-11-23T19:32:08.264952Z","updated":"2020-11-24T18:59:11.246120Z","dose":"20g/day","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"High flow oxygen","comments":null,"report":6560},{"id":12910,"duration":{"id":6872,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":11026,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12910},{"id":11027,"answer":"In a novel combination with another drug","answer_other":"","regimen":12910}],"created":"2020-11-23T19:36:46.123871Z","updated":"2020-11-24T18:59:11.252131Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6560},{"id":12911,"duration":{"id":6873,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6916,"name":"Clarithromycin","url":"cure-api2.ncats.io/v1/drugs/6916","rxNorm_id":null,"notes":null},"use_drug":[{"id":11028,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12911},{"id":11029,"answer":"In a novel combination with another drug","answer_other":"","regimen":12911}],"created":"2020-11-23T19:36:46.131211Z","updated":"2020-11-24T18:59:11.257724Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6560},{"id":12912,"duration":{"id":6874,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6675,"name":"Ceftriaxone","url":"cure-api2.ncats.io/v1/drugs/6675","rxNorm_id":null,"notes":null},"use_drug":[{"id":11084,"answer":"Other","answer_other":"Likely for bacterial cover","regimen":12912}],"created":"2020-11-23T19:36:46.137782Z","updated":"2020-11-24T18:59:11.314320Z","dose":null,"frequency":"","route":"","severity":"Inpatient","severity_detail":null,"comments":null,"report":6560},{"id":12913,"duration":{"id":6875,"approximate_duration":null,"dates_unknown":false},"drug":{"id":11417,"name":"Tilorone","url":"cure-api2.ncats.io/v1/drugs/11417","rxNorm_id":null,"notes":null},"use_drug":[{"id":11032,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12913},{"id":11033,"answer":"In a novel combination with another drug","answer_other":"","regimen":12913}],"created":"2020-11-23T19:36:46.144319Z","updated":"2020-11-24T18:59:11.268907Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6560},{"id":12914,"duration":{"id":6876,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":11034,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12914},{"id":11035,"answer":"In a novel combination with another drug","answer_other":"","regimen":12914}],"created":"2020-11-23T19:42:38.379291Z","updated":"2020-11-24T18:59:11.274709Z","dose":"400mg","frequency":"","route":"IV","severity":"ICU/Critical Care","severity_detail":"High flow oxygen therapy","comments":null,"report":6560}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8622,"answer":"Clinical assessment","answer_other":"","report":6560},{"id":8623,"answer":"PCR","answer_other":"","report":6560},{"id":8624,"answer":"Imaging","answer_other":"","report":6560}],"how_diagnosis":[{"id":14780,"answer":"Clinical assessment","answer_other":"","report":6560},{"id":14781,"answer":"Imaging","answer_other":"","report":6560},{"id":14782,"answer":"PCR","answer_other":"","report":6560}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4722,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6560}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"},{"id":550,"name":"Respiratory Tract Infections"}],"races":[],"created":"2020-11-23T19:12:32.287610Z","updated":"2020-11-24T18:59:11.226282Z","title":"Pulse Therapy With Corticosteroids and Intravenous Immunoglobulin in the Management of Severe Tocilizumab-Resistant COVID-19: A Report of Three Clinical Cases. Case 2.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32656044,"doi":"10.7759/cureus.9038","article_url":"https://pubmed.ncbi.nlm.nih.gov/32656044/","pub_year":2020,"published_authors":"Sheianov MV\r\nUdalov YD\r\nOchkin SS\r\nBashkov AN\r\nSamoilov AS","article_author_email":"msheyanov@mail.ru","journal":"Cureus","abstract":"We present the cases of three patients with severe, life-threatening coronavirus disease 2019 (COVID-19) who had failed to achieve substantial improvement on intial treatment. They subsequently received pulse therapy with methylprednisolone [1,000 mg/day intravenously (IV) for three consecutive days] and IV immunoglobulin (20 g/day). This treatment regimen was associated with a prompt resolution of respiratory failure, elimination of clinical manifestations of the cytokine release syndrome (CRS), and reversal of pulmonary CT changes. The treatment was generally safe and well-tolerated. There was no evidence of protracted persistence of the virus in the patients. Further randomized controlled trials are required to better understand the efficacy and safety of high-dose methylprednisolone and IV immunoglobulin, separately or in combination with each other, in the treatment of severe, life-threatening COVID-19.          \r\n        Keywords:      \r\n                  corticosteroids; covid-19; cytokine release syndrome; immunoglobulin; methylprednisolone; pulse therapy; sars-cov-2.","article_type":"","study_type":"Case Report","number_of_patients":null,"article_patient_number":"2","full_text_available":false,"outcome":"Patient was cured/recovered","surgery":"No","age":"51-60 years","sex":"Female","ethnicity":null,"country_contracted":"Russian Federation","country_treated":"Russian Federation","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"Obesity, Chronic Pancreatitis","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Pneumonia, dyspnea","severity":"Inpatient","prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6675,6916,7629,8342,8412,9077,11417,10776]},{"id":6562,"regimens":[{"id":12915,"duration":{"id":6877,"approximate_duration":null,"dates_unknown":false},"drug":{"id":9077,"name":"Methylprednisolone","url":"cure-api2.ncats.io/v1/drugs/9077","rxNorm_id":null,"notes":null},"use_drug":[{"id":11036,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12915},{"id":11037,"answer":"In a novel combination with another drug","answer_other":"","regimen":12915}],"created":"2020-11-23T20:25:47.333130Z","updated":"2020-11-24T19:07:09.802548Z","dose":"125mg, then 1000mg","frequency":"","route":"IV, pulse therapy","severity":"Inpatient","severity_detail":"Low flow oxygen","comments":null,"report":6562},{"id":12916,"duration":{"id":6878,"approximate_duration":null,"dates_unknown":false},"drug":{"id":7629,"name":"Enoxaparin","url":"cure-api2.ncats.io/v1/drugs/7629","rxNorm_id":null,"notes":null},"use_drug":[{"id":11085,"answer":"Other","answer_other":"For thromboprophylaxis","regimen":12916}],"created":"2020-11-23T20:25:47.341095Z","updated":"2020-11-24T19:07:09.892193Z","dose":null,"frequency":"","route":"","severity":"Inpatient","severity_detail":"Low flow oxygen","comments":null,"report":6562},{"id":12917,"duration":{"id":6879,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8783,"name":"Lopinavir-Ritonavir","url":"cure-api2.ncats.io/v1/drugs/8783","rxNorm_id":null,"notes":null},"use_drug":[{"id":11040,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12917},{"id":11041,"answer":"In a novel combination with another drug","answer_other":"","regimen":12917}],"created":"2020-11-23T20:25:47.347373Z","updated":"2020-11-24T19:07:09.893034Z","dose":null,"frequency":"","route":"","severity":"Inpatient","severity_detail":"Low flow oxygen","comments":null,"report":6562},{"id":12918,"duration":{"id":6880,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":11042,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12918},{"id":11043,"answer":"In a novel combination with another drug","answer_other":"","regimen":12918}],"created":"2020-11-23T20:25:47.353514Z","updated":"2020-11-24T19:07:09.893917Z","dose":null,"frequency":"","route":"","severity":"Inpatient","severity_detail":"Low flow oxygen","comments":null,"report":6562},{"id":12919,"duration":{"id":6881,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10942,"name":"Umifenovir","url":"cure-api2.ncats.io/v1/drugs/10942","rxNorm_id":null,"notes":null},"use_drug":[{"id":11044,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12919},{"id":11045,"answer":"In a novel combination with another drug","answer_other":"","regimen":12919}],"created":"2020-11-23T20:25:47.359987Z","updated":"2020-11-24T19:07:09.826319Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"Low flow oxygen","comments":null,"report":6562},{"id":12920,"duration":{"id":6882,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6675,"name":"Ceftriaxone","url":"cure-api2.ncats.io/v1/drugs/6675","rxNorm_id":null,"notes":null},"use_drug":[{"id":11086,"answer":"Other","answer_other":"Likely for bacterial cover","regimen":12920}],"created":"2020-11-23T20:25:47.366214Z","updated":"2020-11-24T19:07:09.894772Z","dose":null,"frequency":"","route":"","severity":"Inpatient","severity_detail":"Low flow oxygen","comments":null,"report":6562},{"id":12921,"duration":{"id":6883,"approximate_duration":null,"dates_unknown":false},"drug":{"id":9362,"name":"Norepinephrine","url":"cure-api2.ncats.io/v1/drugs/9362","rxNorm_id":null,"notes":null},"use_drug":[{"id":11087,"answer":"Other","answer_other":"For ionotrpic support","regimen":12921}],"created":"2020-11-23T20:25:47.372294Z","updated":"2020-11-24T19:07:09.895563Z","dose":null,"frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"High flow oxygen, septic shock","comments":null,"report":6562},{"id":12922,"duration":{"id":6884,"approximate_duration":"7 Days","dates_unknown":true},"drug":{"id":8971,"name":"Meropenem","url":"cure-api2.ncats.io/v1/drugs/8971","rxNorm_id":null,"notes":null},"use_drug":[{"id":11088,"answer":"Other","answer_other":"For bacterial cover","regimen":12922}],"created":"2020-11-23T20:25:47.378365Z","updated":"2020-11-24T19:07:09.896357Z","dose":null,"frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"High flow oxygen therapy","comments":null,"report":6562},{"id":12923,"duration":{"id":6885,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8412,"name":"Immunoglobulins, Intravenous","url":"cure-api2.ncats.io/v1/drugs/8412","rxNorm_id":null,"notes":null},"use_drug":[{"id":11052,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12923},{"id":11053,"answer":"In a novel combination with another drug","answer_other":"","regimen":12923}],"created":"2020-11-23T20:25:47.384119Z","updated":"2020-11-24T19:07:09.848473Z","dose":"20g","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"High flow oxygen therapy","comments":null,"report":6562}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8625,"answer":"Clinical assessment","answer_other":"","report":6562},{"id":8626,"answer":"Imaging","answer_other":"","report":6562},{"id":8627,"answer":"PCR","answer_other":"","report":6562}],"how_diagnosis":[{"id":14786,"answer":"Clinical assessment","answer_other":"","report":6562},{"id":14787,"answer":"PCR","answer_other":"","report":6562},{"id":14788,"answer":"Imaging","answer_other":"","report":6562}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4724,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6562}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-11-23T20:06:48.690224Z","updated":"2020-11-24T19:07:09.794574Z","title":"Pulse Therapy With Corticosteroids and Intravenous Immunoglobulin in the Management of Severe Tocilizumab-Resistant COVID-19: A Report of Three Clinical Cases. Case 3.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32656044,"doi":"10.7759/cureus.9038","article_url":"https://pubmed.ncbi.nlm.nih.gov/32656044/","pub_year":2020,"published_authors":"Sheianov MV\r\nUdalov YD\r\nOchkin SS\r\nBashkov AN\r\nSamoilov AS","article_author_email":"Author email could not be found.","journal":"Cureus","abstract":"We present the cases of three patients with severe, life-threatening coronavirus disease 2019 (COVID-19) who had failed to achieve substantial improvement on intial treatment. They subsequently received pulse therapy with methylprednisolone [1,000 mg/day intravenously (IV) for three consecutive days] and IV immunoglobulin (20 g/day). This treatment regimen was associated with a prompt resolution of respiratory failure, elimination of clinical manifestations of the cytokine release syndrome (CRS), and reversal of pulmonary CT changes. The treatment was generally safe and well-tolerated. There was no evidence of protracted persistence of the virus in the patients. Further randomized controlled trials are required to better understand the efficacy and safety of high-dose methylprednisolone and IV immunoglobulin, separately or in combination with each other, in the treatment of severe, life-threatening COVID-19.          \r\n        Keywords:      \r\n                  corticosteroids; covid-19; cytokine release syndrome; immunoglobulin; methylprednisolone; pulse therapy; sars-cov-2.","article_type":"Original","study_type":"Case Report","number_of_patients":3,"article_patient_number":"3","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"No","age":"31-40 years","sex":"Male","ethnicity":null,"country_contracted":"Russian Federation","country_treated":"Russian Federation","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Pneumonia, septic shock, dyspnea","severity":"ICU/Critical Care","prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6675,7629,8412,8783,8971,9077,9362,10776,10942]},{"id":6567,"regimens":[{"id":13027,"duration":{"id":6926,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":11197,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13027},{"id":11199,"answer":"In a novel combination with another drug","answer_other":"","regimen":13027},{"id":11198,"answer":"In a novel population (e.g. pediatrics/neonates, pregnant women, immunosuppressed, etc.)","answer_other":"","regimen":13027}],"created":"2020-11-25T22:52:09.261933Z","updated":"2020-11-27T17:44:10.533273Z","dose":"200mg","frequency":"BID","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6567},{"id":13028,"duration":{"id":6927,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8783,"name":"Lopinavir-Ritonavir","url":"cure-api2.ncats.io/v1/drugs/8783","rxNorm_id":null,"notes":null},"use_drug":[{"id":11200,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13028},{"id":11201,"answer":"In a novel combination with another drug","answer_other":"","regimen":13028},{"id":11202,"answer":"In a novel population (e.g. pediatrics/neonates, pregnant women, immunosuppressed, etc.)","answer_other":"","regimen":13028}],"created":"2020-11-25T22:52:09.270110Z","updated":"2020-11-27T17:44:10.539662Z","dose":"200/50mg","frequency":"BID","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6567},{"id":13029,"duration":{"id":6928,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":11203,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13029},{"id":11204,"answer":"In a novel combination with another drug","answer_other":"","regimen":13029},{"id":11205,"answer":"In a novel population (e.g. pediatrics/neonates, pregnant women, immunosuppressed, etc.)","answer_other":"","regimen":13029}],"created":"2020-11-25T22:52:09.276462Z","updated":"2020-11-27T17:44:10.545610Z","dose":"400mg","frequency":"","route":"IV","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6567},{"id":13030,"duration":{"id":6929,"approximate_duration":"6days","dates_unknown":true},"drug":{"id":5926,"name":"Anakinra","url":"cure-api2.ncats.io/v1/drugs/5926","rxNorm_id":null,"notes":null},"use_drug":[{"id":11206,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13030},{"id":11207,"answer":"In a novel combination with another drug","answer_other":"","regimen":13030},{"id":11208,"answer":"In a novel population (e.g. pediatrics/neonates, pregnant women, immunosuppressed, etc.)","answer_other":"","regimen":13030}],"created":"2020-11-25T22:52:09.283186Z","updated":"2020-11-27T17:44:10.551536Z","dose":"100mg","frequency":"BID","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6567}],"site_of_infection":[],"specific_site":[],"how_outcome":[],"how_diagnosis":[{"id":14828,"answer":"PCR","answer_other":"","report":6567}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Deteriorated","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4744,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6567},{"id":4745,"answer":"Co-Infection or Complex Co-morbidities","answer_other":"","report":6567}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-11-24T22:11:00.600034Z","updated":"2020-11-27T17:44:10.525195Z","title":"IL-1R blockade is not effective in patients with hematological malignancies and severe SARS-CoV-2 infection.Case 1.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32583087,"doi":"10.1007/s00277-020-04160-w","article_url":"https://pubmed.ncbi.nlm.nih.gov/32583087/","pub_year":2020,"published_authors":"Villegas C\r\nPoza M\r\nTalayero P\r\nTeller JMC\r\nZafra D\r\nGarcia C\r\nVera E\r\nHidalgo M\r\nLopez N\r\nCuellar C\r\nZamanillo I\r\nÃÃ±iguez R\r\nPaz-Artal E\r\nAguado JM\r\nMartinez-Lopez J","article_author_email":"Author email could not be found.","journal":"Annals of hematology","abstract":"No abstract available","article_type":"Original","study_type":"Case Series","number_of_patients":5,"article_patient_number":"1","full_text_available":true,"outcome":"Patient died","surgery":"No","age":"61-70 years","sex":"Male","ethnicity":null,"country_contracted":"Spain","country_treated":"Spain","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":true,"other_comorbid":"Diffuse large B cell lymphoma","pregnant":false,"unknown":false,"site_of_disease":"lungs","clinical_syndrome":"respiratory tract infection","severity":"ICU/Critical Care","prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"While the patient was still on treatment","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"5 hematological patients diagnosed with SARS-CoV-2 infection (COVID-19) treated with anakinra without any clinical benefit. Unfortunately, all patients died from severe respiratory failure a median 6 days (range 1â29 days) after anakinra was started.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[5926,8342,8783,10776]},{"id":6575,"regimens":[{"id":13023,"duration":{"id":6922,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":11190,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13023},{"id":11191,"answer":"In a novel combination with another drug","answer_other":"","regimen":13023}],"created":"2020-11-25T22:16:52.250777Z","updated":"2020-11-27T19:04:58.307037Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6575},{"id":13024,"duration":{"id":6923,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":11192,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13024},{"id":11193,"answer":"In a novel combination with another drug","answer_other":"","regimen":13024}],"created":"2020-11-25T22:16:52.258971Z","updated":"2020-11-27T19:04:58.313591Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6575},{"id":13025,"duration":{"id":6924,"approximate_duration":"1 day","dates_unknown":true},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":11194,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13025},{"id":11195,"answer":"In a novel combination with another drug","answer_other":"","regimen":13025}],"created":"2020-11-25T22:20:28.511908Z","updated":"2020-11-27T19:04:58.350912Z","dose":"600 mg","frequency":"stat","route":"IV","severity":"ICU/Critical Care","severity_detail":null,"comments":null,"report":6575},{"id":13088,"duration":null,"drug":{"id":8314,"name":"Hydrocortisone","url":"cure-api2.ncats.io/v1/drugs/8314","rxNorm_id":null,"notes":null},"use_drug":[{"id":11341,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13088},{"id":11342,"answer":"In a novel combination with another drug","answer_other":"","regimen":13088}],"created":"2020-11-27T19:04:58.346205Z","updated":"2020-11-27T19:04:58.351778Z","dose":"100mg","frequency":"tds","route":"","severity":null,"severity_detail":null,"comments":null,"report":6575}],"site_of_infection":[],"specific_site":[],"how_outcome":[],"how_diagnosis":[{"id":14822,"answer":"Clinical assessment","answer_other":"","report":6575},{"id":14823,"answer":"Imaging","answer_other":"","report":6575},{"id":14824,"answer":"PCR","answer_other":"","report":6575}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Deteriorated","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4742,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6575}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":399,"name":"Diarrhea (Infectious)"},{"id":396,"name":"Pneumonia"},{"id":550,"name":"Respiratory Tract Infections"}],"races":[],"created":"2020-11-25T22:16:28.157199Z","updated":"2020-11-27T19:04:58.298639Z","title":"A Fatal Case of Coronavirus Disease 2019 (COVID-19) in a Patient With Idiopathic Pulmonary Fibrosis.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32642347,"doi":"10.7759/cureus.8432","article_url":"https://pubmed.ncbi.nlm.nih.gov/32642347/","pub_year":2020,"published_authors":"Rajasurya V\r\nGunasekaran K\r\nDamarla V\r\nKolluru A","article_author_email":"Author email could not be found.","journal":"Cureus","abstract":"The number of cases of coronavirus disease 2019 (COVID-19) has been exponentially increasing everyday. It is important to recognize the comorbidities and risk factors associated with this highly contagious and serious disease that has caused thousands of deaths worldwide. Patients with certain conditions like diabetes, hypertension, cardiovascular disease and chronic lung diseases have been reported to develop serious complications from COVID-19. Idiopathic pulmonary fibrosis (IPF) is a disease that is more prevalent in the elderly population, the same group that are more susceptible to serious complications from COVID-19. Our literature search did not reveal any review about COVID-19 in IPF patients. We report a patient with IPF who was exposed to COVID-19 from her spouse and died from its complications. This case would help to raise the awareness among IPF patients to follow the necessary precautions to reduce the risk of contracting the disease.          \r\n        Keywords:      \r\n                  acute hypoxemic respiratory failure; corona virus; covid-19; idiopathic pulmonary fibrosis; ipf.","article_type":"Original","study_type":"Case Report","number_of_patients":1,"article_patient_number":"1","full_text_available":true,"outcome":"Patient died","surgery":"No","age":"71-80 years","sex":"Female","ethnicity":null,"country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":true,"diabetes_mellitus":false,"hypertension":true,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"Idiopathic pulmonary fibrosis","pregnant":false,"unknown":false,"site_of_disease":"lungs, kidney, liver, circulatory system","clinical_syndrome":"pneumonia, respiratory tract infection, fever, dyspnea, diarrhea, respiratory failure, multi-organ dysfunction","severity":"ICU/Critical Care","prev_treatment":"","unusual":"COVID-19 in a Patient With Idiopathic Pulmonary Fibrosis","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"While the patient was still on treatment","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"This patient had a medical history including hypertension and idiopathic pulmonary fibrosis. Their normal medication regimen included nintedanib (100 mg, BID) and metoprolol 12.5 mg (QD). They were also typically on two liters of oxygen per minute for chronic hypoxia respiratory failure form IPF. Imagine revealed multifocal consolidations in both lungs. They were intubated and suffered form hypoxic respiratory failure, severe septic shock, and multi organ dysfunction (worsening renal function, liver function, circulatory collapse, and respiratory failure) requiring norepinephrine, vasopressin, phenylephrine, and angiotensin II. She was started on IV hydrocortisone (100 mg, TID).","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6122,8314,8342,10776]},{"id":6576,"regimens":[{"id":13026,"duration":{"id":6925,"approximate_duration":"21 days","dates_unknown":true},"drug":{"id":10215,"name":"Ruxolitinib","url":"cure-api2.ncats.io/v1/drugs/10215","rxNorm_id":null,"notes":null},"use_drug":[{"id":11196,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13026}],"created":"2020-11-25T22:36:56.905699Z","updated":"2020-11-27T19:11:41.682541Z","dose":"10 mg","frequency":"BID","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6576},{"id":13094,"duration":{"id":6980,"approximate_duration":"2 days","dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":11345,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13094}],"created":"2020-11-27T19:11:41.703022Z","updated":"2020-11-27T19:11:41.707019Z","dose":"8mg/kg","frequency":"OD","route":"","severity":null,"severity_detail":null,"comments":null,"report":6576}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8644,"answer":"Clinical assessment","answer_other":"","report":6576},{"id":8645,"answer":"Imaging","answer_other":"","report":6576}],"how_diagnosis":[{"id":14825,"answer":"Clinical assessment","answer_other":"","report":6576},{"id":14826,"answer":"Imaging","answer_other":"","report":6576},{"id":14827,"answer":"PCR","answer_other":"","report":6576}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Improved","previous_drugs":[{"id":10776,"name":"Tocilizumab"}],"comments":[],"article_language":"English","why_new_way":[{"id":4743,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6576}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"},{"id":550,"name":"Respiratory Tract Infections"}],"races":[],"created":"2020-11-25T22:36:12.728951Z","updated":"2020-11-27T19:11:41.674354Z","title":"Ruxolitinib for tocilizumab-refractory severe COVID-19 infection.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32593183,"doi":"10.1111/bjh.16979","article_url":"https://pubmed.ncbi.nlm.nih.gov/32593183/","pub_year":2020,"published_authors":"Innes AJ\r\nCook LB\r\nMarks S\r\nBataillard E\r\nCrossette-Thambiah C\r\nSivasubramaniam G\r\nApperley J\r\nMilojkovic D","article_author_email":"Author email could not be found.","journal":"British journal of haematology","abstract":"Whilst the majority of patients with COVIDâ19 infection have mild selfâlimiting symptoms, for some the SARSâCoV2 virus can trigger a severe hyperinflammatory syndrome which is life threatening. AntiâIL6 therapy has shown promise in restraining the hyperinflammatory syndrome and while ILâ6 is a pleiotropic mediatory of the inflammatory response, redundancy within inflammatory pathways means that the use of such targeted monoclonal therapy may have too restricted a repertoire in some patients. We present the case of a 53âyearâold haematopoetic stem cell transplant recipient who developed a severe COVIDâ19 that was refractory to antiâIL6 therapy, but responded to JakâStat inhibition with ruxolitinib, demonstrating its safety and efficacy in this setting.          \r\n        Keywords:      \r\n                  COVID-19; immunosupression; infection; transplant.","article_type":"Original","study_type":"Case Report","number_of_patients":1,"article_patient_number":"1","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"No","age":"51-60 years","sex":"Male","ethnicity":null,"country_contracted":"United Kingdom","country_treated":"United Kingdom","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":true,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":true,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"status post haploidential stem cell transplant for chronic myeloid leukaemia  in  blast  phase  in  2017. Acute  and chronic  graft-versus-host  disease  requiring  multiple  treatments  including  corticosteroids,  infliximab, etanercerpt  and  mesenchymal  stromal  cells,  but  was  most  recently  quiescent  with  corticosteroid, ciclosporin  and  mycophenolate  maintenance.","pregnant":false,"unknown":false,"site_of_disease":"lungs","clinical_syndrome":"pneumonia, respiratory tract infection, dyspnea","severity":"Inpatient","prev_treatment":"","unusual":"use of Ruxolitinib for tocilizumab-refractory severe COVID-19 infection","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"This patient has a medical history including a haploidential stem cell transplant for chronic myeloid leukemia in blast phase in 2017 and diabetes. His post transplant course was complicated by acute and chronic graft-versus-host disease requiring treatments including corticosteroids, infliximab, entaercerpt and mesenchymal stroll cells and most recently corticosteroid cyclosporin and mycophenolate maintenance. Antibiotics, antifungals, and low-molecular weight heparin was administered and subsequently tocilizumab (two doses, 8 mg/kg, 24 hours apart) without improvement. Ruxolitinib was ini ally administered 5 mg BID for 4 days and then upped to 10 mg BID for 6 days and then decreased to 5 mg BID for the final 10 days.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[10215,10776]},{"id":6577,"regimens":[{"id":13031,"duration":{"id":6930,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":11209,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13031},{"id":11210,"answer":"In a novel combination with another drug","answer_other":"","regimen":13031}],"created":"2020-11-25T23:41:49.068824Z","updated":"2020-11-27T17:48:55.677294Z","dose":"200mg","frequency":"BID","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6577},{"id":13032,"duration":{"id":6931,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8783,"name":"Lopinavir-Ritonavir","url":"cure-api2.ncats.io/v1/drugs/8783","rxNorm_id":null,"notes":null},"use_drug":[{"id":11211,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13032},{"id":11212,"answer":"In a novel combination with another drug","answer_other":"","regimen":13032}],"created":"2020-11-25T23:41:49.076905Z","updated":"2020-11-27T17:48:55.683792Z","dose":"200/50mg","frequency":"BID","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6577},{"id":13033,"duration":{"id":6932,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":11213,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13033},{"id":11214,"answer":"In a novel combination with another drug","answer_other":"","regimen":13033}],"created":"2020-11-25T23:41:49.083576Z","updated":"2020-11-27T17:48:55.689774Z","dose":"100mg","frequency":"BID","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6577},{"id":13059,"duration":null,"drug":{"id":5926,"name":"Anakinra","url":"cure-api2.ncats.io/v1/drugs/5926","rxNorm_id":null,"notes":null},"use_drug":[{"id":11264,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13059},{"id":11265,"answer":"In a novel combination with another drug","answer_other":"","regimen":13059}],"created":"2020-11-27T17:48:55.713090Z","updated":"2020-11-27T17:48:55.717752Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6577}],"site_of_infection":[],"specific_site":[],"how_outcome":[],"how_diagnosis":[{"id":14829,"answer":"PCR","answer_other":"","report":6577}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Deteriorated","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4746,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6577},{"id":4747,"answer":"Co-Infection or Complex Co-morbidities","answer_other":"","report":6577}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-11-25T23:40:47.957630Z","updated":"2020-11-27T17:48:55.669442Z","title":"IL-1R blockade is not effective in patients with hematological malignancies and severe SARS-CoV-2 infection. Case 2","status":"Approved","anonymous":false,"published":true,"pubmed_id":32583087,"doi":"10.1007/s00277-020-04160-w","article_url":"https://pubmed.ncbi.nlm.nih.gov/32583087/","pub_year":2020,"published_authors":"Villegas C\r\nPoza M\r\nTalayero P\r\nTeller JMC\r\nZafra D\r\nGarcia C\r\nVera E\r\nHidalgo M\r\nLopez N\r\nCuellar C\r\nZamanillo I\r\nÃÃ±iguez R\r\nPaz-Artal E\r\nAguado JM\r\nMartinez-Lopez J","article_author_email":"Author email could not be found.","journal":"Annals of hematology","abstract":"No abstract available","article_type":"Original","study_type":"Case Series","number_of_patients":5,"article_patient_number":"2","full_text_available":true,"outcome":"Patient died","surgery":"No","age":"41-50 years","sex":"Female","ethnicity":null,"country_contracted":"Spain","country_treated":"Spain","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":true,"other_comorbid":"Rosai-Dorfman syndrome","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Respiratory tract infection","severity":"ICU/Critical Care","prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"While the patient was still on treatment","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"5 hematological patients diagnosed with SARS-CoV-2 infection (COVID-19) treated with anakinra without any clinical benefit. Unfortunately, all patients died from severe respiratory failure a median 6 days (range 1â29 days) after anakinra was started.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[5926,8342,8783,10776]},{"id":6579,"regimens":[{"id":13037,"duration":{"id":6936,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":11221,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13037},{"id":11222,"answer":"In a novel combination with another drug","answer_other":"","regimen":13037}],"created":"2020-11-26T00:20:12.710119Z","updated":"2020-11-27T17:52:12.888498Z","dose":"200mg","frequency":"BID","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6579},{"id":13038,"duration":{"id":6937,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8783,"name":"Lopinavir-Ritonavir","url":"cure-api2.ncats.io/v1/drugs/8783","rxNorm_id":null,"notes":null},"use_drug":[{"id":11223,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13038},{"id":11224,"answer":"In a novel combination with another drug","answer_other":"","regimen":13038}],"created":"2020-11-26T00:20:12.717644Z","updated":"2020-11-27T17:52:12.894716Z","dose":"200/50mg","frequency":"BID","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6579},{"id":13039,"duration":{"id":6938,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":11225,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13039},{"id":11226,"answer":"In a novel combination with another drug","answer_other":"","regimen":13039}],"created":"2020-11-26T00:20:12.724567Z","updated":"2020-11-27T17:52:12.900099Z","dose":"100mg","frequency":"BID","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6579},{"id":13040,"duration":{"id":6939,"approximate_duration":null,"dates_unknown":false},"drug":{"id":5926,"name":"Anakinra","url":"cure-api2.ncats.io/v1/drugs/5926","rxNorm_id":null,"notes":null},"use_drug":[{"id":11227,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13040},{"id":11228,"answer":"In a novel combination with another drug","answer_other":"","regimen":13040}],"created":"2020-11-26T00:20:12.730899Z","updated":"2020-11-27T17:52:12.905621Z","dose":"100mg","frequency":"BID","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6579}],"site_of_infection":[],"specific_site":[],"how_outcome":[],"how_diagnosis":[{"id":14831,"answer":"PCR","answer_other":"","report":6579}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Deteriorated","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4750,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6579},{"id":4751,"answer":"Co-Infection or Complex Co-morbidities","answer_other":"","report":6579}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-11-26T00:18:30.457855Z","updated":"2020-11-27T17:52:12.880876Z","title":"IL-1R blockade is not effective in patients with hematological malignancies and severe SARS-CoV-2 infection.Case 4.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32583087,"doi":"10.1007/s00277-020-04160-w","article_url":"https://pubmed.ncbi.nlm.nih.gov/32583087/","pub_year":2020,"published_authors":"Villegas C\r\nPoza M\r\nTalayero P\r\nTeller JMC\r\nZafra D\r\nGarcia C\r\nVera E\r\nHidalgo M\r\nLopez N\r\nCuellar C\r\nZamanillo I\r\nÃÃ±iguez R\r\nPaz-Artal E\r\nAguado JM\r\nMartinez-Lopez J","article_author_email":"Author email could not be found.","journal":"Annals of hematology","abstract":"No abstract available","article_type":"Original","study_type":"Case Series","number_of_patients":5,"article_patient_number":"4","full_text_available":true,"outcome":"Patient died","surgery":"No","age":"81-89 years","sex":"Male","ethnicity":null,"country_contracted":"Spain","country_treated":"Spain","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":true,"other_comorbid":"WaldenstrÃ¶mâs macroglobulinemia","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"respiratory tract infection","severity":"Inpatient","prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"While the patient was still on treatment","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"5 hematological patients diagnosed with SARS-CoV-2 infection (COVID-19) treated with anakinra without any clinical benefit.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[5926,8342,8783,10776]},{"id":6580,"regimens":[{"id":13041,"duration":{"id":6940,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":11229,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13041},{"id":11230,"answer":"In a novel combination with another drug","answer_other":"","regimen":13041}],"created":"2020-11-26T00:41:08.371089Z","updated":"2020-11-27T17:53:43.416058Z","dose":"200mg","frequency":"BID","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6580},{"id":13042,"duration":{"id":6941,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":11231,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13042},{"id":11232,"answer":"In a novel combination with another drug","answer_other":"","regimen":13042}],"created":"2020-11-26T00:41:08.379215Z","updated":"2020-11-27T17:53:43.422523Z","dose":"400mg","frequency":"BID","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6580},{"id":13043,"duration":{"id":6942,"approximate_duration":null,"dates_unknown":false},"drug":{"id":5926,"name":"Anakinra","url":"cure-api2.ncats.io/v1/drugs/5926","rxNorm_id":null,"notes":null},"use_drug":[{"id":11233,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13043},{"id":11234,"answer":"In a novel combination with another drug","answer_other":"","regimen":13043}],"created":"2020-11-26T00:41:08.421938Z","updated":"2020-11-27T17:53:43.428365Z","dose":"100mg","frequency":"BID","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6580}],"site_of_infection":[],"specific_site":[],"how_outcome":[],"how_diagnosis":[{"id":14832,"answer":"PCR","answer_other":"","report":6580}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Deteriorated","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4752,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6580},{"id":4753,"answer":"Co-Infection or Complex Co-morbidities","answer_other":"","report":6580}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-11-26T00:40:07.797862Z","updated":"2020-11-27T17:53:43.408267Z","title":"IL-1R blockade is not effective in patients with hematological malignancies and severe SARS-CoV-2 infection.Case 5.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32583087,"doi":"10.1007/s00277-020-04160-w","article_url":"https://pubmed.ncbi.nlm.nih.gov/32583087/","pub_year":2020,"published_authors":"Villegas C\r\nPoza M\r\nTalayero P\r\nTeller JMC\r\nZafra D\r\nGarcia C\r\nVera E\r\nHidalgo M\r\nLopez N\r\nCuellar C\r\nZamanillo I\r\nÃÃ±iguez R\r\nPaz-Artal E\r\nAguado JM\r\nMartinez-Lopez J","article_author_email":"Author email could not be found.","journal":"Annals of hematology","abstract":"No abstract available","article_type":"Original","study_type":"Case Series","number_of_patients":5,"article_patient_number":"5","full_text_available":true,"outcome":"Patient died","surgery":"No","age":"51-60 years","sex":"Female","ethnicity":null,"country_contracted":"Spain","country_treated":"Spain","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":true,"other_comorbid":"Diffuse large B cell lymphoma","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"respiratory tract infection","severity":"Inpatient","prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"While the patient was still on treatment","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"5 hematological patients diagnosed with SARS-CoV-2 infection (COVID-19) treated with anakinra without any clinical benefit.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[5926,8342,10776]},{"id":6583,"regimens":[{"id":13055,"duration":{"id":6953,"approximate_duration":null,"dates_unknown":false},"drug":{"id":11396,"name":"Darunavir-Ritonavir","url":"cure-api2.ncats.io/v1/drugs/11396","rxNorm_id":null,"notes":null},"use_drug":[{"id":11268,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13055},{"id":11269,"answer":"In a novel combination with another drug","answer_other":"","regimen":13055}],"created":"2020-11-27T17:47:54.282657Z","updated":"2020-11-30T19:40:23.315790Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6583},{"id":13056,"duration":{"id":6954,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":11270,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13056},{"id":11271,"answer":"In a novel combination with another drug","answer_other":"","regimen":13056}],"created":"2020-11-27T17:47:54.288758Z","updated":"2020-11-30T19:40:23.322281Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6583},{"id":13057,"duration":{"id":6955,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":11272,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13057},{"id":11273,"answer":"In a novel combination with another drug","answer_other":"","regimen":13057}],"created":"2020-11-27T17:47:54.295194Z","updated":"2020-11-30T19:40:23.328231Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6583},{"id":13058,"duration":{"id":6956,"approximate_duration":null,"dates_unknown":false},"drug":{"id":7629,"name":"Enoxaparin","url":"cure-api2.ncats.io/v1/drugs/7629","rxNorm_id":null,"notes":null},"use_drug":[{"id":11274,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13058},{"id":11275,"answer":"In a novel combination with another drug","answer_other":"","regimen":13058}],"created":"2020-11-27T17:47:54.301294Z","updated":"2020-11-30T19:40:23.334111Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6583}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8649,"answer":"Clinical assessment","answer_other":"","report":6583}],"how_diagnosis":[{"id":14839,"answer":"Clinical assessment","answer_other":"","report":6583},{"id":14840,"answer":"Imaging","answer_other":"","report":6583}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4756,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6583}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"},{"id":550,"name":"Respiratory Tract Infections"}],"races":[{"id":518,"answer":"White","answer_other":""}],"created":"2020-11-27T17:42:58.484391Z","updated":"2020-11-30T19:40:23.307979Z","title":"Acute myopathic quadriplegia in patients with COVID-19 in the intensive care unit. Case 1","status":"Approved","anonymous":false,"published":true,"pubmed_id":32601119,"doi":"10.1212/WNL.0000000000010280","article_url":"https://pubmed.ncbi.nlm.nih.gov/32601119/","pub_year":2020,"published_authors":"Madia F\r\nMerico B\r\nPrimiano G\r\nCutuli SL\r\nDe Pascale G\r\nServidei S","article_author_email":"Author email could not be found.","journal":"Neurology","abstract":"It is well known that the spectrum of SARS-CoV-2 infection ranges from asymptomatic or\r\nmildly symptomatic patients to rapidly progressive, acute respiratory distress syndrome\r\n(ARDS) and death. Although various reports indicated the presence of myalgia in 44%â70%\r\nand increased creatine kinase (CK) in about 33% of hospitalized patients,1 or <skeletal muscle\r\ninjury> (increased CK and myalgia) in 23%,2 the characterization of neuromuscular involvement is still unsatisfactory, and no electrophysiologic studies have been performed. Very\r\nrecently, patients who developed the Guillain-BarrÂ´e syndrome (GBS) in the course of coronavirus disease 2019 (COVID-19) have been described.3 In the past literature, there were a few\r\nreports of neuromuscular involvement in association with other beta-coronavirus, including\r\ncritical illness myopathy (CIM) or polyneuropathy.1,4 Moreover, myopathic changes, as fiber\r\natrophy or necrosis, have been reported in postmortem muscle samples of 8 patients who died\r\nof SARS (severe acute respiratory syndrome) due to SARS-CoV infection.4","article_type":"Original","study_type":"Case Report","number_of_patients":6,"article_patient_number":"1","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"51-60 years","sex":"Male","ethnicity":"Hispanic/Latino","country_contracted":"Italy","country_treated":"Italy","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"None","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Pneumonia, acute flaccid quadriplegia","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"Mechanical ventilation +\r\nPneumonia with characteristic bilateral patchy ground-glass opacities and interstitial changes and various superimposed infections or sepsis.\r\n Treatment given: Levofloxacin, linezolid, oxacillin, piperacillin/ tazobactam, darunavir/ ritonavir,\r\nhydroxychloroquine, tocilizumab, and enoxaparin","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[11396,7629,8342,10776]},{"id":6584,"regimens":[{"id":13060,"duration":{"id":6957,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8783,"name":"Lopinavir-Ritonavir","url":"cure-api2.ncats.io/v1/drugs/8783","rxNorm_id":null,"notes":null},"use_drug":[{"id":11276,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13060},{"id":11277,"answer":"In a novel combination with another drug","answer_other":"","regimen":13060}],"created":"2020-11-27T18:07:56.600485Z","updated":"2020-11-30T19:40:52.394849Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6584},{"id":13061,"duration":{"id":6958,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":11278,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13061},{"id":11279,"answer":"In a novel combination with another drug","answer_other":"","regimen":13061}],"created":"2020-11-27T18:07:56.608512Z","updated":"2020-11-30T19:40:52.401198Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6584},{"id":13062,"duration":{"id":6959,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":11281,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13062},{"id":11282,"answer":"In a novel combination with another drug","answer_other":"","regimen":13062}],"created":"2020-11-27T18:07:56.614746Z","updated":"2020-11-30T19:40:52.406816Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6584},{"id":13063,"duration":{"id":6960,"approximate_duration":null,"dates_unknown":false},"drug":{"id":7629,"name":"Enoxaparin","url":"cure-api2.ncats.io/v1/drugs/7629","rxNorm_id":null,"notes":null},"use_drug":[{"id":11283,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13063},{"id":11284,"answer":"In a novel combination with another drug","answer_other":"","regimen":13063}],"created":"2020-11-27T18:07:56.620721Z","updated":"2020-11-30T19:40:52.412927Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6584}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8650,"answer":"Clinical assessment","answer_other":"","report":6584}],"how_diagnosis":[{"id":14841,"answer":"Clinical assessment","answer_other":"","report":6584},{"id":14842,"answer":"Imaging","answer_other":"","report":6584}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4757,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6584}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"},{"id":550,"name":"Respiratory Tract Infections"}],"races":[{"id":519,"answer":"White","answer_other":""}],"created":"2020-11-27T18:06:31.578622Z","updated":"2020-11-30T19:40:52.386587Z","title":"Acute myopathic quadriplegia in patients with COVID-19 in the intensive care unit. Case 2","status":"Approved","anonymous":false,"published":true,"pubmed_id":32601119,"doi":"10.1212/WNL.0000000000010280","article_url":"https://pubmed.ncbi.nlm.nih.gov/32601119/","pub_year":2020,"published_authors":"Madia F\r\nMerico B\r\nPrimiano G\r\nCutuli SL\r\nDe Pascale G\r\nServidei S","article_author_email":"Author email could not be found.","journal":"Neurology","abstract":"It is well known that the spectrum of SARS-CoV-2 infection ranges from asymptomatic or\r\nmildly symptomatic patients to rapidly progressive, acute respiratory distress syndrome\r\n(ARDS) and death. Although various reports indicated the presence of myalgia in 44%â70%\r\nand increased creatine kinase (CK) in about 33% of hospitalized patients,1 or <skeletal muscle\r\ninjury> (increased CK and myalgia) in 23%,2 the characterization of neuromuscular involvement is still unsatisfactory, and no electrophysiologic studies have been performed. Very\r\nrecently, patients who developed the Guillain-BarrÂ´e syndrome (GBS) in the course of coronavirus disease 2019 (COVID-19) have been described.3 In the past literature, there were a few\r\nreports of neuromuscular involvement in association with other beta-coronavirus, including\r\ncritical illness myopathy (CIM) or polyneuropathy.1,4 Moreover, myopathic changes, as fiber\r\natrophy or necrosis, have been reported in postmortem muscle samples of 8 patients who died\r\nof SARS (severe acute respiratory syndrome) due to SARS-CoV infection.","article_type":"Original","study_type":"Case Report","number_of_patients":6,"article_patient_number":"2","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"61-70 years","sex":"Male","ethnicity":"Hispanic/Latino","country_contracted":"Italy","country_treated":"Italy","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"Myelofibrosis on therapy with low dose (12.5 mg) of prednisone","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Pneumonia, acute flaccid quadriplegia","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"Therapies given: Linezolid, piperacillin/ tazobactam, lopinavir/ ritonavir, hydroxychloroquine, tocilizumab, and enoxaparin\r\nMechanical ventilation +\r\nPneumonia with characteristic bilateral patchy ground-glass opacities and interstitial changes and various\r\nsuperimposed infections or sepsis.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[7629,8342,8783,10776]},{"id":6585,"regimens":[{"id":13067,"duration":{"id":6961,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":11290,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13067},{"id":11291,"answer":"In a novel combination with another drug","answer_other":"","regimen":13067}],"created":"2020-11-27T18:32:34.550914Z","updated":"2020-11-30T19:41:21.089620Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6585},{"id":13068,"duration":{"id":6962,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8783,"name":"Lopinavir-Ritonavir","url":"cure-api2.ncats.io/v1/drugs/8783","rxNorm_id":null,"notes":null},"use_drug":[{"id":11292,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13068},{"id":11293,"answer":"In a novel combination with another drug","answer_other":"","regimen":13068}],"created":"2020-11-27T18:32:34.558837Z","updated":"2020-11-30T19:41:21.095962Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6585},{"id":13069,"duration":{"id":6963,"approximate_duration":null,"dates_unknown":false},"drug":{"id":11396,"name":"Darunavir-Ritonavir","url":"cure-api2.ncats.io/v1/drugs/11396","rxNorm_id":null,"notes":null},"use_drug":[{"id":11294,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13069},{"id":11295,"answer":"In a novel combination with another drug","answer_other":"","regimen":13069}],"created":"2020-11-27T18:32:34.565678Z","updated":"2020-11-30T19:41:21.101509Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6585},{"id":13070,"duration":{"id":6964,"approximate_duration":null,"dates_unknown":false},"drug":{"id":7066,"name":"Corticosteroids","url":"cure-api2.ncats.io/v1/drugs/7066","rxNorm_id":null,"notes":null},"use_drug":[{"id":11303,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13070},{"id":11304,"answer":"In a novel combination with another drug","answer_other":"","regimen":13070}],"created":"2020-11-27T18:32:34.572208Z","updated":"2020-11-30T19:41:21.107963Z","dose":"","frequency":"","route":"IV","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6585},{"id":13071,"duration":{"id":6965,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":11305,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13071},{"id":11306,"answer":"In a novel combination with another drug","answer_other":"","regimen":13071}],"created":"2020-11-27T18:32:34.578742Z","updated":"2020-11-30T19:41:21.113643Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6585},{"id":13072,"duration":{"id":6966,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":11307,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13072},{"id":11308,"answer":"In a novel combination with another drug","answer_other":"","regimen":13072}],"created":"2020-11-27T18:32:34.585764Z","updated":"2020-11-30T19:41:21.119291Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6585},{"id":13073,"duration":{"id":6967,"approximate_duration":null,"dates_unknown":false},"drug":{"id":7629,"name":"Enoxaparin","url":"cure-api2.ncats.io/v1/drugs/7629","rxNorm_id":null,"notes":null},"use_drug":[{"id":11309,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13073},{"id":11310,"answer":"In a novel combination with another drug","answer_other":"","regimen":13073}],"created":"2020-11-27T18:32:34.592795Z","updated":"2020-11-30T19:41:21.125039Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6585}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8651,"answer":"Clinical assessment","answer_other":"","report":6585}],"how_diagnosis":[{"id":14843,"answer":"Clinical assessment","answer_other":"","report":6585},{"id":14844,"answer":"Imaging","answer_other":"","report":6585}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4758,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6585}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"},{"id":550,"name":"Respiratory Tract Infections"}],"races":[{"id":520,"answer":"White","answer_other":""}],"created":"2020-11-27T18:30:16.718399Z","updated":"2020-11-30T19:41:21.081197Z","title":"Acute myopathic quadriplegia in patients with COVID-19 in the intensive care unit. Case 3","status":"Approved","anonymous":false,"published":true,"pubmed_id":32601119,"doi":"10.1212/WNL.0000000000010280","article_url":"https://pubmed.ncbi.nlm.nih.gov/32601119/","pub_year":2020,"published_authors":"Madia F\r\nMerico B\r\nPrimiano G\r\nCutuli SL\r\nDe Pascale G\r\nServidei S","article_author_email":"Author email could not be found.","journal":"Neurology","abstract":"It is well known that the spectrum of SARS-CoV-2 infection ranges from asymptomatic or\r\nmildly symptomatic patients to rapidly progressive, acute respiratory distress syndrome\r\n(ARDS) and death. Although various reports indicated the presence of myalgia in 44%â70%\r\nand increased creatine kinase (CK) in about 33% of hospitalized patients,1 or <skeletal muscle\r\ninjury> (increased CK and myalgia) in 23%,2 the characterization of neuromuscular involvement is still unsatisfactory, and no electrophysiologic studies have been performed. Very\r\nrecently, patients who developed the Guillain-BarrÂ´e syndrome (GBS) in the course of coronavirus disease 2019 (COVID-19) have been described.3 In the past literature, there were a few\r\nreports of neuromuscular involvement in association with other beta-coronavirus, including\r\ncritical illness myopathy (CIM) or polyneuropathy.1,4 Moreover, myopathic changes, as fiber\r\natrophy or necrosis, have been reported in postmortem muscle samples of 8 patients who died\r\nof SARS (severe acute respiratory syndrome) due to SARS-CoV infection.4","article_type":"Original","study_type":"Case Report","number_of_patients":6,"article_patient_number":"3","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"51-60 years","sex":"Male","ethnicity":"Hispanic/Latino","country_contracted":"Italy","country_treated":"Italy","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"None","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Pneumonia, acute flaccid quadriplegia","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"Mechanical ventilation +\r\nPneumonia with characteristic bilateral patchy ground-glass opacities and interstitial changes and various superimposed infections or sepsis\r\nTherapies used:  Azithromycin, ceftriaxone, levofloxacin, linezolid, vancomycin, amikacin, meropenem, lopinavir/ ritonavir, darunavir/ ritonavir, endovenous corticosteroids, hydroxychloroquine, tocilizumab, and enoxaparin","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6122,7066,11396,7629,8342,8783,10776]},{"id":6587,"regimens":[{"id":13082,"duration":{"id":6975,"approximate_duration":null,"dates_unknown":false},"drug":{"id":11396,"name":"Darunavir-Ritonavir","url":"cure-api2.ncats.io/v1/drugs/11396","rxNorm_id":null,"notes":null},"use_drug":[{"id":11331,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13082},{"id":11332,"answer":"In a novel combination with another drug","answer_other":"","regimen":13082}],"created":"2020-11-27T18:58:29.277123Z","updated":"2020-11-30T19:42:26.691024Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6587},{"id":13083,"duration":{"id":6976,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":11333,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13083},{"id":11334,"answer":"In a novel combination with another drug","answer_other":"","regimen":13083}],"created":"2020-11-27T18:58:29.285422Z","updated":"2020-11-30T19:42:26.697289Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6587},{"id":13084,"duration":{"id":6977,"approximate_duration":null,"dates_unknown":false},"drug":{"id":7066,"name":"Corticosteroids","url":"cure-api2.ncats.io/v1/drugs/7066","rxNorm_id":null,"notes":null},"use_drug":[{"id":11335,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13084},{"id":11336,"answer":"In a novel combination with another drug","answer_other":"","regimen":13084}],"created":"2020-11-27T18:58:29.292045Z","updated":"2020-11-30T19:42:26.702936Z","dose":"","frequency":"","route":"IV","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6587},{"id":13085,"duration":{"id":6978,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":11337,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13085},{"id":11338,"answer":"In a novel combination with another drug","answer_other":"","regimen":13085}],"created":"2020-11-27T18:58:29.298290Z","updated":"2020-11-30T19:42:26.709100Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6587},{"id":13086,"duration":{"id":6979,"approximate_duration":null,"dates_unknown":false},"drug":{"id":7629,"name":"Enoxaparin","url":"cure-api2.ncats.io/v1/drugs/7629","rxNorm_id":null,"notes":null},"use_drug":[{"id":11339,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13086},{"id":11340,"answer":"In a novel combination with another drug","answer_other":"","regimen":13086}],"created":"2020-11-27T18:58:29.304592Z","updated":"2020-11-30T19:42:26.714858Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6587}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8652,"answer":"Clinical assessment","answer_other":"","report":6587}],"how_diagnosis":[{"id":14848,"answer":"Clinical assessment","answer_other":"","report":6587},{"id":14849,"answer":"Imaging","answer_other":"","report":6587}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4760,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6587}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"},{"id":550,"name":"Respiratory Tract Infections"}],"races":[{"id":522,"answer":"White","answer_other":""}],"created":"2020-11-27T18:56:44.952103Z","updated":"2020-11-30T19:42:26.683381Z","title":"Acute myopathic quadriplegia in patients with COVID-19 in the intensive care unit. Case 5","status":"Approved","anonymous":false,"published":true,"pubmed_id":32601119,"doi":"10.1212/WNL.0000000000010280","article_url":"https://pubmed.ncbi.nlm.nih.gov/32601119/","pub_year":2020,"published_authors":"Madia F\r\nMerico B\r\nPrimiano G\r\nCutuli SL\r\nDe Pascale G\r\nServidei S","article_author_email":"Author email could not be found.","journal":"Neurology","abstract":"It is well known that the spectrum of SARS-CoV-2 infection ranges from asymptomatic or\r\nmildly symptomatic patients to rapidly progressive, acute respiratory distress syndrome\r\n(ARDS) and death. Although various reports indicated the presence of myalgia in 44%â70%\r\nand increased creatine kinase (CK) in about 33% of hospitalized patients,1 or <skeletal muscle\r\ninjury> (increased CK and myalgia) in 23%,2 the characterization of neuromuscular involvement is still unsatisfactory, and no electrophysiologic studies have been performed. Very\r\nrecently, patients who developed the Guillain-BarrÂ´e syndrome (GBS) in the course of coronavirus disease 2019 (COVID-19) have been described.3 In the past literature, there were a few\r\nreports of neuromuscular involvement in association with other beta-coronavirus, including\r\ncritical illness myopathy (CIM) or polyneuropathy.1,4 Moreover, myopathic changes, as fiber\r\natrophy or necrosis, have been reported in postmortem muscle samples of 8 patients who died\r\nof SARS (severe acute respiratory syndrome) due to SARS-CoV infection.4","article_type":"Original","study_type":"Case Report","number_of_patients":6,"article_patient_number":"5","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"51-60 years","sex":"Male","ethnicity":"Hispanic/Latino","country_contracted":"Italy","country_treated":"Italy","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"None","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Pneumonia, acute flaccid quadriplegia","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"Mechanical ventilation +\r\npneumonia with characteristic bilateral patchy ground-glass opacities and interstitial changes and various superimposed infections or sepsis.\r\nTherapies used:  Linezolid, imipenem, amoxicillin, darunavir/ ritonavir, endovenous corticosteroids, hydroxychloroquine, tocilizumab, and enoxaparin","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[7066,11396,7629,8342,10776]},{"id":6594,"regimens":[{"id":13109,"duration":{"id":7000,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8783,"name":"Lopinavir-Ritonavir","url":"cure-api2.ncats.io/v1/drugs/8783","rxNorm_id":null,"notes":null},"use_drug":[{"id":11371,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13109},{"id":11372,"answer":"In a novel combination with another drug","answer_other":"","regimen":13109}],"created":"2020-11-28T19:03:21.553785Z","updated":"2020-12-01T15:11:42.733765Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6594},{"id":13110,"duration":{"id":7001,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":11373,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13110},{"id":11374,"answer":"In a novel combination with another drug","answer_other":"","regimen":13110}],"created":"2020-11-28T19:03:21.561752Z","updated":"2020-12-01T15:11:42.740178Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6594},{"id":13111,"duration":{"id":7002,"approximate_duration":null,"dates_unknown":false},"drug":{"id":9780,"name":"Piperacillin-Tazobactam","url":"cure-api2.ncats.io/v1/drugs/9780","rxNorm_id":null,"notes":null},"use_drug":[{"id":11678,"answer":"Other","answer_other":"Likely given for bacterial cover","regimen":13111}],"created":"2020-11-28T19:03:21.568200Z","updated":"2020-12-01T15:11:42.811752Z","dose":null,"frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":null,"comments":null,"report":6594},{"id":13112,"duration":{"id":7003,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":11377,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13112},{"id":11378,"answer":"In a novel combination with another drug","answer_other":"","regimen":13112}],"created":"2020-11-28T19:03:21.574466Z","updated":"2020-12-01T15:11:42.817468Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6594}],"site_of_infection":[],"specific_site":[],"how_outcome":[],"how_diagnosis":[{"id":14861,"answer":"Clinical assessment","answer_other":"","report":6594},{"id":14862,"answer":"Imaging","answer_other":"","report":6594},{"id":14863,"answer":"PCR","answer_other":"","report":6594}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Deteriorated","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4768,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6594}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"},{"id":550,"name":"Respiratory Tract Infections"}],"races":[],"created":"2020-11-28T18:59:08.737319Z","updated":"2020-12-01T15:11:42.725963Z","title":"Veno-venous Extracorporeal Membrane Oxygenation Support in COVID-19 Respiratory Distress Syndrome: Initial Experience. Case 1.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32597627,"doi":"10.1097/MAT.0000000000001198","article_url":"https://pubmed.ncbi.nlm.nih.gov/32597627/","pub_year":2020,"published_authors":"Loforte A\r\nDal Checco E\r\nGliozzi G\r\nBenedetto M\r\nCavalli GG\r\nMariani C\r\nPiccone G\r\nAgulli M\r\nPacini D\r\nBaiocchi M","article_author_email":"Author email could not be found.","journal":"ASAIO journal (American Society for Artificial Internal Organs : 1992)","abstract":"SARS-CoV-2 may cause severe respiratory failure due to massive alveolar damage. Currently, no adequate curative therapy for Coronavirus Disease 2019 (COVID-19) disease exists. By considering overall impact of COVID-19 pandemic outbreak, an increased need of extracorporeal membrane oxygenation (ECMO) support becomes evident. We report on our preliminary institutional experience with COVID-19 patients receiving venovenous ECMO support.","article_type":"Original","study_type":"Case Report","number_of_patients":4,"article_patient_number":"1","full_text_available":true,"outcome":"Patient died","surgery":"No","age":"41-50 years","sex":"Male","ethnicity":null,"country_contracted":"Italy","country_treated":"Italy","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"lungs","clinical_syndrome":"pneumonia, respiratory tract infection, respiratory failure","severity":"ICU/Critical Care","prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"While the patient was still on treatment","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"This patient experienced severe respiratory failure and a BAL Escherichia coli + superinfection. They received extracorporeal membrane oxygenation support, neuromuscular blockers, nitric oxide, and underwent prone positioning while in the ICU for 28 days.","previously_treated":"","flagged":false,"other_coinfections":"BAL Escherichia coli infection","disease":630,"drugs":[8342,8783,9780,10776]},{"id":6595,"regimens":[{"id":13113,"duration":{"id":7004,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8783,"name":"Lopinavir-Ritonavir","url":"cure-api2.ncats.io/v1/drugs/8783","rxNorm_id":null,"notes":null},"use_drug":[{"id":11379,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13113},{"id":11380,"answer":"In a novel combination with another drug","answer_other":"","regimen":13113}],"created":"2020-11-28T19:21:03.855480Z","updated":"2020-12-01T15:11:06.708153Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6595},{"id":13114,"duration":{"id":7005,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":11381,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13114},{"id":11382,"answer":"In a novel combination with another drug","answer_other":"","regimen":13114}],"created":"2020-11-28T19:21:03.863201Z","updated":"2020-12-01T15:11:06.714469Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6595},{"id":13115,"duration":{"id":7006,"approximate_duration":null,"dates_unknown":false},"drug":{"id":9780,"name":"Piperacillin-Tazobactam","url":"cure-api2.ncats.io/v1/drugs/9780","rxNorm_id":null,"notes":null},"use_drug":[{"id":11679,"answer":"Other","answer_other":"Likely given for bacterial cover","regimen":13115}],"created":"2020-11-28T19:21:03.869629Z","updated":"2020-12-01T15:11:06.752295Z","dose":null,"frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":null,"comments":null,"report":6595},{"id":13116,"duration":{"id":7007,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":11385,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13116},{"id":11386,"answer":"In a novel combination with another drug","answer_other":"","regimen":13116}],"created":"2020-11-28T19:21:03.876012Z","updated":"2020-12-01T15:11:06.725554Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6595}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8659,"answer":"Clinical assessment","answer_other":"","report":6595}],"how_diagnosis":[{"id":14864,"answer":"Clinical assessment","answer_other":"","report":6595},{"id":14865,"answer":"Imaging","answer_other":"","report":6595},{"id":14866,"answer":"PCR","answer_other":"","report":6595}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4769,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6595}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"},{"id":550,"name":"Respiratory Tract Infections"}],"races":[],"created":"2020-11-28T19:20:11.162615Z","updated":"2020-12-01T15:11:06.700148Z","title":"Veno-venous Extracorporeal Membrane Oxygenation Support in COVID-19 Respiratory Distress Syndrome: Initial Experience. Case 2.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32597627,"doi":"10.1097/MAT.0000000000001198","article_url":"https://pubmed.ncbi.nlm.nih.gov/32597627/","pub_year":2020,"published_authors":"Loforte A\r\nDal Checco E\r\nGliozzi G\r\nBenedetto M\r\nCavalli GG\r\nMariani C\r\nPiccone G\r\nAgulli M\r\nPacini D\r\nBaiocchi M","article_author_email":"Author email could not be found.","journal":"ASAIO journal (American Society for Artificial Internal Organs : 1992)","abstract":"SARS-CoV-2 may cause severe respiratory failure due to massive alveolar damage. Currently, no adequate curative therapy for Coronavirus Disease 2019 (COVID-19) disease exists. By considering overall impact of COVID-19 pandemic outbreak, an increased need of extracorporeal membrane oxygenation (ECMO) support becomes evident. We report on our preliminary institutional experience with COVID-19 patients receiving venovenous ECMO support.","article_type":"Original","study_type":"Case Report","number_of_patients":4,"article_patient_number":"2","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"31-40 years","sex":"Male","ethnicity":null,"country_contracted":"Italy","country_treated":"Italy","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"lungs","clinical_syndrome":"respiratory tract infection, pneumonia, respiratory failure","severity":"ICU/Critical Care","prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"While the patient was still on treatment","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"This patient was admitted to the ICU for 21 days where they received ECMO ventilation, neuromuscular blockers, nitric oxide, and underwent prone positioning.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[8342,8783,9780,10776]},{"id":6596,"regimens":[{"id":13117,"duration":{"id":7008,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":11387,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13117},{"id":11388,"answer":"In a novel combination with another drug","answer_other":"","regimen":13117}],"created":"2020-11-28T19:31:04.309786Z","updated":"2020-12-01T15:13:58.414076Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6596},{"id":13118,"duration":{"id":7009,"approximate_duration":null,"dates_unknown":false},"drug":{"id":9780,"name":"Piperacillin-Tazobactam","url":"cure-api2.ncats.io/v1/drugs/9780","rxNorm_id":null,"notes":null},"use_drug":[{"id":11680,"answer":"Other","answer_other":"Likely given for bacterial cover","regimen":13118}],"created":"2020-11-28T19:31:04.317799Z","updated":"2020-12-01T15:13:58.451582Z","dose":null,"frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":null,"comments":null,"report":6596},{"id":13119,"duration":{"id":7010,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":11391,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13119},{"id":11392,"answer":"In a novel combination with another drug","answer_other":"","regimen":13119}],"created":"2020-11-28T19:31:04.324690Z","updated":"2020-12-01T15:13:58.425961Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6596}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8660,"answer":"Clinical assessment","answer_other":"","report":6596}],"how_diagnosis":[{"id":14867,"answer":"Clinical assessment","answer_other":"","report":6596},{"id":14868,"answer":"Imaging","answer_other":"","report":6596},{"id":14869,"answer":"PCR","answer_other":"","report":6596}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4770,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6596}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"},{"id":550,"name":"Respiratory Tract Infections"}],"races":[],"created":"2020-11-28T19:30:24.140359Z","updated":"2020-12-01T15:13:58.406140Z","title":"Veno-venous Extracorporeal Membrane Oxygenation Support in COVID-19 Respiratory Distress Syndrome: Initial Experience. Case 3.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32597627,"doi":"10.1097/MAT.0000000000001198","article_url":"https://pubmed.ncbi.nlm.nih.gov/32597627/","pub_year":2020,"published_authors":"Loforte A\r\nDal Checco E\r\nGliozzi G\r\nBenedetto M\r\nCavalli GG\r\nMariani C\r\nPiccone G\r\nAgulli M\r\nPacini D\r\nBaiocchi M","article_author_email":"Author email could not be found.","journal":"ASAIO journal (American Society for Artificial Internal Organs : 1992)","abstract":"SARS-CoV-2 may cause severe respiratory failure due to massive alveolar damage. Currently, no adequate curative therapy for Coronavirus Disease 2019 (COVID-19) disease exists. By considering overall impact of COVID-19 pandemic outbreak, an increased need of extracorporeal membrane oxygenation (ECMO) support becomes evident. We report on our preliminary institutional experience with COVID-19 patients receiving venovenous ECMO support.","article_type":"Original","study_type":"Case Report","number_of_patients":4,"article_patient_number":"3","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"61-70 years","sex":"Male","ethnicity":null,"country_contracted":"Italy","country_treated":"Italy","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"lungs","clinical_syndrome":"respiratory tact infection, pneumonia, respiratory tract infection","severity":"ICU/Critical Care","prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"This patient underwent ECMO ventilation and experienced a pseudomonas aeruginosa superinfection. They received neuromuscular blockers and nitric oxide.","previously_treated":"","flagged":false,"other_coinfections":"BAL pseudomonas aeruginosa infection","disease":630,"drugs":[8342,9780,10776]},{"id":6597,"regimens":[{"id":13120,"duration":{"id":7011,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":11393,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13120},{"id":11394,"answer":"In a novel combination with another drug","answer_other":"","regimen":13120}],"created":"2020-11-28T19:39:49.817384Z","updated":"2020-12-01T15:15:59.636116Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6597},{"id":13121,"duration":{"id":7012,"approximate_duration":null,"dates_unknown":false},"drug":{"id":9780,"name":"Piperacillin-Tazobactam","url":"cure-api2.ncats.io/v1/drugs/9780","rxNorm_id":null,"notes":null},"use_drug":[{"id":11681,"answer":"Other","answer_other":"Likely given for bacterial cover","regimen":13121}],"created":"2020-11-28T19:39:49.824790Z","updated":"2020-12-01T15:15:59.680216Z","dose":null,"frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":null,"comments":null,"report":6597},{"id":13122,"duration":{"id":7013,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":11397,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13122},{"id":11398,"answer":"In a novel combination with another drug","answer_other":"","regimen":13122}],"created":"2020-11-28T19:39:49.830999Z","updated":"2020-12-01T15:15:59.648037Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6597},{"id":13123,"duration":{"id":7014,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":11399,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13123},{"id":11400,"answer":"In a novel combination with another drug","answer_other":"","regimen":13123}],"created":"2020-11-28T19:39:49.837324Z","updated":"2020-12-01T15:15:59.653659Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6597}],"site_of_infection":[],"specific_site":[],"how_outcome":[],"how_diagnosis":[{"id":14870,"answer":"Clinical assessment","answer_other":"","report":6597},{"id":14871,"answer":"Imaging","answer_other":"","report":6597},{"id":14872,"answer":"PCR","answer_other":"","report":6597}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Deteriorated","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4771,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6597}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"},{"id":550,"name":"Respiratory Tract Infections"}],"races":[],"created":"2020-11-28T19:39:08.647097Z","updated":"2020-12-01T15:15:59.628392Z","title":"Veno-venous Extracorporeal Membrane Oxygenation Support in COVID-19 Respiratory Distress Syndrome: Initial Experience. Case 4.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32597627,"doi":"10.1097/MAT.0000000000001198","article_url":"https://pubmed.ncbi.nlm.nih.gov/32597627/","pub_year":2020,"published_authors":"Loforte A\r\nDal Checco E\r\nGliozzi G\r\nBenedetto M\r\nCavalli GG\r\nMariani C\r\nPiccone G\r\nAgulli M\r\nPacini D\r\nBaiocchi M","article_author_email":"Author email could not be found.","journal":"ASAIO journal (American Society for Artificial Internal Organs : 1992)","abstract":"SARS-CoV-2 may cause severe respiratory failure due to massive alveolar damage. Currently, no adequate curative therapy for Coronavirus Disease 2019 (COVID-19) disease exists. By considering overall impact of COVID-19 pandemic outbreak, an increased need of extracorporeal membrane oxygenation (ECMO) support becomes evident. We report on our preliminary institutional experience with COVID-19 patients receiving venovenous ECMO support.","article_type":"Original","study_type":"Case Report","number_of_patients":4,"article_patient_number":"4","full_text_available":true,"outcome":"Patient died","surgery":"No","age":"51-60 years","sex":"Male","ethnicity":null,"country_contracted":"Italy","country_treated":"Italy","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"lungs","clinical_syndrome":"respiratory tract infection, pneumonia, respiratory failure","severity":"ICU/Critical Care","prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"While the patient was still on treatment","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"This patient was admitted to the ICU for 23 days, they received neuromuscular blockers, nitric oxide, corticosteroids, and underwent prone positioning. They died while being weaned off ECMO.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6122,8342,9780,10776]},{"id":6601,"regimens":[{"id":13148,"duration":{"id":7039,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":11438,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13148},{"id":11439,"answer":"In a novel combination with another drug","answer_other":"","regimen":13148}],"created":"2020-11-30T18:25:25.522469Z","updated":"2020-12-01T17:02:47.741750Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6601},{"id":13149,"duration":{"id":7040,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":11440,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13149},{"id":11441,"answer":"In a novel combination with another drug","answer_other":"","regimen":13149}],"created":"2020-11-30T18:25:25.530276Z","updated":"2020-12-01T17:02:47.748948Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6601},{"id":13150,"duration":{"id":7041,"approximate_duration":null,"dates_unknown":false},"drug":{"id":11339,"name":"Convalescent plasma","url":"cure-api2.ncats.io/v1/drugs/11339","rxNorm_id":null,"notes":null},"use_drug":[{"id":11442,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13150},{"id":11443,"answer":"In a novel combination with another drug","answer_other":"","regimen":13150}],"created":"2020-11-30T18:25:25.536364Z","updated":"2020-12-01T17:02:47.755106Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6601}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8671,"answer":"Clinical assessment","answer_other":"","report":6601},{"id":8672,"answer":"Imaging","answer_other":"","report":6601}],"how_diagnosis":[{"id":14893,"answer":"Imaging","answer_other":"","report":6601},{"id":14894,"answer":"Clinical assessment","answer_other":"","report":6601},{"id":14895,"answer":"PCR","answer_other":"","report":6601}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-11-30T02:18:00.123926Z","updated":"2020-12-01T17:02:47.733971Z","title":"A case of cytokine hemofiltration and extracorporeal life support as treatment of coronavirus disease 2019 (COVID-19) respiratory failure.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32624302,"doi":"10.1016/j.jtcvs.2020.05.082","article_url":"https://pubmed.ncbi.nlm.nih.gov/32624302/","pub_year":2020,"published_authors":"Al-Qudsi O\r\nWhitson B\r\nBhatt A\r\nChucta S\r\nTripathi R","article_author_email":"Author email could not be found.","journal":"The Journal of thoracic and cardiovascular surgery","abstract":"No abstract available","article_type":"Original","study_type":"Case Report","number_of_patients":1,"article_patient_number":"1","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"51-60 years","sex":"Female","ethnicity":null,"country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"obesity","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"respiratory tract infection","severity":"ICU/Critical Care","prev_treatment":"","unusual":"As her oxygenation and lung compliance continued to worsen despite optimal medical therapy, she was placed on veno-venous extracorporeal life support (VV-ECLS) in accordance with institutional guidelines. Due to her worsening clinical status, the decision was made to proceed with cytokine hemofiltration. Access for hemofiltration was obtained with a standard 13-French dual-lumen hemodialysis catheter. Her treatment regimen consisted of 2 sessions on consecutive days, each lasting 12 hours. The treatments were performed using a SeaStar CLR 2.0 (SeaStar Medical, Denver, Colo) high cut-off filter and continuous veno-venous hemofiltration using a clearance therapy of 35 mL/kg/h and a filtration fraction of <0.1. Within 12 hours of each treatment, both IL-6 levels and TNF-Î± dropped by a magnitude of 25%.","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"The novel use of cytokine hemofiltration for treatment of severe ARDS secondary to COVID-19 in a patient on VV-ECLS.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[11339,8342,10776]},{"id":6606,"regimens":[{"id":13138,"duration":{"id":7029,"approximate_duration":"2 Days","dates_unknown":true},"drug":{"id":9137,"name":"Milrinone","url":"cure-api2.ncats.io/v1/drugs/9137","rxNorm_id":null,"notes":null},"use_drug":[{"id":11683,"answer":"It was not used in a new way","answer_other":"","regimen":13138}],"created":"2020-11-30T18:11:52.837240Z","updated":"2020-12-01T21:45:33.476834Z","dose":"0.5 mcg/kg/min","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"Mechanical ventilation and prone positioning","comments":null,"report":6606},{"id":13139,"duration":{"id":7030,"approximate_duration":"1 Day","dates_unknown":true},"drug":{"id":9362,"name":"Norepinephrine","url":"cure-api2.ncats.io/v1/drugs/9362","rxNorm_id":null,"notes":null},"use_drug":[{"id":11684,"answer":"It was not used in a new way","answer_other":"","regimen":13139}],"created":"2020-11-30T18:11:52.845542Z","updated":"2020-12-01T21:45:33.477803Z","dose":"0.2 mcg/kg/min","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"Mechanical ventilation and prone positioning","comments":null,"report":6606},{"id":13140,"duration":{"id":7031,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8971,"name":"Meropenem","url":"cure-api2.ncats.io/v1/drugs/8971","rxNorm_id":null,"notes":null},"use_drug":[{"id":11685,"answer":"It was not used in a new way","answer_other":"","regimen":13140},{"id":11686,"answer":"Other","answer_other":"Started empirically","regimen":13140}],"created":"2020-11-30T18:11:52.852349Z","updated":"2020-12-01T21:45:33.478705Z","dose":null,"frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"Mechanical ventilation and prone positioning","comments":null,"report":6606},{"id":13141,"duration":{"id":7032,"approximate_duration":null,"dates_unknown":false},"drug":{"id":11121,"name":"Vancomycin","url":"cure-api2.ncats.io/v1/drugs/11121","rxNorm_id":11124,"notes":""},"use_drug":[{"id":11687,"answer":"It was not used in a new way","answer_other":"","regimen":13141},{"id":11688,"answer":"Other","answer_other":"Started empirically","regimen":13141}],"created":"2020-11-30T18:11:52.858846Z","updated":"2020-12-01T21:45:33.479553Z","dose":null,"frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"Mechanical ventilation and prone positioning","comments":null,"report":6606},{"id":13142,"duration":{"id":7033,"approximate_duration":null,"dates_unknown":false},"drug":{"id":7921,"name":"Fluconazole","url":"cure-api2.ncats.io/v1/drugs/7921","rxNorm_id":null,"notes":null},"use_drug":[{"id":11689,"answer":"It was not used in a new way","answer_other":"","regimen":13142},{"id":11690,"answer":"Other","answer_other":"Started empirically","regimen":13142}],"created":"2020-11-30T18:11:52.865346Z","updated":"2020-12-01T21:45:33.480399Z","dose":null,"frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"Mechanical ventilation and prone positioning","comments":null,"report":6606},{"id":13143,"duration":{"id":7034,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8233,"name":"Heparin","url":"cure-api2.ncats.io/v1/drugs/8233","rxNorm_id":null,"notes":null},"use_drug":[{"id":11691,"answer":"Other","answer_other":"For suspect thrombosis","regimen":13143}],"created":"2020-11-30T18:11:52.871774Z","updated":"2020-12-01T21:45:33.481265Z","dose":null,"frequency":"Therapeutic dosages","route":"","severity":"ICU/Critical Care","severity_detail":"Mechanical ventilation and prone positioning","comments":null,"report":6606},{"id":13144,"duration":{"id":7035,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":11437,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13144},{"id":11436,"answer":"In a novel combination with another drug","answer_other":"","regimen":13144}],"created":"2020-11-30T18:11:52.877732Z","updated":"2020-12-01T21:45:33.405923Z","dose":"12 mg/kg","frequency":"q12h","route":"","severity":"ICU/Critical Care","severity_detail":"Mechanical ventilation and prone positioning","comments":null,"report":6606},{"id":13145,"duration":{"id":7036,"approximate_duration":"5 Days","dates_unknown":true},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":11446,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13145},{"id":11447,"answer":"In a novel combination with another drug","answer_other":"","regimen":13145}],"created":"2020-11-30T18:11:52.884022Z","updated":"2020-12-01T21:45:33.411968Z","dose":"5 mg/kg","frequency":"QD","route":"","severity":"ICU/Critical Care","severity_detail":"Mechanical ventilation and prone positioning","comments":null,"report":6606},{"id":13146,"duration":{"id":7037,"approximate_duration":"5 Days","dates_unknown":true},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":11448,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13146},{"id":11449,"answer":"In a novel combination with another drug","answer_other":"","regimen":13146}],"created":"2020-11-30T18:11:52.890623Z","updated":"2020-12-01T21:45:33.417964Z","dose":"7 mg/kg","frequency":"QD","route":"","severity":"ICU/Critical Care","severity_detail":"Mechanical ventilation and prone positioning","comments":null,"report":6606},{"id":13147,"duration":{"id":7038,"approximate_duration":"5 Days","dates_unknown":true},"drug":{"id":9077,"name":"Methylprednisolone","url":"cure-api2.ncats.io/v1/drugs/9077","rxNorm_id":null,"notes":null},"use_drug":[{"id":11450,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13147},{"id":11451,"answer":"In a novel combination with another drug","answer_other":"","regimen":13147}],"created":"2020-11-30T18:11:52.896767Z","updated":"2020-12-01T21:45:33.423724Z","dose":"1mg/kg","frequency":"QD","route":"","severity":"ICU/Critical Care","severity_detail":"Mechanical ventilation and prone positioning","comments":null,"report":6606}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8675,"answer":"Clinical assessment","answer_other":"","report":6606},{"id":8676,"answer":"PCR","answer_other":"","report":6606}],"how_diagnosis":[{"id":14890,"answer":"Clinical assessment","answer_other":"","report":6606},{"id":14891,"answer":"Imaging","answer_other":"","report":6606},{"id":14892,"answer":"PCR","answer_other":"","report":6606},{"id":14973,"answer":"Serology","answer_other":"","report":6606}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4780,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6606},{"id":4781,"answer":"Unusual disease presentation","answer_other":"","report":6606}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-11-30T18:04:08.916512Z","updated":"2020-12-01T21:45:33.362384Z","title":"New onset severe right ventricular failure associated with COVID-19 in a young infant without previous heart disease.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32600496,"doi":"10.1017/S1047951120001857","article_url":"https://pubmed.ncbi.nlm.nih.gov/32600496/","pub_year":2020,"published_authors":"Rodriguez-Gonzalez M\r\nRodrÃ­guez-Campoy P\r\nSÃ¡nchez-CÃ³dez M\r\nGutiÃ©rrez-Rosa I\r\nCastellano-Martinez A\r\nRodrÃ­guez-BenÃ­tez A","article_author_email":"doctormoisesrodriguez@gmail.com","journal":"Cardiology in the young","abstract":"We present our recent experience with an infant with a personal history of short bowel syndrome that presented with fever, cyanosis, and cardiogenic shock secondary to severe pulmonary hypertension and right ventricular failure without pulmonary thromboembolism. He did not present signs of toxin-mediated disease or Kawasaki disease. He was finally diagnosed with SARS-CoV-2 infection. If this presentation is confirmed in future research, the severe cardiovascular impairment in children with COVID-19 could be also attributable to the primary pulmonary infection, not only to a multisystem inflammatory syndrome but also in children without heart disease.          \r\n        Keywords:      \r\n                  COVID-19; SARS-CoV-2; cardiogenic shock; heart failure; paediatric multisystem inflammatory syndrome; pulmonary hypertension.","article_type":"Original","study_type":"Case Report","number_of_patients":1,"article_patient_number":"","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"<1 year","sex":"Male","ethnicity":null,"country_contracted":"Spain","country_treated":"Spain","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"Short bowel syndrome secondary to multiple intestinal resections during the neonatal period.","pregnant":false,"unknown":false,"site_of_disease":"Lungs, Heart","clinical_syndrome":"Pneumonia, cardiogenic shock secondary to severe pulmonary hypertension, irritability, tachypnoea, cyanosis, tachycardia, hypotension, poor perfusion, weak peripheral pulses, hepatomegaly","severity":"ICU/Critical Care","prev_treatment":"","unusual":"The 12-lead electrocardiogram showed sinus tachycardia, right axis deviation, and right ventricular hypertrophy. Transthoracic echocardiography did not reveal any CHD with normal dimensions and systolic function of the left ventricle (left ventricular ejection fraction 62%). However, it showed severely dilated right chambers, severe right ventricular systolic dysfunction, and supra-systemic pulmonary hypertension. A thoracic angioCT-scan ruled out massive pulmonary thromboembolism but showed a pattern of ground glass and numerous consolidations of predominance in the posterior-basal segments of both lungs","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"Patient had received domiciliary parenteral nutrition through a central tunnelled line at the superior vena cava. He was also under antithrombotic prophylaxis with lowmolecular- weight heparin due to previous episodes of local thrombotic obstructions of thecentral line. Of note, the parents had forgotten to administer the heparin for 3 days since presentation.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6122,7921,8233,8342,8971,9077,9137,9362,10776,11121]},{"id":6614,"regimens":[{"id":13177,"duration":{"id":7067,"approximate_duration":"3days","dates_unknown":true},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":11504,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13177},{"id":11721,"answer":"In a novel combination with another drug","answer_other":"","regimen":13177}],"created":"2020-11-30T20:24:56.065742Z","updated":"2020-12-02T16:24:42.366280Z","dose":null,"frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":null,"comments":null,"report":6614},{"id":13178,"duration":{"id":7068,"approximate_duration":"3days","dates_unknown":true},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":11505,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13178},{"id":11722,"answer":"In a novel combination with another drug","answer_other":"","regimen":13178}],"created":"2020-11-30T20:24:56.074046Z","updated":"2020-12-02T16:24:42.367109Z","dose":null,"frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":null,"comments":null,"report":6614},{"id":13179,"duration":{"id":7069,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":11506,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13179},{"id":11507,"answer":"In a novel combination with another drug","answer_other":"","regimen":13179}],"created":"2020-11-30T20:25:45.335648Z","updated":"2020-12-02T16:24:42.333292Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6614},{"id":13180,"duration":{"id":7070,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6675,"name":"Ceftriaxone","url":"cure-api2.ncats.io/v1/drugs/6675","rxNorm_id":null,"notes":null},"use_drug":[{"id":11723,"answer":"Other","answer_other":"Likely given for bacterial cover","regimen":13180}],"created":"2020-11-30T20:25:45.343031Z","updated":"2020-12-02T16:24:42.367907Z","dose":null,"frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":null,"comments":null,"report":6614}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8683,"answer":"Clinical assessment","answer_other":"","report":6614}],"how_diagnosis":[{"id":14911,"answer":"Clinical assessment","answer_other":"","report":6614},{"id":14912,"answer":"Imaging","answer_other":"","report":6614},{"id":14913,"answer":"PCR","answer_other":"","report":6614}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4793,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6614},{"id":4794,"answer":"Co-Infection or Complex Co-morbidities","answer_other":"","report":6614}],"adverse_event_outcome":[{"id":89,"answer":"Other Serious or Important Medical Events","report":6614}],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-11-30T20:03:38.523541Z","updated":"2020-12-02T16:24:42.313419Z","title":"SARS-CoV-2 Infection in Patients with Down Syndrome, Congenital Heart Disease, and Pulmonary Hypertension: Is Down Syndrome a Risk Factor? Case 3.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32610168,"doi":"10.1016/j.jpeds.2020.06.076","article_url":"https://pubmed.ncbi.nlm.nih.gov/32610168/","pub_year":2020,"published_authors":"Krishnan US\r\nKrishnan SS\r\nJain S\r\nChavolla-Calderon MB\r\nLewis M\r\nChung WK\r\nRosenzweig EB","article_author_email":"Author email could not be found.","journal":"The Journal of pediatrics","abstract":"With increasing information available about the epidemiology, pathophysiology, and management of patients affected with severe acute respiratory syndrome corona virus-2 infection, patients with Down syndrome, congenital heart disease, airway obstruction, and pulmonary hypertension present a unique challenge. This case series describes 3 patients with Down syndrome and respiratory failure secondary to coronavirus infection.","article_type":"Original","study_type":"Case Series","number_of_patients":3,"article_patient_number":"3","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"21-30 years","sex":"Male","ethnicity":null,"country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":true,"diabetes_mellitus":false,"hypertension":true,"cardiovascular_disease":true,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":true,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"obesity (body mass index of 48) with Down syndrome and OSA, had an unrepaired partial AVSD with a small primum atrial shunt and no ventricular shunt. Mild pulmonary hypertension.","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"respiratory tract infection","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":true,"adverse_events":"QTc interval prolongation due to azithromycin and hydroxychloroquine","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"A cardiac catheterization at 6 years of age had indicated minimal atrial shunting and mild pulmonary hypertension, which was attributed to OSA, for which night-time CPAP was recommended. At 19 years of age, he was reevaluated for worsening dyspnea. Echocardiography and cardiac catheterization revealed systemic right heart pressures with minimal atrial shunting and an indexed pulmonary vascular resistance of 17 Wood unitsâsquare meter.2 He was treated as an outpatient with ambrisentan and tadalafil for pulmonary hypertension. He was intubated and diagnosed with SARS-CoV-2 pneumonia-associated respiratory failure. Ambrisentan and tadalafil were continued for pulmonary hypertension. He was given ceftriaxone intravenously and inhaled nitric oxide with improved oxygen saturation. He also received a dose of tocilizumab as part of a clinical trial. The intensive care team used strategies for acute respiratory distress syndrome, including prone ventilation with gradually improving ventilatory requirements. During hospitalization, he received a tracheostomy and has since been discharged home on tracheostomy collar by day and night time CPAP.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6122,6675,8342,10776]},{"id":6643,"regimens":[{"id":13275,"duration":{"id":7165,"approximate_duration":null,"dates_unknown":false},"drug":{"id":9362,"name":"Norepinephrine","url":"cure-api2.ncats.io/v1/drugs/9362","rxNorm_id":null,"notes":null},"use_drug":[{"id":11706,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13275},{"id":11707,"answer":"In a novel combination with another drug","answer_other":"","regimen":13275}],"created":"2020-12-01T23:46:18.094090Z","updated":"2020-12-02T00:09:51.427373Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"Intubation and mechanical ventilation","comments":null,"report":6643},{"id":13276,"duration":{"id":7166,"approximate_duration":"5 Days","dates_unknown":true},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":11708,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13276},{"id":11709,"answer":"In a novel combination with another drug","answer_other":"","regimen":13276}],"created":"2020-12-01T23:46:18.102748Z","updated":"2020-12-02T00:09:51.433744Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"Intubation and mechanical ventilation","comments":null,"report":6643},{"id":13277,"duration":{"id":7167,"approximate_duration":"5 Days","dates_unknown":true},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":11710,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13277},{"id":11711,"answer":"In a novel combination with another drug","answer_other":"","regimen":13277}],"created":"2020-12-01T23:46:18.108925Z","updated":"2020-12-02T00:09:51.439550Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"Intubation and mechanical ventilation","comments":null,"report":6643},{"id":13278,"duration":{"id":7168,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":11712,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13278},{"id":11713,"answer":"In a novel combination with another drug","answer_other":"","regimen":13278}],"created":"2020-12-01T23:46:18.115357Z","updated":"2020-12-02T00:09:51.445003Z","dose":"","frequency":"1 Dose","route":"","severity":"ICU/Critical Care","severity_detail":"Intubation and mechanical ventilation","comments":null,"report":6643}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8716,"answer":"Clinical assessment","answer_other":"","report":6643}],"how_diagnosis":[{"id":14983,"answer":"Clinical assessment","answer_other":"","report":6643},{"id":14984,"answer":"Imaging","answer_other":"","report":6643},{"id":14985,"answer":"PCR","answer_other":"","report":6643}],"author_username":"Paige Evans","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Nurse","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4823,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6643},{"id":4824,"answer":"Unusual disease presentation","answer_other":"","report":6643}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":399,"name":"Diarrhea (Infectious)"},{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-12-01T23:40:25.600410Z","updated":"2020-12-02T00:09:51.419549Z","title":"Gastrointestinal Findings in a Patient With COVID-19.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32637437,"doi":"10.14309/crj.0000000000000392","article_url":"https://pubmed.ncbi.nlm.nih.gov/32637437/","pub_year":2020,"published_authors":"Makar M\r\nJohn Pisano T\r\nMinacapelli CD\r\nRustgi V","article_author_email":"Michaelmakar5@gmail.com","journal":"ACG case reports journal","abstract":"The novel coronavirus (severe acute respiratory syndrome coronavirus 2) that causes coronavirus disease 2019 was discovered in December 2019 in Wuhan, China, and has rapidly spread across the world becoming a pandemic and disrupting societies, economies, and public health. Digestive symptoms and gastrointestinal (GI) manifestations are increasingly being reported in patients with the virus. There is also a growing body of evidence to suggest that liver injury is frequent. We present a patient diagnosed with coronavirus who presented with several days of GI symptoms and discuss the relevance of GI disease and liver injury in these patients.","article_type":"Original","study_type":"Case Report","number_of_patients":1,"article_patient_number":"","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"71-80 years","sex":"Female","ethnicity":null,"country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":true,"hypertension":true,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"Lung","clinical_syndrome":"Pneumonia, shock, nonbilious, nonbloody vomiting, watery diarrhea, diffuse wheezing and bilateral crackles","severity":null,"prev_treatment":"","unusual":"Unusual clinical manifestation by gastrointestinal symptoms.","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"While the patient was still on treatment","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6122,8342,9362,10776]},{"id":6688,"regimens":[{"id":13405,"duration":{"id":7294,"approximate_duration":"5days","dates_unknown":true},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":11975,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13405},{"id":11976,"answer":"In a novel combination with another drug","answer_other":"","regimen":13405}],"created":"2020-12-04T22:54:40.410801Z","updated":"2020-12-10T19:37:04.885435Z","dose":"600mg/400mg","frequency":"BID","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6688},{"id":13406,"duration":{"id":7295,"approximate_duration":null,"dates_unknown":false},"drug":{"id":7629,"name":"Enoxaparin","url":"cure-api2.ncats.io/v1/drugs/7629","rxNorm_id":null,"notes":null},"use_drug":[{"id":11977,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13406},{"id":11978,"answer":"In a novel combination with another drug","answer_other":"","regimen":13406}],"created":"2020-12-04T22:54:40.418866Z","updated":"2020-12-10T19:37:04.892247Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6688},{"id":13407,"duration":{"id":7296,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":12123,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13407}],"created":"2020-12-04T22:54:40.425315Z","updated":"2020-12-10T19:37:04.939317Z","dose":null,"frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":null,"comments":null,"report":6688},{"id":13408,"duration":{"id":7297,"approximate_duration":null,"dates_unknown":false},"drug":{"id":11301,"name":"Remdesivir","url":"cure-api2.ncats.io/v1/drugs/11301","rxNorm_id":null,"notes":null},"use_drug":[{"id":12124,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13408}],"created":"2020-12-04T22:54:40.431879Z","updated":"2020-12-10T19:37:04.940198Z","dose":null,"frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":null,"comments":null,"report":6688},{"id":13409,"duration":{"id":7298,"approximate_duration":null,"dates_unknown":false},"drug":{"id":7561,"name":"Eculizumab","url":"cure-api2.ncats.io/v1/drugs/7561","rxNorm_id":null,"notes":null},"use_drug":[{"id":12125,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13409}],"created":"2020-12-04T22:54:40.438261Z","updated":"2020-12-10T19:37:04.941040Z","dose":null,"frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":null,"comments":null,"report":6688}],"site_of_infection":[{"id":93,"answer":"Lung","report":6688}],"specific_site":[{"id":41,"answer":"respiratory tract infection","report":6688}],"how_outcome":[{"id":8819,"answer":"Clinical assessment","answer_other":"","report":6688}],"how_diagnosis":[{"id":15098,"answer":"Clinical assessment","answer_other":"","report":6688}],"author_username":"Belinda Nhundu","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4877,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6688}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-12-04T22:41:53.658216Z","updated":"2020-12-10T19:37:04.877089Z","title":"Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19.Case 1.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32771488,"doi":"10.1016/j.clim.2020.108555","article_url":"https://pubmed.ncbi.nlm.nih.gov/32771488/","pub_year":2020,"published_authors":"Laurence J\r\nMulvey JJ\r\nSeshadri M\r\nRacanelli A\r\nHarp J\r\nSchenck EJ\r\nZappetti D\r\nHorn EM\r\nMagro CM","article_author_email":"jlaurenc@med.cornell.edu","journal":"Clinical immunology (Orlando, Fla.)","abstract":"Respiratory failure and acute kidney injury (AKI) are associated with high mortality in SARS-CoV-2-associated Coronavirus disease 2019 (COVID-19). These manifestations are linked to a hypercoaguable, pro-inflammatory state with persistent, systemic complement activation. Three critical COVID-19 patients recalcitrant to multiple interventions had skin biopsies documenting deposition of the terminal complement component C5b-9, the lectin complement pathway enzyme MASP2, and C4d in microvascular endothelium. Administration of anti-C5 monoclonal antibody eculizumab led to a marked decline in D-dimers and neutrophil counts in all three cases, and normalization of liver functions and creatinine in two. One patient with severe heart failure and AKI had a complete remission. The other two individuals had partial remissions, one with resolution of his AKI but ultimately succumbing to respiratory failure, and another with a significant decline in FiO2 requirements, but persistent renal failure. In conclusion, anti-complement therapy may be beneficial in at least some patients with critical COVID-19.","article_type":"Original","study_type":"Case Series","number_of_patients":3,"article_patient_number":"1","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"","age":"21-30 years","sex":"Male","ethnicity":null,"country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"Lungs, Gastrointestinal","clinical_syndrome":"respiratory infection, diarrhea","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"","follow_up_period":null,"relapse":"","reminder":false,"when_reminder":"1 week","additional_info":"","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[7561,7629,8342,11301,10776]},{"id":6701,"regimens":[{"id":13429,"duration":{"id":7318,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8971,"name":"Meropenem","url":"cure-api2.ncats.io/v1/drugs/8971","rxNorm_id":null,"notes":null},"use_drug":[{"id":12015,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13429},{"id":12021,"answer":"In a novel combination with another drug","answer_other":"","regimen":13429},{"id":12017,"answer":"In a novel population (e.g. pediatrics/neonates, pregnant women, immunosuppressed, etc.)","answer_other":"","regimen":13429}],"created":"2020-12-09T04:36:22.073142Z","updated":"2020-12-09T04:42:56.235507Z","dose":"","frequency":"","route":"IV","severity":"ICU/Critical Care","severity_detail":"Intubation and mechanical ventilation","comments":null,"report":6701},{"id":13430,"duration":{"id":7319,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8745,"name":"Linezolid","url":"cure-api2.ncats.io/v1/drugs/8745","rxNorm_id":null,"notes":null},"use_drug":[{"id":12018,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13430},{"id":12019,"answer":"In a novel combination with another drug","answer_other":"","regimen":13430},{"id":12020,"answer":"In a novel population (e.g. pediatrics/neonates, pregnant women, immunosuppressed, etc.)","answer_other":"","regimen":13430}],"created":"2020-12-09T04:36:22.081372Z","updated":"2020-12-09T04:42:56.241891Z","dose":"","frequency":"","route":"IV","severity":"ICU/Critical Care","severity_detail":"Intubation and mechanical ventilation","comments":null,"report":6701},{"id":13431,"duration":{"id":7320,"approximate_duration":null,"dates_unknown":false},"drug":{"id":9077,"name":"Methylprednisolone","url":"cure-api2.ncats.io/v1/drugs/9077","rxNorm_id":null,"notes":null},"use_drug":[{"id":12022,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13431},{"id":12023,"answer":"In a novel combination with another drug","answer_other":"","regimen":13431},{"id":12024,"answer":"In a novel population (e.g. pediatrics/neonates, pregnant women, immunosuppressed, etc.)","answer_other":"","regimen":13431}],"created":"2020-12-09T04:36:22.088531Z","updated":"2020-12-09T04:42:56.248051Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"Intubation and mechanical ventilation","comments":null,"report":6701},{"id":13432,"duration":{"id":7321,"approximate_duration":null,"dates_unknown":false},"drug":{"id":7629,"name":"Enoxaparin","url":"cure-api2.ncats.io/v1/drugs/7629","rxNorm_id":null,"notes":null},"use_drug":[{"id":12025,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13432},{"id":12026,"answer":"In a novel combination with another drug","answer_other":"","regimen":13432},{"id":12027,"answer":"In a novel population (e.g. pediatrics/neonates, pregnant women, immunosuppressed, etc.)","answer_other":"","regimen":13432}],"created":"2020-12-09T04:36:22.095285Z","updated":"2020-12-09T04:42:56.253811Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"Intubation and mechanical ventilation","comments":null,"report":6701},{"id":13433,"duration":{"id":7322,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":12028,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13433},{"id":12029,"answer":"In a novel combination with another drug","answer_other":"","regimen":13433},{"id":12030,"answer":"In a novel population (e.g. pediatrics/neonates, pregnant women, immunosuppressed, etc.)","answer_other":"","regimen":13433}],"created":"2020-12-09T04:36:22.102068Z","updated":"2020-12-09T04:42:56.259626Z","dose":"12mg/kg","frequency":"One Dose","route":"","severity":"ICU/Critical Care","severity_detail":"Intubation and mechanical ventilation","comments":null,"report":6701},{"id":13434,"duration":{"id":7323,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8412,"name":"Immunoglobulins, Intravenous","url":"cure-api2.ncats.io/v1/drugs/8412","rxNorm_id":null,"notes":null},"use_drug":[{"id":12031,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13434},{"id":12032,"answer":"In a novel combination with another drug","answer_other":"","regimen":13434},{"id":12033,"answer":"In a novel population (e.g. pediatrics/neonates, pregnant women, immunosuppressed, etc.)","answer_other":"","regimen":13434}],"created":"2020-12-09T04:36:22.108709Z","updated":"2020-12-09T04:42:56.265918Z","dose":"2g/kg","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"Intubation and mechanical ventilation","comments":null,"report":6701}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8794,"answer":"Clinical assessment","answer_other":"","report":6701}],"how_diagnosis":[{"id":15118,"answer":"Clinical assessment","answer_other":"","report":6701},{"id":15119,"answer":"PCR","answer_other":"","report":6701}],"author_username":"Paige Evans","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Nurse","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4896,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6701},{"id":4897,"answer":"Unusual disease presentation","answer_other":"","report":6701},{"id":4898,"answer":"There is no standard/approved therapy in this patient population","answer_other":"","report":6701}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":399,"name":"Diarrhea (Infectious)"},{"id":396,"name":"Pneumonia"}],"races":[{"id":540,"answer":"White","answer_other":""}],"created":"2020-12-09T04:23:25.642742Z","updated":"2020-12-09T04:42:56.226529Z","title":"Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with 2019 Novel Coronavirus (SARS-CoV-2) Infection. Case 2.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32733733,"doi":"10.1155/2020/8875987","article_url":"https://pubmed.ncbi.nlm.nih.gov/32733733/","pub_year":2020,"published_authors":"Kest H\r\nKaushik A\r\nDeBruin W\r\nColletti M\r\nGoldberg D","article_author_email":"kesth@sjhmc.org","journal":"Case reports in pediatrics","abstract":"We report three critically ill pediatric patients (aged 6-10 years), presenting with features of multisystem inflammatory syndrome in children (MIS-C) from April 4 to May 10, 2020, to a tertiary-care center in New Jersey, United States. All patients tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and were previously healthy. Clinical presentations were similar with fever, abdominal pain, gastrointestinal complaints, and/or rash. One patient had altered mental status with cerebrospinal fluid (CSF) findings consistent with aseptic meningitis. Laboratory values were remarkable for high levels of C-reactive protein, D-dimers, B-type natriuretic peptide (BNP), and troponin in all patients. All had low albumin levels. Evaluation for other infectious etiologies was negative. All of the patients were critically ill, requiring admission to the intensive care unit. All had circulatory shock and needed inotropes. Two patients had respiratory failure requiring advanced respiratory support and one had cardiac dysfunction. All patients received steroids, and two received intravenous immunoglobulin (IVIG). One patient received tocilizumab. None of the children died. MIS-C is a recently recognized pediatric illness spectrum in association with SARS-CoV-2 infection, and clinical characterization is essential for understanding disease mechanisms to inform clinical practice.","article_type":"Original","study_type":"Case Report","number_of_patients":3,"article_patient_number":"2","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"No","age":"6-10 years","sex":"Female","ethnicity":"Hispanic/Latino","country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"Lungs, Gastrointestinal System, Lungs","clinical_syndrome":"Respiratory failure, headaches, vomiting, abdominal pain, diarrhea, conjunctivitis, rash","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[7629,8412,8745,8971,9077,10776]},{"id":6703,"regimens":[{"id":13448,"duration":{"id":7337,"approximate_duration":null,"dates_unknown":false},"drug":{"id":9780,"name":"Piperacillin-Tazobactam","url":"cure-api2.ncats.io/v1/drugs/9780","rxNorm_id":null,"notes":null},"use_drug":[{"id":12061,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13448},{"id":12062,"answer":"In a novel combination with another drug","answer_other":"","regimen":13448}],"created":"2020-12-09T17:01:18.486944Z","updated":"2020-12-09T17:22:05.711358Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"Oxygen therapy","comments":null,"report":6703},{"id":13449,"duration":{"id":7338,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":12063,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13449},{"id":12064,"answer":"In a novel combination with another drug","answer_other":"","regimen":13449}],"created":"2020-12-09T17:01:18.494720Z","updated":"2020-12-09T17:22:05.717856Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"Oxygen therapy","comments":null,"report":6703},{"id":13450,"duration":{"id":7339,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":12065,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13450},{"id":12066,"answer":"In a novel combination with another drug","answer_other":"","regimen":13450}],"created":"2020-12-09T17:01:18.501080Z","updated":"2020-12-09T17:22:05.723382Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"Oxygen therapy","comments":null,"report":6703},{"id":13451,"duration":{"id":7340,"approximate_duration":null,"dates_unknown":false},"drug":{"id":9077,"name":"Methylprednisolone","url":"cure-api2.ncats.io/v1/drugs/9077","rxNorm_id":null,"notes":null},"use_drug":[{"id":12067,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13451},{"id":12068,"answer":"In a novel combination with another drug","answer_other":"","regimen":13451}],"created":"2020-12-09T17:01:18.507283Z","updated":"2020-12-09T17:22:05.728906Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"Oxygen therapy","comments":null,"report":6703},{"id":13452,"duration":{"id":7341,"approximate_duration":null,"dates_unknown":false},"drug":{"id":7629,"name":"Enoxaparin","url":"cure-api2.ncats.io/v1/drugs/7629","rxNorm_id":null,"notes":null},"use_drug":[{"id":12069,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13452},{"id":12070,"answer":"In a novel combination with another drug","answer_other":"","regimen":13452}],"created":"2020-12-09T17:01:18.513603Z","updated":"2020-12-09T17:22:05.734447Z","dose":"60mg","frequency":"QD","route":"","severity":"Inpatient","severity_detail":"Oxygen therapy","comments":null,"report":6703},{"id":13453,"duration":{"id":7342,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":12071,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13453},{"id":12072,"answer":"In a novel combination with another drug","answer_other":"","regimen":13453}],"created":"2020-12-09T17:01:18.519937Z","updated":"2020-12-09T17:22:05.739881Z","dose":"600mg","frequency":"Single Dose","route":"","severity":"Inpatient","severity_detail":"Oxygen therapy","comments":null,"report":6703},{"id":13454,"duration":{"id":7343,"approximate_duration":null,"dates_unknown":false},"drug":{"id":11420,"name":"Low Molecular Weight Heparin","url":"cure-api2.ncats.io/v1/drugs/11420","rxNorm_id":null,"notes":null},"use_drug":[{"id":12073,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13454},{"id":12074,"answer":"In a novel combination with another drug","answer_other":"","regimen":13454}],"created":"2020-12-09T17:07:12.287562Z","updated":"2020-12-09T17:22:05.745742Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"Oxygen therapy","comments":null,"report":6703}],"site_of_infection":[],"specific_site":[],"how_outcome":[],"how_diagnosis":[{"id":15128,"answer":"Clinical assessment","answer_other":"","report":6703},{"id":15129,"answer":"Imaging","answer_other":"","report":6703}],"author_username":"Paige Evans","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Nurse","author_affiliation":"None","author_country":"","outcome_computed":"Deteriorated","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4905,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6703},{"id":4906,"answer":"Unusual disease presentation","answer_other":"","report":6703}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-12-09T05:15:10.640990Z","updated":"2020-12-09T17:22:05.703761Z","title":"Aortic thrombus in patients with severe COVID-19: review of three cases. Case 1.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32648092,"doi":"10.1007/s11239-020-02219-z","article_url":"https://pubmed.ncbi.nlm.nih.gov/32648092/","pub_year":2020,"published_authors":"de Carranza M\r\nSalazar DE\r\nTroya J\r\nAlcÃ¡zar R\r\nPeÃ±a C\r\nAragÃ³n E\r\nDomÃ­nguez M\r\nTorres J\r\nMuÃ±oz-Rivas N","article_author_email":"mariadecarranzalopez@gmail.com","journal":"Journal of thrombosis and thrombolysis","abstract":"Coronavirus disease 2019 (COVID-19) could predispose to both venous and arterial thromboembolism, in an exaggerated immune response to the virus, especially in severe patients. Even though aortic clots are a rare entity, the pro-coagulant nature of COVID-19 is associated with thrombosis in atypical locations and should be considered in patients with severe abnormalities in coagulation parameters. We describe a series of three cases of aortic thrombi diagnosed by computerized tomography (CT) angiography in patients with confirmed SARS-CoV-2 infection.          \r\n        Keywords:      \r\n                  Aortic thrombi; COVID-19; Severe pneumonia.","article_type":"Original","study_type":"Case Report","number_of_patients":3,"article_patient_number":"1","full_text_available":true,"outcome":"Patient died","surgery":"No","age":"71-80 years","sex":"Male","ethnicity":null,"country_contracted":"Spain","country_treated":"Spain","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"Dyslipidemia","pregnant":false,"unknown":false,"site_of_disease":"Lungs, Heart","clinical_syndrome":"Multilobar interstitial opacities, multilobar pneumonia, respiratory failure, three floating thrombi in the aortic arch and descending aorta","severity":null,"prev_treatment":"","unusual":"Aortic thrombi as an unusual manifestation of COVID-19.","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6122,7629,8342,11420,9077,9780,10776]},{"id":6707,"regimens":[{"id":13455,"duration":{"id":7344,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":12075,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13455},{"id":12076,"answer":"In a novel combination with another drug","answer_other":"","regimen":13455}],"created":"2020-12-09T17:25:21.572506Z","updated":"2020-12-09T17:48:14.585423Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"High flow oxygen","comments":null,"report":6707},{"id":13456,"duration":{"id":7345,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":12077,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13456},{"id":12078,"answer":"In a novel combination with another drug","answer_other":"","regimen":13456}],"created":"2020-12-09T17:25:21.580237Z","updated":"2020-12-09T17:48:14.591891Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"High flow oxygen","comments":null,"report":6707},{"id":13457,"duration":{"id":7346,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6675,"name":"Ceftriaxone","url":"cure-api2.ncats.io/v1/drugs/6675","rxNorm_id":null,"notes":null},"use_drug":[{"id":12079,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13457},{"id":12080,"answer":"In a novel combination with another drug","answer_other":"","regimen":13457}],"created":"2020-12-09T17:25:21.586531Z","updated":"2020-12-09T17:48:14.597528Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"High flow oxygen","comments":null,"report":6707},{"id":13458,"duration":{"id":7347,"approximate_duration":null,"dates_unknown":false},"drug":{"id":9077,"name":"Methylprednisolone","url":"cure-api2.ncats.io/v1/drugs/9077","rxNorm_id":null,"notes":null},"use_drug":[{"id":12081,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13458},{"id":12082,"answer":"In a novel combination with another drug","answer_other":"","regimen":13458}],"created":"2020-12-09T17:25:21.593023Z","updated":"2020-12-09T17:48:14.603200Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"High flow oxygen","comments":null,"report":6707},{"id":13459,"duration":{"id":7348,"approximate_duration":null,"dates_unknown":false},"drug":{"id":7629,"name":"Enoxaparin","url":"cure-api2.ncats.io/v1/drugs/7629","rxNorm_id":null,"notes":null},"use_drug":[{"id":12083,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13459},{"id":12084,"answer":"In a novel combination with another drug","answer_other":"","regimen":13459}],"created":"2020-12-09T17:25:21.599290Z","updated":"2020-12-09T17:48:14.608771Z","dose":"40mg","frequency":"QD","route":"","severity":"Inpatient","severity_detail":"High flow oxygen","comments":null,"report":6707},{"id":13460,"duration":{"id":7349,"approximate_duration":null,"dates_unknown":false},"drug":{"id":11420,"name":"Low Molecular Weight Heparin","url":"cure-api2.ncats.io/v1/drugs/11420","rxNorm_id":null,"notes":null},"use_drug":[{"id":12085,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13460},{"id":12086,"answer":"In a novel combination with another drug","answer_other":"","regimen":13460}],"created":"2020-12-09T17:25:21.606058Z","updated":"2020-12-09T17:48:14.615137Z","dose":"60mg then 40mg","frequency":"","route":"","severity":"Inpatient","severity_detail":"High flow oxygen","comments":null,"report":6707},{"id":13461,"duration":{"id":7350,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":12087,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13461},{"id":12088,"answer":"In a novel combination with another drug","answer_other":"","regimen":13461}],"created":"2020-12-09T17:25:21.612059Z","updated":"2020-12-09T17:48:14.620957Z","dose":"","frequency":"Single Dose","route":"","severity":"Inpatient","severity_detail":"High flow oxygen","comments":null,"report":6707},{"id":13462,"duration":{"id":7351,"approximate_duration":null,"dates_unknown":false},"drug":{"id":5692,"name":"Acetylsalicylic Acid","url":"cure-api2.ncats.io/v1/drugs/5692","rxNorm_id":null,"notes":null},"use_drug":[{"id":12089,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13462},{"id":12090,"answer":"In a novel combination with another drug","answer_other":"","regimen":13462}],"created":"2020-12-09T17:25:21.618093Z","updated":"2020-12-09T17:48:14.626620Z","dose":"","frequency":"","route":"IV","severity":"Inpatient","severity_detail":"High flow oxygen","comments":null,"report":6707}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8802,"answer":"Clinical assessment","answer_other":"","report":6707},{"id":8803,"answer":"Imaging","answer_other":"","report":6707}],"how_diagnosis":[{"id":15130,"answer":"Clinical assessment","answer_other":"","report":6707},{"id":15131,"answer":"Imaging","answer_other":"","report":6707}],"author_username":"Paige Evans","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Nurse","author_affiliation":"None","author_country":"","outcome_computed":"Deteriorated","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4907,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6707},{"id":4908,"answer":"Unusual disease presentation","answer_other":"","report":6707}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-12-09T17:23:37.382638Z","updated":"2020-12-09T17:48:14.577683Z","title":"Aortic thrombus in patients with severe COVID-19: review of three cases. Case 2.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32648092,"doi":"10.1007/s11239-020-02219-z","article_url":"https://pubmed.ncbi.nlm.nih.gov/32648092/","pub_year":2020,"published_authors":"de Carranza M\r\nSalazar DE\r\nTroya J\r\nAlcÃ¡zar R\r\nPeÃ±a C\r\nAragÃ³n E\r\nDomÃ­nguez M\r\nTorres J\r\nMuÃ±oz-Rivas N","article_author_email":"mariadecarranzalopez@gmail.com","journal":"Journal of thrombosis and thrombolysis","abstract":"Coronavirus disease 2019 (COVID-19) could predispose to both venous and arterial thromboembolism, in an exaggerated immune response to the virus, especially in severe patients. Even though aortic clots are a rare entity, the pro-coagulant nature of COVID-19 is associated with thrombosis in atypical locations and should be considered in patients with severe abnormalities in coagulation parameters. We describe a series of three cases of aortic thrombi diagnosed by computerized tomography (CT) angiography in patients with confirmed SARS-CoV-2 infection.          \r\n        Keywords:      \r\n                  Aortic thrombi; COVID-19; Severe pneumonia.","article_type":"Original","study_type":"Case Report","number_of_patients":3,"article_patient_number":"2","full_text_available":true,"outcome":"Patient deteriorated","surgery":"No","age":"71-80 years","sex":"Male","ethnicity":null,"country_contracted":"Spain","country_treated":"Spain","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":true,"hypertension":true,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"Dyslipidemia","pregnant":false,"unknown":false,"site_of_disease":"Lungs, Heart, Brain","clinical_syndrome":"Asthenia, lower back pain, multilobar bilateral opacities, complete ischemic stroke, occlusion of the left internal carotid artery (two intraluminal thrombi)","severity":null,"prev_treatment":"","unusual":"Aortic thrombi as an unusual clinical manifestation of COVID-19.","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"While the patient was still on treatment","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"On day 11th from admission (day 26 from the onset of the symptoms), the patient presented an abrupt episode of loss of strength in the right body with fall to the ground. This episode was diagnosed as a complete ischemic stroke.\r\n\r\nLMWH dose was increased to anticoagulant doses, and the patient was discharged to a\r\nmid-stay center to complete rehabilitation.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[5692,6122,6675,7629,8342,11420,9077,10776]},{"id":6708,"regimens":[{"id":13463,"duration":{"id":7352,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":12091,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13463},{"id":12092,"answer":"In a novel combination with another drug","answer_other":"","regimen":13463}],"created":"2020-12-09T17:50:11.112254Z","updated":"2020-12-09T18:02:28.995630Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6708},{"id":13464,"duration":{"id":7353,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":12093,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13464},{"id":12094,"answer":"In a novel combination with another drug","answer_other":"","regimen":13464}],"created":"2020-12-09T17:50:11.120527Z","updated":"2020-12-09T18:02:29.002178Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6708},{"id":13465,"duration":{"id":7354,"approximate_duration":null,"dates_unknown":false},"drug":{"id":9077,"name":"Methylprednisolone","url":"cure-api2.ncats.io/v1/drugs/9077","rxNorm_id":null,"notes":null},"use_drug":[{"id":12095,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13465},{"id":12096,"answer":"In a novel combination with another drug","answer_other":"","regimen":13465}],"created":"2020-12-09T17:50:11.126775Z","updated":"2020-12-09T18:02:29.007576Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6708},{"id":13466,"duration":{"id":7355,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":12097,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13466},{"id":12098,"answer":"In a novel combination with another drug","answer_other":"","regimen":13466}],"created":"2020-12-09T17:50:11.133469Z","updated":"2020-12-09T18:02:29.013010Z","dose":"600mg","frequency":"Single Dose","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6708},{"id":13467,"duration":{"id":7356,"approximate_duration":null,"dates_unknown":false},"drug":{"id":11420,"name":"Low Molecular Weight Heparin","url":"cure-api2.ncats.io/v1/drugs/11420","rxNorm_id":null,"notes":null},"use_drug":[{"id":12099,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13467},{"id":12100,"answer":"In a novel combination with another drug","answer_other":"","regimen":13467}],"created":"2020-12-09T17:51:17.009923Z","updated":"2020-12-09T18:02:29.018640Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6708}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8804,"answer":"Clinical assessment","answer_other":"","report":6708},{"id":8805,"answer":"Imaging","answer_other":"","report":6708}],"how_diagnosis":[{"id":15132,"answer":"Clinical assessment","answer_other":"","report":6708},{"id":15133,"answer":"Imaging","answer_other":"","report":6708}],"author_username":"Paige Evans","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Nurse","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[{"id":6122,"name":"Azithromycin"},{"id":8342,"name":"Hydroxychloroquine"}],"comments":[],"article_language":"English","why_new_way":[{"id":4909,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6708},{"id":4910,"answer":"Unusual disease presentation","answer_other":"","report":6708}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-12-09T17:48:44.632270Z","updated":"2020-12-09T18:02:28.987883Z","title":"Aortic thrombus in patients with severe COVID-19: review of three cases. Case 3.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32648092,"doi":"10.1007/s11239-020-02219-z","article_url":"https://pubmed.ncbi.nlm.nih.gov/32648092/","pub_year":2020,"published_authors":"de Carranza M\r\nSalazar DE\r\nTroya J\r\nAlcÃ¡zar R\r\nPeÃ±a C\r\nAragÃ³n E\r\nDomÃ­nguez M\r\nTorres J\r\nMuÃ±oz-Rivas N","article_author_email":"mariadecarranzalopez@gmail.com","journal":"Journal of thrombosis and thrombolysis","abstract":"Coronavirus disease 2019 (COVID-19) could predispose to both venous and arterial thromboembolism, in an exaggerated immune response to the virus, especially in severe patients. Even though aortic clots are a rare entity, the pro-coagulant nature of COVID-19 is associated with thrombosis in atypical locations and should be considered in patients with severe abnormalities in coagulation parameters. We describe a series of three cases of aortic thrombi diagnosed by computerized tomography (CT) angiography in patients with confirmed SARS-CoV-2 infection.          \r\n        Keywords:      \r\n                  Aortic thrombi; COVID-19; Severe pneumonia.","article_type":"Original","study_type":"Case Report","number_of_patients":3,"article_patient_number":"3","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"No","age":"61-70 years","sex":"Male","ethnicity":null,"country_contracted":"Spain","country_treated":"Spain","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":true,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"Former smoker, severe obstructive sleep apnea syndrome","pregnant":false,"unknown":false,"site_of_disease":"Lungs, Heart","clinical_syndrome":"Pneumonia, dyspnea, extensive pulmonary opacities, lymphopenia, a floating thrombus in the middle segment of the descending thoracic aorta","severity":null,"prev_treatment":"","unusual":"Aortic thrombi as an unusual clinical manifestation of COVID-19.","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6122,8342,11420,9077,10776]},{"id":6709,"regimens":[{"id":13468,"duration":{"id":7357,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":12132,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13468},{"id":12133,"answer":"In a novel combination with another drug","answer_other":"","regimen":13468}],"created":"2020-12-09T19:13:31.516720Z","updated":"2020-12-11T20:49:10.900582Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"Nasal cannula oxygen therapy","comments":null,"report":6709},{"id":13469,"duration":{"id":7358,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":12134,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13469},{"id":12135,"answer":"In a novel combination with another drug","answer_other":"","regimen":13469}],"created":"2020-12-09T19:13:31.524441Z","updated":"2020-12-11T20:49:10.907424Z","dose":"400mg","frequency":"One Dose","route":"IV","severity":"Inpatient","severity_detail":"She was placed on a bilevel positive airway pressure (BiPAP) machine and transferred to a negative pressure room","comments":null,"report":6709}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8820,"answer":"Clinical assessment","answer_other":"","report":6709}],"how_diagnosis":[{"id":15134,"answer":"Clinical assessment","answer_other":"","report":6709},{"id":15135,"answer":"Imaging","answer_other":"","report":6709},{"id":15136,"answer":"PCR","answer_other":"","report":6709}],"author_username":"Paige Evans","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Nurse","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4911,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6709}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":399,"name":"Diarrhea (Infectious)"},{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-12-09T19:12:51.679322Z","updated":"2020-12-11T20:49:10.892570Z","title":"The Role of Interleukin-6 Inhibitors in the Treatment of COVID-19 Infections: A Case Series. Case 1.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32685300,"doi":"10.7759/cureus.8631","article_url":"https://pubmed.ncbi.nlm.nih.gov/32685300/","pub_year":2020,"published_authors":"Tadepalli S\r\nVanjarapu JMR\r\nDe Dona A\r\nCheriyath P\r\nNookala V","article_author_email":"tadepalli.satish@gmail.com","journal":"Cureus","abstract":"An outbreak of severe acute respiratory distress syndrome coronavirus 2 (SARS-CoV-2) infection started in December 2019 in China that resulted in a global health emergency. The World Health Organization later named the disease as coronavirus disease 2019 (COVID-19). Currently, there is no effective treatment available and the data are evolving through continuous clinical trials and ongoing research. Severe infections present with hypoxemic respiratory failure from acute respiratory distress syndrome as one of the major complications. We report two cases of COVID-19 patients who initially presented with moderate to severe symptoms. Later, their clinical course worsened despite ongoing treatment with multiple medications such as hydroxychloroquine and azithromycin until they were started on tocilizumab. Within a short period after they were administered tocilizumab, their oxygen saturation improved and other inflammatory markers such as D-dimer levels, lactate dehydrogenase, and ferritin levels decreased. There is an increase in the amount of research citing the role of various cytokines in the pathophysiology of COVID-19. Targeting the inflammatory mediators in the pathogenesis, especially interleukin-6 pathway inhibitors, would improve overall morbidity and mortality, thus decreasing the burden on healthcare systems.          \r\n        Keywords:      \r\n                  covid 19; hypoxemic respiratory failure; inflammation; interleukin (il)-6; novel coronavirus; pathophysiology; pneumonia; sars-cov-2; tocilizumab.","article_type":"Original","study_type":"Case Report","number_of_patients":2,"article_patient_number":"1","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"No","age":"61-70 years","sex":"Female","ethnicity":null,"country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":true,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"atrial fibrillation on apixaban, antiphospholipid syndrome, breast cancer status post lumpectomy and radiation, diverticulitis, and rheumatoid arthritis","pregnant":false,"unknown":false,"site_of_disease":"Lungs, Gastrointestinal System","clinical_syndrome":"Nausea, vomiting, diarrhea, pneumonia","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"Within 48 hours of Tocilizumab treatment, her fevers trended down, and her symptoms started subsiding.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6122,10776]},{"id":6718,"regimens":[{"id":13493,"duration":{"id":7382,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":12126,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13493},{"id":12127,"answer":"In a novel combination with another drug","answer_other":"","regimen":13493}],"created":"2020-12-10T20:13:44.492328Z","updated":"2020-12-11T22:36:19.417582Z","dose":"600mg/400mg","frequency":"BID","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6718},{"id":13494,"duration":{"id":7383,"approximate_duration":null,"dates_unknown":false},"drug":{"id":7629,"name":"Enoxaparin","url":"cure-api2.ncats.io/v1/drugs/7629","rxNorm_id":null,"notes":null},"use_drug":[{"id":12128,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13494},{"id":12129,"answer":"In a novel combination with another drug","answer_other":"","regimen":13494}],"created":"2020-12-10T20:13:44.500336Z","updated":"2020-12-11T22:36:19.424148Z","dose":"0.5mg/kg","frequency":"QD","route":"IM","severity":"Inpatient","severity_detail":"","comments":null,"report":6718},{"id":13495,"duration":{"id":7384,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":12130,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13495},{"id":12131,"answer":"In a novel combination with another drug","answer_other":"","regimen":13495}],"created":"2020-12-10T20:13:44.506730Z","updated":"2020-12-11T22:36:19.429686Z","dose":"800mg","frequency":"QD","route":"IV","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6718},{"id":13496,"duration":{"id":7385,"approximate_duration":"10days","dates_unknown":true},"drug":{"id":11301,"name":"Remdesivir","url":"cure-api2.ncats.io/v1/drugs/11301","rxNorm_id":null,"notes":null},"use_drug":[{"id":12146,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13496},{"id":12147,"answer":"In a novel combination with another drug","answer_other":"","regimen":13496}],"created":"2020-12-10T20:13:44.513329Z","updated":"2020-12-11T22:36:19.435644Z","dose":"5mg/kg","frequency":"","route":"IV","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6718},{"id":13497,"duration":{"id":7386,"approximate_duration":"1day","dates_unknown":true},"drug":{"id":7561,"name":"Eculizumab","url":"cure-api2.ncats.io/v1/drugs/7561","rxNorm_id":null,"notes":null},"use_drug":[{"id":12148,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13497},{"id":12149,"answer":"In a novel combination with another drug","answer_other":"","regimen":13497}],"created":"2020-12-10T20:13:44.519589Z","updated":"2020-12-11T22:36:19.441371Z","dose":"900mg","frequency":"","route":"IV","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6718}],"site_of_infection":[],"specific_site":[],"how_outcome":[],"how_diagnosis":[{"id":15154,"answer":"Clinical assessment","answer_other":"","report":6718}],"author_username":"Belinda Nhundu","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"","outcome_computed":"Deteriorated","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4920,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6718}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-12-10T19:38:21.917009Z","updated":"2020-12-11T22:36:19.409514Z","title":"Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19.Case 2.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32771488,"doi":"10.1016/j.clim.2020.108555","article_url":"https://pubmed.ncbi.nlm.nih.gov/32771488/","pub_year":2020,"published_authors":"Laurence J\r\nMulvey JJ\r\nSeshadri M\r\nRacanelli A\r\nHarp J\r\nSchenck EJ\r\nZappetti D\r\nHorn EM\r\nMagro CM","article_author_email":"Author email could not be found.","journal":"Clinical immunology (Orlando, Fla.)","abstract":"Respiratory failure and acute kidney injury (AKI) are associated with high mortality in SARS-CoV-2-associated Coronavirus disease 2019 (COVID-19). These manifestations are linked to a hypercoaguable, pro-inflammatory state with persistent, systemic complement activation. Three critical COVID-19 patients recalcitrant to multiple interventions had skin biopsies documenting deposition of the terminal complement component C5b-9, the lectin complement pathway enzyme MASP2, and C4d in microvascular endothelium. Administration of anti-C5 monoclonal antibody eculizumab led to a marked decline in D-dimers and neutrophil counts in all three cases, and normalization of liver functions and creatinine in two. One patient with severe heart failure and AKI had a complete remission. The other two individuals had partial remissions, one with resolution of his AKI but ultimately succumbing to respiratory failure, and another with a significant decline in FiO2 requirements, but persistent renal failure. In conclusion, anti-complement therapy may be beneficial in at least some patients with critical COVID-19.","article_type":"Original","study_type":"Case Series","number_of_patients":3,"article_patient_number":"2","full_text_available":true,"outcome":"Patient died","surgery":"No","age":"21-30 years","sex":"Male","ethnicity":null,"country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"respiratory tract infection","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"a Clostridium difficile infection developed during his prolonged treatment with antibiotics, used in concern for an occult infection in the face of persistent pneumothoraxes, including vancomycin, meropenem, and piperacillin, and therapy was revised to include levofloxacin.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[7561,7629,8342,11301,10776]},{"id":6719,"regimens":[{"id":13498,"duration":{"id":7387,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":12136,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13498},{"id":12137,"answer":"In a novel combination with another drug","answer_other":"","regimen":13498}],"created":"2020-12-11T20:50:50.965439Z","updated":"2020-12-11T21:01:38.150127Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6719},{"id":13499,"duration":{"id":7388,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":12138,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13499},{"id":12139,"answer":"In a novel combination with another drug","answer_other":"","regimen":13499}],"created":"2020-12-11T20:50:50.973584Z","updated":"2020-12-11T21:01:38.156843Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6719},{"id":13500,"duration":{"id":7389,"approximate_duration":null,"dates_unknown":false},"drug":{"id":11415,"name":"Vitamin C","url":"cure-api2.ncats.io/v1/drugs/11415","rxNorm_id":687,"notes":""},"use_drug":[{"id":12140,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13500},{"id":12141,"answer":"In a novel combination with another drug","answer_other":"","regimen":13500}],"created":"2020-12-11T20:50:50.980137Z","updated":"2020-12-11T21:01:38.163103Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6719},{"id":13501,"duration":{"id":7390,"approximate_duration":null,"dates_unknown":false},"drug":{"id":11091,"name":"Zinc","url":"cure-api2.ncats.io/v1/drugs/11091","rxNorm_id":null,"notes":null},"use_drug":[{"id":12142,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13501},{"id":12143,"answer":"In a novel combination with another drug","answer_other":"","regimen":13501}],"created":"2020-12-11T20:50:50.986748Z","updated":"2020-12-11T21:01:38.169015Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6719},{"id":13502,"duration":{"id":7391,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":12144,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13502},{"id":12145,"answer":"In a novel combination with another drug","answer_other":"","regimen":13502}],"created":"2020-12-11T20:50:50.993635Z","updated":"2020-12-11T21:01:38.174726Z","dose":"400mg","frequency":"One Dose","route":"IV","severity":"Inpatient","severity_detail":"Nasal cannula oxygen therapy","comments":null,"report":6719}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8821,"answer":"Clinical assessment","answer_other":"","report":6719}],"how_diagnosis":[{"id":15155,"answer":"Clinical assessment","answer_other":"","report":6719},{"id":15156,"answer":"PCR","answer_other":"","report":6719},{"id":15157,"answer":"Imaging","answer_other":"","report":6719}],"author_username":"Paige Evans","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Nurse","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4921,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6719}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[],"races":[],"created":"2020-12-11T20:49:41.991403Z","updated":"2020-12-11T21:01:38.140369Z","title":"The Role of Interleukin-6 Inhibitors in the Treatment of COVID-19 Infections: A Case Series. Case 2.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32685300,"doi":"10.7759/cureus.8631","article_url":"https://pubmed.ncbi.nlm.nih.gov/32685300/","pub_year":2020,"published_authors":"Tadepalli S\r\nVanjarapu JMR\r\nDe Dona A\r\nCheriyath P\r\nNookala V","article_author_email":"tadepalli.satish@gmail.com","journal":"Cureus","abstract":"An outbreak of severe acute respiratory distress syndrome coronavirus 2 (SARS-CoV-2) infection started in December 2019 in China that resulted in a global health emergency. The World Health Organization later named the disease as coronavirus disease 2019 (COVID-19). Currently, there is no effective treatment available and the data are evolving through continuous clinical trials and ongoing research. Severe infections present with hypoxemic respiratory failure from acute respiratory distress syndrome as one of the major complications. We report two cases of COVID-19 patients who initially presented with moderate to severe symptoms. Later, their clinical course worsened despite ongoing treatment with multiple medications such as hydroxychloroquine and azithromycin until they were started on tocilizumab. Within a short period after they were administered tocilizumab, their oxygen saturation improved and other inflammatory markers such as D-dimer levels, lactate dehydrogenase, and ferritin levels decreased. There is an increase in the amount of research citing the role of various cytokines in the pathophysiology of COVID-19. Targeting the inflammatory mediators in the pathogenesis, especially interleukin-6 pathway inhibitors, would improve overall morbidity and mortality, thus decreasing the burden on healthcare systems.    \r\n          Keywords:        \r\n            covid 19; hypoxemic respiratory failure; inflammation; interleukin (il)-6; novel coronavirus; pathophysiology; pneumonia; sars-cov-2; tocilizumab.","article_type":"Original","study_type":"Case Report","number_of_patients":2,"article_patient_number":"2","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"61-70 years","sex":"Female","ethnicity":null,"country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":true,"lung_disease":false,"diabetes_mellitus":true,"hypertension":true,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"Atrial fibrillation on apixaban","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Bilateral airspace disease, cough, shortness of breath, fever","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"While the patient was still on treatment","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"Within 24 hours of Tocilizumab treatment, her fevers started trending down, her oxygen saturation improved to mid-90s, and other inflammatory markers such as D-dimer, ferritin, and C-reactive protein started trending down. On day 12, she was discharged to the rehabilitation facility for further management and physical therapy.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6122,8342,10776,11415,11091]},{"id":6721,"regimens":[{"id":13512,"duration":{"id":7401,"approximate_duration":"5days","dates_unknown":true},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":12168,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13512},{"id":12169,"answer":"In a novel combination with another drug","answer_other":"","regimen":13512}],"created":"2020-12-11T23:17:41.014251Z","updated":"2020-12-11T23:30:33.711641Z","dose":"600mg/400mg","frequency":"BID","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6721},{"id":13513,"duration":{"id":7402,"approximate_duration":null,"dates_unknown":false},"drug":{"id":7629,"name":"Enoxaparin","url":"cure-api2.ncats.io/v1/drugs/7629","rxNorm_id":null,"notes":null},"use_drug":[{"id":12170,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13513},{"id":12171,"answer":"In a novel combination with another drug","answer_other":"","regimen":13513}],"created":"2020-12-11T23:17:41.021954Z","updated":"2020-12-11T23:30:33.718208Z","dose":"0.5mg/kg","frequency":"","route":"IM","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6721},{"id":13514,"duration":{"id":7403,"approximate_duration":null,"dates_unknown":false},"drug":{"id":11301,"name":"Remdesivir","url":"cure-api2.ncats.io/v1/drugs/11301","rxNorm_id":null,"notes":null},"use_drug":[{"id":12172,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13514},{"id":12173,"answer":"In a novel combination with another drug","answer_other":"","regimen":13514}],"created":"2020-12-11T23:17:41.028191Z","updated":"2020-12-11T23:30:33.723711Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6721},{"id":13515,"duration":{"id":7404,"approximate_duration":"4days","dates_unknown":true},"drug":{"id":7561,"name":"Eculizumab","url":"cure-api2.ncats.io/v1/drugs/7561","rxNorm_id":null,"notes":null},"use_drug":[{"id":12174,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13515},{"id":12175,"answer":"In a novel combination with another drug","answer_other":"","regimen":13515}],"created":"2020-12-11T23:17:41.034269Z","updated":"2020-12-11T23:30:33.729218Z","dose":"400mg/900mg/1200mg","frequency":"","route":"IV","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6721},{"id":13516,"duration":{"id":7405,"approximate_duration":"1day","dates_unknown":true},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[],"created":"2020-12-11T23:24:36.938118Z","updated":"2020-12-11T23:30:33.735807Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6721}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8825,"answer":"Clinical assessment","answer_other":"","report":6721},{"id":8826,"answer":"Serology","answer_other":"","report":6721}],"how_diagnosis":[{"id":15161,"answer":"Clinical assessment","answer_other":"","report":6721}],"author_username":"Belinda Nhundu","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4924,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6721}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-12-11T22:36:49.683457Z","updated":"2020-12-11T23:30:33.634670Z","title":"Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19.Case 3.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32771488,"doi":"10.1016/j.clim.2020.108555","article_url":"https://pubmed.ncbi.nlm.nih.gov/32771488/","pub_year":2020,"published_authors":"Laurence J\r\nMulvey JJ\r\nSeshadri M\r\nRacanelli A\r\nHarp J\r\nSchenck EJ\r\nZappetti D\r\nHorn EM\r\nMagro CM","article_author_email":"Author email could not be found.","journal":"Clinical immunology (Orlando, Fla.)","abstract":"Respiratory failure and acute kidney injury (AKI) are associated with high mortality in SARS-CoV-2-associated Coronavirus disease 2019 (COVID-19). These manifestations are linked to a hypercoaguable, pro-inflammatory state with persistent, systemic complement activation. Three critical COVID-19 patients recalcitrant to multiple interventions had skin biopsies documenting deposition of the terminal complement component C5b-9, the lectin complement pathway enzyme MASP2, and C4d in microvascular endothelium. Administration of anti-C5 monoclonal antibody eculizumab led to a marked decline in D-dimers and neutrophil counts in all three cases, and normalization of liver functions and creatinine in two. One patient with severe heart failure and AKI had a complete remission. The other two individuals had partial remissions, one with resolution of his AKI but ultimately succumbing to respiratory failure, and another with a significant decline in FiO2 requirements, but persistent renal failure. In conclusion, anti-complement therapy may be beneficial in at least some patients with critical COVID-19.","article_type":"Original","study_type":"Case Series","number_of_patients":3,"article_patient_number":"3","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"61-70 years","sex":"Male","ethnicity":null,"country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":true,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"respiratory tract infection","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[7561,7629,8342,11301,10776]},{"id":6729,"regimens":[{"id":13529,"duration":{"id":7418,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":12198,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13529},{"id":12199,"answer":"In a novel population (e.g. pediatrics/neonates, pregnant women, immunosuppressed, etc.)","answer_other":"","regimen":13529}],"created":"2020-12-15T15:47:49.156302Z","updated":"2020-12-15T16:01:31.580447Z","dose":"400mg","frequency":"","route":"IV","severity":"Inpatient","severity_detail":"Patient required 6L O2 to maintain 95% oxygen saturation","comments":null,"report":6729},{"id":13530,"duration":{"id":7419,"approximate_duration":"4 days","dates_unknown":true},"drug":{"id":11301,"name":"Remdesivir","url":"cure-api2.ncats.io/v1/drugs/11301","rxNorm_id":null,"notes":null},"use_drug":[{"id":12200,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13530},{"id":12201,"answer":"In a novel population (e.g. pediatrics/neonates, pregnant women, immunosuppressed, etc.)","answer_other":"","regimen":13530}],"created":"2020-12-15T15:47:49.163980Z","updated":"2020-12-15T16:01:31.586647Z","dose":"200mg on day 1; then 100mg/day for 4 days","frequency":"QD","route":"IV","severity":"Inpatient","severity_detail":"","comments":null,"report":6729}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8835,"answer":"Clinical assessment","answer_other":"","report":6729},{"id":8837,"answer":"Serology","answer_other":"","report":6729}],"how_diagnosis":[{"id":15178,"answer":"Clinical assessment","answer_other":"","report":6729},{"id":15179,"answer":"PCR","answer_other":"","report":6729},{"id":15180,"answer":"Imaging","answer_other":"","report":6729}],"author_username":"Kate Borkowski","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Nurse","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4932,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6729},{"id":4933,"answer":"There is no standard/approved therapy in this patient population","answer_other":"","report":6729}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-12-15T15:46:00.790831Z","updated":"2020-12-15T16:01:31.572835Z","title":"Tocilizumab and Remdesivir in a Pregnant Patient With Coronavirus Disease 2019 (COVID-19).","status":"Approved","anonymous":false,"published":true,"pubmed_id":32618794,"doi":"10.1097/AOG.0000000000004050","article_url":"https://pubmed.ncbi.nlm.nih.gov/32618794/","pub_year":2020,"published_authors":"Naqvi M\r\nZakowski P\r\nGlucksman L\r\nSmithson S\r\nBurwick RM","article_author_email":"mariam.naqvi@cshs.org","journal":"Obstetrics and gynecology","abstract":"Background:        \r\n            There are limited data regarding treatment options for pregnant women with severe coronavirus disease 2019 (COVID-19).    \r\n          Case:        \r\n            A 35-year-old primigravid patient at 22 weeks of gestation presented with 7 days of fever, cough, anosmia, and dyspnea. Nasopharyngeal swab was positive for the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and a chest X-ray demonstrated bilateral patchy infiltrates. Laboratory evaluation was notable for marked elevation of interleukin-6 and C-reactive protein concentrations. On hospital day 3, owing to increased dyspnea and oxygen requirement, the patient was treated with tocilizumab followed by 5 days of remdesivir. She responded well, recovered to room air, and was discharged home after a 9-day hospitalization.    \r\n          Conclusion:        \r\n            Tocilizumab and remdesivir may be effective for treatment of severe COVID-19 in pregnancy, but additional data are needed to guide risk-benefit considerations.","article_type":"Original","study_type":"Case Report","number_of_patients":1,"article_patient_number":"","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"No","age":"31-40 years","sex":"Female","ethnicity":null,"country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":true,"lung_disease":false,"diabetes_mellitus":true,"hypertension":true,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":true,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Pneumonia","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"This was a primigravid patient at 22 2/7 weeks of gestation presented to the emergency department after 7 days of fever, cough, anosmia, and dyspnea. She was discharged home in stable condition at 23 3/7 weeks of gestation and was advised to self-isolate until she was symptom-free for 7 days.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[11301,10776]},{"id":6733,"regimens":[{"id":13536,"duration":{"id":7425,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":12209,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13536},{"id":12210,"answer":"In a novel combination with another drug","answer_other":"","regimen":13536}],"created":"2020-12-15T17:07:19.011917Z","updated":"2020-12-15T17:20:30.151643Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6733},{"id":13537,"duration":{"id":7426,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8783,"name":"Lopinavir-Ritonavir","url":"cure-api2.ncats.io/v1/drugs/8783","rxNorm_id":null,"notes":null},"use_drug":[{"id":12211,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13537},{"id":12212,"answer":"In a novel combination with another drug","answer_other":"","regimen":13537}],"created":"2020-12-15T17:07:19.019920Z","updated":"2020-12-15T17:20:30.158222Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6733},{"id":13538,"duration":{"id":7427,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":12213,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13538},{"id":12214,"answer":"In a novel combination with another drug","answer_other":"","regimen":13538}],"created":"2020-12-15T17:07:19.025864Z","updated":"2020-12-15T17:20:30.163727Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6733}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8843,"answer":"Clinical assessment","answer_other":"","report":6733}],"how_diagnosis":[{"id":15188,"answer":"Clinical assessment","answer_other":"","report":6733},{"id":15189,"answer":"Imaging","answer_other":"","report":6733}],"author_username":"Reema Charles","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4941,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6733}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[{"id":557,"answer":"White","answer_other":""}],"created":"2020-12-15T17:04:15.957685Z","updated":"2020-12-15T17:20:30.143145Z","title":"Acutely altered mental status as the main clinical presentation of multiple strokes in critically ill patients with COVID-19. Case 1","status":"Approved","anonymous":false,"published":true,"pubmed_id":32808174,"doi":"10.1007/s10072-020-04679-w","article_url":"https://pubmed.ncbi.nlm.nih.gov/32808174/","pub_year":2020,"published_authors":"DÃ­az-PÃ©rez C\r\nRamos C\r\nLÃ³pez-Cruz A\r\nMuÃ±oz Olmedo J\r\nLÃ¡zaro GonzÃ¡lez J\r\nDe Vega-RÃ­os E\r\nGonzÃ¡lez-Ãvila C\r\nHervÃ¡s C\r\nTrillo S\r\nVivancos J","article_author_email":"Author email could not be found.","journal":"Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","abstract":"Background and aims:        \r\n            Cerebral infarction in COVID-19 patients might be associated with a hypercoagulable state related to a systemic inflammatory response. Its diagnosis might be challenging. We present two critically ill patients with COVID-19 who presented acutely altered mental status as the main manifestation of multiple strokes.    \r\n          Methods:        \r\n            Clinical presentation and diagnostic work-up of the patients.    \r\n          Results:        \r\n            Two patients in their sixties were hospitalized with a bilateral pneumonia COVID-19. They developed respiratory failure and were admitted to ICU for mechanical ventilation and intense medical treatment. They were started on low-molecular-weight heparin since admission. Their laboratory results showed lymphopenia and increased levels of C-reactive protein and D-dimer. Case 1 developed hypofibrinogenemia and presented several cutaneous lesions with biopsy features of thrombotic vasculopathy. Case 2 was performed a CT pulmonary angiogram at ICU showing a bilateral pulmonary embolism. When waking up, both patients were conscious but with a remarkable global altered mental status without focal neurological deficits. A brain MRI revealed multiple acute bilateral ischemic lesions with areas of hemorrhagic transformation in both patients (case 1: affecting the left frontal and temporal lobes and both occipital lobes; case 2: affecting both frontal and left occipital lobes). Cardioembolic source and acquired antiphospholipid syndrome were ruled out. COVID-19-associated coagulopathy was suspected as the possible main etiology of the strokes.    \r\n          Conclusion:        \r\n            Acutely altered mental status might be the main manifestation of multiple brain infarctions in critically ill COVID-19 patients. It should be specially considered in those with suspected COVID-19-associated coagulopathy. Full-dose anticoagulation and clinical-radiological monitoring might reduce their neurological consequences.    \r\n          Keywords:        \r\n            Acutely altered mental status; COVID-19; Multiple strokes.","article_type":"Original","study_type":"Case Report","number_of_patients":2,"article_patient_number":"1","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"61-70 years","sex":"Male","ethnicity":"Not Hispanic/Latino","country_contracted":"Spain","country_treated":"Spain","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"Lungs and brain","clinical_syndrome":"Bilateral Pneumonia, with coagulopathy","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"While the patient was still on treatment","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"Low-molecular-weight heparin (LMWH) 60 mg q.d +\r\nSystemic corticosteroids +\r\nA remarkable complication was hypofibrinogenemia (73 mg/dl) with prolonged prothrombin time (18.6 s [normal 0â13.9]) and slight thrombocytopenia (99,000 cells/Î¼l [normal 150,000â400,000]), consistent with disseminated intravascular coagulation according to the International Society on Thrombosis and Haemostasis criteria. \r\nNeurological examination revealed drowsiness, inattention, disorientation, and slow speech with no focal neurologic deficits. The symptoms fluctuated and psychomotor agitation partially responded to quetiapine. The electroencephalogram pattern was suggestive of moderate diffuse encephalopathy.\r\nA brain MRI was performed demonstrating multiple ischemic lesions affecting the left frontal and temporal lobes and both occipital lobes with extensive areas of hemorrhagic transformation.\r\nHe developed several cutaneous lesions with biopsy features of thrombotic vasculopathy. These findings, together with the analytic disturbances, pointed to COVID-19-associated coagulopathy as the main etiology suspected for the strokes.\r\nMechanical ventilation +","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[8342,8783,10776]},{"id":6734,"regimens":[{"id":13542,"duration":{"id":7431,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":12221,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13542},{"id":12222,"answer":"In a novel combination with another drug","answer_other":"","regimen":13542}],"created":"2020-12-15T17:45:42.345076Z","updated":"2020-12-15T17:57:53.112359Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6734},{"id":13543,"duration":{"id":7432,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8783,"name":"Lopinavir-Ritonavir","url":"cure-api2.ncats.io/v1/drugs/8783","rxNorm_id":null,"notes":null},"use_drug":[{"id":12223,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13543},{"id":12224,"answer":"In a novel combination with another drug","answer_other":"","regimen":13543}],"created":"2020-12-15T17:45:42.352774Z","updated":"2020-12-15T17:57:53.118982Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6734},{"id":13544,"duration":{"id":7433,"approximate_duration":null,"dates_unknown":false},"drug":{"id":9077,"name":"Methylprednisolone","url":"cure-api2.ncats.io/v1/drugs/9077","rxNorm_id":null,"notes":null},"use_drug":[{"id":12225,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13544},{"id":12226,"answer":"In a novel combination with another drug","answer_other":"","regimen":13544}],"created":"2020-12-15T17:47:02.411725Z","updated":"2020-12-15T17:57:53.124929Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6734},{"id":13545,"duration":{"id":7434,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":12227,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13545},{"id":12228,"answer":"In a novel combination with another drug","answer_other":"","regimen":13545}],"created":"2020-12-15T17:47:02.418512Z","updated":"2020-12-15T17:57:53.130811Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6734}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8846,"answer":"Clinical assessment","answer_other":"","report":6734}],"how_diagnosis":[{"id":15193,"answer":"Clinical assessment","answer_other":"","report":6734},{"id":15194,"answer":"Imaging","answer_other":"","report":6734}],"author_username":"Reema Charles","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4945,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6734}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[{"id":558,"answer":"White","answer_other":""}],"created":"2020-12-15T17:20:57.079584Z","updated":"2020-12-15T17:57:53.103244Z","title":"Acutely altered mental status as the main clinical presentation of multiple strokes in critically ill patients with COVID-19. Case 2","status":"Approved","anonymous":false,"published":true,"pubmed_id":32808174,"doi":"10.1007/s10072-020-04679-w","article_url":"https://pubmed.ncbi.nlm.nih.gov/32808174/","pub_year":2020,"published_authors":"DÃ­az-PÃ©rez C\r\nRamos C\r\nLÃ³pez-Cruz A\r\nMuÃ±oz Olmedo J\r\nLÃ¡zaro GonzÃ¡lez J\r\nDe Vega-RÃ­os E\r\nGonzÃ¡lez-Ãvila C\r\nHervÃ¡s C\r\nTrillo S\r\nVivancos J","article_author_email":"Author email could not be found.","journal":"Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","abstract":"Background and aims:        \r\n            Cerebral infarction in COVID-19 patients might be associated with a hypercoagulable state related to a systemic inflammatory response. Its diagnosis might be challenging. We present two critically ill patients with COVID-19 who presented acutely altered mental status as the main manifestation of multiple strokes.    \r\n          Methods:        \r\n            Clinical presentation and diagnostic work-up of the patients.    \r\n          Results:        \r\n            Two patients in their sixties were hospitalized with a bilateral pneumonia COVID-19. They developed respiratory failure and were admitted to ICU for mechanical ventilation and intense medical treatment. They were started on low-molecular-weight heparin since admission. Their laboratory results showed lymphopenia and increased levels of C-reactive protein and D-dimer. Case 1 developed hypofibrinogenemia and presented several cutaneous lesions with biopsy features of thrombotic vasculopathy. Case 2 was performed a CT pulmonary angiogram at ICU showing a bilateral pulmonary embolism. When waking up, both patients were conscious but with a remarkable global altered mental status without focal neurological deficits. A brain MRI revealed multiple acute bilateral ischemic lesions with areas of hemorrhagic transformation in both patients (case 1: affecting the left frontal and temporal lobes and both occipital lobes; case 2: affecting both frontal and left occipital lobes). Cardioembolic source and acquired antiphospholipid syndrome were ruled out. COVID-19-associated coagulopathy was suspected as the possible main etiology of the strokes.    \r\n          Conclusion:        \r\n            Acutely altered mental status might be the main manifestation of multiple brain infarctions in critically ill COVID-19 patients. It should be specially considered in those with suspected COVID-19-associated coagulopathy. Full-dose anticoagulation and clinical-radiological monitoring might reduce their neurological consequences.    \r\n          Keywords:        \r\n            Acutely altered mental status; COVID-19; Multiple strokes.","article_type":"Original","study_type":"Case Report","number_of_patients":2,"article_patient_number":"2","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"61-70 years","sex":"Male","ethnicity":"Not Hispanic/Latino","country_contracted":"Spain","country_treated":"Spain","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":true,"hypertension":true,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"Lungs and brain","clinical_syndrome":"Pneumonia, pulmonary embolism and encephalopathy","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"While the patient was still on treatment","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"Mechanical ventilation +\r\nLMWH +\r\nDue to persistent high D-dimer levels, a CT pulmonary angiogram was performed showing a bilateral pulmonary embolism.\r\nWhen waking up in the ICU, he was conscious without focal neurological deficits but with remarkable global altered mental status, fluctuating inattention, disorientation, inconsistent speech, and psychomotor agitation that required risperidone.\r\nAn electroencephalogram showed moderate encephalopathy and a brain MRI revealed acute bilateral ischemic lesions affecting both frontal and left occipital lobes, with several microhemorrhagic foci \r\nCardioembolic source and acquired antiphospholipid syndrome were ruled out.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[8342,8783,9077,10776]},{"id":6743,"regimens":[{"id":13576,"duration":{"id":7465,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":12301,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13576},{"id":12302,"answer":"In a novel combination with another drug","answer_other":"","regimen":13576}],"created":"2020-12-16T20:30:55.735117Z","updated":"2020-12-16T20:44:13.262396Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"Patient required mechanical ventilation","comments":null,"report":6743},{"id":13577,"duration":{"id":7466,"approximate_duration":null,"dates_unknown":false},"drug":{"id":11339,"name":"Convalescent plasma","url":"cure-api2.ncats.io/v1/drugs/11339","rxNorm_id":null,"notes":null},"use_drug":[{"id":12303,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13577},{"id":12304,"answer":"In a novel combination with another drug","answer_other":"","regimen":13577}],"created":"2020-12-16T20:30:55.742759Z","updated":"2020-12-16T20:44:13.268761Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"Patient required mechanical ventilation","comments":null,"report":6743},{"id":13578,"duration":{"id":7467,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8412,"name":"Immunoglobulins, Intravenous","url":"cure-api2.ncats.io/v1/drugs/8412","rxNorm_id":null,"notes":null},"use_drug":[{"id":12306,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13578},{"id":12305,"answer":"In a novel combination with another drug","answer_other":"","regimen":13578}],"created":"2020-12-16T20:30:55.748985Z","updated":"2020-12-16T20:44:13.274303Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"Patient required mechanical ventilation","comments":null,"report":6743}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8859,"answer":"Clinical assessment","answer_other":"","report":6743}],"how_diagnosis":[{"id":15212,"answer":"Clinical assessment","answer_other":"","report":6743},{"id":15213,"answer":"PCR","answer_other":"","report":6743}],"author_username":"Kate Borkowski","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Nurse","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4958,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6743},{"id":4959,"answer":"Co-Infection or Complex Co-morbidities","answer_other":"","report":6743}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[],"races":[],"created":"2020-12-16T20:29:24.713512Z","updated":"2020-12-16T20:44:13.254135Z","title":"Antirheumatic drugs, B cell depletion and critical COVID-19: correspondence on 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine'. Case 2.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32859609,"doi":"10.1136/annrheumdis-2020-218778","article_url":"https://pubmed.ncbi.nlm.nih.gov/32859609/","pub_year":2020,"published_authors":"Notz Q\r\nMeybohm P\r\nKranke P\r\nWeismann D\r\nLotz C\r\nSchmalzing M","article_author_email":"Notz_Q@ukw.de","journal":"Annals of the rheumatic diseases","abstract":"In a recent case series, Mathian et al reported on 17 patients suffering from systemic lupus erythematosus and COVID-19.1 All of these patients received long-term hydroxychloroquine treatment and initial signs and symptoms of COVID-19 were similar to those previously described. However, as 50% of the patients remained hospitalised at the time of publication, the authors cannot comment on the duration and eventual outcome of COVID-19 in all of their patients. Furthermore, it is emerging that hydroxychloroquine does not alter COVID-19. As such, we actually believe that other immunosuppressive, antirheumatic medications require more attention. Mathian et al rightfully pointed out that besides long-term hydroxychloroquine treatment, steroids and other baseline immunosuppressant drugs are often present in patients with rheumatic diseases. In this context, we found an altered immune response and noticeable prolongation of COVID-19 from the onset of symptoms to intensive care unit (ICU) admission in two patients pretreated with rituximab (RTX).","article_type":"Original","study_type":"Case Report","number_of_patients":2,"article_patient_number":"","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"No","age":"51-60 years","sex":"Male","ethnicity":null,"country_contracted":"Germany","country_treated":"Germany","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":true,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":true,"other_comorbid":"Mantle cell lymphoma (requiring Rituximab infusions)","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"","severity":null,"prev_treatment":"","unusual":"The patient was neither able to establish any anti-SARS-CoV-2-spike-receptor binding domaine (RBD) antibody titres, nor eliminate the virus, as pharyngeal swabs and tracheal aspirates tested positive for SARS-CoV-2 until ICU discharge.","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"","reminder":false,"when_reminder":"1 week","additional_info":"After a complex clinical course, including acute renal failure, massive bilateral pulmonary embolism, episodes of ventricular tachycardia and a subarachnoid haemorrhage, the patient was successfully weaned from mechanical ventilation and finally discharged from ICU on day 58 without major respiratory or neurological residues.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[11339,8412,10776]},{"id":6764,"regimens":[{"id":13648,"duration":{"id":7535,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":12446,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13648},{"id":12447,"answer":"In a novel combination with another drug","answer_other":"","regimen":13648}],"created":"2020-12-22T16:44:33.763700Z","updated":"2020-12-22T16:59:50.139940Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"Patient was transferred to the intensive care unit on the same day where he was intubated and put on lung-protective mechanical ventilation.","comments":null,"report":6764},{"id":13649,"duration":{"id":7536,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8783,"name":"Lopinavir-Ritonavir","url":"cure-api2.ncats.io/v1/drugs/8783","rxNorm_id":null,"notes":null},"use_drug":[{"id":12448,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13649},{"id":12449,"answer":"In a novel combination with another drug","answer_other":"","regimen":13649}],"created":"2020-12-22T16:44:33.771435Z","updated":"2020-12-22T16:59:50.146276Z","dose":"200/50 mg","frequency":"QD","route":"","severity":"ICU/Critical Care","severity_detail":"This drug was rapidly switched to darunavir-cobicistat.","comments":null,"report":6764},{"id":13650,"duration":{"id":7537,"approximate_duration":null,"dates_unknown":false},"drug":{"id":7166,"name":"Darunavir-Cobicistat","url":"cure-api2.ncats.io/v1/drugs/7166","rxNorm_id":null,"notes":null},"use_drug":[{"id":12450,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13650},{"id":12451,"answer":"In a novel combination with another drug","answer_other":"","regimen":13650}],"created":"2020-12-22T16:44:33.777851Z","updated":"2020-12-22T16:59:50.152077Z","dose":"800/150mg","frequency":"QD","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6764},{"id":13651,"duration":{"id":7538,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":12452,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13651},{"id":12453,"answer":"In a novel combination with another drug","answer_other":"","regimen":13651}],"created":"2020-12-22T16:44:33.784390Z","updated":"2020-12-22T16:59:50.157913Z","dose":"500mg","frequency":"QD","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6764},{"id":13652,"duration":{"id":7539,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":12454,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13652},{"id":12455,"answer":"In a novel combination with another drug","answer_other":"","regimen":13652}],"created":"2020-12-22T16:44:33.790616Z","updated":"2020-12-22T16:59:50.163637Z","dose":"","frequency":"Once","route":"SQ","severity":"ICU/Critical Care","severity_detail":"To counteract cytokine storm.","comments":null,"report":6764},{"id":13653,"duration":{"id":7540,"approximate_duration":null,"dates_unknown":false},"drug":{"id":11415,"name":"Vitamin C","url":"cure-api2.ncats.io/v1/drugs/11415","rxNorm_id":687,"notes":""},"use_drug":[{"id":12456,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13653},{"id":12457,"answer":"In a novel combination with another drug","answer_other":"","regimen":13653}],"created":"2020-12-22T16:44:33.796927Z","updated":"2020-12-22T16:59:50.169594Z","dose":"50 mg/kg","frequency":"QID","route":"IV","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6764}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8879,"answer":"Clinical assessment","answer_other":"","report":6764},{"id":8880,"answer":"PCR","answer_other":"","report":6764},{"id":8881,"answer":"Culture","answer_other":"","report":6764}],"how_diagnosis":[{"id":15270,"answer":"Clinical assessment","answer_other":"","report":6764},{"id":15271,"answer":"PCR","answer_other":"","report":6764},{"id":15272,"answer":"Imaging","answer_other":"","report":6764}],"author_username":"Kate Borkowski","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Nurse","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4998,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6764}],"adverse_event_outcome":[{"id":112,"answer":"Required Intervention to Prevent Permanent Impairment/Damage","report":6764},{"id":111,"answer":"Non-Serious Medical Event","report":6764}],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[{"id":572,"answer":"White","answer_other":""}],"created":"2020-12-22T16:38:46.919501Z","updated":"2020-12-22T16:59:50.131884Z","title":"Oxalate Nephropathy Caused by Excessive Vitamin C Administration in 2 Patients WithÂ COVID-19. Case 1.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32838081,"doi":"10.1016/j.ekir.2020.07.008","article_url":"https://pubmed.ncbi.nlm.nih.gov/32838081/","pub_year":2020,"published_authors":"Fontana F\r\nCazzato S\r\nGiovanella S\r\nBallestri M\r\nLeonelli M\r\nMori G\r\nAlfano G\r\nLigabue G\r\nMagistroni R\r\nCenacchi G\r\nAntoniotti R\r\nBonucchi D\r\nCappelli G","article_author_email":"francesco.fontana@unimore.it","journal":"Kidney international reports","abstract":"AKI in critically ill patients with COVID-19 can be multifactorial, and the toxicity of drugs used to treat septic status could contribute to kidney damage. We describe ATI and oxalate nephropathy likely caused by excessive vitamin C administration in 2 patients who underwent kidney biopsy procedures for slowly resolving AKI after acute respiratory distress syndrome (ARDS) due to COVID-19.","article_type":"Original","study_type":"Case Report","number_of_patients":2,"article_patient_number":"","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"No","age":"41-50 years","sex":"Male","ethnicity":null,"country_contracted":"Italy","country_treated":"Italy","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":true,"cardiovascular_disease":true,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"Brugada syndrome","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Pneumonia","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":true,"adverse_events":"The clinical course was immediately complicated by septic shock with the need for inotropes, and the patient developed multiorgan failure with hepatic dysfunction and AKI with anuria; he was started on continuous venovenous hemodiafiltration on day 2. ATI and oxalate nephropathy likely caused by excessive vitamin C administration.","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"The patientâs respiratory status improved, and he was extubated by day 15 from hospitalization; swabs for SARS-CoV-2 were negative from day 18. Despite an increase in urine output, kidney function did not show any improvement and the patient was transferred to the nephrology unit; at day 36 a biopsy specimen of the kidney was obtained. In the following days, partial improvement of kidney function was observed; the patient was discharged home on day 42.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6122,7166,8342,8783,10776,11415]},{"id":6769,"regimens":[{"id":13664,"duration":{"id":7552,"approximate_duration":"7 days","dates_unknown":true},"drug":{"id":5926,"name":"Anakinra","url":"cure-api2.ncats.io/v1/drugs/5926","rxNorm_id":null,"notes":null},"use_drug":[{"id":12475,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13664},{"id":12476,"answer":"In a novel combination with another drug","answer_other":"","regimen":13664}],"created":"2020-12-23T05:12:13.970471Z","updated":"2020-12-23T18:24:23.261173Z","dose":"100 mg/6 h Ã 3 days , followed by 100 mg/24 h Ã 4 days","frequency":"","route":"Subcutaneous","severity":"Inpatient","severity_detail":null,"comments":null,"report":6769},{"id":13665,"duration":{"id":7562,"approximate_duration":"6 days","dates_unknown":true},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":12477,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13665},{"id":12478,"answer":"In a novel combination with another drug","answer_other":"","regimen":13665}],"created":"2020-12-23T05:12:13.978055Z","updated":"2020-12-23T18:24:23.309572Z","dose":"400 mg every 12 h at day 1, followed by 200 mg every 12 hours for 5 days","frequency":"BD","route":"PO","severity":"Inpatient","severity_detail":null,"comments":null,"report":6769},{"id":13666,"duration":{"id":7554,"approximate_duration":"21 days","dates_unknown":true},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":12479,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13666},{"id":12480,"answer":"In a novel combination with another drug","answer_other":"","regimen":13666}],"created":"2020-12-23T05:12:13.984845Z","updated":"2020-12-23T18:24:23.273147Z","dose":"500 mg every 24 h for 7 days, and then every 48 h for 14 days","frequency":"","route":"PO","severity":"Inpatient","severity_detail":"","comments":null,"report":6769},{"id":13667,"duration":{"id":7555,"approximate_duration":"3 days","dates_unknown":true},"drug":{"id":9077,"name":"Methylprednisolone","url":"cure-api2.ncats.io/v1/drugs/9077","rxNorm_id":null,"notes":null},"use_drug":[{"id":12481,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13667},{"id":12482,"answer":"In a novel combination with another drug","answer_other":"","regimen":13667}],"created":"2020-12-23T05:12:13.991117Z","updated":"2020-12-23T18:24:23.278472Z","dose":"250 mg/day bolus","frequency":"OD","route":"iv","severity":"Inpatient","severity_detail":"","comments":null,"report":6769},{"id":13668,"duration":{"id":7556,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":12483,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13668},{"id":12484,"answer":"In a novel combination with another drug","answer_other":"","regimen":13668}],"created":"2020-12-23T05:12:13.997509Z","updated":"2020-12-23T18:24:23.283930Z","dose":"2 doses","frequency":"","route":"IV","severity":"Inpatient","severity_detail":"","comments":null,"report":6769}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8891,"answer":"Clinical assessment","answer_other":"","report":6769},{"id":8892,"answer":"Imaging","answer_other":"","report":6769},{"id":8893,"answer":"PCR","answer_other":"","report":6769}],"how_diagnosis":[{"id":15281,"answer":"Clinical assessment","answer_other":"","report":6769},{"id":15282,"answer":"Imaging","answer_other":"","report":6769},{"id":15283,"answer":"PCR","answer_other":"","report":6769}],"author_username":"Reema Charles","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":5004,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6769}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[{"id":577,"answer":"White","answer_other":""}],"created":"2020-12-23T05:10:55.903931Z","updated":"2020-12-23T18:24:23.253283Z","title":"High dose subcutaneous Anakinra to treat acute respiratory distress syndrome secondary to cytokine storm syndrome among severely ill COVID-19 patients. Case 2","status":"Approved","anonymous":false,"published":true,"pubmed_id":32843231,"doi":"10.1016/j.jaut.2020.102537","article_url":"https://pubmed.ncbi.nlm.nih.gov/32843231/","pub_year":2020,"published_authors":"Iglesias-JuliÃ¡n E\r\nLÃ³pez-Veloso M\r\nde-la-Torre-Ferrera, et al","article_author_email":"Author email could not be found.","journal":"Journal of autoimmunity","abstract":"Objective:        \r\n            Severely ill COVID-19 patients may end in acute respiratory distress syndrome (ARDS) and multi-organ failure. Some of them develop a systemic hyperinflammatory state produced by the massive release of inflammatory agents, known as cytokine storm syndrome (CSS). Inhibition of IL-1 by Anakinra (ANK) is a potential life-saving therapy for severe CSS cases. We propose a rationale for the use of subcutaneous ANK and review our initial experience in a small cohort of severe COVID-19 CSS patients.    \r\n          Methods:        \r\n            Retrospective cohort study of COVID-19 patients developing ARDS (PaO2/FiO2 <300) and exhibiting signs of hyperinflammation (ferritin >1000 ng/mL and/or d-dimers > 1.5 Î¼g/mL, plus IL-6 < 40 mg/mL) that received ANK. For comparison, a propensity score matched historical cohort of patients treated with IL-6 inhibitor Tocilizumab (TCZ) was used. Patients had previously received combinations of azithromycin, hydroxy-chloroquine, and methyl-prednisolone. Laboratory findings, respiratory function and adverse effects were monitored. Resolution of ARDS within the first 7 days of treatment was considered a favorable outcome.    \r\n          Results:        \r\n            Subcutaneous ANK (100 mg every 6 h) was given to 9 COVID-19 ARDS CSS patients (77.8% males). Median age was 62 years (range, 42 to 87). A TCZ cohort of 18 patients was selected by propensity score matching and treated with intravenous single dose of 600 mg for patients weighing >75 Kg, or 400 mg if < 75 Kg. Prior to treatment, median PaO2/FiO2 ratio of the ANK and TCZ cohorts were 193 and 249, respectively (p = 0.131). After 7 days of treatment, PaO2/FiO2 ratio improved in both groups to 279 (104-335) and 331 (140-476, p = 0.099) respectively. On day 7, there was significant reduction of ferritin (p = 0.046), CRP (p = 0.043), and IL-6 (p = 0.043) levels in the ANK cohort but only of CRP (p = 0.001) in the TCZ group. Favorable outcome was achieved in 55.6% and 88.9% of the ANK and TCZ cohorts, respectively (p = 0.281). Two patients that failed to respond to TCZ improved after ANK treatment. Aminotransferase levels significantly increased between day 1 and day 7 (p = 0.004) in the TCZ group. Mortality was the same in both groups (11%). There were not any opportunistic infection in the groups nor other adverse effects attributable to treatment.    \r\n          Conclusion:        \r\n            Overall, 55.6% of COVID-19 ARDS CSS patients treated with ANK exhibited favorable outcome, not inferior to a TCZ treated matched cohort. ANK may be a potential alternative to TCZ for patients with elevated aminotransferases, and may be useful in non-responders to TCZ.    \r\n          Keywords:        \r\n            Acute respiratory distress syndrome; Anakinra; COVID-19; Cytokine storm syndrome; IL-1; SARS-CoV2; Tocilizumab.","article_type":"Original","study_type":"Case Report","number_of_patients":9,"article_patient_number":"2","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"No","age":"61-70 years","sex":"Male","ethnicity":"Not Hispanic/Latino","country_contracted":"Spain","country_treated":"Spain","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"Ex-smoker","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Pneumonia","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"ANK given 4 days after second dose of TCZ\r\nDays from admission to ANK treatment - 12\r\nDischarge at day 10 after initiation of ANK","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[5926,6122,8342,9077,10776]},{"id":6772,"regimens":[{"id":13677,"duration":{"id":7568,"approximate_duration":"7 days","dates_unknown":true},"drug":{"id":5926,"name":"Anakinra","url":"cure-api2.ncats.io/v1/drugs/5926","rxNorm_id":null,"notes":null},"use_drug":[{"id":12501,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13677},{"id":12502,"answer":"In a novel combination with another drug","answer_other":"","regimen":13677}],"created":"2020-12-23T19:06:09.329272Z","updated":"2020-12-23T19:26:51.973663Z","dose":"100 mg/6 h Ã 3 days, followed by 100 mg/24 h Ã 4 days","frequency":"","route":"subcutaneous","severity":"Inpatient","severity_detail":"","comments":null,"report":6772},{"id":13678,"duration":{"id":7569,"approximate_duration":"6 days","dates_unknown":true},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":12503,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13678},{"id":12504,"answer":"In a novel combination with another drug","answer_other":"","regimen":13678}],"created":"2020-12-23T19:06:09.336956Z","updated":"2020-12-23T19:26:51.979959Z","dose":"400 mg every 12 h at day 1, followed by 200 mg every 12 hours for 5 days","frequency":"BD","route":"PO","severity":"Inpatient","severity_detail":"","comments":null,"report":6772},{"id":13679,"duration":{"id":7570,"approximate_duration":"21 days","dates_unknown":true},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":12505,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13679},{"id":12506,"answer":"In a novel combination with another drug","answer_other":"","regimen":13679}],"created":"2020-12-23T19:06:09.342934Z","updated":"2020-12-23T19:26:51.985482Z","dose":"500 mg every 24 h for 7 days, and then every 48 h for 14 days","frequency":"","route":"PO","severity":"Inpatient","severity_detail":"","comments":null,"report":6772},{"id":13680,"duration":{"id":7571,"approximate_duration":"3 days, followed by mg/kg/day","dates_unknown":true},"drug":{"id":9077,"name":"Methylprednisolone","url":"cure-api2.ncats.io/v1/drugs/9077","rxNorm_id":null,"notes":null},"use_drug":[{"id":12507,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13680},{"id":12508,"answer":"In a novel combination with another drug","answer_other":"","regimen":13680}],"created":"2020-12-23T19:06:09.348917Z","updated":"2020-12-23T19:26:51.991226Z","dose":"250 mg/day bolus","frequency":"","route":"IV","severity":"Inpatient","severity_detail":"","comments":null,"report":6772},{"id":13681,"duration":{"id":7572,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":12509,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13681},{"id":12510,"answer":"In a novel combination with another drug","answer_other":"","regimen":13681}],"created":"2020-12-23T19:06:09.354957Z","updated":"2020-12-23T19:26:51.996811Z","dose":"","frequency":"","route":"IV","severity":"Inpatient","severity_detail":"","comments":null,"report":6772}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8900,"answer":"Clinical assessment","answer_other":"","report":6772},{"id":8901,"answer":"Imaging","answer_other":"","report":6772},{"id":8902,"answer":"PCR","answer_other":"","report":6772}],"how_diagnosis":[{"id":15290,"answer":"Clinical assessment","answer_other":"","report":6772},{"id":15291,"answer":"Imaging","answer_other":"","report":6772},{"id":15292,"answer":"PCR","answer_other":"","report":6772}],"author_username":"Reema Charles","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":5007,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6772}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[{"id":580,"answer":"White","answer_other":""}],"created":"2020-12-23T19:03:55.592821Z","updated":"2020-12-23T19:26:51.965061Z","title":"High dose subcutaneous Anakinra to treat acute respiratory distress syndrome secondary to cytokine storm syndrome among severely ill COVID-19 patients. Case 7","status":"Approved","anonymous":false,"published":true,"pubmed_id":32843231,"doi":"10.1016/j.jaut.2020.102537","article_url":"https://pubmed.ncbi.nlm.nih.gov/32843231/","pub_year":2020,"published_authors":"Iglesias-JuliÃ¡n E\r\nLÃ³pez-Veloso M\r\nde-la-Torre-Ferrera N, et al","article_author_email":"Author email could not be found.","journal":"Journal of autoimmunity","abstract":"Objective:        \r\n            Severely ill COVID-19 patients may end in acute respiratory distress syndrome (ARDS) and multi-organ failure. Some of them develop a systemic hyperinflammatory state produced by the massive release of inflammatory agents, known as cytokine storm syndrome (CSS). Inhibition of IL-1 by Anakinra (ANK) is a potential life-saving therapy for severe CSS cases. We propose a rationale for the use of subcutaneous ANK and review our initial experience in a small cohort of severe COVID-19 CSS patients.    \r\n          Methods:        \r\n            Retrospective cohort study of COVID-19 patients developing ARDS (PaO2/FiO2 <300) and exhibiting signs of hyperinflammation (ferritin >1000 ng/mL and/or d-dimers > 1.5 Î¼g/mL, plus IL-6 < 40 mg/mL) that received ANK. For comparison, a propensity score matched historical cohort of patients treated with IL-6 inhibitor Tocilizumab (TCZ) was used. Patients had previously received combinations of azithromycin, hydroxy-chloroquine, and methyl-prednisolone. Laboratory findings, respiratory function and adverse effects were monitored. Resolution of ARDS within the first 7 days of treatment was considered a favorable outcome.    \r\n          Results:        \r\n            Subcutaneous ANK (100 mg every 6 h) was given to 9 COVID-19 ARDS CSS patients (77.8% males). Median age was 62 years (range, 42 to 87). A TCZ cohort of 18 patients was selected by propensity score matching and treated with intravenous single dose of 600 mg for patients weighing >75 Kg, or 400 mg if < 75 Kg. Prior to treatment, median PaO2/FiO2 ratio of the ANK and TCZ cohorts were 193 and 249, respectively (p = 0.131). After 7 days of treatment, PaO2/FiO2 ratio improved in both groups to 279 (104-335) and 331 (140-476, p = 0.099) respectively. On day 7, there was significant reduction of ferritin (p = 0.046), CRP (p = 0.043), and IL-6 (p = 0.043) levels in the ANK cohort but only of CRP (p = 0.001) in the TCZ group. Favorable outcome was achieved in 55.6% and 88.9% of the ANK and TCZ cohorts, respectively (p = 0.281). Two patients that failed to respond to TCZ improved after ANK treatment. Aminotransferase levels significantly increased between day 1 and day 7 (p = 0.004) in the TCZ group. Mortality was the same in both groups (11%). There were not any opportunistic infection in the groups nor other adverse effects attributable to treatment.    \r\n          Conclusion:        \r\n            Overall, 55.6% of COVID-19 ARDS CSS patients treated with ANK exhibited favorable outcome, not inferior to a TCZ treated matched cohort. ANK may be a potential alternative to TCZ for patients with elevated aminotransferases, and may be useful in non-responders to TCZ.    \r\n          Keywords:        \r\n            Acute respiratory distress syndrome; Anakinra; COVID-19; Cytokine storm syndrome; IL-1; SARS-CoV2; Tocilizumab.","article_type":"Original","study_type":"Case Report","number_of_patients":9,"article_patient_number":"7","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"No","age":"41-50 years","sex":"Male","ethnicity":"Not Hispanic/Latino","country_contracted":"Spain","country_treated":"Spain","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Pneumonia","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"Days from admission to ANK treatment - 4 \r\nDischarge 8 days after initiation of ANK","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[5926,6122,8342,9077,10776]},{"id":6797,"regimens":[{"id":13733,"duration":{"id":7625,"approximate_duration":"One dose","dates_unknown":true},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":12609,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13733},{"id":12610,"answer":"In a novel combination with another drug","answer_other":"","regimen":13733}],"created":"2020-12-25T05:06:35.440991Z","updated":"2020-12-25T05:23:59.204786Z","dose":"400 mg","frequency":"Once","route":"IV","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6797},{"id":13734,"duration":{"id":7626,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":12611,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13734},{"id":12612,"answer":"In a novel combination with another drug","answer_other":"","regimen":13734}],"created":"2020-12-25T05:06:35.448679Z","updated":"2020-12-25T05:23:59.211033Z","dose":"200 mg","frequency":"BD","route":"PO","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6797},{"id":13735,"duration":{"id":7627,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8783,"name":"Lopinavir-Ritonavir","url":"cure-api2.ncats.io/v1/drugs/8783","rxNorm_id":null,"notes":null},"use_drug":[{"id":12613,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13735},{"id":12614,"answer":"In a novel combination with another drug","answer_other":"","regimen":13735}],"created":"2020-12-25T05:06:35.454945Z","updated":"2020-12-25T05:23:59.217063Z","dose":"","frequency":"OD","route":"IV","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6797},{"id":13736,"duration":{"id":7628,"approximate_duration":null,"dates_unknown":false},"drug":{"id":9780,"name":"Piperacillin-Tazobactam","url":"cure-api2.ncats.io/v1/drugs/9780","rxNorm_id":null,"notes":null},"use_drug":[{"id":12615,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13736},{"id":12616,"answer":"In a novel combination with another drug","answer_other":"","regimen":13736}],"created":"2020-12-25T05:06:35.461041Z","updated":"2020-12-25T05:23:59.222747Z","dose":"","frequency":"q6h","route":"IV","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6797},{"id":13737,"duration":{"id":7629,"approximate_duration":null,"dates_unknown":false},"drug":{"id":9114,"name":"Metronidazole","url":"cure-api2.ncats.io/v1/drugs/9114","rxNorm_id":null,"notes":null},"use_drug":[{"id":12617,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13737},{"id":12618,"answer":"In a novel combination with another drug","answer_other":"","regimen":13737}],"created":"2020-12-25T05:06:35.467402Z","updated":"2020-12-25T05:23:59.228120Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6797}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8954,"answer":"Clinical assessment","answer_other":"","report":6797},{"id":8955,"answer":"PCR","answer_other":"","report":6797}],"how_diagnosis":[{"id":15362,"answer":"Clinical assessment","answer_other":"","report":6797},{"id":15363,"answer":"Imaging","answer_other":"","report":6797},{"id":15364,"answer":"PCR","answer_other":"","report":6797}],"author_username":"Reema Charles","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":5033,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6797}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[{"id":602,"answer":"White","answer_other":""}],"created":"2020-12-25T05:02:37.601960Z","updated":"2020-12-25T05:23:59.197026Z","title":"Efficacy and safety of tocilizumab in critically ill adults with COVID-19 infection in Bahrain: A report of 5 cases. Case 1","status":"Approved","anonymous":false,"published":true,"pubmed_id":32632355,"doi":"10.1016/j.rmcr.2020.101139","article_url":"https://pubmed.ncbi.nlm.nih.gov/32632355/","pub_year":2020,"published_authors":"ElSeirafi MM\r\nHasan HM\r\nSridharan K\r\nZamoori A\r\nAlkhawaja S\r\nPasha SAA","article_author_email":"Author email could not be found.","journal":"Respiratory medicine case reports","abstract":"Tocilizumab has been recognized as one of the few existing biologic useful for combating COVID-19 infections especially in critically ill patient. We had experience in treating five critically ill patients with severe lung injury who were COVID-19 positive with tocilizumab. In the present case series, we have attempted to summarize their clinical profile, changes in laboratory biomarkers and outcomes.","article_type":"Original","study_type":"Case Report","number_of_patients":5,"article_patient_number":"1","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"No","age":"90+ years","sex":"Male","ethnicity":"Not Hispanic/Latino","country_contracted":"Bahrain","country_treated":"Bahrain","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":true,"hypertension":true,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"Dyslipidemia and benign prostatic hyperplasia","pregnant":false,"unknown":false,"site_of_disease":"Lungs, gastrointestinal tract and kidneys","clinical_syndrome":"Respiratory tract infection, diarrhea and hematuria","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"While the patient was still on treatment","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"Non-invasive ventilation +\r\nThe COVID-19 rt-PCR test was negative after 8 days of ICU admission that corresponds to 4th day following tocilizumab administration. A repeat COVID-19 rt-PCR test was also negative after 3 days and the patient was discharged from ICU.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[8342,8783,9114,9780,10776]},{"id":6798,"regimens":[{"id":13738,"duration":{"id":7630,"approximate_duration":"2 doses","dates_unknown":true},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":12619,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13738},{"id":12620,"answer":"In a novel combination with another drug","answer_other":"","regimen":13738}],"created":"2020-12-25T05:22:48.345877Z","updated":"2020-12-25T05:36:17.671873Z","dose":"400 mg, 2 doses","frequency":"","route":"IV","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6798},{"id":13739,"duration":{"id":7631,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":12621,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13739},{"id":12622,"answer":"In a novel combination with another drug","answer_other":"","regimen":13739}],"created":"2020-12-25T05:22:48.354055Z","updated":"2020-12-25T05:36:17.678294Z","dose":"200 mg","frequency":"BD","route":"PO","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6798},{"id":13740,"duration":{"id":7632,"approximate_duration":null,"dates_unknown":false},"drug":{"id":9780,"name":"Piperacillin-Tazobactam","url":"cure-api2.ncats.io/v1/drugs/9780","rxNorm_id":null,"notes":null},"use_drug":[{"id":12623,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13740},{"id":12624,"answer":"In a novel combination with another drug","answer_other":"","regimen":13740}],"created":"2020-12-25T05:22:48.360538Z","updated":"2020-12-25T05:36:17.684121Z","dose":"","frequency":"","route":"IV","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6798},{"id":13741,"duration":{"id":7633,"approximate_duration":null,"dates_unknown":false},"drug":{"id":11339,"name":"Convalescent plasma","url":"cure-api2.ncats.io/v1/drugs/11339","rxNorm_id":null,"notes":null},"use_drug":[{"id":12625,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13741},{"id":12626,"answer":"In a novel combination with another drug","answer_other":"","regimen":13741}],"created":"2020-12-25T05:22:48.367410Z","updated":"2020-12-25T05:36:17.689698Z","dose":"2 doses","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6798}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8956,"answer":"Clinical assessment","answer_other":"","report":6798},{"id":8957,"answer":"PCR","answer_other":"","report":6798}],"how_diagnosis":[{"id":15365,"answer":"Clinical assessment","answer_other":"","report":6798},{"id":15366,"answer":"Imaging","answer_other":"","report":6798},{"id":15367,"answer":"PCR","answer_other":"","report":6798}],"author_username":"Reema Charles","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":5034,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6798}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[{"id":603,"answer":"White","answer_other":""}],"created":"2020-12-25T05:21:03.532214Z","updated":"2020-12-25T05:36:17.664074Z","title":"Efficacy and safety of tocilizumab in critically ill adults with COVID-19 infection in Bahrain: A report of 5 cases. Case 2","status":"Approved","anonymous":false,"published":true,"pubmed_id":32632355,"doi":"10.1016/j.rmcr.2020.101139","article_url":"https://pubmed.ncbi.nlm.nih.gov/32632355/","pub_year":2020,"published_authors":"ElSeirafi MM\r\nHasan HM\r\nSridharan K\r\nZamoori A\r\nAlkhawaja S\r\nPasha SAA","article_author_email":"Author email could not be found.","journal":"Respiratory medicine case reports","abstract":"Tocilizumab has been recognized as one of the few existing biologic useful for combating COVID-19 infections especially in critically ill patient. We had experience in treating five critically ill patients with severe lung injury who were COVID-19 positive with tocilizumab. In the present case series, we have attempted to summarize their clinical profile, changes in laboratory biomarkers and outcomes.","article_type":"Original","study_type":"Case Report","number_of_patients":5,"article_patient_number":"2","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"No","age":"51-60 years","sex":"Male","ethnicity":"Not Hispanic/Latino","country_contracted":"Bahrain","country_treated":"Bahrain","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":true,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Pneumonia","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"While the patient was still on treatment","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"The patient was initiated on oral hydroxychloroquine at 200 mg twice daily and injection ceftriaxone. As the patient required an increased requirement of oxygen therapy, piperacillin/tazobactam replaced ceftriaxone and two doses of plasma therapy was infused. As the patient did not show any signs of improvement, injection tocilizumab was administered at 400 mg for two doses. The patient improved significantly on the third day following tocilizumab injection and rt-PCR test for COVID-19 was negative on the fourth day. A repeat rt-PCR test was also negative after 6 days and the patient was discharged from ICU.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[11339,8342,9780,10776]},{"id":6799,"regimens":[{"id":13742,"duration":{"id":7634,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":12627,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13742},{"id":12628,"answer":"In a novel combination with another drug","answer_other":"","regimen":13742}],"created":"2020-12-25T06:36:50.854219Z","updated":"2020-12-25T07:11:55.635833Z","dose":"200 mg","frequency":"BD","route":"PO","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6799},{"id":13743,"duration":{"id":7635,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6675,"name":"Ceftriaxone","url":"cure-api2.ncats.io/v1/drugs/6675","rxNorm_id":null,"notes":null},"use_drug":[{"id":12629,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13743},{"id":12630,"answer":"In a novel combination with another drug","answer_other":"","regimen":13743}],"created":"2020-12-25T06:36:50.861868Z","updated":"2020-12-25T07:11:55.642103Z","dose":"","frequency":"","route":"IV","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6799},{"id":13744,"duration":{"id":7636,"approximate_duration":null,"dates_unknown":false},"drug":{"id":9780,"name":"Piperacillin-Tazobactam","url":"cure-api2.ncats.io/v1/drugs/9780","rxNorm_id":null,"notes":null},"use_drug":[{"id":12631,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13744},{"id":12632,"answer":"In a novel combination with another drug","answer_other":"","regimen":13744}],"created":"2020-12-25T06:36:50.868401Z","updated":"2020-12-25T07:11:55.647634Z","dose":"","frequency":"","route":"IV","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6799},{"id":13745,"duration":{"id":7637,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":12633,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13745},{"id":12634,"answer":"In a novel combination with another drug","answer_other":"","regimen":13745}],"created":"2020-12-25T06:36:50.874453Z","updated":"2020-12-25T07:11:55.706523Z","dose":null,"frequency":"","route":"IV","severity":"ICU/Critical Care","severity_detail":null,"comments":null,"report":6799},{"id":13746,"duration":{"id":7638,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10130,"name":"Ribavirin","url":"cure-api2.ncats.io/v1/drugs/10130","rxNorm_id":null,"notes":null},"use_drug":[{"id":12635,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13746},{"id":12636,"answer":"In a novel combination with another drug","answer_other":"","regimen":13746}],"created":"2020-12-25T06:36:50.880845Z","updated":"2020-12-25T07:11:55.658786Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6799},{"id":13747,"duration":{"id":7639,"approximate_duration":null,"dates_unknown":false},"drug":{"id":11275,"name":"Pegylated Interferon","url":"cure-api2.ncats.io/v1/drugs/11275","rxNorm_id":null,"notes":null},"use_drug":[{"id":12637,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13747},{"id":12638,"answer":"In a novel combination with another drug","answer_other":"","regimen":13747}],"created":"2020-12-25T06:36:50.887268Z","updated":"2020-12-25T07:11:55.664410Z","dose":"Single dose","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":null,"comments":null,"report":6799},{"id":13748,"duration":{"id":7640,"approximate_duration":null,"dates_unknown":false},"drug":{"id":11339,"name":"Convalescent plasma","url":"cure-api2.ncats.io/v1/drugs/11339","rxNorm_id":null,"notes":null},"use_drug":[{"id":12639,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13748},{"id":12640,"answer":"In a novel combination with another drug","answer_other":"","regimen":13748}],"created":"2020-12-25T06:36:50.893511Z","updated":"2020-12-25T07:11:55.670206Z","dose":"2 doses","frequency":"","route":"IV","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6799},{"id":13749,"duration":{"id":7641,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":12641,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13749},{"id":12642,"answer":"In a novel combination with another drug","answer_other":"","regimen":13749}],"created":"2020-12-25T06:36:50.899378Z","updated":"2020-12-25T07:11:55.675605Z","dose":"400 mg, 2 doses","frequency":"","route":"IV","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6799}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8958,"answer":"Clinical assessment","answer_other":"","report":6799},{"id":8959,"answer":"PCR","answer_other":"","report":6799}],"how_diagnosis":[{"id":15368,"answer":"Clinical assessment","answer_other":"","report":6799},{"id":15369,"answer":"Imaging","answer_other":"","report":6799},{"id":15370,"answer":"PCR","answer_other":"","report":6799}],"author_username":"Reema Charles","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":5035,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6799}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[{"id":604,"answer":"White","answer_other":""}],"created":"2020-12-25T06:33:55.010716Z","updated":"2020-12-25T07:11:55.628021Z","title":"Efficacy and safety of tocilizumab in critically ill adults with COVID-19 infection in Bahrain: A report of 5 cases. Case 3","status":"Approved","anonymous":false,"published":true,"pubmed_id":32632355,"doi":"10.1016/j.rmcr.2020.101139","article_url":"https://pubmed.ncbi.nlm.nih.gov/32632355/","pub_year":2020,"published_authors":"ElSeirafi MM\r\nHasan HM\r\nSridharan K\r\nZamoori A\r\nAlkhawaja S\r\nPasha SAA","article_author_email":"Author email could not be found.","journal":"Respiratory medicine case reports","abstract":"Tocilizumab has been recognized as one of the few existing biologic useful for combating COVID-19 infections especially in critically ill patient. We had experience in treating five critically ill patients with severe lung injury who were COVID-19 positive with tocilizumab. In the present case series, we have attempted to summarize their clinical profile, changes in laboratory biomarkers and outcomes.","article_type":"Original","study_type":"Case Report","number_of_patients":5,"article_patient_number":"3","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"61-70 years","sex":"Male","ethnicity":"Not Hispanic/Latino","country_contracted":"Bahrain","country_treated":"Bahrain","began_treatment_year":"2020","hiv":false,"asthma":true,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"Obesity","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Pneumonia","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"While the patient was still on treatment","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"Nasopharyngeal swab for COVID-19 was positive and the patient was initiated on oral hydroxychloroquine 200 mg twice daily along with ceftriaxone, piperacillin/tazobactam, aizthromycin, ribavirin, pegylated interferon (received single dose) and plasma therapy (two doses). The patient did not show any signs of improvement but his oxygen requirement increased for maintaining appropriate oxygen saturation. The patient was shifted to ICU and was administered two doses of 400 mg tocilizumab infusion. Patient improved the following day with a negative COVID-19 test results twice on alternate days and the patient was discharge from ICU.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6122,6675,11339,8342,11275,9780,10130,10776]},{"id":6800,"regimens":[{"id":13750,"duration":{"id":7642,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":12643,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13750},{"id":12644,"answer":"In a novel combination with another drug","answer_other":"","regimen":13750}],"created":"2020-12-25T06:51:51.520817Z","updated":"2020-12-25T07:10:20.916990Z","dose":"200 mg","frequency":"BD","route":"PO","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6800},{"id":13751,"duration":{"id":7643,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6675,"name":"Ceftriaxone","url":"cure-api2.ncats.io/v1/drugs/6675","rxNorm_id":null,"notes":null},"use_drug":[{"id":12645,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13751},{"id":12646,"answer":"In a novel combination with another drug","answer_other":"","regimen":13751}],"created":"2020-12-25T06:51:51.530376Z","updated":"2020-12-25T07:10:20.923299Z","dose":"","frequency":"","route":"IV","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6800},{"id":13752,"duration":{"id":7644,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8783,"name":"Lopinavir-Ritonavir","url":"cure-api2.ncats.io/v1/drugs/8783","rxNorm_id":null,"notes":null},"use_drug":[{"id":12647,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13752},{"id":12648,"answer":"In a novel combination with another drug","answer_other":"","regimen":13752}],"created":"2020-12-25T06:51:51.537067Z","updated":"2020-12-25T07:10:20.928794Z","dose":null,"frequency":"","route":"IV","severity":"ICU/Critical Care","severity_detail":null,"comments":null,"report":6800},{"id":13753,"duration":{"id":7645,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":12649,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13753},{"id":12650,"answer":"In a novel combination with another drug","answer_other":"","regimen":13753}],"created":"2020-12-25T06:51:51.543458Z","updated":"2020-12-25T07:10:20.988848Z","dose":null,"frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":null,"comments":null,"report":6800},{"id":13754,"duration":{"id":7646,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10130,"name":"Ribavirin","url":"cure-api2.ncats.io/v1/drugs/10130","rxNorm_id":null,"notes":null},"use_drug":[{"id":12651,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13754},{"id":12652,"answer":"In a novel combination with another drug","answer_other":"","regimen":13754}],"created":"2020-12-25T06:51:51.549692Z","updated":"2020-12-25T07:10:20.940163Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6800},{"id":13755,"duration":{"id":7647,"approximate_duration":null,"dates_unknown":false},"drug":{"id":11275,"name":"Pegylated Interferon","url":"cure-api2.ncats.io/v1/drugs/11275","rxNorm_id":null,"notes":null},"use_drug":[{"id":12653,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13755},{"id":12654,"answer":"In a novel combination with another drug","answer_other":"","regimen":13755}],"created":"2020-12-25T06:51:51.569732Z","updated":"2020-12-25T07:10:20.945872Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6800},{"id":13756,"duration":{"id":7648,"approximate_duration":null,"dates_unknown":false},"drug":{"id":11339,"name":"Convalescent plasma","url":"cure-api2.ncats.io/v1/drugs/11339","rxNorm_id":null,"notes":null},"use_drug":[{"id":12655,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13756},{"id":12656,"answer":"In a novel combination with another drug","answer_other":"","regimen":13756}],"created":"2020-12-25T06:51:51.575760Z","updated":"2020-12-25T07:10:20.951739Z","dose":"2 doses","frequency":"","route":"IV","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6800},{"id":13757,"duration":{"id":7649,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":12657,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13757},{"id":12658,"answer":"In a novel combination with another drug","answer_other":"","regimen":13757}],"created":"2020-12-25T06:51:51.581880Z","updated":"2020-12-25T07:10:20.957224Z","dose":"400 mg, 2 doses","frequency":"","route":"IV","severity":"ICU/Critical Care","severity_detail":null,"comments":null,"report":6800}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8960,"answer":"Clinical assessment","answer_other":"","report":6800},{"id":8961,"answer":"PCR","answer_other":"","report":6800}],"how_diagnosis":[{"id":15371,"answer":"Clinical assessment","answer_other":"","report":6800},{"id":15372,"answer":"Imaging","answer_other":"","report":6800},{"id":15373,"answer":"PCR","answer_other":"","report":6800}],"author_username":"Reema Charles","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":5036,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6800}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[{"id":605,"answer":"White","answer_other":""}],"created":"2020-12-25T06:49:43.851862Z","updated":"2020-12-25T07:10:20.909151Z","title":"Efficacy and safety of tocilizumab in critically ill adults with COVID-19 infection in Bahrain: A report of 5 cases. Case 4","status":"Approved","anonymous":false,"published":true,"pubmed_id":32632355,"doi":"10.1016/j.rmcr.2020.101139","article_url":"https://pubmed.ncbi.nlm.nih.gov/32632355/","pub_year":2020,"published_authors":"ElSeirafi MM\r\nHasan HM\r\nSridharan K\r\nZamoori A\r\nAlkhawaja S\r\nPasha SAA","article_author_email":"Author email could not be found.","journal":"Respiratory medicine case reports","abstract":"Tocilizumab has been recognized as one of the few existing biologic useful for combating COVID-19 infections especially in critically ill patient. We had experience in treating five critically ill patients with severe lung injury who were COVID-19 positive with tocilizumab. In the present case series, we have attempted to summarize their clinical profile, changes in laboratory biomarkers and outcomes.","article_type":"Original","study_type":"Case Report","number_of_patients":5,"article_patient_number":"4","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"31-40 years","sex":"Male","ethnicity":"Not Hispanic/Latino","country_contracted":"Bahrain","country_treated":"Bahrain","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"None","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Pneumonia","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"While the patient was still on treatment","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"The patient received oral hydroxychloroquine 200 mg twice daily along with ceftriaxone, lopinavir/ritonavir, aizthromycin, ribavirin, pegylated interferon (received single dose) and plasma therapy (two doses). Patient did not show any signs of improvement. His oxygen requirement continued to increase. Two doses of tocilizumab 400 mg were administered. Following the second dose of tocilizumab, the patient showed marked signs of improvement and four days later he was found to be negative for COVID-19 test and a repeat test after two days was still negative. The patient was discharged from ICU on day 5.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6122,6675,11339,8342,8783,11275,10130,10776]},{"id":6801,"regimens":[{"id":13758,"duration":{"id":7650,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":12659,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13758},{"id":12660,"answer":"In a novel combination with another drug","answer_other":"","regimen":13758}],"created":"2020-12-25T07:10:02.604716Z","updated":"2020-12-25T07:21:50.350770Z","dose":"","frequency":"","route":"IV","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6801},{"id":13759,"duration":{"id":7651,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6675,"name":"Ceftriaxone","url":"cure-api2.ncats.io/v1/drugs/6675","rxNorm_id":null,"notes":null},"use_drug":[{"id":12661,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13759},{"id":12662,"answer":"In a novel combination with another drug","answer_other":"","regimen":13759}],"created":"2020-12-25T07:10:02.612525Z","updated":"2020-12-25T07:21:50.357152Z","dose":"","frequency":"","route":"IV","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6801},{"id":13760,"duration":{"id":7652,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8459,"name":"Interferon","url":"cure-api2.ncats.io/v1/drugs/8459","rxNorm_id":null,"notes":null},"use_drug":[{"id":12663,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13760},{"id":12664,"answer":"In a novel combination with another drug","answer_other":"","regimen":13760}],"created":"2020-12-25T07:10:02.618971Z","updated":"2020-12-25T07:21:50.362883Z","dose":"","frequency":"","route":"IV","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6801},{"id":13761,"duration":{"id":7653,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10130,"name":"Ribavirin","url":"cure-api2.ncats.io/v1/drugs/10130","rxNorm_id":null,"notes":null},"use_drug":[{"id":12665,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13761},{"id":12666,"answer":"In a novel combination with another drug","answer_other":"","regimen":13761}],"created":"2020-12-25T07:10:02.625330Z","updated":"2020-12-25T07:21:50.368912Z","dose":"","frequency":"","route":"IV","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6801},{"id":13762,"duration":{"id":7654,"approximate_duration":null,"dates_unknown":false},"drug":{"id":11339,"name":"Convalescent plasma","url":"cure-api2.ncats.io/v1/drugs/11339","rxNorm_id":null,"notes":null},"use_drug":[{"id":12667,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13762},{"id":12668,"answer":"In a novel combination with another drug","answer_other":"","regimen":13762}],"created":"2020-12-25T07:10:02.631506Z","updated":"2020-12-25T07:21:50.374505Z","dose":"","frequency":"","route":"IV","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6801},{"id":13763,"duration":{"id":7655,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":12669,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13763},{"id":12670,"answer":"In a novel combination with another drug","answer_other":"","regimen":13763}],"created":"2020-12-25T07:10:02.637799Z","updated":"2020-12-25T07:21:50.380048Z","dose":"400 mg, 2 doses","frequency":"","route":"IV","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6801}],"site_of_infection":[],"specific_site":[],"how_outcome":[],"how_diagnosis":[{"id":15374,"answer":"Clinical assessment","answer_other":"","report":6801},{"id":15375,"answer":"Imaging","answer_other":"","report":6801},{"id":15376,"answer":"PCR","answer_other":"","report":6801}],"author_username":"Reema Charles","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"","outcome_computed":"Deteriorated","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":5037,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6801}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[{"id":606,"answer":"White","answer_other":""}],"created":"2020-12-25T07:08:18.558908Z","updated":"2020-12-25T07:21:50.342818Z","title":"Efficacy and safety of tocilizumab in critically ill adults with COVID-19 infection in Bahrain: A report of 5 cases. Case 5","status":"Approved","anonymous":false,"published":true,"pubmed_id":32632355,"doi":"10.1016/j.rmcr.2020.101139","article_url":"https://pubmed.ncbi.nlm.nih.gov/32632355/","pub_year":2020,"published_authors":"ElSeirafi MM\r\nHasan HM\r\nSridharan K\r\nZamoori A\r\nAlkhawaja S\r\nPasha SAA","article_author_email":"Author email could not be found.","journal":"Respiratory medicine case reports","abstract":"Tocilizumab has been recognized as one of the few existing biologic useful for combating COVID-19 infections especially in critically ill patient. We had experience in treating five critically ill patients with severe lung injury who were COVID-19 positive with tocilizumab. In the present case series, we have attempted to summarize their clinical profile, changes in laboratory biomarkers and outcomes.","article_type":"Original","study_type":"Case Report","number_of_patients":5,"article_patient_number":"5","full_text_available":true,"outcome":"Patient died","surgery":"No","age":"51-60 years","sex":"Male","ethnicity":"Not Hispanic/Latino","country_contracted":"Bahrain","country_treated":"Bahrain","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":true,"site_of_disease":"Lungs","clinical_syndrome":"Pneumonia","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"While the patient was still on treatment","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"The patient showed initial improvement followed by deterioration as his requirements for oxygen increased. One day following the second dose of tocilizumab injection, the nasopharyngeal test for COVID-19 was negative and a repeat test after two days confirmed the same. The patient also had positive blood culture (for Methicillin-resistant Staphylococcus aureus) with elevated procalcitonin and white blood cell count. The patient went into septic shock with multi-organ dysfunction. Despite active measures, the patient died on 16th day of admission due to refractory hypoxemia and circulatory failure.","previously_treated":"","flagged":false,"other_coinfections":"Methicillin-resistant Staphylococcus aureus - Blood culture","disease":630,"drugs":[6122,6675,11339,8459,10130,10776]},{"id":6809,"regimens":[{"id":13797,"duration":{"id":7689,"approximate_duration":"5 days","dates_unknown":true},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":12733,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13797},{"id":12734,"answer":"In a novel combination with another drug","answer_other":"","regimen":13797}],"created":"2020-12-27T21:17:06.654176Z","updated":"2020-12-27T21:26:23.784853Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6809},{"id":13798,"duration":{"id":7690,"approximate_duration":"5 days","dates_unknown":true},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":12735,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13798},{"id":12736,"answer":"In a novel combination with another drug","answer_other":"","regimen":13798}],"created":"2020-12-27T21:17:06.661893Z","updated":"2020-12-27T21:26:23.790987Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6809},{"id":13799,"duration":{"id":7691,"approximate_duration":null,"dates_unknown":false},"drug":{"id":9077,"name":"Methylprednisolone","url":"cure-api2.ncats.io/v1/drugs/9077","rxNorm_id":null,"notes":null},"use_drug":[{"id":12737,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13799},{"id":12738,"answer":"In a novel combination with another drug","answer_other":"","regimen":13799}],"created":"2020-12-27T21:17:06.667948Z","updated":"2020-12-27T21:26:23.796777Z","dose":"40 mg","frequency":"BD","route":"IV","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6809},{"id":13800,"duration":{"id":7692,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":12739,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13800},{"id":12740,"answer":"In a novel combination with another drug","answer_other":"","regimen":13800}],"created":"2020-12-27T21:17:06.674163Z","updated":"2020-12-27T21:26:23.802454Z","dose":"Single dose","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6809}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8967,"answer":"Clinical assessment","answer_other":"","report":6809}],"how_diagnosis":[{"id":15398,"answer":"Clinical assessment","answer_other":"","report":6809},{"id":15399,"answer":"Imaging","answer_other":"","report":6809},{"id":15400,"answer":"PCR","answer_other":"","report":6809}],"author_username":"Reema Charles","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":5044,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6809}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[{"id":613,"answer":"White","answer_other":""}],"created":"2020-12-27T21:13:32.309066Z","updated":"2020-12-27T21:26:23.776084Z","title":"Red blood cell exchange to avoid intubating a COVID-19 positive patient with sickle cell disease?","status":"Approved","anonymous":false,"published":true,"pubmed_id":32629539,"doi":"10.1002/jca.21809","article_url":"https://pubmed.ncbi.nlm.nih.gov/32629539/","pub_year":2020,"published_authors":"Allison D\r\nCampbell-Lee S\r\nCrane J\r\nVidanovic V\r\nWebb S\r\nFraidenburg D\r\nHussain F","article_author_email":"Author email could not be found.","journal":"Journal of clinical apheresis","abstract":"As the COVID-19 pandemic continues to claim lives across the globe, insufficient data exists regarding the optimal treatment. It is well known that patients 55 years of age or older and patients with certain chronic diseases are at higher risk of severe illness, including acute respiratory distress syndrome and death. A potentially fatal pulmonary complication of sickle cell disease, acute chest syndrome, can be precipitated by acute infections, including respiratory viruses. We report the case of a patient with sickle cell disease (HbSC) who developed COVID-19 pneumonia and acute chest syndrome who was treated with emergent red blood cell exchange in order to avoid endotracheal intubation.    \r\n          Keywords:        \r\n            HbSC; SARS-CoV-2; acute chest syndrome.","article_type":"Original","study_type":"Case Report","number_of_patients":1,"article_patient_number":"","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"21-30 years","sex":"Male","ethnicity":"Not Hispanic/Latino","country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"Sickle cell disease (HbSC phenotype)","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Pneumonia","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"Eleven days prior, he presented to the outside facility complaining of vasoâocclusive crisis pain, fever, chills, cough, and shortness of breath. He had a history of frequent admissions for pain, had been on hydroxyurea previously but had last filled this prescription more than 4 months earlier and had not been seen in our outpatient sickle cell clinic for more than 1 year. He had regularly been filling his maintenance pain medication, oxycodoneâacetaminophen every 6âhours as needed.\r\nBased on hospital records, he was initially started on ceftriaxone and doxycycline, but this was changed to piperacillin and tazobactam on hospital day 3. \r\nBased on height of 170âcm and weight of 65âkg, the total blood volume was 4.5 L, and 2857âmL of the patient's native RBCs were removed and replaced with 2441âmL of HbSânegative donor RBCs (eight units) with an average unit hematocrit of 60%.\r\nWithin 2âhours of completing the procedure, his respiratory status improved and his oxygen saturation was 98% on 2 L/min via nasal cannula. With his improvement, he was transferred from the ICU to the COVIDâ19 medical floor where he remained afebrile and breathing room air at rest, while needing 2 L/min via nasal cannula on exertion. He was discharged home on hospital day 12 with home oxygen for ambulation as well as with prescriptions for his maintenance pain medications and to restart hydroxyurea.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6122,8342,9077,10776]},{"id":6821,"regimens":[{"id":13828,"duration":{"id":7720,"approximate_duration":"14 days","dates_unknown":true},"drug":{"id":10215,"name":"Ruxolitinib","url":"cure-api2.ncats.io/v1/drugs/10215","rxNorm_id":null,"notes":null},"use_drug":[{"id":12792,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13828}],"created":"2020-12-28T20:43:16.128931Z","updated":"2020-12-28T20:56:36.315911Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6821},{"id":13829,"duration":{"id":7721,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":12793,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13829}],"created":"2020-12-28T20:43:16.136798Z","updated":"2020-12-28T20:56:36.322791Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"Was given after Ruxolitinib after there was no clinical improvement.","comments":null,"report":6821},{"id":13830,"duration":{"id":7722,"approximate_duration":null,"dates_unknown":false},"drug":{"id":9905,"name":"Prednisolone","url":"cure-api2.ncats.io/v1/drugs/9905","rxNorm_id":null,"notes":null},"use_drug":[{"id":12794,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13830}],"created":"2020-12-28T20:43:16.143388Z","updated":"2020-12-28T20:56:36.328351Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"Given after Ruxolitinib treatment","comments":null,"report":6821}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8969,"answer":"Clinical assessment","answer_other":"","report":6821}],"how_diagnosis":[{"id":15424,"answer":"Clinical assessment","answer_other":"","report":6821},{"id":15425,"answer":"PCR","answer_other":"","report":6821},{"id":15426,"answer":"Imaging","answer_other":"","report":6821}],"author_username":"Kate Borkowski","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Nurse","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":5058,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6821},{"id":5059,"answer":"Co-Infection or Complex Co-morbidities","answer_other":"","report":6821}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-12-28T20:41:23.994861Z","updated":"2020-12-28T20:56:36.307363Z","title":"Combined IL-6 and JAK/STAT inhibition therapy in COVID-19-related sHLH, potential game changer. Case 1.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32584421,"doi":"10.1111/bjh.16966","article_url":"https://pubmed.ncbi.nlm.nih.gov/32584421/","pub_year":2020,"published_authors":"Portsmore S\r\nTran Nguyen TN\r\nBeacham E\r\nNeelakantan P","article_author_email":"pratap.neelakantan@nhs.net","journal":"British journal of haematology","abstract":"Coronavirus disease 2019 (COVIDâ19), caused by novel SARSâCoVâ2, leads to significant mortality and morbidity with increasing evidence for inflammatory pathways being implicated in the lung damage it causes. Severe COVIDâ19 patients present with increased inflammatory markers, akin to secondary haemophagocytic lymphohistiocytosis (sHLH), that have been shown to predict mortality. There is emerging evidence for the use of an interleukin (ILâ6) inhibitor, tocilizumab (TCZ), for suppression of the inflammatory cytokine storm in this context. Ruxolitinib (RXB), a JAKâSTAT inhibitor, has also been shown to have proven efficacy in the treatment of sHLH. Both agents appear to be promising in the fight against SARSâCoVâ2 infection, leading to an increasing number of trials being registered with their use. Until this point, no single agent has shown a survival benefit against SARSâCoVâ2 and it is possible that monotherapy may not suppress inflammation enough to overcome the COVIDâ19 related cytokine storm and hyperâinflammation.    \r\n          Keywords:        \r\n            Ruxolitinib; Tocilizumab; cytokine storm; secondary haemophagocytic lymphohistiocytosis; severe COVID.","article_type":"Original","study_type":"Case Report","number_of_patients":2,"article_patient_number":"","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"No","age":"71-80 years","sex":"Female","ethnicity":null,"country_contracted":"United Kingdom","country_treated":"United Kingdom","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":true,"other_comorbid":"B-cell Lymphoma","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Pneumonia, neutropenic sepsis","severity":null,"prev_treatment":"","unusual":"Initial investigations showed pancytopenia with elevated C-reactive protein (CRP), patchy left-sided opacification on her chest X -ray (CXR), normal oxygen saturations and a positive SARS-CoV-2 swab. She was treated for neutropenic sepsis and was discharged after eleven days. She re-presented three days later (day 0) with confusion, breathlessness and fever. CXR showed changes consistent with COVID infection.","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"","reminder":false,"when_reminder":"1 week","additional_info":"Patient required CPAP during admission. Patient was discharged one month after readmission.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[9905,10215,10776]},{"id":6822,"regimens":[{"id":13831,"duration":{"id":7723,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8783,"name":"Lopinavir-Ritonavir","url":"cure-api2.ncats.io/v1/drugs/8783","rxNorm_id":null,"notes":null},"use_drug":[{"id":12795,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13831}],"created":"2020-12-28T21:00:10.276686Z","updated":"2020-12-28T21:13:54.588694Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"Part of the RECOVERY trial; Patient was intubated on admission day 16.","comments":null,"report":6822},{"id":13832,"duration":{"id":7724,"approximate_duration":"3 doses","dates_unknown":true},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":12797,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13832}],"created":"2020-12-28T21:00:10.284731Z","updated":"2020-12-28T21:13:54.595942Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"Patient was intubated on admission day 16.","comments":null,"report":6822},{"id":13833,"duration":{"id":7725,"approximate_duration":"14 days","dates_unknown":true},"drug":{"id":10215,"name":"Ruxolitinib","url":"cure-api2.ncats.io/v1/drugs/10215","rxNorm_id":null,"notes":null},"use_drug":[{"id":12798,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13833}],"created":"2020-12-28T21:00:10.291019Z","updated":"2020-12-28T21:13:54.601507Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"Patient was intubated on admission day 16.","comments":null,"report":6822},{"id":13834,"duration":{"id":7726,"approximate_duration":null,"dates_unknown":false},"drug":{"id":9905,"name":"Prednisolone","url":"cure-api2.ncats.io/v1/drugs/9905","rxNorm_id":null,"notes":null},"use_drug":[{"id":12799,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13834}],"created":"2020-12-28T21:00:10.297292Z","updated":"2020-12-28T21:13:54.607595Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"Given after Ruxolitinib treatment","comments":null,"report":6822}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8970,"answer":"Clinical assessment","answer_other":"","report":6822}],"how_diagnosis":[{"id":15427,"answer":"Clinical assessment","answer_other":"","report":6822},{"id":15428,"answer":"PCR","answer_other":"","report":6822}],"author_username":"Kate Borkowski","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Nurse","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":5060,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6822},{"id":5061,"answer":"Co-Infection or Complex Co-morbidities","answer_other":"","report":6822}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-12-28T20:57:16.639754Z","updated":"2020-12-28T21:13:54.581133Z","title":"Combined IL-6 and JAK/STAT inhibition therapy in COVID-19-related sHLH, potential game changer. Case 2.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32584421,"doi":"10.1111/bjh.16966","article_url":"https://pubmed.ncbi.nlm.nih.gov/32584421/","pub_year":2020,"published_authors":"Portsmore S\r\nTran Nguyen TN\r\nBeacham E\r\nNeelakantan P","article_author_email":"pratap.neelakantan@nhs.net","journal":"British journal of haematology","abstract":"Coronavirus disease 2019 (COVIDâ19), caused by novel SARSâCoVâ2, leads to significant mortality and morbidity with increasing evidence for inflammatory pathways being implicated in the lung damage it causes. Severe COVIDâ19 patients present with increased inflammatory markers, akin to secondary haemophagocytic lymphohistiocytosis (sHLH), that have been shown to predict mortality. There is emerging evidence for the use of an interleukin 6 (ILâ6) inhibitor, tocilizumab (TCZ), for suppression of the inflammatory cytokine storm in this context. Ruxolitinib (RXB), a JAKâSTAT inhibitor, has also been shown to have proven efficacy in the treatment of sHLH. Both agents appear to be promising in the fight against SARSâCoVâ2 infection, leading to an increasing number of trials being registered with their use. Until this point, no single agent has shown a survival benefit against SARSâCoVâ2 and it is possible that monotherapy may not suppress inflammation enough to overcome the COVIDâ19 related cytokine storm and hyperâinflammation.    \r\n          Keywords:        \r\n            Ruxolitinib; Tocilizumab; cytokine storm; secondary haemophagocytic lymphohistiocytosis; severe COVID.","article_type":"Original","study_type":"Case Report","number_of_patients":2,"article_patient_number":"","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"No","age":"51-60 years","sex":"Male","ethnicity":null,"country_contracted":"United Kingdom","country_treated":"United Kingdom","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":true,"other_comorbid":"Hx of non-Hodgkin's Lymphoma (remission for nine months before this admission)","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Pneumonia","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"He was successfully extubated on day 53 and stepped down from ICU on day 56. Patient was discharged 9 weeks after admission.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[8783,9905,10215,10776]},{"id":6824,"regimens":[{"id":13841,"duration":{"id":7733,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":12808,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13841}],"created":"2020-12-29T15:39:48.276623Z","updated":"2020-12-29T15:48:07.467828Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"Patient required O2 by nasal cannula","comments":null,"report":6824},{"id":13842,"duration":{"id":7734,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6675,"name":"Ceftriaxone","url":"cure-api2.ncats.io/v1/drugs/6675","rxNorm_id":null,"notes":null},"use_drug":[{"id":12809,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13842}],"created":"2020-12-29T15:39:48.284387Z","updated":"2020-12-29T15:48:07.474488Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"Patient required O2 by nasal cannula","comments":null,"report":6824},{"id":13843,"duration":{"id":7735,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":12810,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13843},{"id":12811,"answer":"In a novel combination with another drug","answer_other":"","regimen":13843}],"created":"2020-12-29T15:39:48.290964Z","updated":"2020-12-29T15:48:07.480251Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"Patient condition deteriorated on the third day of hospitalisation and he required invasive mechanical ventilation.","comments":null,"report":6824},{"id":13844,"duration":{"id":7736,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8783,"name":"Lopinavir-Ritonavir","url":"cure-api2.ncats.io/v1/drugs/8783","rxNorm_id":null,"notes":null},"use_drug":[{"id":12812,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13844},{"id":12813,"answer":"In a novel combination with another drug","answer_other":"","regimen":13844}],"created":"2020-12-29T15:39:48.297206Z","updated":"2020-12-29T15:48:07.485761Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"Patient condition deteriorated on the third day of hospitalisation and he required invasive mechanical ventilation.","comments":null,"report":6824},{"id":13845,"duration":{"id":7737,"approximate_duration":"2 doses","dates_unknown":true},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":12814,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13845}],"created":"2020-12-29T15:39:48.303624Z","updated":"2020-12-29T15:48:07.491583Z","dose":"400mg","frequency":"QD","route":"IV","severity":"ICU/Critical Care","severity_detail":"Patient condition deteriorated on the third day of hospitalisation and he required invasive mechanical ventilation.","comments":null,"report":6824}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8973,"answer":"Clinical assessment","answer_other":"","report":6824},{"id":8974,"answer":"PCR","answer_other":"","report":6824}],"how_diagnosis":[{"id":15431,"answer":"Clinical assessment","answer_other":"","report":6824},{"id":15432,"answer":"PCR","answer_other":"","report":6824},{"id":15433,"answer":"Imaging","answer_other":"","report":6824}],"author_username":"Kate Borkowski","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Nurse","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":5063,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6824},{"id":5064,"answer":"Unusual disease presentation","answer_other":"","report":6824}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-12-29T15:37:57.556824Z","updated":"2020-12-29T15:48:07.459996Z","title":"Rhabdomyolysis as an initial presentation in a patient diagnosed with COVID-19.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32587121,"doi":"10.1136/bcr-2020-236719","article_url":"https://pubmed.ncbi.nlm.nih.gov/32587121/","pub_year":2020,"published_authors":"Valente-Acosta B\r\nMoreno-Sanchez F\r\nFueyo-Rodriguez O\r\nPalomar-Lever A","article_author_email":"benjamin.valente-acosta1@alumni.lshtm.ac.uk","journal":"BMJ case reports","abstract":"The presence of rhabdomyolysis secondary to multiple infections has been reported, predominantly viral, but also bacterial and fungal. It is well known that COVID-19 can present a wide variety of complications during the course of infection; however, the presence of rhabdomyolysis as an initial condition has not been reported so far. We report a case of rhabdomyolysis as an initial presentation in a patient diagnosed with SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) infection.    \r\n          Keywords:        \r\n            acute renal failure; pneumonia (infectious disease).","article_type":"Original","study_type":"Case Report","number_of_patients":1,"article_patient_number":"","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"No","age":"71-80 years","sex":"Male","ethnicity":"Hispanic/Latino","country_contracted":"Mexico","country_treated":"Mexico","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":true,"other_immunodeficiency":false,"other_comorbid":"Benign prostatic hyperplasia","pregnant":false,"unknown":false,"site_of_disease":"Lungs, muscles","clinical_syndrome":"Pneumonia, Rhabdomyolysis","severity":null,"prev_treatment":"","unusual":"At admission, the patient's creatinine level was increased, at 1.68âmg/dL, and his C-reactive protein (CRP) and procalcitonin (PCT) were elevated, at 2.9âmg/dL and 2.89âng/mL, respectively. His interleukin (IL)-6 was also increased (233âpg/mL). His muscle enzymes were markedly elevated (creatine phosphokinase at 8720 U/L and myoglobin at 2079 ng/mL).","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"On the seventh day after admission, his condition started to improve and he showed a decrease in lactic dehydrogenase, ferritin, CRP and PCT levels. It was possible to extubate him on the 12th day after admission. His clinical condition continued to improve and after a negative SARS-CoV2 test, we were able to finally discharge him to his home on the 16th day after admission.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6122,6675,8342,8783,10776]},{"id":6840,"regimens":[{"id":13883,"duration":{"id":7775,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":12878,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13883}],"created":"2021-01-04T19:41:05.898571Z","updated":"2021-01-04T19:57:00.089585Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6840},{"id":13884,"duration":{"id":7776,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8233,"name":"Heparin","url":"cure-api2.ncats.io/v1/drugs/8233","rxNorm_id":null,"notes":null},"use_drug":[{"id":12879,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13884}],"created":"2021-01-04T19:41:05.906417Z","updated":"2021-01-04T19:57:00.095859Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6840}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8992,"answer":"Clinical assessment","answer_other":"","report":6840}],"how_diagnosis":[{"id":15468,"answer":"Clinical assessment","answer_other":"","report":6840},{"id":15469,"answer":"PCR","answer_other":"","report":6840}],"author_username":"Belinda Nhundu","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":5088,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6840}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[],"races":[],"created":"2021-01-04T17:40:31.017969Z","updated":"2021-01-04T19:57:00.081640Z","title":"Thrombotic events following tocilizumab therapy in critically ill COVID-19 patients: a FaÃ§ade for prognostic markers.Case 1.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32922212,"doi":"10.1186/s12959-020-00236-9","article_url":"https://pubmed.ncbi.nlm.nih.gov/32922212/","pub_year":2020,"published_authors":"Atallah B\r\nEl Nekidy W\r\nMallah SI\r\nCherfan A\r\nAbdelWareth L\r\nMallat J\r\nHamed F","article_author_email":"Author email could not be found.","journal":"Thrombosis journal","abstract":"Hospitals in the Middle East Gulf region have experienced an influx of COVID-19 patients to their medical wards and intensive care units. The hyper coagulability of these patients has been widely reported on a global scale. However, many of the experimental treatments used to manage the various complications of COVID-19 have not been widely studied in this context. The effect of the current treatment protocols on patients' diagnostic and prognostic biomarkers may thus impact the validity of the algorithms adopted.","article_type":"Original","study_type":"Case Series","number_of_patients":5,"article_patient_number":"1","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"Yes","age":"51-60 years","sex":"Male","ethnicity":null,"country_contracted":"United Arab Emirates","country_treated":"United Arab Emirates","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":true,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"","clinical_syndrome":"","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"CT angiogram showed partially detaching/floating thrombi noted 4 cm infrarenal abdominal aorta, compromising the lumen and leading to acute limb ischemia with extensive abdominal and bilateral lower extremity thrombus. Ddimer was still over 6 times ULN while all other markers were lower than at admission.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[8233,10776]},{"id":6842,"regimens":[{"id":13885,"duration":{"id":7777,"approximate_duration":null,"dates_unknown":false},"drug":{"id":7629,"name":"Enoxaparin","url":"cure-api2.ncats.io/v1/drugs/7629","rxNorm_id":null,"notes":null},"use_drug":[{"id":12880,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13885},{"id":12881,"answer":"In a novel combination with another drug","answer_other":"","regimen":13885}],"created":"2021-01-04T19:50:35.629498Z","updated":"2021-01-04T19:55:40.730711Z","dose":"40mg","frequency":"QD","route":"IM","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6842},{"id":13886,"duration":{"id":7778,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":12882,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13886},{"id":12883,"answer":"In a novel combination with another drug","answer_other":"","regimen":13886}],"created":"2021-01-04T19:50:35.637912Z","updated":"2021-01-04T19:55:40.737537Z","dose":"400mg","frequency":"","route":"IV","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6842}],"site_of_infection":[],"specific_site":[],"how_outcome":[],"how_diagnosis":[{"id":15470,"answer":"Clinical assessment","answer_other":"","report":6842},{"id":15471,"answer":"PCR","answer_other":"","report":6842}],"author_username":"Belinda Nhundu","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"","outcome_computed":"Deteriorated","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":5089,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6842}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[],"races":[],"created":"2021-01-04T19:48:58.301524Z","updated":"2021-01-04T19:55:40.722851Z","title":"Thrombotic events following tocilizumab therapy in critically ill COVID-19 patients: a FaÃ§ade for prognostic markers.Case 2.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32922212,"doi":"10.1186/s12959-020-00236-9","article_url":"https://pubmed.ncbi.nlm.nih.gov/32922212/","pub_year":2020,"published_authors":"Atallah B\r\nEl Nekidy W\r\nMallah SI\r\nCherfan A\r\nAbdelWareth L\r\nMallat J\r\nHamed F","article_author_email":"Author email could not be found.","journal":"Thrombosis journal","abstract":"Hospitals in the Middle East Gulf region have experienced an influx of COVID-19 patients to their medical wards and intensive care units. The hypercoagulability of these patients has been widely reported on a global scale. However, many of the experimental treatments used to manage the various complications of COVID-19 have not been widely studied in this context. The effect of the current treatment protocols on patients' diagnostic and prognostic biomarkers may thus impact the validity of the algorithms adopted.","article_type":"Original","study_type":"Case Series","number_of_patients":5,"article_patient_number":"2","full_text_available":true,"outcome":"Patient died","surgery":"No","age":"71-80 years","sex":"Male","ethnicity":null,"country_contracted":"United Arab Emirates","country_treated":"United Arab Emirates","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":true,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"","clinical_syndrome":"","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"Patient died of massive PE in the setting of chronic Covid infection.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[7629,10776]},{"id":6843,"regimens":[{"id":13887,"duration":{"id":7779,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":12884,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13887}],"created":"2021-01-04T20:32:14.252398Z","updated":"2021-01-11T18:35:05.705659Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6843},{"id":13888,"duration":{"id":7780,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8233,"name":"Heparin","url":"cure-api2.ncats.io/v1/drugs/8233","rxNorm_id":null,"notes":null},"use_drug":[{"id":12914,"answer":"It was not used in a new way","answer_other":"","regimen":13888}],"created":"2021-01-04T20:32:14.260328Z","updated":"2021-01-11T18:35:05.734639Z","dose":"40mg","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":null,"comments":null,"report":6843}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8993,"answer":"Clinical assessment","answer_other":"","report":6843}],"how_diagnosis":[{"id":15472,"answer":"PCR","answer_other":"","report":6843}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":5090,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6843}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[],"races":[],"created":"2021-01-04T20:01:11.475187Z","updated":"2021-01-11T18:35:05.697846Z","title":"Thrombotic events following tocilizumab therapy in critically ill COVID-19 patients: a FaÃ§ade for prognostic markers.Case 3.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32922212,"doi":"10.1186/s12959-020-00236-9","article_url":"https://pubmed.ncbi.nlm.nih.gov/32922212/","pub_year":2020,"published_authors":"Atallah B\r\nEl Nekidy W\r\nMallah SI\r\nCherfan A\r\nAbdelWareth L\r\nMallat J\r\nHamed F","article_author_email":"Author email could not be found.","journal":"Thrombosis journal","abstract":"Hospitals in the Middle East Gulf region have experienced an influx of COVID-19 patients to their medical wards and intensive care units. The hypercoagulability of these patients has been widely reported on a global scale. However, many of the experimental treatments used to manage the various complications of COVID-19 have not been widely studied in this context. The effect of the current treatment protocols on patients' diagnostic and prognostic biomarkers may thus impact the validity of the algorithms adopted.","article_type":"Original","study_type":"Case Series","number_of_patients":5,"article_patient_number":"3","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"No","age":"31-40 years","sex":"Male","ethnicity":null,"country_contracted":"United Arab Emirates","country_treated":"United Arab Emirates","began_treatment_year":"2020","hiv":false,"asthma":true,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"respiratory tract infection","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"CTPA performed in response to worsening pleuritic chest pain revealed subsegmental\r\npulmonary embolus within the right lower lobe basilar pulmonary artery.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[8233,10776]},{"id":6844,"regimens":[{"id":13889,"duration":{"id":7781,"approximate_duration":null,"dates_unknown":false},"drug":{"id":7629,"name":"Enoxaparin","url":"cure-api2.ncats.io/v1/drugs/7629","rxNorm_id":null,"notes":null},"use_drug":[{"id":12913,"answer":"It was not used in a new way","answer_other":"","regimen":13889}],"created":"2021-01-04T21:00:50.610455Z","updated":"2021-01-11T18:33:25.413079Z","dose":"40mg","frequency":"BID","route":"","severity":"Inpatient","severity_detail":null,"comments":null,"report":6844},{"id":13890,"duration":{"id":7782,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":12887,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13890}],"created":"2021-01-04T21:00:50.618293Z","updated":"2021-01-11T18:33:25.391021Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6844}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8994,"answer":"Clinical assessment","answer_other":"","report":6844}],"how_diagnosis":[{"id":15473,"answer":"Clinical assessment","answer_other":"","report":6844},{"id":15474,"answer":"Imaging","answer_other":"","report":6844},{"id":15475,"answer":"PCR","answer_other":"","report":6844}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":5091,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6844}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[],"races":[],"created":"2021-01-04T20:45:24.377966Z","updated":"2021-01-11T18:33:25.376615Z","title":"Thrombotic events following tocilizumab therapy in critically ill COVID-19 patients: a FaÃ§ade for prognostic markers.Case 4.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32922212,"doi":"10.1186/s12959-020-00236-9","article_url":"https://pubmed.ncbi.nlm.nih.gov/32922212/","pub_year":2020,"published_authors":"Atallah B\r\nEl Nekidy W\r\nMallah SI\r\nCherfan A\r\nAbdelWareth L\r\nMallat J\r\nHamed F","article_author_email":"Author email could not be found.","journal":"Thrombosis journal","abstract":"Hospitals in the Middle East Gulf region have experienced an influx of COVID-19 patients to their medical wards and intensive care units. The hypercoagulability of these patients has been widely reported on a global scale. However, many of the experimental treatments used to manage the various complications of COVID-19 have not been widely studied in this context. The effect of the current treatment protocols on patients' diagnostic and prognostic biomarkers may thus impact the validity of the algorithms adopted.","article_type":"Original","study_type":"Case Series","number_of_patients":5,"article_patient_number":"4","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"No","age":"31-40 years","sex":"Male","ethnicity":null,"country_contracted":"United Arab Emirates","country_treated":"United Arab Emirates","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"respiratory tract infection","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"CTPA obtained due to progressive hypoxia revealed large saddle embolus. Extension of embolus into the upper and lower lobar pulmonary arteries was evident, with resulting right heart strain. Patient received systemic alteplase followed by heparin drip for therapeutic anticoagulation. Patient improved and was\r\ntransferred to a medical ward","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[7629,10776]},{"id":6845,"regimens":[{"id":13891,"duration":{"id":7783,"approximate_duration":null,"dates_unknown":false},"drug":{"id":7629,"name":"Enoxaparin","url":"cure-api2.ncats.io/v1/drugs/7629","rxNorm_id":null,"notes":null},"use_drug":[{"id":12912,"answer":"It was not used in a new way","answer_other":"","regimen":13891}],"created":"2021-01-04T21:15:20.897056Z","updated":"2021-01-11T18:13:16.844905Z","dose":null,"frequency":"","route":"","severity":"Inpatient","severity_detail":null,"comments":null,"report":6845},{"id":13892,"duration":{"id":7784,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":12889,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13892}],"created":"2021-01-04T21:15:20.905051Z","updated":"2021-01-11T18:13:16.822196Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6845}],"site_of_infection":[],"specific_site":[],"how_outcome":[],"how_diagnosis":[{"id":15476,"answer":"Clinical assessment","answer_other":"","report":6845},{"id":15477,"answer":"PCR","answer_other":"","report":6845}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Deteriorated","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":5092,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6845}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[],"races":[],"created":"2021-01-04T21:05:35.763689Z","updated":"2021-01-11T18:13:16.807996Z","title":"Thrombotic events following tocilizumab therapy in critically ill COVID-19 patients: a FaÃ§ade for prognostic markers.Case 5.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32922212,"doi":"10.1186/s12959-020-00236-9","article_url":"https://pubmed.ncbi.nlm.nih.gov/32922212/","pub_year":2020,"published_authors":"Atallah B\r\nEl Nekidy W\r\nMallah SI\r\nCherfan A\r\nAbdelWareth L\r\nMallat J\r\nHamed F","article_author_email":"Author email could not be found.","journal":"Thrombosis journal","abstract":"Hospitals in the Middle East Gulf region have experienced an influx of COVID-19 patients to their medical wards and intensive care units. The hypercoagulability of these patients has been widely reported on a global scale. However, many of the experimental treatments used to manage the various complications of COVID-19 have not been widely studied in this context. The effect of the current treatment protocols on patients' diagnostic and prognostic biomarkers may thus impact the validity of the algorithms adopted.","article_type":"Original","study_type":"Case Series","number_of_patients":5,"article_patient_number":"5","full_text_available":true,"outcome":"Patient died","surgery":"No","age":"51-60 years","sex":"Male","ethnicity":null,"country_contracted":"United Arab Emirates","country_treated":"United Arab Emirates","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":true,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"respiratory tract infection","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"CT Chest with IV Contrast: Multiple filling defects noted bilaterally in the pulmonary tree; findings consistent with pulmonary embolism.Small filling defect seen in the internal jugular veins bilaterally, consistent with thrombi.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[7629,10776]}]